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The Biological engineering is a scientific discipline that is experiencing a period of expan‐
sion with important impacts in all areas of medicine. The technological approach and the
high level of innovation make bioengineering extremely dynamic and this forces researchers
to continuous updating. It involves the publication of the results of the latest scientific re‐
search.
This book covers a wide range of aspects and issues related to advances in bioengineering
research, with a particular focus on innovative technologies and applications. The book con‐
sists of 13 scientific contributions divided in four sections: Materials Science; Biosensors,
Electronics and Telemetry; Light Therapy; Computing and Analysis Techniques.
In the first section, consisting of five chapters, issues concerning the chemical synthesis of
new (nano)materials and physical modifications of biomaterials are addressed. In the sec‐
tion entitled “Biosensors”, two chapters treat the issues concerning the electronics of analyti‐
cal devices and the wireless transmission of acquired data. The third section addresses
themes linked to light therapy. The last four chapters, grouped in the section entitled “Com‐
puting and Analysis Techniques”, show new computational approaches suitable for solving
bioengineering problems.
Pier Andrea Serra








Synthesis of New Biocompatible Polymers and
Fabrication of Nanosheets
Yu Nagase and Yosuke Okamura
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/59633
1. Introduction
Synthetic polymers have been investigated for the applications in the medical field as bioma‐
terials, and used for processing biomedical devices and artificial organs which could be used
in living organs. However, most of the polymers are not suitable for a long-term implantation
when the materials contact with flowing blood or internal organs, because the material surface
could not avoid the initiation of the process leading to thrombosis. Therefore, the development
of the materials, which are continuously showing a stable biocompatibility during the long-
term use, is desired for the advanced medical devices. For example, segmented polyurethanes
have been widely used in practical applications for medical devices due to their high mechan‐
ical strength and biocompatibility [1, 2].
On the other hand, the phosphorylcholine (PC) group is a polar component of phospholipid
molecules, which cover the surface of cell membranes. It has been well known that synthetic
polymer materials containing PC group exhibit biocompatibility including nonthromboge‐
nicity. Firstly, Ishihara et al. has been developed 2-methacryloyloxyethyl phosphorylcholine
(MPC) polymer as an excellent biocompatible material, which efficiently reduces the adhesion
of cells and proteins to the polymer surface [3 – 7]. The design of the MPC polymer was inspired
by the chemical structure of the phospholipid polar group in biomembranes. Then, in recent
years, the MPC polymer has been widely applied in biological and medical fields. Furthermore,
the applications of MPC polymer to medical devices and other uses have been greatly
advanced in these years [8 – 15]. However, most of MPC polymers do not possess the thermal
stability and the mechanical strength, which were derived from the polymethacrylate type
main chain. Then, if these physical properties of MPC polymers improved satisfactorily while
maintaining the excellent biocompatibility, novel biocompatible polymer materials could be
developed.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
In these years, we have succeeded in the syntheses of novel diamine and diol monomers
containing PC moiety for the preparations of polyamides, polyimides, polyesters and polyur‐
ethanes from these monomers [16 – 23]. It was found that the obtained polymers exhibited the
excellent biocompatibility derived from PC unit in addition to the processability, the durability
to solvents, the thermal stability and the mechanical strength, which were derived from the
main chain components.
By the way, the development of practical biomaterials will desire the collaborations among
chemists, biologists, material scientists. We focused in the field of nanotechnology, especially
the processing for free-standing ultrathin films consisting of polymers with a thickness less
than 100 nm (often called nanosheets), which exhibited the unique properties such as high
adhesive strength, flexibility, transparency and smoothness [24-26]. If the nanosheets could be
fabricated from such PC-containing polymers, the applications as new biomaterials would be
significantly advanced. Then, we attempted to prepare the nanosheets from the obtained
copoly(ester-urethane)s and to investigate the physical properties and the biocompatibility of
the nanosheet surface.
This chapter covered the subject of our recent study to develop new biomaterials containing
a phospholipid moiety. We describe the preparations of aromatic polyimides and segmented
polyurethanes containing PC group, which are obtained by polycondensation or polyaddition
using PC-containing diamine and diol monomers. In addition, the fabrication of ultra-thin
films, so called nanosheets, composed of these PC-containing polymers is described in detail.
The obtained nanosheets exhibited the high adhesive strength, indicating that the nanosheets
could conform closely to the desired surfaces due to their exquisite flexibility and low
roughness. In this chapter, the physical properties such as thermal stability, biological function
as blood compatibility, and surface property of the obtained polymers and nanosheets are
discussed to reveal the possibility of a new biocompatible polymer material.
2. Preparations of polymer materials
2.1. Syntheses of monomers containing PC group
In order to prepare polyamides, polyimides and polyurethanes, we have investigated the
syntheses of diamine and diol monomers containing PC moiety. At first, the synthesis of 2-
(3,5-diaminophenylcarbonyloxy)ethyl phosphorylcholine (DAPC) was carried out to prepare
PC-containing polyamide [16]. Then, copolyamides were prepared by the polycondensation
of DAPC with isophthaloyl chloride and another diamine comonomer. It was revealed that
the obtained copolyamide films exhibited the excellent blood compatibility. These results
would be due to the PC unit located at the surface of the polymer film, where the surface is
covered with PC unit, and the interaction between the polymer surface and blood ingredients
such as cells and platelets is very weak. However, the molecular weight and the PC content of
copolyamides from DAPC were not enough to produce a self-standing film and to exhibit the
higher biocompatibility, respectively, which would be due to the low reactivity and also the
highly hygroscopic property of DAPC. Thus, we have developed a new structure of high
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molecular weight polymer in order to create the practical biomaterials for several applications,
which exhibit the excellent biocompatibility in addition to the processability, the durability to
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Sheme 1. Synthesis of diamine monomer containing PC moiety (BAPPC).
For this purpose, we designed a new diamine monomer containing PC group, 2-[3,5-bis(4-
aminophenoxy)phenylcarbonyloxy]ethyl phosphorylcholine (BAPPC). BAPPC is expected to
show the higher reactivity in the polymerization than DAPC, which would be due to the
relatively higher reactive amino groups on p-position of phenoxy groups. The synthetic route
of BAPPC is outlined in Scheme 1. The compound 3 was prepared as an intermediate, which
were obtained by the esterification of 2 with 2-bromoethanol. Then, the reaction of 3 with 2-
chloro-2-oxo-1,3,2-dioxaphospholane (COP) yielded a phospholane compound. The purifica‐
tion of the product by a silica-gel column chromatography was difficult because it was easily
hydrolyzed. Therefore, the extraction of the crude products with chloroform followed by
washing with distilled water gave the pure phospholane compound. Finally, BAPPC (melting
point=109°C) was obtained by opening the cyclic phosphoric ester moiety with trimethyla‐
mine, followed by the reduction of the nitro groups of 4 with H2 catalyzed by Pd. Although
the several reaction steps are necessary to prepare this monomer, all of the reaction steps
proceeded smoothly in high yields [18].
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Sheme 2. Synthesis of diol monomer containing PC moiety (BHPC).
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On the other hand, the synthesis of diol monomer containing PC unit was investigated to
prepare polyurethanes or polyesters [21]. The synthetic route of the desired diol monomer, 2-
(3,5-bis(2-hydroxyethoxy)benzoyloxy)ethyl phosphorylcholine (BHPC), is outlined in Scheme
2. The terminal benzyl groups of compounds 5, 6 and 7 were introduced as a protection group
of the diol moiety. The key intermediate, 6, was synthesized by esterification of 5 with ethylene
glycol, and the incorporation of the PC group was achieved by the reaction of 6 with COP,
followed by the ring-opening reaction of the cyclic phosphoric ester moiety with trimethyla‐
mine. Finally, deprotection of the benzyl groups of 7 by Pd-catalyzed hydrogen reduction with
H2 gas to afford the desired diol monomer, BHPC. This reaction proceeded quantitatively to
give the pure product of BHPC as a white solid (melting point=34°C), although it was so
hygroscopic that the obtained solid softened when exposed to moisture.
2.2. Syntheses and properties of polyimides
In these years, we have achieved the syntheses of polyamides, poly(urethane-urea)s and
poly(amide-ester)s containing PC moiety by polycondensation or polyaddition using the novel
diamine monomer, BAPPC, and investigated the physical and biological properties of the
obtained polymers, as described in our literatures [18 – 20]. These aromatic polymers contain‐
ing PC group showed the thermal stability up to ca. 250°C, where the thermal degradation of
PC component would started over 200°C that was confirmed by the thermogravimetric
analysis of polymers. The heat resistance of these PC-containing polymers over 200°C is
enough to use for biomaterial devices, for example, for the thermal sterilization process over
150°C. In addition, the tough films could be prepared by solvent casting from poly(urethane-
urea)s and poly(amide-ester)s, which were copolymerized with polycarbonate diol as the soft
segment, and the elastomeric property was observed in these films [20]. Furthermore, it has
been found that these PC-containing aromatic polymers efficiently reduced the adhesion of
proteins and platelets, where the number of adhered platelets of PC-containing polymers was
reduced in nearly one-tenth amount as compared with that of polymers without PC group.
These results indicate that the PC unit plays an important role for the blood compatibility of
the polymers. The amount of adhered proteins and platelets decreased as the increase of the
content of PC unit in the copolymers, therefore, the composition of the PC unit was a dominant
factor in the reduction of the adhesion of proteins and platelets.
In this chapter, we will describe our recent study for the synthesis of polyimide containing PC
group as a biocompatible hard material. The desired copolyimides were carried out by the
polycondensation of BAPPC and bis(p-diaminophenyloxy)benzene (BAPB) with 4,4'-hexa‐
fluoroisopropylidene diphthalic anhydride (6FDA), followed by the chemical imidization with
triethylamine and acetic anhydride, as shown in Scheme 3. As the acid anhydride, 6FDA was
used to make the polyimide soluble in some solvents. Table 1 summarizes the compositions
and molecular weights of the obtained copolyimides. Four kinds of copolyimides with PC
content were prepared by changing the ratio of BAPPC and BAPB in the feed of polymeriza‐
tion. The obtained copolyimides showed the number-average molecular weights (Mn) at
around 1 x 104.
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Sheme 3. Preparation of copolyimides containing PC moiety (PIPC).
a) The molar ratio of monomers, BAPPC and BAPB, in the polymerazition.
b) PC contents in the copolymers were estimated by 1H-NMR spectra.
c) Number-avarage and weight-avarage molecular weights, Mn and Mw, were determinated by GPC using 20mM LiBr
solution in DMF as an eluent.
Table 1. Composition and molecular weight of polyimides (PIPC).
These copolyimides were soluble in aprotic polar solvents, such as dimethylformamide (DMF),
dimethylsulfoxide (DMSO) and N-methyl-2-pyrrolidinone (NMP), at room temperature,
whereas they were insoluble in water, methanol, ethanol and acetone. This solubility in specific
solvents is advantageous in the processing for medical devices, and the insolubility in other
solvents enables the material durable to these solvents. For the solubility in some solvents, the
solubility of these copolyimides depended on the PC content of polymers. For example, only
PIPC-1 in Table 1 was soluble in chloroform and tetrahydrofuran (THF), but PIPC-2, 3 and 4
were insoluble in these low boiling point solvents. By the way, polyimide without PC unit,
which was prepared from 6FDA and BAPD, was soluble in chloroform and THF. Therefore,
the solubility of these copolyimides decreased with increasing PC content, where the maxi‐
mum PC content that allowed the solubility in chloroform and THF was 15-20 wt. %. It was
speculated that polar PC groups in the side chains would have a strong interaction, which
would make the polymer insoluble in these solvent.
On the other hand, it was found by the thermogravimetric analysis that the weight loss of the
PIPC series started at ca. 250°C, similar to polyamide and poly(urethane-urea) containing PC
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group, whereas the decomposition temperature of the polyimide without PC group was over
400°C. In addition, the hard but brittle films were prepared from these polyimides by solvent
casting method.
2.3. Syntheses and properties of segmented polyurethane
Segmented polyurethanes generally consist of short alternating blocks of soft and hard
segments, and exhibit an elastomeric property. The biocompatibility of segmented polyur‐
ethane is thought to arise from the microphase separation of the soft and hard segments.
However, the biostability of segmented polyurethane is not suitable for long-term implanta‐
tion. It has been suggested that the biodegradation and cracking of polyurethane that occurred
in vivo was due to the adsorption of proteins, adhesion of macrophages and peroxide
formation [27 – 29], which resulted in the reduction of the mechanical strength of segmented
polyurethane. Moreover, the soft segment of segmented polyurethane was reportedly
degraded by oxygen radicals produced by adherent macrophages [30]. Therefore, several
studies of surface or chemically modified segmented polyurethanes have been conducted to
improve biostability by reducing the adhesion of cells and proteins [31 – 35]. Ishihara et al.
have also investigated a polymer composite consisting of segmented polyurethane and MPC
polymer to reduce protein adsorption to the polymer surface and to improve the biocompat‐
ibility of segmented polyurethane [36 – 41].
In our previous studies, we have prepared segmented poly(urethane-urea)s containing PC
group by using the PC-containing diamine monomer, BAPPC, as a coupling reagent in the
polyaddition of diols with diisocyanate [19]. The obtained polymers exhibited excellent
biocompatibility, the film surface of which efficiently reduced the adhesion of human platelets.
In addition, stress-strain measurements revealed that the poly(urethane-urea) films exhibited
high elastic mechanical properties, where the Young’s modulus increased with increasing PC
content. The aim of the next study was to prepare another type of PC-containing polyurethane
from diol monomer (BHPC). Cooper and his co-worker have reported that a PC-containing
polyurethane could be prepared using glycerophosphorylcholine as a diol monomer [42]. We
have designed the BHPC molecule based on the concepts that BHPC would be more hydro‐
phobic than glycerophosphorylcholine and easier to handle as a monomer for polycondensa‐
tion or polyaddition. We expected that both of the primary hydroxyl groups of BHPC would
make the polymer have a high molecular weight due to its higher reactivity than glycero‐
phosphorylcholine with its secondary hydroxyl group. Recently, Khan et al. have reported a
potential application of poly(carbonate-urethane) as a long-term biomedical implant material
due to its resistance to biodegradation and its biocompatibility [43, 44]. Therefore, we selected
polycarbonate diol (PCD) to construct the soft segment of PC-containing segmented polyur‐
ethane.
As shown in Scheme 4, the syntheses of segmented polyurethanes containing PC group and
polycarbonate segment with different contents were carried out by polyaddition of BHPC and
PCD with 4,4’-diphenylmethane diisocyanate (MDI). The compositions and the molecular
weights of the obtained polymers are summarized in Table 2. The observed PC contents in mol
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have designed the BHPC molecule based on the concepts that BHPC would be more hydro‐
phobic than glycerophosphorylcholine and easier to handle as a monomer for polycondensa‐
tion or polyaddition. We expected that both of the primary hydroxyl groups of BHPC would
make the polymer have a high molecular weight due to its higher reactivity than glycero‐
phosphorylcholine with its secondary hydroxyl group. Recently, Khan et al. have reported a
potential application of poly(carbonate-urethane) as a long-term biomedical implant material
due to its resistance to biodegradation and its biocompatibility [43, 44]. Therefore, we selected
polycarbonate diol (PCD) to construct the soft segment of PC-containing segmented polyur‐
ethane.
As shown in Scheme 4, the syntheses of segmented polyurethanes containing PC group and
polycarbonate segment with different contents were carried out by polyaddition of BHPC and
PCD with 4,4’-diphenylmethane diisocyanate (MDI). The compositions and the molecular
weights of the obtained polymers are summarized in Table 2. The observed PC contents in mol
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% were determined by 1H-NMR and were in good agreement with the molar ratio of BHPC
and PCD in the feed of polymerizations.
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Sheme 4. Preparation of segmented polyurethane containing PC moiety (SPUPC).
a) The molar ratio of monomers, BHPC and PCD, in the polymerization.
b) PC contents in the copolymers were estimated by 1H-NMR spectra.
c) Number-avarage and weight-avarage molecular weights, Mn and Mw, were determinated by GPC using DMF as an
eluent.
Table 2. Compositions and molecular weights of segmented polyurethanes (SPUPC).
The obtained polyurethanes, SPUPC-1, 2 and 3, exhibited a good solubility in aprotic polar
solvents such as DMF, DMSO and NMP at room temperature, whereas SPUPC-4 was insoluble
in these solvents. In addition, SPUPC-1 and 2 were soluble in the low boiling solvents,
chloroform and THF, but SPUPC-3 and 4 were insoluble in chloroform and THF. Therefore, a
trade-off relation was observed between the solubility and the PC content of polyurethanes,
which was similar to PIPC series. It would be due to the strong interaction of polar PC group
in the side chain and the highly polar urethane bond in the main chain. To obtain a soluble
polymer with high PC content, a different concept for the molecular design or the polymeri‐
zation process should be developed the solubility of these PC-containing polymers. Recently,
we have developed PC-containing poly(ester-urethane)s, the solubility of which was im‐
proved to some extent by the introduction of ester bond in addition to the highly polar urethane
component [22, 23].
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The flexible and self-standing films could be prepared from these segmented polyurethanes
by a solvent casting method using DMSO as a solvent. Then, the elastic mechanical properties
were observed for these segmented polyurethane films, where the Young’s modulus increased
with increasing PC content. Furthermore, the introduction of such a polar phospholipid group
was effective in improving the resistance to protein and platelet adhesions on the polymer
film, which was the result of surface properties derived from the PC moiety [21].
3. Fabrication of ultra-thin films (nanosheets)
3.1. Preparation and characterization of nanosheets composed of PIPC and SPUPC
Self-standing nanosheets are easily fabricated by a “sacrificial layer method” as depicted in
Fig. 1a [26]. The sacrificial layer can be dissolved with appropriate solvents which do not
dissolve nanosheets themselves. In parallel, solvents used for dissolving polymers of nano‐
sheets must not dissolve the sacrificial layer. To this end, we selected poly(vinyl alcohol) (PVA)
as a water-soluble sacrificial layer to obtain self-standing nanosheets composed of PIPC-1 and
SPUPC-2, because these polymers were soluble in chloroform which did not dissolve PVA. A
fabrication procedure of PIPC-1 nanosheet is described as follows. First, an aqueous solution
of 10 mg/mL PVA was dropped onto a silicon oxide (SiO2) substrate, which has an extremely
flat surface. The substrate was spin-coated at 4,000 rpm for 20 s and then dried. Next, a
chloroform solution of 10 mg/mL PIPC-1 was spin-coated on the PVA-coated substrate under
the same conditions. When the substrate was immersed into distilled water, the PIPC-1
nanosheet was detached from the substrate due to dissolution of only the PVA layer with
water. The obtained PIPC-1 nanosheet was transparent, amazingly flexible, and maintained
the size and shape of the SiO2 substrate (Fig. 1b, left). In fact, the thickness was 42 ± 2 nm and
the roughness was nanometer scale. Furthermore, the thickness was easily controlled by
adjusting the concentration of PIPC-1 just before spin-coating as shown in Fig. 1c. As described
in section 2.2, the solubility of PIPC series is dependent on the content of the PC unit. For
instance, PIPC-4 with high PC content was insoluble in chloroform but soluble in the aprotic
polar solvents as DMSO. However, the PVA sacrificial layer is dissolved with DMSO. To this
end, we can select other component of the water-soluble sacrificial layer, e.g. sodium alginate
(Na-Alg), which is insoluble in DMSO. According to this technique, we could prepare the self-
standing nanosheets composed of SPUPC series [45]. In the case of a chloroform solution of 10
mg/mL SPUPC-2, the thickness of the nanosheet was 66 ± 4 nm. Intriguingly, these nanosheets
composed of SPUPC series, which were elastic polymers, tended to shrink after detaching from
the substrate as seen in Fig. 1b, right. This tendency suggested that the nanosheet extended on
the substrate by the centrifugal force during the spin-coating, and resulted in shrinking due
to its elasticity when they were released from the substrate. This tendency was not observed
in the nanosheets composed of non-elastic polymers such as PIPC series. In these years, we
have prepared the self-standing nanosheets composed of versatile polymers such as polystyr‐
ene and poly(methyl methacrylate), etc., and typical biodegradable polymers such as poly(lac‐
tic acid), their copolymers and polycaprolactone, etc. [24, 25].
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Fig. 1 Fabrication of self-standing nanosheets composed of PIPC-1 and SPUPC-2. (a) Fabrication
procedure of the nanosheets by spin-coating. (b) Macroscopic images of PIPC-1 (left) and SPUPC-2
(right) nanosheets suspended in water. (c) Relationship between thickness of the PIPC-1 nanosheets
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Figure 1. Fab ication of self- tanding nanosheets composed of PIPC-1 and SPUPC-2. (a) Fabricatio  procedure of the nano‐
sheets by spin-c ating. (b) Macroscopic images of PIPC-1 (left) and SPUPC-2 (right) nanosheets suspend d in water. (c)
Relationship between thickness of the PIPC-1 nano heets nd concentration of PIPC-1 solution before spin coating.
We analyzed the mechanical properties of the nanosheets by using a bulging test developed
for nanosheets [46]. In fact, the PIPC-1 nanosheet with a thickness of approximately 40 nm was
physically adhered to a steel plate with a hole as shown in Fig. 2a. The plate was fixed to a
custom-made chamber and air was supplied with a syringe pump until bursting the nano‐
sheets. During the analysis, pressure applied to the nanosheets and its deflection was moni‐
tored in real time by a differential pressure gauge and a stereomicroscope, respectively. Based
on the equations as shown in Fig. 2a, we obtained a strain-stress curve as shown in Fig. 2b.
From the slope of the elastic region of the curve, the Young’s modulus of the PIPC-1 nanosheet
was calculated to be 196 ± 9 MPa. This value was 10-folds lower compared to that of the bulk
polyimide films (3-7 GPa), indicating that the PIPC-1 nanosheet was softer than the bulk
polyimide film. We have demonstrated that the poly(lactic acid) nanosheets with a thicnkess
less than 100 nm represent the same tenency [24]. Mattsson et al. have explored the relationship
between the glass transition temperature (Tg) and thickness of the ultra-thin films of polystyr‐
ene using a Brillouin light scattering method. In fact, Tg of polystyrene films with a thickness
of approximately 20 nm was decreased to 37°C compared to that of bulk polystyrene (Tg:
109°C), explaining that the interactions between polymer chains decreased in the ultra-thin
films [47]. This may be one of the reasons why the Tg of the PIPC-1 nanosheet would be lower
than that of bulk polyimide.
Next, we analyzed the relationship between adhesive strength of the PIPC-1 nanosheets and
their thickness with a scratch tester for thin films [48]. As depicted in Fig. 3a, the nanosheets
were physically adhered on the SiO2 substrate, and the surface of the nanosheets were
horizontally scratched with a diamond tip under the following conditions; radius of curvature
of a diamond tip: 25 μm, scratch length: 100 μm, and scratch rate: 10 μm/s. Critical loads just
after detaching the nanosheet from the substrate were monitored. Then, the adhesive strength
of the nanosheets was difined as the critical loads divided by the thickness of the nanosheets.
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Fig. 4 Adhesive strength of the PIPC-1 nanosheet. (a) Schematic image of scratch tester
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3.2. Biocompatibility of nanosheet surface
Platelets are one of blood cells and involved in both normal hemostasis and pathological
thrombosis [49]. In development of biocompatible materials with the possibility to contact with
blood, what the most critical point is to inhibit non-specific interactions between platelets and
the surface of the materials. To this end, we evaluated the blood compatibility of the surface
of the nanosheets composed of PC polymers. Poly(ethylene terephtalate) (PET) plates were
used as model surfaces, to which the nanosheets were adhered. The nanosheet-coated PET
plates were immersed into 0.5 mL of platelet-rich plasma (PRP) obtained from healthy
volunteers and incubated at physiological temperature for 2 h. Finally, PRP was removed and
the substrates were washed out with phosphate buffered saline. The surface of the plates was
observed with a scanning electron microscope. As shown in Fig. 4, platelets with filopodial
extensions were non-specifically adhered to the bared PET plate and the nanosheet-coated PET
plate without PC units (PI and SPU). PI is a polyimide obtained by the polycondensation of
BAPB with 6FDA followed by the chemical imidization, and SPU is a segmented polyurethane
obtained by the polyaddition of 3,5-bis(2-hydroxyethoxy)benzene and PCD (molar ratio:
70/30) with MDI. In the case of the PET plates coated with PIPC-1 and SPUPC-2 nanoheets,
reduction of platelet adhesion was clearly observed as compared with PET plate and PI/SPU
coated plates. Therefore, it was confirmed that the surface of PC-polymer nanosheets exhibited
the good blood compatibility. In other words, these results indicate that sealing of the nano‐






Fig. 4 SEM images of nanosheet surfaces with or without PC unit after contact with
platelet-rich plasma for 2h at 37oC.Figure 4. SEM mages of n nosheet surfaces with or without PC unit after contact with plateled-rich plasma for 2h at
37°C
3.3. Fragmentation of the nanosheets to coat irregular and uneven surfaces
As described above, we have succeeded in the preparation of the self-standing nanosheets,
which represent unique properties such as good adhesiveness, amazingly flexibility and high
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transparency. However, such nanosheets possess centimeter size and are only suitable for
adhesion to relatively broad surfaces. They are often difficult to adhere to irregular and uneven
surfaces because of centimeter size. In our recent study, we have discovered that the frag‐
mented submillimeter-sized nanosheets composed of poly(lactic acid) were adhered to the
various surfaces in a spread out configuration that looks like “patchwork” [25, 26]. Once the
nanosheets dried on the surface, they were difficult to detach from the surface by even washing
with water. Moreover, we have demonstrated that the irregular and uneven surfaces such as
a needles and rubbers etc. are effectively coated with the patchwork-like coating of the
fragmented nanosheets by just casting or dipping [25, 26]. In this section, we introduce the
fragmented nanosheets composed of PIPC and SPUPC series to coat irregular and uneven
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Fig. 5 (a) Fabrication of fragmented nanosheets composed of PIPC-1 and SPUPC-2. (b)
Macroscopic image of fragmented PIPC-1 nanosheets (left tube) suspended in distilled water.
Right tube shows only distilled water. (c) SEM images of fragmented nanosheet surfaces after
contact with platelet-rich plasma for 2h at 37oC.
Figure 5. (a) Fabr ation of fragmented nanosheets composed od PIPC-1 and SPUPC-2. (b) Macro copic im g  of frag‐
mented PIPC-1 nanosheets (left tube)suspended in distilled water. Right tube shows only distilled water. (c) SEM im‐
ages of fragmented nanosheet surfaces after contact with platelet-rich plasma for 2h at 37°C.
We herein focus on the fragmented PIPC-1 nanosheets as follows. First, we fabricated abundant
self-standing nanosheets with centimeter size by a simple multi-layering process of water-
soluble PVA and PIPC nanosheets combined with a peeling technique, according to our reports
[25, 26]. Concretely, a 100 mg/mL solution of PVA as a water-soluble sacrificial layer was first
spin-coated on a SiO2 substrate at 4000 rpm for 20 s, followed by a drying process as depicted
in Fig. 5a. Next, a chloroform solution of 10 mg/mL PIPC-1 was spin-coated on the PVA-coated
substrate under the same conditions. Moreover, the multi-layering of PVA and PIPC-1 was
repeated twenty times on the substrate. By dissolution of PVA layers in water, tewenty sheets
of PIPC-1 nanosheets were obtained. Next, the obtained PIPC-1 nanosheets were fragmented
with a homogenzer. When the PIPC-1 nanosheets (size: 40 × 40 mm, thickness: 42 nm) in
distilled water were homogenized at 30,000 rpm for 10 min, they were instantly fragmented.
The obtained nanosheets were homogeneously suspended in water and the turbidity of the
suspension was quite increased as shown in Fig. 5b. In fact, the surface area of one fragmented
nanosheet 10 min after homogenizaion was significantly decreased to 6800 ± 208 μm2, esti‐
mating that the average size of the nanosheet was approximately 80 μm. Using the same
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surfaces because of centimeter size. In our recent study, we have discovered that the frag‐
mented submillimeter-sized nanosheets composed of poly(lactic acid) were adhered to the
various surfaces in a spread out configuration that looks like “patchwork” [25, 26]. Once the
nanosheets dried on the surface, they were difficult to detach from the surface by even washing
with water. Moreover, we have demonstrated that the irregular and uneven surfaces such as
a needles and rubbers etc. are effectively coated with the patchwork-like coating of the
fragmented nanosheets by just casting or dipping [25, 26]. In this section, we introduce the
fragmented nanosheets composed of PIPC and SPUPC series to coat irregular and uneven
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Fig. 5 (a) Fabrication of fragmented nanosheets composed of PIPC-1 and SPUPC-2. (b)
Macroscopic image of fragmented PIPC-1 nanosheets (left tube) suspended in distilled water.
Right tube shows only distilled water. (c) SEM images of fragmented nanosheet surfaces after
contact with platelet-rich plasma for 2h at 37oC.
Figure 5. (a) Fabr ation of fragmented nanosheets composed od PIPC-1 and SPUPC-2. (b) Macro copic im g  of frag‐
mented PIPC-1 nanosheets (left tube)suspended in distilled water. Right tube shows only distilled water. (c) SEM im‐
ages of fragmented nanosheet surfaces after contact with platelet-rich plasma for 2h at 37°C.
We herein focus on the fragmented PIPC-1 nanosheets as follows. First, we fabricated abundant
self-standing nanosheets with centimeter size by a simple multi-layering process of water-
soluble PVA and PIPC nanosheets combined with a peeling technique, according to our reports
[25, 26]. Concretely, a 100 mg/mL solution of PVA as a water-soluble sacrificial layer was first
spin-coated on a SiO2 substrate at 4000 rpm for 20 s, followed by a drying process as depicted
in Fig. 5a. Next, a chloroform solution of 10 mg/mL PIPC-1 was spin-coated on the PVA-coated
substrate under the same conditions. Moreover, the multi-layering of PVA and PIPC-1 was
repeated twenty times on the substrate. By dissolution of PVA layers in water, tewenty sheets
of PIPC-1 nanosheets were obtained. Next, the obtained PIPC-1 nanosheets were fragmented
with a homogenzer. When the PIPC-1 nanosheets (size: 40 × 40 mm, thickness: 42 nm) in
distilled water were homogenized at 30,000 rpm for 10 min, they were instantly fragmented.
The obtained nanosheets were homogeneously suspended in water and the turbidity of the
suspension was quite increased as shown in Fig. 5b. In fact, the surface area of one fragmented
nanosheet 10 min after homogenizaion was significantly decreased to 6800 ± 208 μm2, esti‐
mating that the average size of the nanosheet was approximately 80 μm. Using the same
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prosedure, we also prepared the fragmented nanosheets composed of SPUPC-2 (surface area:
3900 ± 1300 μm2, thickness: 66 nm).
In order to evaluate the blood compatibility, the fragmented PIPC-1 or SPUPC-2 nanosheets
were adhered to a bared PET plate as a model surface. They consisted of a patchwork-like
coating in the same manner as the fragmented PLLA nanosheets [25, 26]. The nanosheet-coated
PET plates were immersed into PRP and incubated at 37°C for 2 h. As shown in Fig. 5c, very
few platelets were adhered to the PIPC-1 and SPUPC-2 coated PET plate. Moreover, some lines
were observed on the plates, that correspond to wrinkles (not cracks) formed during drying
of patchwork-like coating. In the case of the bared PET plates, abundant platelets were
activated and non-specifically adhered. Therefore, we demonstrated that patchwork-like
coating with the fragmented nanosheets with PC units acts as an aqueous surface modifier to
provide blood compatibility.
4. Conclusions
We have synthesized novel aromatic diamine and diol monomers containing PC group to
develop the new biocompatible polycondensation-or polyaddition-type polymers. The
obtained polymers exhibited good solubility with aprotic polar solvents and thermostability
unlike MPC polymers. Using these polymers, we have succeeded in the fabrication of self-
standing nanosheets with a thickness less than 100 nm. The PC-polymer nanosheets exhibited
high adhesiveness to the various surfaces, and the surface of adhered nanosheets represented
the good blood compatibility based on the platelet adhesion test. Furthermore, we have
developed the fragmented nanosheets with submillimeter-size to coat irregular and uneven
surfaces by controlling the size of the nanosheets. In fact, fragmented nanosheets were
effectively coated with the patchwork-like adhesion behavior by just casting or dipping and
provided blood compatibility to the various surfaces. Hence, these nanosheets composed of
PC-containing polymers may be great promise as novel coating materials and surface modi‐
fiers to provide the biocompatibility to the surface of various medical devices such as catheters,
artificial organs, microfluidic devices, etc.
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A shortage of organs and tissues for transplantation has been present throughout most of the
history of transplantation. Over the past few decades, the increasing incidence of vital organ
failure and the severe shortage of donors have created a wide gap between organ supply and
organ demand, which resulted in very long waiting times to receive an organ as well as an
increasing number of deaths while waiting. Moreover, all manners of projections indicate that
this gap will continue to widen making this a main challenge to modern medicine [1, 2].
Over the years and in order to overcome many challenges in the area of healthcare, techno‐
logical advancements rapidly evolved and became a crucial part of modern medicine by
helping ensure a better lifestyle and an increased life expectancy. Hence, the field of tissue
engineering (TE) emerged in response to that growing need for tissues and organs for
transplantation and has rapidly become one of the most exciting advances in regenerative
medicine. TE is a multidisciplinary field combining principles of biology, medicine and
engineering that aim at generating completely biocompatible fully functional organs or tissues
that could be used to replace damaged or missing tissues in reconstructive surgery [3, 4]. The
numerous and complex problems arising when replacing tissues set very high and diverse
requirements on the used materials: biodegradability, enabling cell attachment and prolifer‐
ation and mechanical strength are some of the possible demands.
It is very difficult to find an adequate material that meets all requirements to function properly
in a bio-environment. A way is to select a material having the required bulk properties such
as mechanical strength and sometimes biodegradability and modify its surface properties via
a surface treatment.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
The success of an implant is determined by the response of its surrounding biological envi‐
ronment. This is governed to a large extent by the surface properties of the biomaterial where
the interaction happens. Correspondingly, considerable efforts have been focused on surface
engineering of biomaterials in order to give them the ability to promote cell adhesion,
proliferation and to maintain cell functions. Therefore, a clear characterization of the physical
and chemical properties of the biomaterial surface has a major scientific importance on cell-
biomaterial interactions allowing the evaluation of the bioactivity of the surface engineered
biomaterial.
Up to present, a large number of surface engineering techniques for improving biocompati‐
bility have been well established. The work generally contains three main steps: after the
surface modification of the biomaterial is done, chemical and physical characterizations are
conducted followed by a biocompatibility assessment through in vitro cell culture [5, 6].
In the past decades, surface treatment of biomaterials with plasma has been extensively studied
[7-9]. Plasma modification of biomaterials gives the opportunity to change the surface
characteristics to achieve better biocompatibility without altering the bulk properties. At the
same time, plasma surface modification is a very versatile technology: the results of plasma
modification can be easily controlled by choosing suitable gases or monomers and the
appropriate conditions in the plasma [10].
1.2. Plasma
In order to introduce plasma it is often stated that plasma is the fourth state of matter in the
sequence: solid, liquid, gas, and plasma. The state of matter changes from solid to liquid to gas
to plasma by increasing the temperature of the material under consideration (see figure 1).
When gas atoms are subjected to energy (thermal, electrical or light) they become ions by
releasing some of their electrons. Collisions between electrons and molecules and bond breaks
in molecules create radicals. Energy will also create excited species that will generate photons.
This is how plasma is created with a unique mixture of electrons, ions, radicals, photons and
neutral atoms and molecules [11, 12].
Figure 1. States of matter [90]
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appropriate conditions in the plasma [10].
1.2. Plasma
In order to introduce plasma it is often stated that plasma is the fourth state of matter in the
sequence: solid, liquid, gas, and plasma. The state of matter changes from solid to liquid to gas
to plasma by increasing the temperature of the material under consideration (see figure 1).
When gas atoms are subjected to energy (thermal, electrical or light) they become ions by
releasing some of their electrons. Collisions between electrons and molecules and bond breaks
in molecules create radicals. Energy will also create excited species that will generate photons.
This is how plasma is created with a unique mixture of electrons, ions, radicals, photons and
neutral atoms and molecules [11, 12].
Figure 1. States of matter [90]
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Based on the relative temperatures of electrons, ions and neutrals, plasmas are classified as
thermal “equilibrium” and non-thermal “non-equilibrium”. Due to the light mass of the
electrons present in the plasma, these electrons are instantly accelerated by the electric field to
higher velocities than the heavier ions in the time available between collisions. When the
collision occurs only a small fraction of the electron energy is lost. This is why the electron
temperature in the plasma is initially higher than that of heavy particles. The resulting plasma
is a non-thermal or cold plasma in which the electron temperature (≈ 10000 °C) is much higher
than the gas temperature (< 200 °C). However, if the pressure is so high that the charged
particles do not move very far before the next collision or the electrical field is very low, the
energy of the electrons may tend towards that of the heavy particles. In this case, the resulting
plasma is a thermal or hot plasma.
Plasmas used in “plasma technology” are usually cold plasmas in the sense that only a small
fraction of the gas molecules are ionized which can provide electrons and ions at the right
energy without excessive heat enabling the use of plasma on heat-sensitive materials such as
polymers [13]. The most commonly used method for generating and sustaining a low-
temperature plasma for technological and technical applications is applying an electric field
to a pure or mixed gas.
Different plasma sources are available and their dimensions are determined largely by the
particular application for which the plasma is intended. There are distinct differences not only
in the physical shape of various plasma sources, but also in the temporal behavior of the
plasmas that are generated in different sources.
2. Plasma generation
2.1. Plasma sources
As already mentioned, for surface modification treatments, various plasma sources are
available. Each of them has its own characteristics such as density, temperature, chemical
composition, etc., and leads to different results. The choice of the proper source for the specific
task requires the study of the characteristics of the various plasmas. In this section, a brief
summary of the most common plasma sources used for the incorporation of amine functional
groups in tissue engineering will be given.
2.1.1. Microwave (MW) plasma
MW discharges are electrical discharges generated by electromagnetic waves with frequencies
between 300 MHz and 10 GHz. MW discharges represent a simple way of plasma generation
both with high (> 100 W/cm3) and low (< 1 W/cm3) power levels and can be used over a wide
region of operating pressures (from 10-3 Pa up to atmospheric pressure). Nowadays, these
discharges are widely used for generation of quasi-equilibrium and non-equilibrium plasmas
for different applications because of the simplicity of control of the plasma internal structure
by means of changes of the plasma characteristics and the possibility of plasma generation
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both in small and large chambers. The plasma absorbed power can be high enough and runs
up to 90% of the incident power [14, 15].
2.1.2. Radiofrequency (RF) plasma
RF discharges usually operate in the frequency range f=1–100 MHz. The power coupling in RF
discharges can be accomplished in different ways: capacitively coupled discharges and
inductively coupled discharges.
• Capacitively coupled plasma (CCP)
CCP is generated with high-frequency RF electric fields, typically 13.56 MHz. In its simplest
form, the RF voltage is applied across two parallel metal plates, generating an oscillating
electric field between them. This field accelerates electrons leading to an ionization avalanche.
The parallel electrodes which are separated by a distance of a few centimeters may be in contact
with the discharge or insulated from it by a dielectric. Gas pressures are typically in the range
1–103 Pa. In a capacitively coupled RF discharge, the electron density is in the range
ne=109-1010 cm-3 and densities up to 1011 cm-3 are possible at higher frequencies.
• Inductively coupled plasma (ICP)
ICP is similar to CCP but the electrode consists of a coil wrapped around the discharge volume
that inductively excites the plasma. ICP is excited by an electric field generated by a trans‐
former from an RF current in a conductor. The changing magnetic field of this conductor
induces an electric field in which the plasma electrons are accelerated. ICPs can achieve high
electron densities (ne=1012 cm-3) at low ion energies [15, 16].
2.1.3. Dielectric Barrier Discharge (DBD)
Dielectric barrier discharges (silent discharges) are non-equilibrium discharges that can be
conveniently operated over a wide temperature and pressure range. DBDs are characterized
by the presence of one or more insulating layers in the current path between metal electrodes
in addition to the discharge space. At a sufficient AC voltage, electrical breakdown occurs in
many independent thin current filaments. These short-lived microdischarges have properties
of transient high pressure glow discharges with electron energies ideally suited for exciting or
dissociating background gas atoms and molecules.
Due to charge build up on the dielectric, the field at the location of a microdischarge is reduced
within a few nanoseconds after breakdown thus terminating the current flow at this location.
The current density in a microdischarge channel can reach 100 to 1000 Acm-2. Due to the short
duration, this normally results in very little transient gas heating in the remaining channel.
The dielectric barrier limits the amount of charge and energy deposited in a microdischarge
and distributes the microdischarges over the entire electrode surface. As long as the external
voltage is rising, additional microdischarges will occur at new positions because the presence
of residual charges on the dielectric has reduced the electric fields at positions where micro‐
discharges have already occurred. When the voltage is reversed, however, the next microdi‐
scharges will form in the old microdischarge locations.
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Its flexibility with respect to geometrical configuration, operating medium and operating
parameters is unprecedented. Conditions optimized in laboratory experiments can easily be
scaled up to large industrial installations.
Although DBD configurations can be operated between line frequency and microwave
frequencies the typical operating range for most technical DBD applications lies between 500
Hz and 500 kHz [17].
Plasma can be used in the continuous wave (CW) or pulsed mode. In the continuous wave
mode, plasma with a specific power is turned on for a specific amount of time. In the pulsed
mode, plasma is intermittently generated with a fixed duty cycle (Δ).
( )on on offΔ = t / t + t (1)
where ton is the time during which the plasma is turned on and toff is the time during which
the plasma is turned off. The mean power (Pmean) is then defined by equation (2) and represents
the average energy dissipated in the plasma period, with Ppeak the power injected during ton[18].
mean peakP *P= D (2)
2.2. Plasma media
Among other physical and chemical techniques to improve the surface biocompatibility
[19-22], plasma surface modification is used to adapt the surface properties by functionaliza‐
tion of the material surface to control the biological response. Different functionalities have
been investigated, such as carboxyl [23], hydroxyl [24] and primary amine [25] (see figure 2).
In this chapter, we will focus on plasma surface modification of biomaterials by means of
primary amine group incorporation.
Figure 2. Primary amine, hydroxyl and carboxyl functionalities
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Amino groups are usually incorporated on the surface using either non-polymer-forming
gases (amine plasma activation) such as ammonia (NH3) or nitrogen (N2), or amine monomers
(amine plasma polymerization) in the plasma medium. The former etches the biomaterial
surface and introduces nitrogen functionalities; the latter deposits a plasma polymer layer
containing nitrogen groups on the surface [26].
Plasma polymerization of amine-based monomers is an efficient way to prepare bioactive
amino functionalized polymer surfaces. Amine-functionalized surfaces have previously been
obtained through plasma polymerization using different monomers such as allylamine [27,
28], ethylenediamine [29-31], n-heptylamine [32, 33], propylamine [34, 35], cyclopropylamine
[18], diaminocyclohexane [36, 37], and butylamine [26].
In the biomedical field, the most common used plasma media are ammonia as non-polymer
forming precursor and allylamine as polymer forming precursor.
Primary amine (-NH2) functional groups can promote covalent immobilization with biomo‐
lecules such as protein like antibodies, collagen and DNA [28, 38]. Moreover, protonated
amines can introduce a localized positive charge in aqueous solution at physiological pH value,
which can potentially be used for electrostatic interactions with negatively charged cells and
proteins and is propitious to promote cell adhesion and proliferation [39, 40].
In this chapter we will focus more on amine plasma polymerization since this is the most
commonly used plasma technique for the incorporation of primary amines. Plasma polymer‐
ization has unique practical advantages which include (i) ultra-thin film deposition, (ii) good
adhesion to the substrate material, and (iii) chemically stable and physically durable nature of
the polymers [38].
3. Characterization techniques
Since the surface of an implant will be readily in contact with the biological environment, the
surface characteristics of a biomaterial will have a major influence on the cell-material
interactions. These characteristics should be analyzed and studied in order to correlate them
with the material biocompatibility and thus try to improve it by changing them.
In order to evaluate the effect of plasma treatments on the surfaces, physical and chemical
characterizations are performed using different techniques, such as: water contact angle
measurement (WCA), Fourier-transform infrared (FTIR) spectroscopy, X-ray photoelectron
spectroscopy (XPS), atomic force microscopy (AFM) and scanning electron microscopy (SEM).
In this section, a brief definition of each of these techniques and their correlation with amine
plasma treatments will be given.
3.1. Water Contact Angle measurements (WCA)
WCA analysis is a simple and widely used test to evaluate the wettability of a surface by
measuring the static contact angle of small droplets of distilled water or other liquids on the
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surface. The contact angle of a material is where a liquid/vapour interface meets a solid surface.
It quantifies the wettability of a solid surface and thus the relative amounts of adhesive (liquid-
to-solid) and cohesive (liquid-to-liquid) forces acting on a liquid [41].
If the WCA is smaller than 90°, the solid surface is considered hydrophilic and if it is larger
than 90°, the solid surface is considered hydrophobic (see figure 3) [42].
Figure 3. Principle of contact angle measurement
Amine plasma treatment causes a decrease in WCA due to the incorporation of hydrophilic
nitrogen and oxygen moieties [43-45] onto the sample surface. Oxygen functionalities can be
incorporated via two different processes. First, the vacuum level does not guarantee total
absence of oxygen impurities in the plasma chamber [46, 47]. Second, after plasma treatment,
samples are exposed to air which can induce a post plasma functionalization by reaction with
oxygen and water vapor [47, 48].
Additionally, depending on the gas and general conditions of the plasma treatment, it is
possible to promote some surface etching/abrasion which can induce changes in surface
topography, thus having a certain effect on the wettability. Material removal occurring during
plasma treatment increases roughness and contributes to improve the wettability properties
of the plasma treated film [44, 49].
3.2. X-ray Photoelectron Spectroscopy (XPS)
X-ray photoelectron spectroscopy is a very powerful surface analysis technique also known
as electron spectroscopy for chemical analysis (ESCA). It works by irradiating a sample with
mono-energetic soft X-rays causing surface electrons to be ejected. The identification of the
elements in the sample can be made directly from the kinetic energies of these ejected photo‐
electrons, and the relative concentrations of elements can be determined from the photoelec‐
tron intensities.
An important advantage of XPS is its ability to obtain information on chemical states from the
variations in binding energies, or chemical shifts, of the photoelectrons [50].
Since a wide range of chemical functionalities is introduced on the surface of a plasma treated
material [43], each of these groups might cause the observed binding energy of a particular
peak (e.g. C 1s or N 1s) to shift to varying degrees. The resulting overall peak shape is a
superposition of many components which are not clearly resolved.
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Curve-fitting can be a powerful method of extracting additional information from XPS data in
which contributions from different chemical species can be quantified.
A high amount in nitrogen atoms does not necessary impart a high amount of amine groups
on the polymer surface. Peak fitting of the high-resolution spectrum of the N 1s peak confirms
the addition of different nitrogen functionalities to the surface during plasma treatment. The
assignments of the different nitrogen groups under the N 1s peak found in literature are:
amines (398.9-399.3 eV) [32, 51, 52], nitriles (399.6 eV) [53], amides (399.8 eV) [32, 51-53], imides
(400.5 eV) [32, 51-53] and quaternary amines (401.3-401.5 eV) [52-54]. Moreover, in the peak
fitting of C 1s in amine plasma deposited films two additional peaks might be observed: 286.4
eV corresponding to C-N (amine) and 288.0 eV corresponding to N-C=O (amide) groups [45,
55]. The areas under the photoelectron peaks in the spectrum are used to calculate the atomic
concentrations.
Another more meaningful identification and quantification method of the present chemical
groups is a combination of XPS with chemical derivatization. Chemical derivatization consists
in inducing a chemical reaction between a targeted chemical group of the amine plasma
polymer film and a chemical reactant containing at least one atom different from the ones
composing the sample. For a successful derivatization process, selectivity of the reagent
towards a particular functional group, its detectivity, kinetics of the reaction, and stability of
the derivatized species are some of the factors necessary to identify [55].
In the case of amine plasma treatments, to selectively probe –NH2 groups, several reactants
such as 4-trifluoromethyl-benzaldehyde (TFBA) [18, 36, 39, 55-60], pentafluoro-benzaldehyde
(PFBA) [61, 62], and para-chlorobenzaldehyde [63] have been used.
The derivatization reaction performed by exposing the treated sample to TFBA vapor is the
most commonly used and it consists in a nucleophilic addition on the carbonyl group (C=O)
that converts an NH2 group into an imine (see figure 4). Hence, NH2 groups are selectively
probed by the reagent CF3 terminal group with a ratio of one CF3 for one NH2. After the
derivatization step, the %NH2 is calculated from XPS according to [56]:
%NH2 = NH 2
N
=
( F / 3)
N
. 100% (3)
where [NH2], [N] and [F] represent respectively the relative concentration of primary amines,
nitrogen and fluorine at the sample surface.
Figure 4. Reaction scheme for TFBA derivatization of primary amine functionalities [91]
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3.3. Fourier-Transform Infrared (FTIR) spectroscopy
FTIR is based on the interaction of an oscillating electromagnetic field with a molecule. In a
specific compound, a particular structural group reveals IR absorption bands within charac‐
teristic spectral regions. In this way, FTIR can be used for assignation of functional groups and
identification of pure compounds.
During plasma polymerization, the monomer undergoes reorganization due to the breakage
and the recombination of bonds. Amine groups are partially transformed into amide, imine
or nitrile functional groups [36, 64]. In various allylamine plasma polymerization studies, one
can see after comparison with the pristine monomer that some bands are significantly
broadened, some disappeared while new bands also appeared. An example of these spectra
can be seen in figure 5. Double peaks of primary amine N-H stretching vibrations at 3380-3290
cm-1 are well resolved on the spectra of the monomer but a wide absorption band is found on
the polymer at 3390 cm-1 which can originate from a primary amine, a secondary amine or an
imine as well. The deformation vibration of primary amines (1510-1650 cm-1) is observed in
both spectra, but is considerably broadened in the spectrum of plasma polymerized allylamine
(PPAa), which indicates the presence of alkene groups or imines. A new band appears for the
polymer at 2200 cm-1 which is associated with the stretching vibration of nitrile (C≡N) groups
[43, 64, 65].
Figure 5. FTIR spectra of allylamine and PPAa [92]
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3.4. Scanning Electron Microscopy (SEM)
SEM images the sample surface by scanning it with a high-energy beam of electrons. Depend‐
ing on the instrument, the resolution can fall somewhere between less than 1 nm and 20 nm.
SEM has been used in different studies involving plasma treatments. For instance, in a study
by Hamerli et al. [43], SEM images showed that allylamine plasma polymerization yields
homogenous pinhole-free layers. In another study by Sanchis et al. [44], SEM images showed
that nitrogen plasma treatment formed micro-cracks on the sample surface. In this way, SEM
can be used on plasma treated samples to give information regarding the deposited film
morphology and the treatment effect on the sample surface.
3.5. Atomic Force Microscopy (AFM)
AFM is a mechanical imaging instrument that measures the three-dimensional topography as
well as physical properties of a surface with a sharpened probe. Typical AFM resolutions are
well below 1 nm.
AFM can be used to study the way plasma polymers grow: AFM images have been used to
show the surface morphology of the deposited films while varying the treatment time [66].
AFM analysis is useful, not only in a qualitative way but also for quantitative determinations,
since it allows a 3D representation of the treated surface and quantifies the effects of the
plasma-etching mechanism by calculation of the surface roughness (root-mean-squared
roughness, Rrms) [44].
4. Effect of plasma process parameters on final layer properties
Many parameters, such as the nature of the precursor, the precursor flow rate, the reactor
chamber’s pressure, the reaction time, the power and frequency of the discharge, the geometry
and physical dimensions of the reactor, etc. are believed to influence the surface properties of
the resulting thin film [67].
In this section, a summary of the effect of plasma process parameters on various amine-
deposited film properties as elucidated by researchers in this field will be given. Process
parameters will be discussed based on different studies, but one should always keep in mind
that various results emerging from different studies are hinted by the possible role of the
distinctive processes (different reactor, plasma media and plasma source) used in each case.
4.1. Discharge power and deposition time effect
Electrical power and treatment time have a large impact on the nature and concentration of
the molecular species formed in the reactor, which in turn significantly influences the depo‐
sition rate and the final atomic composition of the deposited layers.
Effect on deposition rate / film thickness: Lucas et al. [61] studied the power variation (between 3
and 100 W) effect on the deposition rate of allylamine plasma polymers. They found that
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deposition rate increases with increasing power. The same effect was observed by Myung et
al. [64] with power variation between 30 and 90 W. The thickness of the film increases with
increasing plasma power since high power generates high plasma density which increases the
deposition efficiency. However, in another study by Lejeune et al. [57], the increase of
deposition rate with power was found to be valid only up to a certain limit. In fact, the
deposition of a film relies on a dynamic equilibrium between a process of deposition and a
process of sputtering by incoming particles from the plasma. At low power of deposition (P <
Plimit), the first process dominates the equilibrium. The amount of low energetic particles
arriving on the surface of the film increases and the rearrangement of these deposited particles
is low. This growth mode favors the formation of a low density structure (low cross-linking
degree) with a high growth rate. With the increase of the power, the incoming particles have
a higher energy and can penetrate more deeply in the growing film. Structural reorganization
processes such as cross-linking of the polymeric chains and re-sputtering phenomena can
occur. When the power is high enough (P > Plimit), the second process of the dynamic equili‐
brium acts effectively on the deposition: due to the sputtering effect, the growth rate becomes
constant and due to the bombardment effect, the density of the film increases (high cross-
linking degree) (see figure 6). For Lejeune et al. the limiting power was 30 W, but as already
mentioned, results from different sources can only be compared to a certain extent and this
limiting power varies from one treatment to another by taking into account the plasma media,
plasma source, plasma parameters and reactor geometry.
Myung et al. [64] also investigated the effect of treatment time on the deposition rate. They
found that the thickness of the deposited layers increases with the increase of plasma poly‐
merization time. Martin et al. [68] investigated the synergistic effect of plasma power and
deposition time on n-heptylamine plasma polymerized (HApp) film thicknesses using AFM
step height measurements combined with a surface masking technique. The results showed a
dramatic difference between conditions involving high power and long deposition (thickness
average of 47 nm) to those involving low power and short deposition time (thickness average
of 3 nm) (see figure 7).
Effect on film’s atomic composition: Martin et al. [68] also studied the effect of power on the atomic
composition of the layers using XPS analysis. High power yielded relatively lower surface
concentration of nitrogen atoms than the use of low power: by varying the power from 80 W
to 10 W nitrogen content increased by ca. 15%. This is due to the more successful breakdown
of the monomer molecule achieved at higher power, yielding layers which present less
nitrogen atoms. This behavior has also been observed by Shard et al. [35]. However, deposition
time and time-power interaction do not have a significant effect on the atomic composition of
the layers [68].
In the study conducted by Lucas et al. [61], the use of XPS coupled to derivatization reactions
for allylamine plasma polymerization showed that %NH2 decreases with the increase of
power. This was also observed by Lejeune et al. and Müller et al. [57, 69]. The effect of plasma
on the retention of the precursor functional group also depends on the plasma mode. Basarir
et al. [70] worked on plasma polymerization of allylamine using both CW and pulsed modes.
Results showed that pulsed plasma polymerization further increased amine density. In fact,
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in the pulsed mode, the mean power per precursor molecule is lower than that in the CW
mode. In the off-time, dissociated monomers react with each other instead of continuing to
dissociate. Moreover, the use of lower Pmean in pulsed plasma polymerization results in a higher
retention of the primary amine functional group [18, 56].
By using IR spectroscopy on allylamine plasma deposited films, Myung et al. [64] noticed
changes in film composition by varying input power between 30 and 90 W. High-power
plasma led to a higher ratio of C≡N to CH than the ratio of NH to CH, thus to a recombination
of amine functionalities into nitrile (C≡N) groups. This was also observed in two studies by
Hamerli et al. [43, 47]. At high power, monomer fragmentation is accelerated and results in
the formation of imine groups and nitrile groups. A high retention of amine groups is mainly
favored by low input power (< 30 W). This has been confirmed by Wen-Juan et al. [71] where
Figure 6. Growth rate of plasma polymerized allylamine films as a function of power [93]
Figure 7. Square plot summarizing the influence of power and deposition time on the thickness of HApp layers [94]
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power was varied between 5 and 30 W. The increase of plasma power caused more formation
of C=N groups which can be explained by the sufficient fragmentation of monomer at higher
applied powers.
Furthermore, Myung et al. [64] correlated the contact angle to the plasma input power. The
contact angle increases with increasing input power thus causing a decrease of the surface free
energy i.e. a decrease of the surface hydrophilicity. The main factors which resulted in this
effect were the loss of amine functional groups and the formation of cross-linked structures
due to more fragmentation of allylamine by increasing input power. In another study by
Sanchis et al. [44], treatment time effect on surface morphology was investigated via AFM
imaging. Different surface morphologies with a slight increase in surface roughness were
observed as exposure time increased.
As we can see, power has a great influence on the chemical and physical properties of the
deposited films. The synthesis conditions for deposition of plasma polymer films with high
functional group concentration are characterized by low powers thus leading to low precursor
fragmentation. This will result in the reduction of the plasma polymer film cross-linking degree
[56]. However, the control of the cross-linking degree is an important factor for the optimiza‐
tion of the plasma polymer film stability and mechanical and thermal properties [72]. There‐
fore, it is important to evaluate the cross-linking degree in addition to the plasma and polymer
film chemistry in order to choose the appropriate power [70, 73].
4.2. Monomer flow rate effect
Monomer flow rate is an important plasma process parameter that has been investigated in
order to correlate it to the deposited film properties.
Hamerli et al. [43] and Basarir et al. [70] investigated monomer flow effect on amine function‐
ality retention. At constant power and treatment time, higher monomer flow rates yielded
higher amine retention. The increased amine density with increased flow rates can be ex‐
plained by less dissociation of monomers, owing to the decreased plasma power for each
molecule as the monomer flow rate increased.
Another study by Martin et al. [68] showed that the monomer flow rate does not influence the
thickness of the deposited layers.
4.3. Precursor type effect
The precursor type is one of the most important factors in plasma treatments. For instance, in
plasma polymerization, the use of a non-saturated monomer like allylamine is advantageous
compared to saturated ones because in the former case less energy is needed for the polymer‐
ization process. In fact, the double bond in allylamine encourages a deposition by a combina‐
tion of plasma and conventional free-radical polymerization. Because of that, allylamine
typically polymerizes at low energies. Due to less fragmentation, a higher amount of primary
amines can be retained in the plasma polymer [34, 59]. Furthermore, each precursor is
characterized by its own chemical structure and thus its particular bond breaking energies
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which influence to a great extent the selectivity of the fragmentation processes in the plasma.
Therefore, depending on the kind of monomer used, various chemical compositions are
obtained after each plasma treatment [18, 25, 55]. For example, Hamerli et al. [47] used
ammonia and allylamine as plasma precursors. A higher amine concentration was found on
the allylamine modified samples. Mangindaan et al. [60] used allylamine, propylamine and
propargylamine (another unsaturated monomer) as precursors. XPS coupled to derivatization
showed that allylamine incorporates the highest amount of amine functionalities into the
corresponding thin films compared to those synthesized from the two other precursors.
The precursor type also influences the growth mode and thickness of the deposited layers.
Michelmore et al. [66] noticed that films grown from n-heptylamine initially show “island-
like” growth before a continuous smooth film is formed. In contrast, films from allylamine
grow smoothly from the very earliest stages. Moreover, it has been found that monomers
containing double bonds polymerize faster in plasma than their saturated counterparts.
Gancarz et al. [25] have investigated the plasma polymerization of n-butylamine and allyla‐
mine and observed that the deposited layers are much thicker for allylamine plasmas. This
observation has also been confirmed in a study performed by Mangindaan et al. [60].
5. Interaction between plasma induced amino groups and cells
In this section, an overview of literature on plasma treatments used for the incorporation of
amine functionalities and their influence on cell-material interactions will be given. It is
important to note that each precursor compound and each plasma treatment is unique and
will yield different surface chemical and physical properties. Hence, for the same plasma
media, a different plasma treatment will yield specific surface characteristics. And for the same
plasma treatment, a different plasma media will also yield specific surface characteristics.
Moreover, a specific type of cell reacts differently with specific surface properties.
Cell adhesion and proliferation on amine plasma polymer films deposited onto different
substrates have been widely investigated. Different plasma methods have been used and
different cells and biomolecules interactions with the treated surfaces have been investigated
for various biomedical applications. In the following, only some of the main studied bio
applications will be explored. An overview of the various cited works on cell-material
interactions for different amine plasma treatments is given in table 1.
One important studied bio application is hemocompatibility of biomaterials used in blood
contacting devices [74]. Hemocompatibility is considered to be one of the most critical aspects
of biocompatibility. In order to achieve better hemocompatibility, a common approach is to
immobilize heparin on the surface of the implant. Heparin is a strongly acidic, negatively
charged polysaccharide (see figure 8) used in preventing thromboembolic complications due
to its high affinity binding to antithrombin III (ATIII) resulting in its conformational change
thus accelerating its ability to inactivate the coagulation enzymes [75, 76]. Metallic biomaterials
used for vascular devices have excellent mechanical properties and corrosion resistance but
have insufficient long-term hemocompatibility. Yang et al. [77] modified stainless steel using
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radio frequency plasma and a mixed gas of allylamine vapor and NH3. After plasma treatment,
an FTIR and XPS study of the deposited film showed a good retention of the allylamine
structure and thus the presence of primary amine functionalities on the surface. Nevertheless,
the appearance of some new peaks in the spectra of the deposited film suggests that the primary
amine groups are partially transformed into nitrile, amide or imine functional groups. As a
consequence, the hydrophilicity was greatly improved. The water contact angle decreased
from 70.8 to 62.7°. Hemocompatibility improvement was successfully achieved by heparin
immobilization on the plasma polymerized allylamine. Cell culture tests were also conducted
using endothelial cells which were found to adhere and proliferate in a better way on the
plasma polymerized allylamine coating. Both improved hemocompatibility, adhesion and
proliferation of endothelial cells were attributed to a combined effect of increased wettability
and amine based surface chemistry. In another study [78], the improvement of hemocompat‐
ibility of polymeric vascular prosthesis such as polytetrafluoroethylene (PTFE), polystyrene
and silicon was investigated. After depositing diamond-like carbon (DLC) films on the
polymer substrates via acetylene plasma, functionalization was done using ammonia plasma.
The NH3 plasma exposure time was varied from 0 to 300 s resulting in a different heparin
coverage. For the different treatment times, heparin was successfully immobilized on the
functionalized DLC leading to an extended blood coagulation time. The maximum of bound
heparin was obtained at a 30 s treatment. Moreover, different heparin coverages were obtained
for the different substrates. Based on these observations, the authors suggested that the initial
surface roughness and the plasma treatment time i.e. the surface chemical structure influence
the final heparin coverage.
Figure 8. Chemical structure of heparin molecule [95]
In another important studied bio application related to biomedical implant devices, cell
adhesion is very important because it is considered to be the determinant of the success or
failure of implantation. Anchorage-dependent cells such as fibroblasts and osteoblasts need
the adhesion for cell growth, division and spreading [79]. It was found that attachment,
proliferation and function of these anchorage-dependent cells are highly dependent on the
surface properties of biomaterials [80]. The variation of biocompatibility after amine plasma
treatment of many biomaterials has been studied by the means of fibroblast and osteoblast cell
cultures. Wen-Juan et al. [71] and Ren et al. [81] modified silicon surfaces with allylamine
dielectric barrier discharge and microwave plasma respectively. After plasma exposure, the
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contact angle decreased considerably due to the formation of various nitrogen functionalities
as determined by FTIR. Cell culture tests with fibroblasts showed that both cell adhesion as
well as cell proliferation could be improved by allylamine plasma treatment. Comparable
results were obtained by Zelzer et al. [82] using glass substrates.
In a study by Hamerli et al. [43], the surface of polyethylene terephtalate (PET) was modified
via allylamine microwave plasma polymerization. Plasma process parameters such as power
(MW power), monomer flow rate (ØAllylamine) and duty cycle were varied which allowed the
formation of different film chemical compositions. FTIR and XPS indicated that nitrogen as
well as oxygen functionalities were incorporated which resulted in an increased hydrophilic‐
ity. Pictures from scanning electron microscopy showed that homogeneous pinhole-free
allylamine plasma polymer (PPAa) films were obtained. Cell tests revealed improved cell
attachment and spreading on PPAa coated PET compared to plain PET (see figure 9) with a
greater improvement of biocompatibility on plasma polymerized allylamine coated surfaces
containing amine functionalities in relatively high concentration. This is in agreement with
other researches indicating that amino groups rather than others are favorable for protein
adhesion [83, 84].
Figure 9. Photomicrographes of fibroblasts adhering on PET and PPAa membrane surfaces; (a,c) 4h of cultivation, (b,d)
24h of cultivation, (a,b) PET membrane, and (c,d) PPAa coated PET membrane “MW power of 1200W and ØAllylamine of
30 sccm” [96]
In another study by Hamerli et al. [47], PET membranes were modified by ammonia and
allylamine microwave plasma treatments. Both plasma treatments yielded an approximately
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similar decrease in contact angle. Cell tests showed that fibroblast adhesion and spreading was
improved for both plasma treatments compared to plain PET with higher proliferation on
allylamine-modified samples in comparison to ammonia-plasma modified samples. This is
mainly attributed to the higher amine concentration on allylamine modified PET.
Other studies involving osteoblast cell tests were also conducted on amine plasma polymer‐
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6. Conclusions and future trends
From the work presented in this chapter, it is clear that amine plasma based techniques are
powerful versatile tools to modify a material surface in order to make it more biocompatible.
However, despite the vast array of choices offered by plasma processing techniques, there
remain a significant number of hurdles that must be overcome to allow this methodology to
realize its full potential in the area of biocompatible materials. Challenges include issues
associated with analytical characterization, material structure, plasma processing, and
uniform composition and thickness following treatment. A better understanding of the cell-
biomaterial interactions is of crucial importance providing us with essential clues about which
strategies should be pursued. As our fundamental understanding of these complex phenom‐
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6. Conclusions and future trends
From the work presented in this chapter, it is clear that amine plasma based techniques are
powerful versatile tools to modify a material surface in order to make it more biocompatible.
However, despite the vast array of choices offered by plasma processing techniques, there
remain a significant number of hurdles that must be overcome to allow this methodology to
realize its full potential in the area of biocompatible materials. Challenges include issues
associated with analytical characterization, material structure, plasma processing, and
uniform composition and thickness following treatment. A better understanding of the cell-
biomaterial interactions is of crucial importance providing us with essential clues about which
strategies should be pursued. As our fundamental understanding of these complex phenom‐
ena further develops, better control over cell adhesion, proliferation and differentiation will
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be achievable. Up till now, plasma surface modification is mostly studied on two-dimensional
substrates but it can be expected that the study of 3D porous scaffolds will become more
important. It is believed that, in the future, a broader exploration of various plasma strategies,
monomers and biomaterials will enable us to achieve homogeneous scaffolds with desired
mechanical, chemical and biodegradation properties in an industrialized setting.
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1. Introduction
Proteinoids, polymers made of amino acids by thermal condensation polymerization, are
unique synthetic polymers studied by Fox and coworkers [1-7]. When present in certain
concentrations in aqueous solutions, the proteinoids form small microscopic structures called
“proteinoid microspheres” or protocells [4]. The proteinoid, made of most common amino
acids, goes through a self-assembly process in specific conditions, as some of the amino acids
incorporated into proteinoid chains are more hydrophobic than others, thus proteinoids
cluster together like droplets of oil in water [5-7].
The amino acids, either natural or synthetic, are polymerized by step-growth polymerization
in a special procedure discovered by Fox and Harada [8-12]. The procedure involves heating
amino acids until they melt at first, and then the polymerization is initiated to give the
proteinoid. The polymerization takes place at a relatively high temperature (e.g., 180 °C), in
absence of a solvent or a catalyst, and in an inert atmosphere. The accepted explanation of this
polymerization process is that glutamic acid is used as a solvent for the other monomers, as it
is condensed into pyroglutamic acid. The pyroglutamic acid initiates the polymerization with
the rest of the present amino acids [11-14]. A brief description of the polymerization process
is shown in Figure 1.
An important advantage in using biodegradable polymers bearing one or more stereogen‐
ic centers- optically active polymers- is the high variety of features they offer, when used
as carriers for drug delivery systems [15]. This study is intended to broaden the scope of
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
biodegradable  polymers  by  synthesizing  new  proteinoids  carrying  various  stereogenic
centers. The main goal is to provide a large choice of biodegradable proteinoids with pre-
determined characteristics,  while  using amino acids  as  building blocks.  Hence,  the  new
selection is based on chiral building blocks carrying positive/negative charge, hydrophilic/
hydrophobic nature or any desired combination of the above [16]. Homopolymers, random
copolymers  and  block-copolymers  of  two  amino  acids  or  more  can  be  designed  and
synthesized, presenting thereby new proteinoid materials with specific, desired nature. The
large variety of amino acids, either natural or synthetic, makes it possible to obtain a large
library of  different  proteinoids,  by  simply changing the  amino acids  ratios.  One protei‐
noid is completely different from another, by the fact that they are made of different amino
acid monomers. This fact provides each proteinoid special features, and possibly influen‐
ces the character of particles made from it [17-20].
Up until now, most, if not all, of the reported proteinoids in the literature were synthesized
from at least four amino acids and possessed relatively low molecular weights [21,22]. Thus,
high molecular weight proteinoids of narrow size distribution made of two to three natural
amino acids, along with proteinoids containing poly(L-lactic acid) (PLLA) segments are
presented in this study. Furthermore, the study presents NIR fluorescent proteinoid-based
particles, which can be used for colon cancer detection. Some of the methods used have been
published in a previous work [23].
2. Incorporation of poly(L-lactic acid) into the proteinoid backbone
Poly(lactic acid) or PLA is the thermoplastic aliphatic polyester of lactic acid, derived from
renewable sources. It is the one of the most important bioplastics in the world in terms of
Figure 1. Thermal polymerization of amino acids through pyroglutamic acid catalysis.
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renewable sources. It is the one of the most important bioplastics in the world in terms of
Figure 1. Thermal polymerization of amino acids through pyroglutamic acid catalysis.
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consumption volume. PLA can be processed by extrusion, injection molding, film and sheet
casting, and spinning, providing access to a wide range of materials and applications. Two
racemic structures of PLA, the L form and the D form, are known as PLLA and PDLA,
respectively [24].
PLA is already used in many biomedical applications, as it is able to degrade into innocuous
lactic acid and is very safe [25-29]. Medical implants made of PLA and approved by the FDA
are anchors, screws, plates, pins, rods, and as a mesh. Depending on the specific type used,
the implants degrade inside the body within 6 to 24 months. The strength characteristics of
PLA and PLLA implants is well documented [30,31].
PLA can also be used as a compostable packaging material, either cast, injection molded,
or spun. Also, cups, bags, hygene products and diapers have been made from PLA [32].
3. Proteinoid microspheres
After preparation, the crude proteinoids can self-assemble to form micro- and nano-sized
particles [33, 34]. As opposed to polystyrene microparticles, for example, which are formed
during  the  polymerization  process  of  styrene  in  the  presence  of  a  surfactant  [35],  the
proteinoid particles are formed through a self-assembly process. This process is complet‐
ed only after the polymerization itself. The procedure involves either dissolving the dried
crude proteinoid in water by heating and then cooling slowly,[36] or by pH changes of the
proteinoid solution in water [37]. This way, particles of the size range of several nanome‐
ters to 10 μm may be formed [38].
The idea standing behind the unique self-assembly process lies in the existence of many
functional groups as a part of the random polymer backbone. The preparation of proteinoid
microspheres does not require the addition of any toxic cross-linking agents or surfactants.
The conversion of the polypeptidic proteinoid solution into particles with a slight change of
the environment involves a complex process of functional group changes occurring in the
polymer. The great amount of carboxylates in the backbone, or aminium ions when dealing
with a lysine-rich proteinoid, cause the solubility of the proteinoid in certain conditions and
insolubility in the reverse conditions [39]. The hydrophobic portions of the proteinoid are
assembled within the particle matrix, and the carboxylic acid moieties are exposed, as
illustrated in Figure 2 [40].
When the self-assembly procedure is done in the presence of a suitable molecule such as drug
or dye, a proteinoid particle containing the molecule is formed [41]. The proteinoids may be
used to encapsulate materials such as drugs for drug delivery purposes, e.g. for the oral
delivery of methotrexate [40], Hydroxyapetite [42], Cholesterol [37] and for diagnostics
[21,43-48].
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4. Preparation of proteinoids by thermal condensation polymerization
L-glutamic acid was heated to the molten state (180°C) in an oil bath, under nitrogen atmos‐
phere. The molten mass was stirred at 180°C for 30 min. To this, different contents of additional
L-amino acids were added to give a total monomer weight of 5-5.01 g, as specified in Table 1,
and kept at 180°C under nitrogen. The mixture was mechanically stirred at 150 rpm for 3 h.
The product is a highly viscous orange-brown paste, which hardens to give a glassy mass when
cooled to room temperature. Then, water (10 mL) was added to the crude product, and the
mixture was stirred for 20 min. The solution was then intensively dialyzed through a cellulose
membrane (3500 Da MWCO) against distilled water. The content of the dialysis tube was then
lyophilized to obtain a yellow-white proteinoid powder.
Polymer Amino acid content (g)a
L-Glu L-Asp L-Lys L-Phe PLLA
Prot1 5 - - - -
Prot2 2.5 2.5 - - -
Prot3 2.5 - - 2.5 -
Prot4 1.25 2.5 - 1.25 -
Prot5 1.67 1.67 1.67 - -
Prot6 1.67 - 1.67 1.67 -
Prot7 1.25 - 2.5 1.25 -
Prot8 2.25 - - 2.25 0.5
Table 1. Amino acid content of the different proteinoids. aIn all proteinoids made by thermal condensation
polymerization the total monomer content was 5-5.01 g; bmade by microwave-assisted polymerization.
4.1. Polymerization kinetics study at different temperatures
Polymerization  kinetics  was  studied  by  collecting  proteinoid  samples  from the  reaction
vessel at different time periods of the polymerization at 180, 190 and 200°C. The samples
Figure 2. Schematic representation of the self-assembled proteinoid particles. Hydrophobic moieties are represented
by scribbled lines. When lysine is also a part of the proteinoid, as in Prot5-7, some carboxyl groups are exchanged with
amine groups.
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were then analyzed by both ninhydrin test  for  the  determination of  the  primary amine
groups content and Biuret test for the determination of the amide groups content of the
various  proteinoids  [49].  The  results  shown in  Figure  3  refer  to  the  synthesis  of  Prot3,
consisting of L-glutamic acid and L-phenylalanine. Similar results were observed for the
other systems, Prot1-8, as well. It can be seen that at all temperatures, the polymerization
takes place mainly over the first 100 min. After that, both ninhydrin (A) and Biuret (B) tests
show no significant drop of the Ninhydrin signal indicating the amount of free amines or
rise of the peptide bonds shown by the Biuret signal. This figure also shows that as the
temperature of  the reaction was raised,  the rate of  the reaction increased.  However,  the
preferred reaction temperature  is  180°C,  as  the  yield of  the  reaction is  higher  since  the
amino acids decompose faster at the higher temperatures.
Figure 3. Thermal polycondensation kinetics of (L)glutamic acid and (L)phenylalanine to yield Prot3 at different tem‐
peratures by two tests: ninhydrin test (A) and Biuret test (B).
5. Proteinoid analysis and characterization
The molecular weights and polydispersity index of the dried crude proteinoids were deter‐
mined using Gel Permeation Chromatography (GPC) consisting of a Waters Spectra Series
P100 isocratic HPLC pump with an ERMA ERC-7510 refractive index detector and a Rheodyne
(Coatati, CA) injection valve with a 20 μL loop (Waters, MA). The samples were eluted with
super-pure HPLC water through a linear BioSep SEC-s3000 column (Phenomenex) at a flow
rate of 1 mL/min. The molecular weights were determined relative to poly(ethylene glycol)
standards (Polymer Standards Service-USA, Silver Spring, MD) with a molecular weight range
of 100-450000 Da, using Clarity chromatography software. The optical activities of the
proteinoids were determined using a PE 343 polarimeter (PerkinElmer). All of the measure‐
ments were done in water, at 589 nm at 25°C. Table 2 shows the characteristic molecular
weights, polydispersity and optical activity of the prepared proteinoids.











Prot1 26250 11300 11320 2.32 +6.5
Prot2 181540 144940 195300 1.25 -4.4
Prot2e 500240 497280 503070 1.01 +8.1
Prot3 164930 138250 158740 1.19 -9.0
Prot4 87660 84410 85250 1.04 -3.3
Prot5 195080 165870 191440 1.17 -7.4
Prot6 190390 163290 204050 1.16 -15.1
Prot7 72260 56880 42870 1.27 +2.8
Prot8 168300 156600 136800 1.07 -4.6
Table 2. Mw, Mn, Mp, PDI and optical activity of the various proteinoids.aThe proteinoids were prepared at 180°C
according to section 3.2.1; bmolecular masses were measured by GPC, Mp is the molecular mass at the peak; cPDI is the
polydispersity index, given by Mw/Mn; dspecific optical rotation (c=1, in H2O, at 25°C); emade by microwave-assisted
polymerization.
Table 2 indicates relatively low PDI values for the obtained proteinoids. This is unexpected
since the polycondensation of the various amino acids is random and step-growth polymeri‐
zation processes, as in the present case, result usually in very broad size distribution polymers
[50]. The highest PDI (2.32) was observed for Prot1, composed of the single amino acid L-
glutamic acid, while the PDIs of the other proteinoids composed of at least 2 amino acids were
ranging between 1.01 and 1.27. All of the thermally-made proteinoids have relatively high
molecular masses of 26-195 kDa. This indicates that the polymerization procedure by thermal
heating used here provides relatively long polymer chains. This fact may serve as an advantage
for different uses later, since polymers with such high molecular weights are usually mechan‐
ically stronger and resemble natural proteins. Table 2 indicates that the lowest molecular
weight was observed for the proteinoid composed of the single amino acid L-glutamic acid
(Prot1) and the highest one for the proteinoid composed of L-glutamic acid, L-aspartic acid
and L-lysine (Prot 5). Prot2, which was synthesized by microwave-assisted polymerization,
reached an abundantly higher molecular weight. In this procedure, a 500 kDa proteinoid chain
was prepared, about twice the size of the regular thermal proteinoid. This kind of procedure
gives better yield over 60 min, compared to the 3 h needed usually. It can be used further for
higher molecular weights and more rigid proteinoids. However, unfortunately, this kind of
proteinoid does not self-assemble into spherically-shaped particles.
As further indicated from Table 2, all of the proteinoids exhibit optical activity, although the
amino acid monomers are known to racemize during the thermal process [51]. This fact can
become a benefit later in the design of a stereospecific drug carrier, for example.
Fourier Transform Infra-Red (FTIR) measurements of the crude proteinoids were done by the
Attenuated Total Reflectance (ATR) technique, using Bruker ALPHA-FTIR QuickSnapTM
sampling module equipped with Platinum ATR diamond module. All proteinoids showed
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weight was observed for the proteinoid composed of the single amino acid L-glutamic acid
(Prot1) and the highest one for the proteinoid composed of L-glutamic acid, L-aspartic acid
and L-lysine (Prot 5). Prot2, which was synthesized by microwave-assisted polymerization,
reached an abundantly higher molecular weight. In this procedure, a 500 kDa proteinoid chain
was prepared, about twice the size of the regular thermal proteinoid. This kind of procedure
gives better yield over 60 min, compared to the 3 h needed usually. It can be used further for
higher molecular weights and more rigid proteinoids. However, unfortunately, this kind of
proteinoid does not self-assemble into spherically-shaped particles.
As further indicated from Table 2, all of the proteinoids exhibit optical activity, although the
amino acid monomers are known to racemize during the thermal process [51]. This fact can
become a benefit later in the design of a stereospecific drug carrier, for example.
Fourier Transform Infra-Red (FTIR) measurements of the crude proteinoids were done by the
Attenuated Total Reflectance (ATR) technique, using Bruker ALPHA-FTIR QuickSnapTM
sampling module equipped with Platinum ATR diamond module. All proteinoids showed
characteristic peaks of NH stretching at 3360 and 2990 cm-l, amide CO stretching at 1565 cm-1,
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an amide NH bending band at 1450 cm-1 and CO bending at 500-700 cm-1. A representative
spectrum of Prot3 is shown in Figure 4.
Figure 4. FTIR spectrum of Prot3.
The thermal behavior of the proteinoids was determined using Differential Scanning Calo‐
rimetry (DSC) and Thermo Gravimetric Analysis (TGA) with a TGA/DSC 1 STARe system
(Mettler Toledo, Switzerland). The samples were heated between 25 - 400 °C at a rate of 10°C/
min under nitrogen atmosphere. The results are shown in Table 3.
Polymer Tm(°C)a ∆Hm (J/g)a Tdec (°C)b Weight loss (%)
at 400°Cb
Prot1 102 -300.7 300 55
Prot2 89 -428.7 297 57
Prot3 103 -174.9 341 54
Prot4 217 -183.4 330 25
Prot5 78 -251.5 339 57
Prot6 241 -90.1 373 47
Prot7 246 -139.4 385 64
Prot8 117 -420.5 268 47
PLLAc 150 -57.2 349 90
Table 3. Thermal properties of proteinoids produced by thermal polymerization.aTm and ∆Hm were measured by
DSC; bTdec (temperature of decomposition) was measured by TGA/DSC and refer to the exothermal peak in DSC,
ccommercial PLLA 2000 Da parameters were measured similar to the made proteinoids.
The melting temperatures of the different proteinoids range between 78-246°C. The wide range
of temperatures derives from the difference in the monomeric units used in each proteinoid.
When using phenylalanine, as in Prot3, 4, 6 and 7, the resulted proteinoid gains significant
rigidity in the overall structure, due to the aromatic rings which allow pi-stacking. Hence, these
proteinoids melt at higher temperatures. When PLLA is incorporated into the proteinoid, as
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in Prot8 compared to Prot3, the Tm rises mildly (103°C and 117°C, respectively), due to the
presence of 2000 Da rigid polymer chains in the overall proteinoid structure.
The TGA/DSC measurements of the proteinoids show decomposition temperatures of
268-385°C. Most proteinoids lose at this temperature range around 50% of their weight The
decomposition measured at 400°C of most proteinoids is between 47-64%, except Prot4 (25%).
Pure PLLA decomposes at 349°C almost completely (90% weight loss). Prot8, composed of
PLLA segments (10% of the total monomer), has the lowest decomposition temperature of all
proteinoids (268°C). This can be explained by the non-uniformity of the structure of the whole
proteinoid due to the inserted segments of 2000 Da PLLA within the random segments of
polymerized amino acids.
The content of free carboxyl groups in the synthesized proteinoids is an essential factor in
determining their solubility in different media, thus helping to understand their stability at
different sites in the human body with different pHs. In order to determine the free carboxyl
groups in the synthesized proteinoids, a titrimetric method was carried out [40]. Briefly, to a
known quantity of dry proteinoid, a known excess of 0.05 N NaOH was added, followed by
the addition of 37% formaldehyde solution. The unreacted NaOH was back-titrated with
standard 0.05 N HCl. A blank titration was also performed. In addition, human serum albumin
(HSA) was titrated for comparison. Table 6 indicates the carboxyl group contents of the
synthesized proteinoids, showing higher values of 80-155 mmol/g compared with albumin.
This is true also in Prot5-7, where lysine is also a part of the polymer. Moreover, aspartic and
glutamic acid moieties in the proteinoids, along with lysine, impart the hydrophilic nature of
the whole proteinoid. The biodegradability rate of various amino acid polymers increases with
their hydrophilicity [40]. Therefore, it is more appropriate to choose these proteinoids as ideal
biomaterials for drug delivery applications.
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In order to effect the chemical and physical properties of the product, a thermal polymerization
of L-glutamic acid and L-phenylalanine was carried out in the presence of low molecular
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weight poly(L-lactic acid) (PLLA, 2000 Da). The proteinoid-PLLA (Prot8) consists of 2.25 g of
each amino acid and 0.5 g of PLLA. After polymerization, it was washed, dried and charac‐
terized as described earlier. The characterization of Prot8 is included in the tables above.
6. Preparation and characterization of the proteinoid nano/micro-particles
by a self-assembly process
Proteinoid particles were prepared by a self-assembly mechanism. Briefly, 100 mg of the dried
proteinoid were added to 10 mL 10-5N NaCl solution. The mixture was then heated to 80°C
until the crude proteinoid dissolves completely. Proteinoid particles were then formed by
removal of the heating and leaving the mixture to cool to room temperature.
Hydrodynamic diameter and size distribution of the particles dispersed in double distilled
(DD) water were measured at room temperature with a particle DLS analyzer model Nano‐
phox (SympatecGmbH, Germany).
Dried particle size and size distribution were measured with a Scanning Electron Microscope
(SEM). SEM pictures were obtained with a JEOL, JSM-840 Model, Japan. For this purpose, a
drop of dilute particle dispersion in distilled water was spread on a glass surface, and then
dried at room temperature. The dried sample was coated with carbon in vacuum before
viewing under SEM. The average particle size and distribution were determined by the
measurement of the diameter of more than 200 particles with image analysis software
(Analysis Auto, Soft Imaging System GmbH, Germany). Figure 5 exhibits the proteinoid
particles made from self-assembly of Prot8. The procedure produced spherical proteinoid
particles of 103 ± 11 nm hydrodynamic diameter and 70 ± 15 nm dry diameter. The dry diameter
of the proteinoid particles is illustrated by the typical SEM photomicrograph shown in Figure
5A. The hydrodynamic diameter of these particles dispersed in water is illustrated by the
typical light scattering measurement shown in Figure 5B. The difference in the particle size
between the SEM and the light scattering measurements is probably due to the fact that SEM
measurements determine the dry diameter, whereas light scattering measurements take into
account the hydrated water layers adsorbed onto the particle’s surface.
The density of the particles was determined by pycnometry [52]. Briefly, dry pre-weighed
particles were put in a calibrated pycnometer, which was then filled with water. The density
of the sample can then be calculated from the known density of the water, the weight of the
pycnometer filled only with water, the weight of the pycnometer containing both the sample
and water, and the weight of the sample, as described in the literature [52]. Density measure‐
ments indicated that all proteinoid particles possess a very low density, ranging from 0.001 to
0.014 g/mL indicating that the particles formed are probably hollow, as already indicated for
the proteinoids prepared by Fox et al [6,38]. The hollow nature of the particles is significantly
important for applications such as ultrasound imaging agents, drugs and dyes encapsulation,
controlled released, etc.
As suggested in our and in previous studies, the proteinoid forms particles of different sizes
according to the nature of its surrounding. The hydrophobic portions of the crude proteinoid
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are assembled within the particle matrix, while the polar hydrophilic groups (carboxyl and
amines) are exposed to the aqueous environment, as illustrated before in Figure 2 [40].
6.1. Particle stability in storage conditions
Proteinoid particles aqueous dispersions (1 mg/mL) were put in a refrigerator at 4°C for 6
months. Samples were taken at different time periods, filtered through a centrifugation tube
(Vivaspin 3000 Da MWCO) and the filtrate was checked by UV at 200-210 nm, to find aqueous
soluble proteinoid. Also, the particle aqueous dispersions were checked by Nanophox for their
size and size distribution. In order to check the particle stability after drying, the particles were
lyophilized to dryness and then dispersed in an aqueous phase to their original concentration.
The samples size and size distribution were then rechecked by Nanophox. Overall, the
proteinoid particles remain in the same size after 6 months in storage at 4°C. Also, the
degradation and/or dissolution of the proteinoid particles in the aqueous continuous phase
was tested by the filtration centrifugation method and resulted in negative results in the filtrate,
meaning no degradation or dissolution occurs at this temperature over 6 months. When
lyophilized to dryness, the proteinoid particles can be redispersed in water completely while
the particle size and size distribution remain the same. This means that the particles can be
stored as a freeze-dried powder as well, and redispersed when needed, without the need to
add cryoprotectants as mentioned in the literature [53].
6.2. Cytotoxicity of the proteinoid particles
In vitro cytotoxicity of the proteinoid particles was tested by using human colon adenocarci‐
noma LS174T cancer cell line. The tests were done on Prot2, Prot4, Prot5, Prot7 and Prot8. The
Figure 5. Hydrodynamic size histogram (A) and SEM image (B) of Prot8 particles.
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cell line is adherent to the used culture dishes. LS174T cells were grown in MEM that was
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% glutamine and 1%
penicillin/streptomycin. Cells were screened to ensure they remained mycoplasma-free using
Mycoplasma Detection Kit [54]. Cell cytotoxicity was assessed by measuring the release of
cytoplasmic lactate dehydrogenase (LDH) into cell culture supernatants. LDH activity was
assayed using the Cytotoxicity Detection Kit according to the manufacturer's instructions [55].
Cells (3×105 cells per well) were seeded and grown to 90–95% confluency in 24 well plates
before treatment with the proteinoid particles. Cell cultures that were not exposed to the
particles were included in all assays as negative controls. Cell cultures that were treated with
1% Triton-x-100 were used as positive controls. To test if the particles can interact with LDH
kit compounds, cell cultures were exposed to a mixture containing maximal nano/micro-
particles concentration dispersed in PBS and 1% Triton-x-100. The proteinoid particles were
freshly dispersed in PBS (1.25 and 2.5 mg/mL) and then added to the 95% confluent cell culture
in culture medium. The cell cultures were further incubated at 37°C in a humidified 5% CO2
incubator and then checked for cellular cytotoxicity at intervals of 24h. The percentage of cell
cytotoxicity was calculated using the formula shown in the manufacturer's protocol [55]. All
samples were tested in tetraplicates.
Figure 6. Cytotoxic effect of the proteinoid particles on colon adenocarcinoma LS174T cells measured by the LDH as‐
say. Cells (3×105) were incubated for 24 and 48 h with the proteinoid particles dispersed in PBS (1.25 mg/mL and 2.5
mg/mL) according to section 3.2.5.8. Cells were incubated with Triton-x-100 1% as positive control (100% toxicity). In ad‐
dition, cells were incubated with Triton-x-100 1% and each one of the proteinoids to revoke any interaction. Untreated cells
(negative control) were similarly incubated. Each bar represents mean ± standard deviations of 4 separate samples.
When tested by the LDH quantitative assay, Prot2, 4, 5, 7 and 8 particles dispersed in PBS at
concentrations of 1.25 and 2.5 mg/mL had none, or minor cytotoxic effect on the human colon
adenocarcinoma cell line LS174T (Figure 6). Treatment of the cells with Prot2 and Prot5
Engineering of Novel Proteinoids and PLLA-Proteinoid Polymers of Narrow Size Distribution and…
http://dx.doi.org/10.5772/59626
59
particles at both concentrations produced the highest LDH levels (up to 13% toxicity), when
compared to untreated (blank) cells, indicating minor toxicity of these proteinoids to this cell
line. Prot8 had the lowest cytotoxic effect on the cells treated with both concentrations, almost
zero toxicity. This proteinoid is therefore the most suitable for treating cells, considering its
low toxicity.
7. NIR flourescent proteinoid-PLLA particles
7.1. Synthesis of the NIR fluorescent Prot8 particles
The optimal Prot8 particles were used to encapsulate ICG, a well-known NIR dye already in
use in medical diagnostics. The NIR fluorescent particles were prepared by self-assembly of
the crude Prot8, in the presence of ICG. Briefly, 100 mg of the dried fabricated Prot8 were
resuspended in 10 mL of 10-5N NaCl solution. The mixture was then heated to 80°C while
stirring for 15 min. To this solution, 1 mg (1% of the proteinoid polymer) of ICG was added.
The mixture was then removed from the hot plate and was allowed to return to room tem‐
perature. During the cooling process hollow particles were formed and precipitated from
solution. The obtained NIR fluorescent particles dispersed in water were then dialyzed versus
4 L of 10-5 NaCl aqueous solution overnight at room temperature.
7.2. Determination of the encapsulated ICG concentration in the NIR fluorescent Prot8
particles
A calibration curve of free ICG was obtained by measuring the integrals of absorbance peaks
of standard solutions (0.5–10 μg/mL) in PBS, at wavelengths 630–900 nm. The concentration
of the encapsulated ICG was determined by measuring the integral of the absorbance spectrum
at 630-900 nm of a 1 mg/mL dispersion of the NIR fluorescent particles in PBS. An estimation
of encapsulated ICG per mg of particles was determined according to the calibration curve.
7.3. Characterization of the NIR fluorescent Prot8 particles
Hydrodynamic and dry particle size and size distribution were determined by DLS and SEM,
as mentioned above. For the SEM study, the diameter of more than 200 particles with image
analysis software (AnalySIS Auto, Soft Imaging System GmbH, Germany). The self-assembly
procedure produced spherical proteinoid particles of 145 ± 20 nm hydrodynamic diameter and
70 ± 15 nm dry diameter, as shown in Figure 7. The hydrodynamic diameter of these particles
dispersed in water is illustrated by the typical light scattering measurement shown in Figure
7A. The dry diameter of the proteinoid particles is illustrated by the typical SEM photomicro‐
graph shown in Figure 7B.
In addition, absorbance spectra were obtained using a Cary 100 UV-Visible spectrophotometer
(Agilent Technologies Inc.). Excitation and emission spectra were recorded using a Cary
Eclipse spectrofluorometer (Agilent Technologies Inc.). As indicated in Figure 8, no shift of
absorbance of the ICG after encapsulation is observed compared to that of the free ICG.
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particles at both concentrations produced the highest LDH levels (up to 13% toxicity), when
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However, due to the dye encapsulation process, the maximal absorbance peak of the free ICG
changed from 779 nm to 718 nm, probably since the ICG molecules get close to each other
inside the nanoparticle interior and aggregation of the dye may occur causing this change in
absorption peaks [56,57]. Furthermore, a 12 nm blue-shift of the emission spectrum of the NIR
fluorescent particles compared to the free dye in solution is also observed.
The estimation of encapsulated ICG showed that the complete quantity of ICG used in the
encapsulation procedure was encapsulated within the Prot8 nanoparticle interior. Following
particle formation, leakage of the encapsulated ICG into PBS not-containing and containing
4% albumin at room temperature was not observed, indicating that the dye is strongly
associated within the Prot8 particles, probably due to physical interactions between the dye
and the polymer hydrophobic portions assembled in the core of the particles.
As suggested before, the proteinoid forms particles of different sizes according to the nature
of its surrounding [40]. When discussing Prot8, the hydrophobic portions, in this case mainly
the PLLA segments and the aromatic rings of the phenylalanine portion are assembled within
the particle matrix, while the polar hydrophilic groups (mainly carboxylates) are exposed to
the aqueous environment. This way, the self-assembly yields particles that encapsulate within
them the ICG associated with the hydrophobic core via hydrophobic interaction, as illustrated
in Figure 9.
7.4. Optimization of the ICG concentration entrapped within the Prot8 particles
In order to optimize the particles fluorescence intensity, different concentration (0.5, 1, 2 and
5% w/w relative to Prot8) of ICG were added to the Prot8 hot solution, prior to the formation
of the particles through the self-assembly process, as described above. The NIR fluorescent
Figure 7. Hydrodynamic size histogram (A) and SEM image (B) of the P(EF-PLLA) NIR fluorescent nanoparticles.
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Prot8 particles dispersed in PBS were diluted to 1 mg/mL and their fluorescence intensities
were measured at 809 nm. The encapsulated ICG concentration that gave the maximum
fluorescence intensity of the resultant NIR fluorescent particles was 1% w/w relative to Prot8.
At higher dye concentrations, quenching of the fluorescence was observed, as the dye
molecules encapsulated within the Prot8 nanoparticle are close to each other, resulting in non-
emissive energy transfer between them.
7.5. Photostability of the NIR fluorescent Prot8 particles
In order to examine the photostability of  the encapsulated ICG as opposed to free ICG,
photobleaching experiments were performed for both the encapsulated and the free dye.
For  this  purpose,  an  aqueous  solution  of  ICG  (0.05  M)  in  PBS  was  prepared,  and  the
Figure 8. Absorbance and emission spectra of free ICG (dotted lines) and ICG-encapsulated Prot8 particles (solid lines)
dispersed in water.
Figure 9. Schematic representation of the self-assembled NIR fluorescent particles. Hydrophobic moieties are repre‐
sented by scribbled lines, ICG is represented by the interior green dots.
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fluorescence intensity with λex set  at  780 nm and λem set  at  800 nm was measured.  A
dispersion of  NIR fluorescent  Prot8  particles  in  PBS was  prepared,  and diluted to  give
similar  fluorescence  intensity  to  the  dye  at  the  same  wavelengths.  The  excitation  and
emission slits  were  opened to  20  nm and 5  nm,  respectively.  Each of  the  samples  was
illuminated  continuously  with  a  xenon  lamp,  and  the  fluorescence  intensity  was  meas‐
ured over a period of 20 min by a Cary Eclipse fluorescence spectrophotometer (Agilent
Technologies Inc.). Intensity values were normalized for comparison. Figure 10 illustrates
that  during illumination,  the fluorescence intensity of  the ICG-containing Prot8 particles
remains intact  while that  of  the free ICG decreased significantly.  The photobleaching of
ICG is significantly reduced by the encapsulation within the proteinoid-PLLA particles. The
encapsulation probably protects the free dye from light-inducing factors such as oxygen,
oxidizing or reducing agents,  temperature, exposure time and illumination levels,  which
may reduce the fluorescence intensity irreversibly [58,59].
Figure 10. Photostability of the ICG-containing Prot8 particles (A) and free ICG (B) as function of time. Samples of
ICG-containing Prot8 particles and free ICG were illuminated with a Xenon flash lamp for 20 min, as described above.
7.6. In vitro cytotoxicity of the Prot8 particles
In order to revoke cell toxicity of the NIR Prot8 particles, in vitro cytotoxicity of the particles
was tested by using human colorectal adenocarcinoma LS174t, SW480 and HT29 cell lines. The
cell lines are adherent to the used culture dishes. LS174t cells were grown in Minimum
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Essential Medium (MEM) eagle supplemented with heat-inactivated fetal bovine serum (FBS,
10%), penicillin (100 IU/mL), streptomycin (100 μg/mL) and L-glutamine (2 mM). SW480 cells
were maintained in Dulbecco's MEM supplemented with heat-inactivated fetal bovine serum
(FBS, 10%), penicillin (100 IU/mL), streptomycin (100 μg/mL) and L-glutamine (2 mM). HT29
cells were maintained in McCoy's 5A medium supplemented with FBS (10%), penicillin (100
IU/mL), streptomycin (100 μg/mL) and L-glutamine (2 mM). Cells were screened to ensure
they remained mycoplasma-free using Mycoplasma Detection Kit [54]. Cell cytotoxicity was
assessed by measuring the release of cytoplasmic lactate dehydrogenase (LDH) as described
above.
Figure 11 exhibits the cytotoxicity levels of the Prot8 particles at two different concentrations
(1.25 and 2.5 mg/mL). It can be seen that at both concentrations, the Prot8 particles have no
significant cytotoxic effect on all three cell lines, compared to untreated (blank) cells, meaning
that the particles may be used for biomedical applications as suggested, including drug
delivery.
Figure 11. Cytotoxic effect of the NIR fluorescent Prot8 particles on human colorectal adenocarcinoma LS174t, SW480
and HT29 cell lines measured by the LDH assay. Cells (3×105) were incubated for 24 and 48 h with the Prot8 particles
(1.25 and 2.5 mg/mL in PBS). Cells were incubated with 1% Triton-x-100 as positive control (100% toxicity). In addition,
cells were incubated with Triton-x-100 1% and the Prot8 particles (2.5 mg/mL) to revoke any interaction of the particles
with the LDH kit components. Untreated cells (negative control) were similarly incubated. Each bar represents mean ±
standard deviations of 4 separate samples (originally published in [23]).
7.7. In vivo biodistribution in a mouse model
In order to examine the biodistribution in a living body, the NIR fluorescent Prot8 particles (2
mg/mL, 0.01 mg/kg body weight per mouse) were injected i.v. into mice through the tail vein
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7.7. In vivo biodistribution in a mouse model
In order to examine the biodistribution in a living body, the NIR fluorescent Prot8 particles (2
mg/mL, 0.01 mg/kg body weight per mouse) were injected i.v. into mice through the tail vein
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and checked at several time intervals over 24 h. Male BALB/C mice (Harlan Laboratories,
Israel) were utilized in this study under a protocol approved by the Institutional Animal Care
and Use Committee at Bar-Ilan University. The biodistribution of the NIR fluorescent Prot8
particles was studied in normal 8-weeks-old mice, weighing 20-25 g at the time of experiment.
Prior to the experiment, mice were anesthetized by intraperitoneal injection of Ketamine (40-80
mg/kg body weight) and Xylazine (5-10 mg/kg body weight), and the mice’s skin was shaved
with an electric animal clipper.
100 μL of either nanoparticle dispersion or free ICG solution (0.01 mg/kg body weight,
dissolved in PBS) were administered to the mice through tail vein injection at a concentration
of 2 mg/mL. During image acquisition, mice remained anesthetized by the intraperitoneal
injection of Ketamine/Xylazine. Image cubes were obtained from the mice at several time
points up to 24 h after injection. Each treatment group includes 3 mice for each time point (5
min, 20 min, 1 h and 24 h); 2 uninjected mice served as negative control. The experiment was
repeated twice, testing a total of 52 mice. At the end of the experiment, the mice were euthan‐
ized by cervical dislocation, and organs were taken for imaging (liver, spleen, kidney, duode‐
num, colon, brain, heart, tibia bone and blood).
Whole body fluorescence images were acquired using a Maestro II in vivo fluorescence
imaging system (Cambridge Research &Instrumentation, Inc., Woburn, MA). The system is
equipped with a fiber-delivered 300W xenon excitation lamp, and images can be acquired from
λ=500-950 nm by a 1.3 megapixel CCD camera (Sony ICX285 CCD chip). Each pixel within the
image cube therefore has an associated fluorescence spectrum. The software for the Maestro
system (Maestro 2.10.0) contains several algorithms to process the spectral data cubes to
remove undesired auto-fluorescence signal and generate overlaid images for multiple
fluorophores. A deep red excitation/emission filter set was used for our experiments (λex:
700-770 nm, λem>780 nm). The liquid crystal tunable filter (LCTF) was programmed to acquire
image cubes from λ=780 nm-860 nm with an increment of 10 nm per image. The camera was
set to 150 ms (whole body image), 15 ms (liver), 500ms (spleen), 7000ms (kidney), 10 ms
(duodenum), 500 ms (colon), 1000ms (brain), 1000ms (tibia bones), 200ms (heart) and 1000ms
(blood) exposure times. Fluorescence intensity measurements were performed using ImageJ
NIH (National Institutes of Health) software.
Figure 12 shows whole body images of mice injected with the particles over time: at 5 min, 20
min, 1 h and 24 h from injection. 5 min post injection, there is an initial burst of fluorescence
which subsided quickly, while the majority of the fluorescent particles concentrated in the
liver, at 20 min. 24 h post injection, the fluorescence is almost non-existent, signifying the
nanoparticle clearance from the body over 24 h. Biodistribution was tested for free ICG as well,
and no significant differences in distribution and kinetics were found between particles
containing ICG and free ICG up to 24 h post injection. These findings were in complete
agreement with previous reports of ICG and ICG-containing particles pharmacokinetics and
biodistribution, as the free dye in solution, derivatives of the free dye and ICG-containing
particles are all evacuated from the body after 1 h and completely vanished 24 h after i.v.
injection [60,61].
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Figure 12. Typical whole body fluorescence images of the NIR fluorescent Prot8 particles at 5 min, 20 min, 1 h and 24 h
after i.v injection. 12 mice (each experiment group contained 3 mice) were anesthetized and treated with NIR fluores‐
cent Prot8 particles (2 mg/mL, 0.01 mg/kg body weight per mouse). Blood was drawn and organs were harvested at
each time point. 2 uninjected mice served as negative control. 12 mice were injected correspondingly with free ICG
solution, giving similar results (not shown). The experiment was repeated twice with similar results (originally pub‐
lished in [23]).
Figure 13. Fluorescence intensities of different organs taken at 5 min, 20 min, 1 h and 24 h post i.v. injection into mice
tail veins. 12 mice (each experiment group contained 3 mice) were anesthetized and treated with NIR fluorescent Prot8
particles (2 mg/mL, 0.01 mg/kg body weight per mouse). Blood was drawn and organs were harvested at each time
point. 2 uninjected mice served as negative control. The experiment was repeated twice with similar results (originally
published in [23]).
Ex vivo fluorescence images of specific organs and blood were also obtained. Organs from mice
were harvested and blood was drawn 5 min, 20 min, 1 h and 24 h post injection of the particles
into the tail vein. Figure 13 shows the calculated fluorescence intensities of the lungs, bones,
brain, colon, duodenum, heart, liver, kidney, spleen and blood screening. Evidently, this
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analysis shows that the particles penetrated and were found in all checked organs. It is shown
clearly that by 20 min most of the inserted quantity of the fluorescent particles is cleared from
the blood. The particles concentrate mostly at the liver and are probably evacuated from the
body. Interestingly, it is also apparent that the particles pass the blood-brain barrier (BBB),
since they are found in the brain at 20 min post injection. This may open up a scope of drug
targeting to the brain for drug molecules which are usually blocked. Overall, it was demon‐
strated that following a single i.v. injection of the particles, fluorescence intensity at all organs
decreased over time, and only traces of fluorescence could be seen after 24 h.
7.8. Conjugation of the tumor-targeting ligands to the particles
PNA was covalently conjugated to the NIR fluorescent Prot8 particles by the cabodiimide
activation method [62]. Briefly, EDC (1 mg) and Sulfo-NHS (1 mg) were each dissolved in 0.1
M MES (pH 6.0, 1 mL) containing 0.5 M NaCl. The EDC solution (1 mg/mL, 10 μL) was added
to an aqueous solution of PNA (0.25 mg, 62.5 μL), followed by the addition of the sulfo-NHS
solution (1 mg/mL, 25 μL). The mixture was then shaken for 15 min, followed by the addition
of the NIR fluorescent Prot8 particles (2.5 mg in 1 mL PBS). The mixture was then shaken for
90 min. The obtained PNA-conjugated fluorescent particles were then washed from excess
reagents by dilution and filtration through a 30-kDa filtration tube (VS2021 VIVA SPIN) at
1000 rpm (Centrifuge CN-2200 MRC) for 2 min, repeated three times. FITC–PNA, anti-CEA
and anti-rabbit IgG were conjugated to the NIR fluorescent particles through a similar
procedure. The concentration of bound PNA was determined with FITC–PNA by a calibration
curve of FITC–PNA fluorescence using a multiplate reader (TECAN SpectraFluor Plus, Neotec
Scientific Instruments). The concentrations of bound anti-CEA and anti-rabbit IgG were
determined using a mouse IgG ELISA kit (Biotest, Israel). The calculated quantities of bound
PNA and anti-CEA were 3.2 and 1.9 μg per mg particles, respectively.
7.9. Optical detection of human colon tumors in a chicken embryo model
7.9.1. The chicken embryo CAM model
A chicken embryo CAM model was used to test the specific tumor detection by both the non-
conjugated and the bioactive (PNA, anti-CEA or anti-rabbit IgG) conjugated NIR fluorescent
Prot8 particles. Among most commonly used animal models, the chicken egg model allows
the imaging of several tumors in a short time period and is less expensive [62]. Tumor cells
were grafted on CAM according to the literature [62,64]. Briefly, fertile chicken eggs obtained
from a commercial supplier were incubated at 37°C at 60–70% humidity in a forced-draft
incubator. On day 3 of incubation, an artificial air sac was formed, allowing the CAM to drop.
After 8 days of incubation, a window was opened in the shell and the CAM was exposed.
Tumor cells were collected by trypsinization, washed with culture medium and pelleted by
gentle centrifugation. Following removal of the medium, 5x106 cells were resuspended in 30
μL ice-cold Matrigel and inoculated on the CAM at the site of the blood vessels. Eggs were
then sealed and returned to incubation. On day 6 post-grafting, day 14 of incubation, the tumor
diameter ranged from 3 to 5 mm with visible neoangiogenesis.
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Figure 14 shows typical SW480 cell line derived tumors bordered by plastic rings on a chicken
embryo CAM inside the egg.
Figure 14. Light photograph of SW480 cell line derived tumors bordered by a plastic ring on chicken embryo CAM.
Suspensions of 5×106 SW480 cells suspended in Matrigel formed compact structures (asterisk) 8 days after transplanta‐
tion with attraction of host blood vessels (arrow).
7.9.2. CAM tumor detection
Chicken embryos with 6-days-old human adenocarcinoma tumors (LS174t and SW480 cancer
cell lines) implanted on the CAM were treated with the non-conjugated, PNA-conjugated and
anti-CEA-conjugated NIR fluorescent Prot8 particles (40 μL, 2 mg/mL). Additionally, non-
pathological CAM treated with non-conjugated particles and untreated tumors served as
control groups. After 40 minutes, the nanoparticle dispersions were removed and the tumors
were washed with PBS. Then, the tumors and the non-pathological CAM were removed from
the eggs, washed again with PBS and spread on a mat black background for observation using
a Maestro II™ in vivo imaging system (Cambridge Research & Instrumentation, Inc., Woburn,
MA). A NIR excitation/emission filter set was used for the experiments (λex: 710–760 nm, λem
> 750 nm). The Liquid Crystal Tunable Filter (LCTF) was programmed to acquire image cubes
from λ = 790 nm to 860 nm with an increment of 10 nm per image. Fluorescence intensity
measurements were calculated as average intensity over the tumor surface area, using ImageJ
software.
7.9.3. In vivo optical detection of human colon tumors in a CAM model
LS174t and SW480 colorectal cell lines were used to demonstrate the possible use of the NIR
fluorescent Prot8 particles in tumor detection. As mentioned before, LS174t cells express
certain receptors (β-D-galactosyl-(1-3)-N-acetyl-D-galactosamine and CEA) at a much higher
extent than SW480 cells [62,65,66]. This way, the chosen bioactive ligands PNA and anti-CEA,
once conjugated to the Prot8 particles, can lead the particles specifically to the LS174t cancer
cells. As shown in Figure 15, the LS174t tumors treated with bioactive-conjugated particles (B
and C) gained higher fluorescence than SW480 tumors, compared to those treated with non-
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Chicken embryos with 6-days-old human adenocarcinoma tumors (LS174t and SW480 cancer
cell lines) implanted on the CAM were treated with the non-conjugated, PNA-conjugated and
anti-CEA-conjugated NIR fluorescent Prot8 particles (40 μL, 2 mg/mL). Additionally, non-
pathological CAM treated with non-conjugated particles and untreated tumors served as
control groups. After 40 minutes, the nanoparticle dispersions were removed and the tumors
were washed with PBS. Then, the tumors and the non-pathological CAM were removed from
the eggs, washed again with PBS and spread on a mat black background for observation using
a Maestro II™ in vivo imaging system (Cambridge Research & Instrumentation, Inc., Woburn,
MA). A NIR excitation/emission filter set was used for the experiments (λex: 710–760 nm, λem
> 750 nm). The Liquid Crystal Tunable Filter (LCTF) was programmed to acquire image cubes
from λ = 790 nm to 860 nm with an increment of 10 nm per image. Fluorescence intensity
measurements were calculated as average intensity over the tumor surface area, using ImageJ
software.
7.9.3. In vivo optical detection of human colon tumors in a CAM model
LS174t and SW480 colorectal cell lines were used to demonstrate the possible use of the NIR
fluorescent Prot8 particles in tumor detection. As mentioned before, LS174t cells express
certain receptors (β-D-galactosyl-(1-3)-N-acetyl-D-galactosamine and CEA) at a much higher
extent than SW480 cells [62,65,66]. This way, the chosen bioactive ligands PNA and anti-CEA,
once conjugated to the Prot8 particles, can lead the particles specifically to the LS174t cancer
cells. As shown in Figure 15, the LS174t tumors treated with bioactive-conjugated particles (B
and C) gained higher fluorescence than SW480 tumors, compared to those treated with non-
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conjugated particles (A). This is accurate both for Prot8 particles conjugates with PNA (B) and
anti-CEA (C), probably as a result of effective ligand-receptor interactions. In addition, the
SW480 tumors treated with bioactive-conjugated Prot8 particles gained less fluorescence
compared to those treated with the non-conjugated particles. The relative fluorescence
intensities of the treated tumors by the conjugated and non-conjugated Prot8 particles are
summarized in Figure 16. LS174t cells compared to SW480 cells gave fluorescence intensity
ratios of 4:1 and 8:1 for PNA-conjugated particles and anti-CEA-conjugated particles, respec‐
tively. The non-conjugated Prot8 particles also labeled the tumors, however, the difference in
the intensities between the types of tumors were not statistically significant. In this case, the
overall fluorescence in both types of cells was higher than when treated with PNA-conjugated
particles. This fact shows that even the bare non-conjugated particles penetrate the human
cancer cell lines with a good extent. The possible reason is that the Prot8 particles can penetrate
and label the cancerous cells specifically by either receptor-ligand interaction or utilization of
these particles as nutrients for tumor growth, as they resemble biological proteins. The
fluorescence intensity ratios between the types of cells show the significance of the nanoparticle
surface. As seen in Figure 15D, no autofluorescence was observed in untreated tumors,
signifying that all fluorescent signals are related to the fluorescent Prot8 particles labelling.
Figure 15E shows that no non-specific labelling of non-pathological CAM tissue was observed,
indicating the specificity of the Prot8 particles towards the tumor tissue.
Figure 15. Fluorescent (upper) and greyscale (lower) images from a typical experiment of tumor cell lines LS174t and
SW480 implants on chicken embryo CAM treated with non-conjugated (A), PNA-conjugated (B) and anti-CEA-conju‐
gated (C) NIR fluorescent Prot8 particles. Images of untreated tumor cell lines are shown in (D). Images of non-patho‐
logical CAM treated with non-conjugated, PNA-conjugated and anti-CEA-conjugated particles are shown in (E). The
experiment was repeated 5 times with similar results.
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Figure 16. Relative fluorescence intensities of LS274t and SW480 tumors labeled with non-conjugated, PNA-conjugated
and anti-CEA-conjugated particles. Data is presented as the mean value ± SE. Values not sharing a common letter (a, b,
c or d) differ significantly from each other (p<0.05). The calculations are an average of 3 experiments.
In another set of in vivo experiments on LS174t and SW480 tumors implanted on the CAM
model, the specific biomarker anti-CEA was tested against anti-rabbit IgG, serving as a non-
specific agent, as well as a control group of non-conjugated particles. As clearly illustrated in
Figure 17, LS174t tumors treated with anti-CEA-conjugated particles (B) gained greater
fluorescence compared to those treated with non-conjugated particles (A) or anti-rabbit IgG-
conjugated particles (C). This can be explained by the effective ligand-receptor interaction.
Furthermore, the SW480 tumors treated with the anti-CEA-conjugated particles gained less
fluorescence (about 3.5 times) compared to the LS174t tumors treated the same way. The
fluorescent signal of LS174t tumors labeled by anti-CEA-conjugated particles was 4 times
higher than that of the the tumors labeled by the anti-rabbit IgG-conjugated particles. Anti-
rabbit IgG "blocks" the particle from interacting with the tumor receptors by the conjugation
to the surface active moieties, thus serving as a negative control in colon tumor labelling.
Figure 17. Fluorescent and grayscale images from a typical experiment of LS174t and SW480 human tumor cell lines
implanted on chicken embryo CAM treated with the non-conjugated (A), anti-CEA-conjugated (B) and anti-rabbit IgG-
conjugated (C) NIR fluorescent Prot8 particles. Images of untreated tumors are shown in (D). The experiment was re‐
peated 3 times with similar results.
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Figure 16. Relative fluorescence intensities of LS274t and SW480 tumors labeled with non-conjugated, PNA-conjugated
and anti-CEA-conjugated particles. Data is presented as the mean value ± SE. Values not sharing a common letter (a, b,
c or d) differ significantly from each other (p<0.05). The calculations are an average of 3 experiments.
In another set of in vivo experiments on LS174t and SW480 tumors implanted on the CAM
model, the specific biomarker anti-CEA was tested against anti-rabbit IgG, serving as a non-
specific agent, as well as a control group of non-conjugated particles. As clearly illustrated in
Figure 17, LS174t tumors treated with anti-CEA-conjugated particles (B) gained greater
fluorescence compared to those treated with non-conjugated particles (A) or anti-rabbit IgG-
conjugated particles (C). This can be explained by the effective ligand-receptor interaction.
Furthermore, the SW480 tumors treated with the anti-CEA-conjugated particles gained less
fluorescence (about 3.5 times) compared to the LS174t tumors treated the same way. The
fluorescent signal of LS174t tumors labeled by anti-CEA-conjugated particles was 4 times
higher than that of the the tumors labeled by the anti-rabbit IgG-conjugated particles. Anti-
rabbit IgG "blocks" the particle from interacting with the tumor receptors by the conjugation
to the surface active moieties, thus serving as a negative control in colon tumor labelling.
Figure 17. Fluorescent and grayscale images from a typical experiment of LS174t and SW480 human tumor cell lines
implanted on chicken embryo CAM treated with the non-conjugated (A), anti-CEA-conjugated (B) and anti-rabbit IgG-
conjugated (C) NIR fluorescent Prot8 particles. Images of untreated tumors are shown in (D). The experiment was re‐
peated 3 times with similar results.
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7.10. Optical detection of human colon tumors in a mouse model
Experiments were performed according to the protocols of the Israeli National Council for
Animal Experiments by Harlan Biotech, Israel. Cancerous cells (30 μL containing 2×106 LS174t
cells) were injected into the mouse intestinal wall. 2 weeks later the nude mice were anaes‐
thetized and treated with the bio-conjugated NIR fluorescent Prot8 particles (0.1%, 200 μL),
through the anus, using the guidance of a mini-colonoscope. 20 min later each colon was
washed with PBS (5 × 1 mL) and mice were allowed to recover for 4 h. The mice were sacrificed
and the colons were removed. Each colon was spread on a solid surface and imaging was
performed using the Odysey Infra-red Imaging System (Li-Cor Biosciences, Lincoln, NE, USA)
with excitation wavelength of 780 nm and emission wavelength of 800 nm.
Figure 18 shows typical (8 out of 10 mice) fluorescent and grayscale images of the mice colons
after treatment with anti- CEA (A) and anti-rabbit IgG (B) conjugated particles. As illustrated
in Figure 18A, the anti-CEA-conjugated particles detected the tumors specifically and selec‐
tively with good signal to background ratio (SBR), the background refers to the surrounding
non-pathological tissue. Moreover, as illustrated in Figure 18B, the "inactive" anti-rabbit IgG-
conjugated particles did not produce a significant signal of the tumors.
Figure 18. Fluorescent and grayscale images of typical LS174t colon tumors treated with anti-CEA (A) and anti-rabbit
IgG (B)-conjugated NIR fluorescent Prot8 particles. 20 mice (10 in each experiment group) were anesthetized and treat‐
ed with 0.1% particle dispersion in PBS, as described in section 3.2.5.14. 2 untreated mice served as a control group.
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8. Summary and conclusions
In the present study, new proteinoids were prepared using L-glutamic acid, L-aspartic acid,
L-phenylalanine, L-lysine and low molecular weight poly(L-lactic acid). The polymerization
was carried out by a simple straight-forward condensation polymerization in heat. The optimal
conditions for the polymerization were tested, including changing the temperature and using
microwave radiation. The proteinoids made are of high molecular weights with narrow size
distributions and possess optical activity, which can be later used in specific drug delivery
using chirality. The proteinoids are thermally stable and each proteinoid has enough carbox‐
ylic acid and/or amine functional groups, which can be later used to bind covalently desired
molecules, such as drugs and dyes. The incorporation of 2000 Da PLLA into the proteinoid
backbone presented a stable proteinoid as well. Proteinoids were manipulated in several ways
to give proteinoid sphere-shaped nano/micro-particles, and to optimize this process. Specific
conditions were found for the production of hollow particles of narrow size distribution. The
incorporation of PLLA segments into the proteinoids increased the hydrophobic interior part
and resulted in smaller size hollow particles. The particles were found to be non-toxic and
stable over time. Also, encapsulation of different materials was carried out, giving organic-
filled particles and fluorescent particles. In summary, proteinoid formation and cytotoxicity
tests indicate that these particles are suitable for further in vivo testing.
The copolymer Prot8 containing 10% PLLA, was chosen to be used for the biomedical study,
since it provided the smallest particles with the biodegradability derived from the addition of
PLLA to the proteinoid backbone. The proteinoid-PLLA copolymer was self-assembled in the
presence of the NIR fluorescent dye ICG to yield NIR fluorescent Prot8 particles of 70 ± 15 nm
dry diameter. These new NIR fluorescent particles were found to be stable, avoiding leakage
and photobleaching of the NIR dye over time. Furthermore, these particles are non-toxic, as
shown by LDH and XTT assays for cytotoxicity and cell viability on human colorectal
adenocarcinoma cell lines. The particles biodistribution in a mouse model was tested, follow‐
ing an i.v. injection, and the results showed that the particles penetrate a variety of organs,
including the brain and bones. Nevertheless, 1 h post injection, the particles concentrate at
specific sites of the body and are evacuated almost completely over 24 h. It was established,
using the chicken embryo CAM model and the tumor-implanted mouse model, that the NIR
fluorescent particles may be very useful for tumor diagnosis in vivo due to their low auto‐
fluoresence of the background and the deep penetration into biomatrices. In the CAM model,
when the NIR fluorescent proteinoid-PLLA particles are conjugated to a bioactive ligand (PNA
or anti-CEA), they preserve their activity and specifically detect the cancer cells with upregu‐
lated receptors (LS174t vs. SW480). Non-conjugated and anti-rabbit IgG-conjugated NIR
fluorescent particles (control particles) marked the cells without specific recognition at a much
lower fluorescence intensity. In the mouse model, human tumor cells were implanted in mice
colons, and the mice were treated with the NIR fluorescent particles. The results showed that
the anti-CEA-conjugated particles specifically label the colon tumors, as opposed to those
conjugated with anti-rabbit IgG antibodies.
Advances in Bioengineering72
8. Summary and conclusions
In the present study, new proteinoids were prepared using L-glutamic acid, L-aspartic acid,
L-phenylalanine, L-lysine and low molecular weight poly(L-lactic acid). The polymerization
was carried out by a simple straight-forward condensation polymerization in heat. The optimal
conditions for the polymerization were tested, including changing the temperature and using
microwave radiation. The proteinoids made are of high molecular weights with narrow size
distributions and possess optical activity, which can be later used in specific drug delivery
using chirality. The proteinoids are thermally stable and each proteinoid has enough carbox‐
ylic acid and/or amine functional groups, which can be later used to bind covalently desired
molecules, such as drugs and dyes. The incorporation of 2000 Da PLLA into the proteinoid
backbone presented a stable proteinoid as well. Proteinoids were manipulated in several ways
to give proteinoid sphere-shaped nano/micro-particles, and to optimize this process. Specific
conditions were found for the production of hollow particles of narrow size distribution. The
incorporation of PLLA segments into the proteinoids increased the hydrophobic interior part
and resulted in smaller size hollow particles. The particles were found to be non-toxic and
stable over time. Also, encapsulation of different materials was carried out, giving organic-
filled particles and fluorescent particles. In summary, proteinoid formation and cytotoxicity
tests indicate that these particles are suitable for further in vivo testing.
The copolymer Prot8 containing 10% PLLA, was chosen to be used for the biomedical study,
since it provided the smallest particles with the biodegradability derived from the addition of
PLLA to the proteinoid backbone. The proteinoid-PLLA copolymer was self-assembled in the
presence of the NIR fluorescent dye ICG to yield NIR fluorescent Prot8 particles of 70 ± 15 nm
dry diameter. These new NIR fluorescent particles were found to be stable, avoiding leakage
and photobleaching of the NIR dye over time. Furthermore, these particles are non-toxic, as
shown by LDH and XTT assays for cytotoxicity and cell viability on human colorectal
adenocarcinoma cell lines. The particles biodistribution in a mouse model was tested, follow‐
ing an i.v. injection, and the results showed that the particles penetrate a variety of organs,
including the brain and bones. Nevertheless, 1 h post injection, the particles concentrate at
specific sites of the body and are evacuated almost completely over 24 h. It was established,
using the chicken embryo CAM model and the tumor-implanted mouse model, that the NIR
fluorescent particles may be very useful for tumor diagnosis in vivo due to their low auto‐
fluoresence of the background and the deep penetration into biomatrices. In the CAM model,
when the NIR fluorescent proteinoid-PLLA particles are conjugated to a bioactive ligand (PNA
or anti-CEA), they preserve their activity and specifically detect the cancer cells with upregu‐
lated receptors (LS174t vs. SW480). Non-conjugated and anti-rabbit IgG-conjugated NIR
fluorescent particles (control particles) marked the cells without specific recognition at a much
lower fluorescence intensity. In the mouse model, human tumor cells were implanted in mice
colons, and the mice were treated with the NIR fluorescent particles. The results showed that
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In summary, the chapter introduced a new series of newly-made proteinoids of a narrow
selection of amino acid monomers, with high molecular weight and very narrow polydisper‐
sity index. Furthermore, this chapter has described proteinoid fluorescent particles as potential
probes for precancerous colorectal adenomatous polyps or colon cancer tumors. Selective and
specific fluorescent labelling of tumors is possible, with very low background signal, however
improvements are still necessary for optimizing the targeting efficiency of the particles. Recent
and ongoing developments in fluorescence imaging systems will open up the scope for
effective detection of fluorescently labelled neoplasm. The proteinoid particles may further be
developed to serve for both diagnostics and therapy combined.
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Lipid-based nanoparticles (LNPs) are both biocompatible and biodegradable so very well
suited to medicinal application in targeted drug delivery and in vivo imaging. Microbubbles
(MB) are another emerging platform for functional delivery of drugs and in vivo imaging. This
chapter is focused on the principles of LNP and MB construction, action and application,
concluding with a section on the medical benefits that may result from bringing LNP and MB
technologies together. Some applications are mentioned in brief to demonstrate the diagnostic
and therapeutic potential of LNPs and MBs. More specific detail on applications is provided
elsewhere in this book.
2. LNP fundamentals
Structural lipids such as cholesterol and glycerophospholipids are the major components of
biological membranes. Without doubt, one of the great triumphs of nature is the manner in
which lipid molecules such as these are able to form into cellular membranes sufficient to
compartmentalize volumes within cells and between cells. In short, lipids are able to form the
vast macromolecular assemblies that come to make up cellular membranes and other barriers
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
in nature precisely because they have an unrivalled capability for self-association, driven by
weak short range forces and the hydrophobic effect (Figure 1) [1]. This capacity for self-
association can be exploited in the laboratory in order to create self-assembly LNPs (approx
100nm in diameter) (Figure 2) that are proving to be a powerful platform to enable the
functional delivery of active pharmaceutical ingredients (APIs) to target cells in vivo. Suitable
APIs might include biopharmaceutical agents (e.g. DNA, RNA interference effectors), selected
small molecule drugs (e.g. anticancer cytotoxic drugs), and/or imaging agents (e.g. magnetic
resonance imaging contrast metals – gadolinium (III) (Gd3+), radiometals, and/or fluorescent
probes). The number of lipid variations is almost limitless, so too the number and variety of
possible LNPs that may be produced for use in biological situations. Therefore, LNPs offer the
potential opportunity for tailor-made preparation and production leading in the future even
to the possibility of LNP-mediated personalized medicine, no less [2, 3].
Figure 1. Principles of lipid structure and self-assembly.
Advances in Bioengineering80
in nature precisely because they have an unrivalled capability for self-association, driven by
weak short range forces and the hydrophobic effect (Figure 1) [1]. This capacity for self-
association can be exploited in the laboratory in order to create self-assembly LNPs (approx
100nm in diameter) (Figure 2) that are proving to be a powerful platform to enable the
functional delivery of active pharmaceutical ingredients (APIs) to target cells in vivo. Suitable
APIs might include biopharmaceutical agents (e.g. DNA, RNA interference effectors), selected
small molecule drugs (e.g. anticancer cytotoxic drugs), and/or imaging agents (e.g. magnetic
resonance imaging contrast metals – gadolinium (III) (Gd3+), radiometals, and/or fluorescent
probes). The number of lipid variations is almost limitless, so too the number and variety of
possible LNPs that may be produced for use in biological situations. Therefore, LNPs offer the
potential opportunity for tailor-made preparation and production leading in the future even
to the possibility of LNP-mediated personalized medicine, no less [2, 3].
Figure 1. Principles of lipid structure and self-assembly.
Advances in Bioengineering80
Structural lipids of all types consist broadly of a non-polar, hydrophobic “chain” or “tail”
region attached to a “polar” or “head” region (a); biological membranes primarily adopt a
normal topology lamellar LαI fluid mesophase (bilayer) structure (b); under certain circum‐
stances biological membranes adopt other mesophases in particular the inverse topology
hexagonal HII fluid mesophase (c), where hydrophobic chain regions face outwards and
hydrophilic polar regions face inwards to form aqueous channels (the darker circles). (Dia‐
grams reproduced from [1])
However, and there always is a however, LNPs that have seen service in vivo are turning out
to have one fundamental design weakness which can be summarized by saying that those
chemical modifications to LNP surfaces that are necessary for such nanoparticles to be stable
to storage and in biological fluids, plus minimally visible to a host immune system, now turn
out to limit the efficiency of functional delivery once LNPs reach their target cells. Accordingly,
one of the primary ways to overcome this problem in recent years has been to introduce the
concept of nanoparticle triggerability to LNP design [2, 4]. Nanoparticles possess triggerability
(or are said to be triggerable) when designed for stability in biological fluids (from a desired
point of administration to disease-target cells) then become triggered for the controlled release
of associated APIs at target cells either through local changes in local endogenous (intrinsic)
conditions, or through the application of an exogenous (extrinsic) stimulus trained onto target
cell regions where nanoparticles are also located. What we are now learning is that MBs used
in combination with ultrasound can be used in with LNPs, to provide a potent way to introduce
LNP triggerability. Moreover, the introduction of ultrasound critically introduces an oppor‐
tunity for real-time, diagnostic imaging of LNP mediated delivery of APIs to target cells in
vivo. Nanoparticles that combine functional API delivery in vivo with real-time, diagnostic
imaging are known as theranostic nanoparticles (TNPs) [5]. Most importantly, TNPs offer the
opportunity for true image-guided therapy. As such this may well be a primary future of the
MBs-ultrasound-LNP combination as the rest of this chapter will now aim to demonstrate.
Figure 2. Functional lipid-based nanoparticle delivery systems.
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In functional lipid-based nanoparticles (LNPs), active pharmaceutical ingredients (APIs) (A)
are condensed within functional concentric layers of chemical components designed for
delivery into cells and intracellular trafficking (B components, primarily lipids and lipid-
related components), biological stability (C stealth/biocompatibility components–typically
Polyethylene Glycol [PEG]) and biological targeting to target cells (D components, biological
receptor-specific targeting ligands) [2, 3].
3. Liposomes to LNPs
Liposomes are the progenitors of all LNPs, and they are formulated directly from lipid
constituents (Figure 3). Liposomes can be prepared by various techniques. The method based
on hydration of lipid film represents the most exploited technique for preparation of lipo‐
somes. The lipids of known molarities are dissolved in organic solution which is subsequently
slowly evaporated in vacuo to produce a thin film. The film is hydrated with a suitable aqueous
buffer at temperature, which is generally above transition temperature of lipids used. Aqueous
buffer contains also compound which are to be entrapped into liposomes. Size of liposomes
can be reduced by freeze-thaw procedure followed by sonication, extrusion, microfluidisation
or high pressure homogenisation. These procedures can tune size distribution of final liposo‐
mal preparation to desired values. The main parameters characterising liposomes are their
size, spherical shape and degree of lamellarity. Liposomes may consist of one bilayer (unila‐
mellar), several bilayers (oligolamellar) or multiple bilayers (multilamellar). Membrane
rigidity can be adjusted using appropriate lipids and membrane fluidity may be controlled
with the use of phospholipids with higher or lower transition temperature.
Figure 3. Various morphological types of liposomes and real appearance in cryoelectron microscopy.
Small unilamellar vesicles (SUV); Large unilamellar vesicles (LUV); Multilamellar vesicles –
concentric (MLV); Multivesicular vesicles (MVV)
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Liposomes are generally formulated on the nm scale and can be further size refined by passage
through physical membrane pores of known size (extrusion). Liposomes are typically charac‐
terised by their size, spherical shape and degree of lamellarity. They may be composed of a
single bilayer (unilamellar), a few bilayers (oligolamellar), or multiple bilayers (multilamellar).
The rigidity of the membrane can also be modified with the use of suitable lipids; and the
fluidity of the membrane may be controlled using phospholipids with higher or lower LαI −
HII mesophase transition temperatures. In general lipids of stearic acids (fully saturated C18
hydrocarbon chains) bestow rigidity to liposome structures (by favouring LαI fluid mesophas‐
es), whilst lipids of oleic acid (Δ9 unsaturated C18 hydrophobic chains) can result in less stable
structures (by favouring HII fluid mesophases). Liposomes have traditionally been used as
some of the very earliest nanodrug delivery vehicles, encapsulating water-soluble drugs
within their central aqueous cavities in order to improve drug pharmacokinetics [6-8].
Liposome spherical diameters can be investigated by using scattered light off the surface of
the particles with photon correlation spectroscopy. Alternatively cryo-TEM can be used to
provide visual images of liposome sizes and shape. The surface charge of liposomes can be
obtained by measuring their zeta potential (electrokinetic potential). Liposome associated
techniques and characteristics have all been employed in more recent time times to prepare
more chemically diverse LNPs.
4. Cellular imaging
Cellular imaging is ”the visualisation of specific cells in an intact animal”. This term also
collectively denotes the visualisation of any type of the entire cell under different conditions
[9]. While cellular imaging applies to the imaging of whole cells, molecular imaging deals with
the visualisation of molecules and sub-cellular components within individual cells [10]. The
exploitation of molecular probes or imaging agents is essential for the use of both cellular and
molecular imaging strategies. Despite the fact that the method of cellular imaging of extrinsic
fluorophores is highly efficient, the depth of tissue from which the signal emitted represents
often a limiting factor for this technique. The possible use of positron emission tomography
(PET) or single–photon computed tomography (SPECT) methods is also limited due to short-
lived radioisotopes and poor spatial resolution. However, three-dimensional images of tissues
containing water can be obtained by magnetic resonance imaging (MRI). This technique is
characterised by high levels of spatial resolution and imaging of depth tissues is achieved.
A primary limitation of MRI is an inherent lack of sensitivity that can be overcome through
the use of contrast agents that enhance signal sensitivity and hence image quality. MRI contrast
agents consist of molecules that incorporate a paramagnetic metal ion, most commonly
gadolinium (III) (Gd3+) or Iron (Fe3+/Fe2+). The improvement in image quality derives from the
modulating effects of the coordinated metal ions on longitudinal (T1) or transverse (T2)
relaxation times associated with proton resonance signals emanating from bulk water mole‐
cules surrounding the coordinated metal ions. Even though contrast agents incorporating Gd3-
increase both 1//T1 and 1/T2 relaxivities, they are commonly used for T1-weighed (positive
bright) contrast imaging, on condition that 1/T1 contribution is higher in tissue than the
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corresponding effect on 1/T2 enhancement. Due to the fact that more considerable increases
in 1/T2 are induced by iron containing contrast agents, they are usually used in T2- weighed
(negative dark) contrast imaging [11]. Despite the most frequently used MRI contrast agents
are thermodynamically and kinetically stable low molecular weight Gd3+ complexes (that
promote MRI contrast by non-specific enhancement of water proton relaxation rates within
the blood pool), there has been a realization of the need for imaging LNPs suitable for the
targeted delivery of imaging agents to sites of disease pathology such as cancerous lesions in
order to obtain clear contrast images of their extent and location.
For cell populations to be imaged by MRI in vivo, these populations must be distinguishable
from natural background noise signal. For this to happen, cells of interest should become
labelled with appropriate agents, making use of controlling mechanisms such as enhanced
permeability and retention (EPR) mechanism for imaging agents to reach target cells [12,13,14],
followed by controlled target cell entry. According to Frangioni et al., the ideal cellular label
should have the following features: a strong signalling effect, good biocompatibility, does not
interfere with cellular genetics, remains retained only in the target cell population, and allows
temporal imaging for long-lasting periods [15]. Controlled target cell entry is preferably by
ligand-specific receptor-mediated cell entry processes, although alternative mechanisms of cell
entry may also be acceptable (Figure 4) [16].
Figure 4. Cell entry mechanisms: the various uptake mechanisms of macromolecules and nanoparticles into cells are
indicated according to their size (Adapted from [14]).
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LNPs are an ideal platform to combine multimodal imaging (e.g. MRI contrast agent and
fluorescent probes) with multiple functionalities in order to effect multimodal cellular
labelling. Targeting of LNPs to various tissues and cells (e.g. tumour) can be accomplished by
conjugation of LNP surfaces with biological receptor-specific targeting ligands (e.g. monoclo‐
nal antibodies, folate, RGD peptides) [2,3]. One of the best examples of such an imaging LNP
recently described in the literature is shown (Figure 5). This imaging LNP system (Gadonano-
F) is a novel Gd3+-containing, imaging LNP system that was designed to act as a folate receptor
(FR)-targeted, positive contrast agent to enable magnetic resonance imaging (MRI) of FR-
presenting cancerous lesions (primary and metastatic) including breast, lung, intestinal, renal,
and ovarian cancers.
Figure 5. Multimodal imaging Gadonano-F LNPs for targeted delivery of MRI contrast agents to tumour cells.
Gadonano-F LNPs are prepared as above with the indicated lipid components. Double
labelling is made possible using gadolinium metallochelating lipid (Gd.DOTA.DSA) for MRI
positive contrast imaging and rhodamine fluorescent probe conjugated lipid (DOPE-Rhoda)
for fluorescence imaging. Folate association with the Gadonano-F LNP surfaces is made
possible using a polyethylene glycol (PEG) lipid (folate-PEG2000-DSPE), ensuring that Gado‐
nano-F LNPs are enabled for FR-specific targeting to tumour cells in vivo. The remaining PEG
lipid (PEG2000-DSPE) ensures that the Gadonano-F LNPs possess stability in biological fluids
(e.g. serum) (see [14]).
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There are a number of pathways by which LNPs could enter mammalian cells, namely by
phagocytosis, pinocytosis, clathrin and calveolin independent endocytosis [9, 17]. Of these,
phagocytosis is a process of engulfing and internalisation of large particles (1 um) by cells. The
majority of phagocytic cells of the immune system, including macrophages, neutrophils,
monocytes, and microglia, are able to internalise foreign bodies via phagocytosis. Pinocytosis
is a method of particle internalisation by non-phagocytic cells but this is a very non-specific
mechanism of internalisation into cells [9]. On the other hand, clathrin-mediated endocytosis
(receptor-mediated) and caveolin-mediated endocytosis are much the more specific means of
cellular entry, of which the first is ideal for entry of LNPs to cells.
In original preclinical laboratory experiments, Gadonano-F LNPs were prepared and used to
image xenograft tumours (IGROV-1) in mice. At just 2h post-injection the Gadonano-F LNPs
mediated a similar signal enhancement to that attained at 24h post-injection by control
(Gadonano LNPs, lacking folate ligand) (Figure 6). Specifically, Gadonano LNPs accumulated
in tumour by the EPR mechanism (“passive” targeting) [12, 13], and labelled cells for MRI over
a period of 24h. These imaging LNPs were seen to access the entire hyperpermeable, living
volume of the tumour while being excluded from the necrotic regions. By contrast, the FR-
targeted Gadonano-F LNPs accumulated in the tumour and labelled cells for MRI from 2h
onwards, owing to EPR mediated tumour uptake from the blood pool followed by rapid FR-
mediated cell entry probably involving clathrin-mediated endocytosis. FR-targeted imaging
LNPs accumulated in more perivascular and macrophage-rich locations [14,18].
Gadon no-F LNPs accumulated in the tumour and labelled cells for MRI from 2h onwards, owing to EPR mediated tumour uptake 
from the blood pool followed by rapid FR-mediated cell entry probably involving clathrin-mediated endocytosis. FR-targeted 
imaging LNPs accumulated in more perivascular and macrophage-rich locations [14,18].  
Figure 6. Fluorescence microscopy and MRI contrast imaging of 24 h post imaging LNP injection.
On the left 24 h post imaging LNP administration, (a) surface IGROV-1 tumor slices, Gadonano LNPs, (b) midtumor IGROV-1 
slices, Gadonano LNPs, (c) surface IGROV-1 tumor slices, Gadonano-F LNPs, and (d) IGROV-1 midtumor slices, Gadonano-F 
LNPs (green bar represents 50 μm). On the right, MRI contrast images of IGROV-1 tumour bearing Balb/C nude mice: images are 
from control mice injected with Gadonano LNPs (top); images are of mice injected with Gadonano-F LNPs (bottom) (white arrow 
shows location of tumour) (Adapted from [18])
Rapid and effective imaging of FR-bearing tumours by Gadonano-F LNPs in preclinical experiments, has since led to these LNPs 
being prepared for clinical trial by GlobalAcorn Ltd under the name GA101 NANO-GdF (Gadonano LNPs are also being developed 
for clinical trial by GlobalAcorn Ltd under the name GA100 NANO-Gd). Rapid and specific imaging of diseased tissues and tumours
will be of paramount importance for preclinical research and also future diagnostic and theranostic applications in clinic [2,3].  
Microbubbles (MBs) 
Since the MBs were first proposed as suitable tools for ultrasound contrast agents more than three decades ago, there has been a
remarkable progress in the field. In accordance with that, the research has been particularly concerned with the MB preparation
techniques and their standardization, in order to ensure a steady composition and size distribution of MBs, both representing crucial
features for the stability of MBs in vivo and thus providing a sufficient backscatter for ultrasound imaging. Although the very first 
MBs were generally considered to contribute to improvement of the imaging techniques, they were soon proved to serve as excellent 
drug and gene delivery systems both in diagnostics and therapy. Much has been discussed on ultrasound molecular imaging using 
MBs as contrast agents, including novel preparation techniques and their general design; however, the choice of a convenient system 
for drug and gene delivery and concept of MB functionalization is still an issue worth consideration. In this chapter, potential ways 
for application of MBs as contrast agents together with drug and gene delivery are shown, relating to the recently used functionalized 
MBs in vitro and in vivo.
MBs are small gas-filled microspheres whose size typically ranges between 1 and 10 µm in diameter see (Figure 7). They comprise a 
gas-filled core, usually formed by inert, high molecular gases such as sulphur hexafluoride or perfluorocarbons, which due to their
decreased solubility and low diffusion prolong the lifespan of MBs in circulation [19], by means of a stabilizing shell of lipid,
polymer and/or protein [20, 21]. The composition of the shell determines the stiffness and therefore the stability of MBs in blood 
flow, where instability is caused by exposure of MBs to the rigors of systemic circulation [19, 22].  Limits on stability can effect the 
scope of ultrasound imaging utilization in vivo since the half-life of MBs depends on their stability. Generally, lipid shelled MBs are 
considered thinner and more flexible, whilst polymer and protein-shelled bubbles have a thicker and more rigid shell [23]. A thick 
permeable shell is beneficial to enhance the MB stability (also reducing the gas diffusion) and thus might be used for ultrasound drug 
delivery purposes [19, 24, 25]. However, the shell ought to only slightly limit the vibration of MBs in the ultrasound field generated 
by echo imaging systems (otherwise they do not provide sufficient contrast).  
Another important aspect for any MB formulation is their size distribution that dictates the acoustic properties of MBs [22]. As the 
MBs smaller than 1 µm in diameter produce minimal acoustic contrast, the intent is to produce larger MBs [26-29]. On the other 
Figure 6. Fluorescence microscopy and MRI contrast imaging of 24 h post imaging LNP injection.
On the left 24 h post imaging LNP administration, (a) surface IGROV-1 tumor slices, Gadonano
LNPs, (b) midtumor IGROV-1 slices, Gadonano LNPs, (c) surface IGROV-1 tumor slices,
Gadonano-F LNPs, and (d) IGROV-1 midtumor slices, Gadonano-F LNPs (green bar repre‐
sents 50 μm). On the right, MRI contrast images of IGROV-1 tumour bearing Balb/C nude mice:
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images are from control mice injected with Gadonano LNPs (top); images are of mice injected
with Gadonano-F LNPs (bottom) (white arrow shows location of tumour) (Adapted from [18])
Rapid and effective imaging of FR-bearing tumours by Gadonano-F LNPs in preclinical
experiments, has since led to these LNPs being prepared for clinical trial by GlobalAcorn Ltd
under the name GA101 NANO-GdF (Gadonano LNPs are also being developed for clinical
trial by GlobalAcorn Ltd under the name GA100 NANO-Gd). Rapid and specific imaging of
diseased tissues and tumours will be of paramount importance for preclinical research and
also future diagnostic and theranostic applications in clinic [2, 3].
5. Microbubbles (MBs)
Since the MBs were first proposed as suitable tools for ultrasound contrast agents more than
three decades ago, there has been a remarkable progress in the field. In accordance with that,
the research has been particularly concerned with the MB preparation techniques and their
standardization, in order to ensure a steady composition and size distribution of MBs, both
representing crucial features for the stability of MBs in vivo and thus providing a sufficient
backscatter for ultrasound imaging. Although the very first MBs were generally considered to
contribute to improvement of the imaging techniques, they were soon proved to serve as
excellent drug and gene delivery systems both in diagnostics and therapy. Much has been
discussed on ultrasound molecular imaging using MBs as contrast agents, including novel
preparation techniques and their general design; however, the choice of a convenient system
for drug and gene delivery and concept of MB functionalization is still an issue worth
consideration. In this chapter, potential ways for application of MBs as contrast agents together
with drug and gene delivery are shown, relating to the recently used functionalized MBs in
vitro and in vivo.
MBs are small gas-filled microspheres whose size typically ranges between 1 and 10 μm in
diameter see (Figure 7). They comprise a gas-filled core, usually formed by inert, high
molecular gases such as sulphur hexafluoride or perfluorocarbons, which due to their
decreased solubility and low diffusion prolong the lifespan of MBs in circulation [19], by means
of a stabilizing shell of lipid, polymer and/or protein [20, 21]. The composition of the shell
determines the stiffness and therefore the stability of MBs in blood flow, where instability is
caused by exposure of MBs to the rigors of systemic circulation [19, 22]. Limits on stability can
affect the scope of ultrasound imaging utilization in vivo since the half-life of MBs depends on
their stability. Generally, lipid shelled MBs are considered thinner and more flexible, whilst
polymer and protein-shelled bubbles have a thicker and more rigid shell [23]. A thick perme‐
able shell is beneficial to enhance the MB stability (also reducing the gas diffusion) and thus
might be used for ultrasound drug delivery purposes [19, 24, 25]. However, the shell ought to
only slightly limit the vibration of MBs in the ultrasound field generated by echo imaging
systems (otherwise they do not provide sufficient contrast).
Another important aspect for any MB formulation is their size distribution that dictates the
acoustic properties of MBs [22]. As the MBs smaller than 1 μm in diameter produce minimal
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acoustic contrast, the intent is to produce larger MBs [26-29]. On the other hand, the MB size
distribution should not exceed 10 μm of size in diameter; otherwise they get quickly filtered
by the lungs and can pose a risk of embolus [22, 30]. Furthermore, the size distribution is also
believed to affect the drug delivery [22, 31, 32].
6. Ultrasound imaging
In the field of molecular imaging, ultrasound represents a unique imaging technique as it
provides real-time images in a non-invasive way using relatively cheap and easily portable
equipment; thus, ultrasonography is considered to be currently most widely used diagnostic
imaging modality [19]. However, since the liquid phase material with low compressibility,
such as blood, scatters the sound waves poorly, contrast agents were proposed to improve the
ultrasound images, offering the following general advantages: a very small intravenous
injection is needed for imaging; and they are composed of non-toxic, biodegradable materials
[30]. There are several types of ultrasound contrast agents, such as liquid emulsions, liposomes,
and gas-filled MBs [33]. MBs will be described in detail in this chapter. Since the MB-based
contrast agents are similar in size and shape to erythrocytes and also rheologically behave
similarly to the blood, they appear to be of utmost convenience for ultrasound imaging
systems, providing bright contrast [30]. Moreover, due to their larger size (compared to lipid
and polymer based nanocarriers), systematically delivered MBs do not extravasate; instead
they remain in circulation until they dissolve or are actively cleared by the mononuclear
phagocyte system (MPS) [21, 34, 35].
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a. Light microscopy of DPPC/ DPPC/1% DOGS-NTA-Ni MB with carboxyfluorescein-PE
(1%)
b. The same MBs as in (A) observed by epifluorescence microscopy.
c. TEM of MBs. During desiccation of the sample in the vacuum interior of electron micro‐
scope, the MB are pressed to each other, which results in the deformed polygonal shape
d. SEM picture of lyophilised MBs. Intact MB (black arrows), crushed MB shell (white arrow),
hollow inside of MB (white asterisk). Insert: detail of the surface of lyophilised MB.
(Adapted from [48])
7. MBs in the ultrasound field – Different aspects
When exposed to low acoustic pressures, MBs tend to oscillate in a symmetrical, linear way
[36], which means that their expansion and compression is inversely proportional to the local
ultrasound pressure [37]; the phenomenon is known as a stable cavitation or non-inertial
cavitation [38] and comprises stable, low amplitude oscillations of MBs (Figure 8) [23]. Such
stable oscillations create a liquid flow around the MBs, the so called microstreams, which can
apply a shear stress on cell membranes resulting in a transient opening of the cell membranes,
as the shear stress related to micro streaming is relatively high compared to the shear stress
associated with blood flow [23, 36, 39]. With the driving pressure turning into violent or inertial
cavitation [38, 40], MBs undergo rapid expansion and contraction, which result in a violent
bubble destruction [21]. The collapse of MBs is accompanied by shock waves generated in the
fluid near the MB; furthermore, jet formation may occur, which can both contribute to a cell
membrane perforation and increased permeabilization of blood vessels, thus improving
extravasation of circulating drugs into target cells and tissues [20, 23, 41-44]. This phenomenon
is called sonoporation [45] and has been proved visualisation of the pores by scanning electron
microscopy, showing the pores in the plasma membrane (Figure 9) [46, 47]. Despite initial
belief that inertial cavitation of MBs was required to enhance uptake of low molecular weight
drugs, there is now mounting evidence that these stable oscillations may also stimulate the
intracellular delivery of macromolecular drugs and nanoparticles [36]. Two mechanisms have
been postulated to contribute to the uptake of cell impermeable molecules: the formation of
small pores and endocytosis [46, 49]. Whilst the involvement of endocytosis was shown to be
more extensive for larger molecules, the pore formation is considered the main mechanism for
low-weight molecules, such as dextrans [49]. Moreover, when studied in a single-cell model,
it was reported that a direct contact is needed to induce pore formation by stable cavitation,
as larger distances would hamper direct mechanical cavitating MB and cell membrane and
decrease the influence of microstreaming on the cell membrane (Figure 10) [36, 50-52].
Additionally, MBs facilitate cavitation related phenomena, such as temperature rise and free
radical formation [21, 42, 53]; it is assumed that the free radicals increase the cell membrane
permeability for Ca2+ in primary endothelial cells and cardiomyocytes [54-56].
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Last but not least, acoustic radiation forces that may translate MBs in the direction of the
propagating ultrasound wave should be taken into account [21, 36, 57, 58]. Not only can the
acoustic radiation forces be applied to adhere to a specific target, but they can also help to push
the MBs towards the cell surface and thus stimulate interaction with the cell membrane and
promote drug delivery to specific cells [59-62]. Through acoustic radiation forces, MBs can
squeeze through endothelium and tunnel through soft tissue, possibly increasing the deposi‐
tion of shell-loaded materials beyond the vasculature [21, 63, 64].
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Figure 10. Various aspect of haw MBs can effect endothelial cell in capillary vessels.




The use of MBs in echocardiography was first reported in 1968 [65]. Since that time great
progress has been done in preparation of MBs for human and veterinary use. The following
three commercial MB agents Optison TM (GE Healthcare, WI, USA), Definity® (Lantheus
Medical Imaging, MA, USA) and SonoVue® (Bracco, Milano, Italy) currently hold the license
for clinical diagnostic applications (Table 1). The size of the commercial MBs in these agents
is usually larger than 1 um with imaging durations being 5-10 min.






OptisonTM GE Healthcare Albumin C3F8 2.0 - 4.5 5-8x108 2.5-4.5
Definity® Lantheus Medical
Imaging
Phospholipid C3F8 1.1 - 3.3 1.2x1010 2-10
SonoVue® Bracco Phospholipid CF6 2.0-8.0 0.9-6x1010 3-6
Table 1. Specifications of commercial and self-made MBs.
9. Multifunctional MBs for ultrasound imaging and theranostics
The concept of therapeutic agents being encapsulated in or conjugated with MBs has been
developed over the past few years. In addition to the synergistic effects of ultrasound and MBs
to enhance the permeability of biological barriers such as cell membranes, small blood vessels,
and the BBB, as discussed above, MBs can serve as protective drug carriers. Drugs can be pre-
incorporated into carriers such as liposomes, micelles, or microspheres, and these structures
can then be easily attached to lipid MBs, usually via avidin-biotin interactions (Figure 11) [66].
Such advanced MB complexes have extremely high drug loading capacities and the advantage
of being able to encapsulate both hydrophilic and hydrophobic drugs. Encapsulating unstable
agents protects them from degradation in blood, thus prolonging their half-lives in vivo,
improving treatment efficacy, and lowering the required dose [67]. Another advantage is that
the encapsulated agents can be released during the ultrasound-triggered MB destruction
process. Chemotherapeutic drugs can thus be directly and specifically delivered to target
tissues via ultrasound-mediated perforations, whereas the uptake of the drugs by non-target
tissues is reduced. The encapsulated agents are conjugated close to the shell of MBs, increasing
the opportunity for microstreams, shock waves, and microjets to drive them toward the tissues
and enhance their uptake in the ultrasound-treated region [68]. Since MBs act as ultrasound
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and the BBB, as discussed above, MBs can serve as protective drug carriers. Drugs can be pre-
incorporated into carriers such as liposomes, micelles, or microspheres, and these structures
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improving treatment efficacy, and lowering the required dose [67]. Another advantage is that
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process. Chemotherapeutic drugs can thus be directly and specifically delivered to target
tissues via ultrasound-mediated perforations, whereas the uptake of the drugs by non-target
tissues is reduced. The encapsulated agents are conjugated close to the shell of MBs, increasing
the opportunity for microstreams, shock waves, and microjets to drive them toward the tissues
and enhance their uptake in the ultrasound-treated region [68]. Since MBs act as ultrasound
contrast agents, the drug delivery process can also be concurrently monitored by detecting the
drug-loaded MBs [69].
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Figure 11.  Targeted and multifunctional MBs.  
A) Structure of plain MB (upper – schematic picture; bottom – optical microscopy –Nomarski contrast) 
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C) Transmission electron microscopy of the functionalised MB with bound liposomes. Black arrow -  rupture of MB shell owing to 
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Figure 11. Targeted and multifunctional MBs.
10. Targeted MBs
Despite the possibility of employing MBs for targeted ultrasound imaging and drug and gene
delivery using the local ultrasound insonation, attaching targeting ligands on the surface of
MBs, which leads to their accumulation in the target region (Figure 12), makes the MBs even
more specific so that the range of clinical use of MBs is vastly expanded [23]. Owing to their
size, MBs are not supposed to leave the vasculature; thus their use is limited to thrombus,
endothelial cells, atherosclerotic plaques, blood clots, and organs such as spleen and liver [23,
47]. Recently there have also appeared papers referring to the use of MB-enhanced ultrasound
for facilitated brain delivery [70, 71]; although the exact mechanism is still unknown, the
interaction between capillary walls and acoustically driven MBs was found to be one of the
key factors which leads to the disruption of the blood-brain barrier – the main obstacle in the
treatment of neurodegenerative diseases [70, 72]. Since the method is non-invasive, according
to the authors, it could be the way for treatment of such diseases as Parkinson’s disease or
Alzheimer’s disease.
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Figure 12. Passive and active targeting of MBs.
There are different ways how to attach the targeting ligands to the shell of MBs that are generally
distinguished by the method of preparation. The targeting ligand can be either co-incorporat‐
ed in the shell during the MB preparation, or attached to the surface of pre-formulated MBs by
covalent or non-covalent methods [73, 74]. The simplest targeted MB design is based on the use
of a phospholipid, phosphatidylserine, which is incorporated in the MB shell during prepara‐
tion. Due to the fact that phosphatidylserine is a membrane marker of apoptosis, it promotes
the phagocytic uptake of cells and liposomes by Kupffer cells and macrophages [74-76]. While
circulating in the bloodstream, MBs containing phosphatidylserine are actively targeting and
captured by the Kupffer cells in the liver, macrophages in the spleen and active neutrophils in
the areas of inflammation, which is the reason why phosphatidylserine-shell agents are used
to detect the foci that lack active phagocytic capacity, e.g. tumour nods in the liver [73, 77-79].
In these agents, the shell is the ligand (phosphatidylserine); since the molecules of phopshati‐
dylserine are kept together by the hydrophobic, van der Waals, and other intermolecular
interactions, the ligand is attached in a non-covalent manner [73].
Nevertheless, though prepared by straightforward shear-mixing in one simple step, this method
is convenient only for stable ligands, which are able to survive the extreme conditions during
the MB preparations [23]. Particularly some proteins and enzymes might be denatured in the
harsh conditions and might lose binding affinity [73]. Therefore a different approach has been
applied, involving attachment of ligands after MB preparation: non-covalent (strept)avidin-
biotin interaction and covalent binding [23, 73, 80, 81]. Considering the fact that the (strept)avi‐
din-biotin interaction has the strongest effective dissociation constant, it has been the most
widely used technique in biotechnology [82]. Biotin residues might be attached in one single
step to antibodies, carbohydrates and many other targeting ligands, including the MB shell
components [73, 83]. Biotinylated antibodies are abundant and can be easily linked to prema‐
nufactured biotinylated bubbles via a streptavidin linker [84].  Nonetheless,  this coupling
scheme is useful only in preclinical research: streptavidin as a foreign protein is a possible
immunogen which might lead to undesired immune response after multiple injections [85].
Another attractive non-covalent strategy is to use the interaction of a metallochelating lipid
complex, such as nickel-nitrilotriacetyl lipid, with a multiplicity of histidine residues (His-tag)
of a protein [48]. The method offers an easy way to attach a genetically engineered protein to
the MB surface with a His-tag, a commonly applied insert in recombinant protein preparation.
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Figure 12. Passive and active targeting of MBs.
There are different ways how to attach the targeting ligands to the shell of MBs that are generally
distinguished by the method of preparation. The targeting ligand can be either co-incorporat‐
ed in the shell during the MB preparation, or attached to the surface of pre-formulated MBs by
covalent or non-covalent methods [73, 74]. The simplest targeted MB design is based on the use
of a phospholipid, phosphatidylserine, which is incorporated in the MB shell during prepara‐
tion. Due to the fact that phosphatidylserine is a membrane marker of apoptosis, it promotes
the phagocytic uptake of cells and liposomes by Kupffer cells and macrophages [74-76]. While
circulating in the bloodstream, MBs containing phosphatidylserine are actively targeting and
captured by the Kupffer cells in the liver, macrophages in the spleen and active neutrophils in
the areas of inflammation, which is the reason why phosphatidylserine-shell agents are used
to detect the foci that lack active phagocytic capacity, e.g. tumour nods in the liver [73, 77-79].
In these agents, the shell is the ligand (phosphatidylserine); since the molecules of phopshati‐
dylserine are kept together by the hydrophobic, van der Waals, and other intermolecular
interactions, the ligand is attached in a non-covalent manner [73].
Nevertheless, though prepared by straightforward shear-mixing in one simple step, this method
is convenient only for stable ligands, which are able to survive the extreme conditions during
the MB preparations [23]. Particularly some proteins and enzymes might be denatured in the
harsh conditions and might lose binding affinity [73]. Therefore a different approach has been
applied, involving attachment of ligands after MB preparation: non-covalent (strept)avidin-
biotin interaction and covalent binding [23, 73, 80, 81]. Considering the fact that the (strept)avi‐
din-biotin interaction has the strongest effective dissociation constant, it has been the most
widely used technique in biotechnology [82]. Biotin residues might be attached in one single
step to antibodies, carbohydrates and many other targeting ligands, including the MB shell
components [73, 83]. Biotinylated antibodies are abundant and can be easily linked to prema‐
nufactured biotinylated bubbles via a streptavidin linker [84].  Nonetheless,  this coupling
scheme is useful only in preclinical research: streptavidin as a foreign protein is a possible
immunogen which might lead to undesired immune response after multiple injections [85].
Another attractive non-covalent strategy is to use the interaction of a metallochelating lipid
complex, such as nickel-nitrilotriacetyl lipid, with a multiplicity of histidine residues (His-tag)
of a protein [48]. The method offers an easy way to attach a genetically engineered protein to
the MB surface with a His-tag, a commonly applied insert in recombinant protein preparation.
Advances in Bioengineering94
The advantage of metallochelating complex over protein-ligand complexes, e.g. (streptavidin
– biotin, glutathion – glutathion transferase) consists in its specific binding and very low
immunogenicity, if any [86]. However, except for studies using metallochelating liposomes
[86, 87], very little research has been devoted to this issue in terms of MBs; therefore there still
appears to be a high potential for the His-tag – MB applications in the foreseeable future.
Figure 13. Schematic presentation of metallochelating MBs, confocal and electron microscopy of metallochelating MBs
and coupling of proteins with HisTag anchor.
The rGFP-HisTag molecule bound onto the surface of metallochelating liposomes was directly
detected by TEM (A,B). Fluorescence of rGFP was used to prove binding of this protein onto
the MB (C). The binding did not affect the native conformation of rGFP as demonstrated by
the preserved fluorescence characteristics of the protein. Homogenous population of highly
fluorescent rGFP MB was detected by flow cytometry (G). Nonspecific binding of rGFP on
both DPPC liposomes as well as MB lacking DOGS-NTA-Ni was not observed by flow
cytometry and confocal microscopy. Confocal microscopy confirmed co-localisation of bound
rGFP-HisTag (green fluorescence) with the lipids forming MB monolayer. The monolayer was
marked with LisR-PE (red fluorescence) (D, E, F). Confocal microscopy revealed that a small
fraction of MB had also attached liposomes or residual lipid structures of collapsed MB on
their surface (as seen in D, E, F). This is in a good agreement with the electron microscopy data
(D) (Adapted from [48]).
Concerning the covalent coupling methods, the techniques are basically the same as the ones
developed for the attachment of ligands to liposomes [88]. As the covalent coupling does not
require foreign proteins or His-tags (Figure 13), the chances of undesired immune response to
the ligand are low [84]. The simple covalent coupling with the formation of peptide bond
between the carboxyl-carrying MBs and protein aminogroups is achieved by adding carbo‐
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diimide chemistry [89]. First, a carboxyl group is activated with carbodiimide in the presence
of N-hydroxysulfosuccinimide, forming active ester [84]. The resulting ester then reacts with
the protein aminogroup, forming an amide bond. This method is unfortunately unsuitable for
clinical settings as well, as to achieve the desired number of targeting molecules per bubble,
large quantities of expensive antibodies must be added to the reaction mixture, not to mention
that only very few of them are actually coupled by the peptide bonding [73]. An alternative
approach of covalent coupling scheme for antibody attachment to MB surface seems to be thiol-
maleimide chemistry, developed for targeted liposome applications [90]. In this case, malei‐
mide on the shell is coupled with a thiol group on the ligand, forming thiol-ether [74]. This
technique is convenient with respect to a possible oriented coupling; if a ligand has a single
thiol, then a single point attachment to the MB shell should retain affinity of the ligand to this
target [84]. Overall, selective oriented coupling with of thiol-protein with a maleimide-carrying
MB seems more attractive.
Despite the possibility of attaching the ligand directly to the MB surface, it might seem more
suitable to connect the ligand to lipid via an extended spacer arm, such as poly(ethylene glycol)
known as PEG. Up to 30 nm long [91], flexible extended PEG spacer arm separates the ligand
and the anchor from each other [92], so that the spacer arm acts as a “fishing line” [93], improving
the chances of reaching its target and MB adhesion and retention on the receptor-coated surfaces
[73, 92, 94]. On the other hand, similar to the design of long-circulating liposomes, PEG chains,
or PEG chain derivatives, can be incorporated into the shell of MBs in order to form a steric
barrier against coalescence and adsorption of macromolecules, such as antibodies [47, 95]. In
recent papers, the protective role by the PEG chains was shown when the targeting ligand was
attached to shorter PEG chains that were shielded by a PEG overbrush layer (buried-ligand
architecture), significantly increasing the MB in vivo stability, prolonging their circulation life-
time and reducing ligand-mediated immunogenicity; it was also reported that the extent of PEG
protection to depended on the overbrush length [48, 96-99]. PEG overbrush architecture (PEG
- polyethyleneimine with a high degree of substitution) was lately used for complexing and
stabilizing the plasmid as well; as a result, the transfection was significantly enhanced [100].
One of the possible reasons for enhanced drug and gene delivery when PEG overbrush strategy
is applied is the fact that targeting ligands are generally affixed to the free ends of the PEG chains
to direct the MBs to a given target [97], so that the bubbles usually bear thousands of ligands on
their surface. Thus cooperative binding of multiple ligands to a target might increase the affinity
of particles to the target site, boosting the transfection efficacy. A combination of targeted MB
agent BR55 and peptide ligand attached to the bubble shell via a PEG spacer are has even been
applied in a prostate cancer clinical trial [101].
11. Drug- and gene-loading strategies
The main advantage of the use of MB-based particles as a delivery tool for drugs and genes
lies in the dose reduction while maintaining its therapeutic efficacy; the method thus provides
much less toxicity than conventional cytotoxic therapies and at the same time has more
specificity, which has a great potential particularly in cancer treatment [84]. Generally, drugs
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and/or genes can be either (a) co-administered with MBs, (b) enclosed within the MB shell, (c)
incorporated in the MB shell, (d) attached to the surface of the MBs (e) incorporated in
liposomes or nanoparticles that are associated with the MB surface.
11.1. Co-administration of drugs with MBs
In this case, the MBs enhance the permeability of the endothelial wall in different manners; (1)
by rupture of the endothelial wall, so that larger particles such as erythrocytes and polymer
particles are able to extravasate [102]; (2) by MBs causing the temporary membrane opening
when the low pressure is applied [103]; (3) by sonoporation, allowing for radionuclides or
plasmid DNA to pass through [104, 105]. For more detailed description of the mechanisms
concerned, please see the above part “Microbubbles in the Ultrasound Field”.
11.2. Enclosing drugs within the MB shell
Instead of co-injecting drugs and MBs, the bubbles might be modified to contain drugs or DNA
[97, 106-110]. It is virtually possible to load the drugs within the interior of the MBs, which is
very convenient since the drug is completely protected and is not released before applying the
ultrasound [23]. However, since the MBs are relatively small, the space for drug loading is quite
limited. This approach was applied for the first time in 1998 already by the team of Unger, who
used lipid-shelled MB with an addition of paclitaxel containing oil phase. Nonetheless, Unger
reported the methodology seems to be unsuitable for clinical setting for three reasons; firstly,
as the monolayer of the lipid-shelled MB is very thin, only small amount of drug can be loaded;
secondly, this strategy is limited only to hydrophobic drugs; last but not least, due to the very
high mechanical indexes of ultrasound waves necessary for drug release, which resulted only
in 30% of cell death, the in vivo use of such ultrasound setting appears unfeasible [110].
Recently, Kooiman et al. used oil-filled polymer microcapsule model for ultrasound-mediated
delivery of lipophilic drugs; microcapsules with a shell of fluorinated end-capped poly(L-lactic
acid) contained hexadecane oil as a drug-carrier reservoir. At higher diagnostic pressures, the
microcapsules cracked and released the drug [111]. Despite offering a great potential in clinical
use, there are limitations as this approach can be applied only for lipophilic drugs. In another
paper, Tinkov et al. suggested the application of doxorubicin (DOX)-loaded phospholipid MBs
for targeted tumour therapy. DOX as a potent chemotherapy was loaded into the DPPC/DPPG/
PEG2000-DPPE MBs and was tested in a pancreas carcinoma model of the rat. Although an
agglomeration and capillary adhesion with embolisation/occlusion of the pulmonary arteries/
capillaries after intravenous infusion of MBs with any new formulation might appear, in this
case no rat died or showed any signs of pulmonary vascular occlusion [112]. Therefore the
strategy seems suitable for more extensive preclinical therapeutic studies.
11.3. Nucleic acids and MBs
Concerning gene delivery, [113] incorporated plasmid DNA inside the gas core of polymer
MBs, so that the plasmid was even protected from the host nucleases; at the same time high
plasmid load per bubble was achieved [113]. In a recent study, Sun et al. compared the
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transfection efficiency of commercial Definity MBs to modified cationic MBs with longer lipid
chain; as a result, cationic bubbles were binding significantly more DNA, so that multi-fold
enhancement was reached in gene delivery [114]. The results were consistent with the findings
of Panje and Nomikou, et al. and the notion that gene delivery might be augmented with a
higher local DNA concentration [115, 116]. In another study, Florinas et al. designed a non-
viral siRNA gene carrier using a combination of an arginine-grafted bioreducible polymer
(ABP), MBs and ultrasound, for targeting vascular endothelial growth factor (VEGF) in human
ovarian cell line; as a result, MBs in combination with lipoplexes showed significantly higher
loading capacity compared to naked siRNA; furthermore, only siRNA complexes with ABP
and MBs showed significant knock down in human ovarian cell line compared to naked siRNA
when incubated for a short time after sonication treatment [116]. The potential of MBs as gene
carriers is still on its rise, offering a wide range of options by functionalization of the bubbles.
The drugs that have sufficient affinity for the lipid monolayer might be, in principle, incorpo‐
rated directly in lipid-shelled MBs [106]. However, due to the fact that the lipid monolayer is
rather thin, the amount of drug available for incorporation is very low. Furthermore, the thin
shell might not be able to prevent the leakage of drugs from the bubble during their circulation.
Therefore other strategies were developed, such as preparation of MBs with a thick lipid shell
containing triglyceride oil phase and drug dissolved in it [117]. Nevertheless, this approach is
restricted only to hydrophobic fat-soluble drugs, e.g. paclitaxel. A thick polymer shell
represents another variety for drug incorporation suitable for water-soluble materials such as
DNA and proteins.
Electrostatic interactions of the lipids and plasmid DNA (possessing an overall negative
charge) are made possible by the positively charged groups of some synthetic lipids within
the shell [109]. DNA can be loaded on the charged MB shell by simply mixing a plasmid with
the lipid bubbles before use. After insonation, the surface-coupled DNA remains intact and at
the same time is protected against enzymatic degradation [118, 119]. Moreover, the transfection
efficiency is increased by the adherence of DNA to the MBs in comparison with co-adminis‐
tration of MBs and non-adsorbed DNA. At the same time, unbound plasmids should not be
able to penetrate into non-targeted cells and tissues and should be degraded, resulting in high
specificity with a low transfection in non-insonated regions [19]. Nevertheless, in comparison
with the payload of DNA inside the gas core of the bubbles, the loading capacity is restricted
to their surface area, which means that high numbers of MBs must be injected. The develop‐
ment of multi-layered assemblies by sequential adsorption of DNA on the positive MB
template offers another alternative; because DNA can be directly incorporated as an anionic
layer within these assemblies, layer-by-layer methods allow precise control over the loading
(or dose) of DNA by controlling film thickness or the number of layers deposited during the
fabrication. Besides that, these methods are entirely aqueous and, unlike conventional methods
for the encapsulation of DNA in thin polymer films, do not require the use of organic solvents
which residua could be presented in these materials post-assembly. [120].
In conclusion, an important advantage of ultrasound-mediated MB-based transfection is the
ability to attain DNA delivery and expression only in the insonated areas and not in non-
targeted regions. Even if the transfection efficacy is not very high but the encoded protein is
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produced in the target tissue in an amount sufficient to achieve functional biological response,
therapeutic intervention should meet its success [121]. Considering the improvement of
transfection efficacy via implementation of viral particles using positively charged assemblies,
a significant transfection was observed [122]. However, one should be always careful since
undesired immune responses after systemic administration might appear.
11.4. Incorporation of drug loaded LNPs with MBs
An intensive research has been devoted to the development of nanocarrier-MB hybrids,
wherein drug-containing LNPs are physically attached to the surface of MB [21]. These hybrids
therefore possess a high drug loading capacity of the nanocarriers and the systemic targeting
capability and vascular permeabilizing effect of bubbles. Lum et al. were the first to attach
loaded LNPs to MBs via avidin-biotin interaction; they reported on biotinylated lipid MBs to
which avidinylated polystyrene beads were attached [117]. The biotinylated MBs were
prepared by inclusion of DSPE-PEG-biotin in the lipid shell. Since up to 105 LNPs were bound
to each of the bubbles, the drug loading capacity is reasonably enhanced [106]. LNPs seem
highly advantageous as (1) they have been long proved as versatile drug delivery systems; (2)
a plethora of knowledge is available on LNPs for drug delivery; (3) some LNPs are perfectly
and already used in clinical practice. They might also enclose both amphiphilic and hydro‐
phobic drugs in their lipid bilayer, as well as hydrophilic drugs in an aqueous core. Never‐
theless, owing to the fact that biotin-avidin linkage might develop an undesired immune
response, this approach is not suitable for clinical use. Therefore Geers et al. prepared doxor‐
ubicin (DOX)-LNPs loaded MBs containing pDNA or siRNA that in combination with
ultrasound boosted both DOX cytotoxicity and pDNA and siRNA delivery to the cells in vitro
[108, 119, 123, 124]. In their last work, Geers et al. developed a self-assembly of functionalized
phospholipids, DOX-loaded LNPs and perfluorobutan gas [125]. Compared to the other
methods discussed above to load MBs with drugs, this strategy seems the most advantageous
from the loading capacity point of view; though it was estimated that approximately 600 to
1300 LNPs might be bound per singe MB, the amount of loaded DOX is still rather limited. On
the other hand, Klibanov et al. prepared liposome-MB pendants incorporating calcein, a
hydrophilic self-quenching fluorescent dye, or thrombin, a crucial enzyme of the thrombosis
cascade, and they achieved a significant payload volume – up to several cubic micrometres of
internal liposome aqueous core space per bubble-LNP [126].
A different approach was introduced by Fan et al. who developed a novel DOX-loaded MB
containing super-paramagnetic iron oxide (SPIO) nanoparticles for dual modality imaging and
improved image-guided drug delivery [127]. The authors showed that the delivery of SPIO to
brain tumours was improved using magnetic targeting in combination with focused ultra‐
sound. Unfortunately, the improvement of DOX delivery using magnetic targeting was not
the object of assessment. Hernot et al. prepared nanobody-targeted MBs using metabolic and
site-specific biotinylation of nanobodies [128]. The researchers developed a system of carmelid-
derived single-domain antibody-fragments, i.e. molecular tracers, coupled to targeted MBs.
Although they demonstrated the functionality of these modified MBs both in vitro and vivo,
since the biotinylated nanobodies were linked to the surface of biotinylated MBs via strepta‐
vidin linker, these are not suitable for clinical application due to the undesired immune
response.
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11.5. Infusion of MBs
Besides imaging applications, MBs showed to be a suitable tool for therapeutic use, e.g.
targeted drug delivery, gene therapy, thrombolysis, and vascular permeability enhancement
[129]. Certain US-contrast-imaging or therapeutic strategies, such as destruction-reperfusion
or MB-enhanced drug delivery, require a continuous injection of the MBs over several minutes.
Results of previous in vitro, animal, and human studies have shown that continuous infusion
of a US contrast agent can markedly prolong vascular Doppler US enhancement. [130-132].
Most quantitative imaging strategies rely on the ability to administer a consistent dose of
contrast agent. The spatial distribution of MBs inside a syringe varies over time owing to the
buoyancy of the MBs. These changes are rapid and result in significant inhomogeneity in the
concentration and size distribution of the MBs during continuous infusion. The population of
MBs that is pumped from a horizontal syringe outlet differs from the initial population as the
MBs float to the top of the syringe [133]. This effect is often overlooked and underestimated
by experimenters. We believe that this is the main reason for contradictory results published
by several authors that compare bolus versus continuous infusion methods of MB application
[131]. A superior signal contrast of liver metastasis has been achieved by a continuous
application of MBs to patients. US contrast agents for hepatic imaging are traditionally injected
as a bolus.
For i.v. applications, precise concentration and size distribution of MBs is required. Continuous
application of MBs might present a problem, owing to their strong tendency to float and
accumulate directly below the surface. The concentration and size distribution of specific MBs
injected into a patient’s blood vessel can be quite different from the ones in the syringe.Re‐
cently, we have described the device called Infucon for continuous infusion of MBs which
prevents flotation of MBs and their accumulation below the surface. The device has been tested
on New Zealand White rabbits using both commercial Sono-Vue diagnostic MBs and PEGy‐
lated DPPC MBs prepared in our laboratory [48, 134].
The Infucon device consists of several parts: a programmable syringe pump (e.g. LAMBDA
VIT-FIT Brno, Czech Republic) with a syringe filled with SF6, an Infucon stirred vessel
positioned on magnetic stirrer (e.g. Heidolph MR 3000 D, Germany) and fixed in the position
by a holder, and the cannula for application of MBs into the rabbit via ear vein. The schemes
of the device together with its photographs are presented in Figure. 14. The role of the syringe
pump is to force the gas (e.g. SF6) into the Infucon stirred vessel and to inject the MBs into
bloodstream via cannula. The same gas which is used for filling MBs is used in the syringe to
ensure stability of the MBs during the infusion. The main function of the turbine-like stirrer
(which contains two teflon-coated ferrits) is to maintain a uniform dispersion of the MBs in
the solution and to prevent their accumulation to the surface owing to their flotation. The stirrer
is hung up on the collar of the carrying-off capillary outlet. The direction of rotation is selected
to maintain down-stream movement of the fluid and to strip MBs from the surface. The device
itself is designed to be hermetically insulated using an O-ring seal. The cell is made of inert
materials (Teflon®, polypropylene, glass, and Viton®). All parts of the Infucon are compatible
with chemical or heat sterilization. The filter installed in the Infucon head prevents possible
air-born particles from entering the cell. The vial (conical bottom) is filled up with a solution
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of MBs (up to 1.5 mL) via an inlet capillary. The flow rate (usually in the range of 100 - 200 μL/
min) and the time of pump action are programmable parameters. The silicon piston of the
syringe is properly lubricated to ensure very low friction and smooth movement preventing
sudden jumps of the piston resulting in pulsation. A turbine-like stirrer fits the conical bottom
of the vial, therefore very low dead volume of residual MB solution is obtained. The turbine-
like stirrer freely hangs on the fringe of the Teflon outlet capillary. The capillary is tightly
embedded into the Teflon body in order to be prevented from bending. There is also an inlet
aperture for incoming gas in this Teflon body. The gas is delivered from the syringe through
the inlet capillary linked tightly to the head part of the Infucon (Figure 15, 16). The stirred
Infucon cell represents solution of the problem of the continuous infusion of MBs. This device
is independent on mechanical stirring of the infusion syringe. Unlike the system based on the
rotation of the entire syringe, Infucon cell provides a genuinely homogeneous MB dispersion.
The MBs are prevented from flotation by stirring the suspension in a separate cell. The infusion
is driven by inert gas filled in a syringe placed in the infusion pump. The inert gas used both
for filling the MBs and driving the MB infusion is supposed to have stabilizing effect on the
MBs during the process of infusion.
(A) Assembled device, (B) Head of the Infucon. (Adapted from [144])
OC – outlet capillary for the infusion of microbubles (connection to the cannula)
IC – inlet capillary for inert gas from a syringe inserted into the syringe pump
O – O-ring
I – inlet for gas
MS – turbine-like magnetic stirrer with blades
C – fringe of the outlet capillary (OC)
Figure 14. Schematic drawing of the stirred continuous injector Infucon and the photograph of the Infucon device.
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Blue line: gass pushing homogenaous dispersion of MBs
Red line: homogenaous dispesion of MBs driving from Infucon cell into rabbit ear vein via canula
Figure 15. Schematic and real view of the device used for i.v. infusion of MBs into the rabbit.
a. The use of Infucon device during the ultrasound scanning of the rabbit heart.
b. Integration of the Infucon device which is injecting the MB suspension via vena aricularis
into the bloodstream of the rabbit. (Adapted from [144])
12. Medicinal application
Imaging the liver – This clinical application of MBs in radiology is most promising. Some
portion of MBs is taken up by the liver and spleen. The precise mechanism is hitherto uncertain,
but the involvement of the reticulo-endothelial system is probable. In clinical trials, this liver
phase generally lasts about 30 minutes when the licensed agent Levovist is used and a few
hours with some agents. The liver is very well seen with MB-specific imaging models, such as
harmonic imaging, during this phase. The primary practical importance is that numerous focal
liver lesions, especially metastases and hepatocellular carcinoma, appear as defects and the
use of MBs considerably increases their visibility [135-137].
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Imaging the heart – MBs can enhance Doppler flow signals in cardiac ultrasonography, and
this can be useful in several situations, such as detecting valvular stenoses. The left ventricular
cavity is highlighted by MB contrast agents and thus the blood-tissue boundary becomes much
clearer. This is useful in detecting abnormalities in wall motion in a given region, assessment
of ejection fraction, and finding left ventricular thrombus. The evaluation of left ventricular
function is crucial for managing of a number of heart diseases. Both resting and inducible
ischaemia can be accurately diagnosed by real time perfusion imaging in stress echocardiog‐
raphy which can be further enhanced by applying intermittent high power pulses destroying
the majority of the MBs in a scan plane and subsequently watch refilling: the rate at which it
occurs is a measure of microcirculatory flow speed [138].
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13. Therapeutic applications recent advances in molecular, multimodal and
theranostic ultrasound imaging
The importance of MBs usage in treatment is higher than their use as a diagnostic tool. At
present, the different characteristic features of MBs ( arious sizes and the types of gases and
shell materials) precondition them for use as targeting drug carriers. MBs can help in drug
delivery in themselves (by acting as “cavitation nuclei”) and as drug carriers for site-specific
treatment. Due to these characteristics they can be employed as drug carriers for treatment of
various diseases, such as inflammation, thrombus, lymph nodes, cancer, angiogenesis and
atherosclerosis [136].
13.1. Gene therapy
The use of MBs in gene therapy is most challenging. The delivery of genetic material to a
selected site represents the main problem in this emerging area. Drug delivery can be poten‐
tiated by ultrasound which creates transient non-lethal perforations in cell membranes
facilitating penetration of large molecules and particles into the cells (“sonoporating”). During
this process, high acoustic power is necessary, which is beyond that permitting for imaging.
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However, in the presence of MBs the amount of required power is substantially reduced
because the MBs decrease the amount of energy needed for the process of cavitation, leading
to MB collapse due to excessive oscillations induced by ultrasound pulses. Furthermore,
cavitation of MBs in capillary beds leads to a capillary permeability increase, thus improving
local access of the released therapeutic drug [139]. The clinical use of virus-based vectors for
gene therapy is limited. This is due to the fact that immune response can be induced by viral
proteins in the target tissue and elicit a strong inflammatory activation of endothelial cells.
However, it has been shown that when e.g. plasmids and antisense oligonucleotides are used
in non-viral delivery vehicles, transfection efficiency is decreased and the expression of the
gene product is transient. Commonly used MB preparation Levovist enhanced the beta-Gal
gene transfection efficiency more than 6-fold and Optison were used for gene transfer to
cardiomyocytes. The transfection efficiencies are significantly higher than that of no MB and
it is similar to Levovist [97, 100, 114].
13.2. Blood-brain barrier
The blood-brain barrier (BBB) is a specialized system of capillary endothelial cells preventing
harmful substances in the blood stream from entering the brain. They also supply the brain
with nutrients necessary for proper brain functioning. The BBB regulates transport through
both tight junctions and metabolic barriers and is often a rate-limiting factor in determining
permeation of therapeutic drugs into the brain. It is a significant obstacle affecting delivery of
both small molecules and macromolecular agents. Despite the fact that a variety of drugs could
be potentially used to treat brain diseases, no method exists that would allow non-invasive-
targeted delivery through the BBB.
Ultrasound can be used to locally deliver a drug or gene to a specific region of interest in the
brain. The benefit of the MB technique is that it can be used on a very small area of the BBB.
MBs are used in combination with ultrasound exposure. The effects of ultrasound can be
focused upon the vasculature to reduce the acoustic intensity required for BBB opening
production. Several pathways of transcapillary passage after ultrasound sonication have been
recognized, including transcytosis, passage through endothelial cell cytoplasmic openings
holeyed by “nanoschrapnels” produced by explosion of MB, opening of tight junctions by
oscillating MBs and free passage through injured endothelium [136, 140, 141].
13.3. Thrombolysis and thrombus destruction
The major cause of death in Western countries is thrombo-occlusive cardiovascular disease,
with acute ST-elevation myocardial infarction (STEMI) being a serious medical condition
leading to high morbidity and mortality. Two main treatment strategies have been developed
during the past years. Their aim is to immediately restore coronary blood flow. In the first
studies it was shown that fibrinolysis may be accelerated by ultrasound alone. Besides that,
fibrinolysis can be even more increased by the addition of MBs which are destroyed by
ultrasound induced high pressure. Three mechanisms leading to this increase have been
proposed. The first is the occurrence of complete stress based on micro-jets formed after the
destruction of the MBs by ultrasound. The second mechanism is the generation of reactive
oxygen species in endothelial cells. The third proposed mechanism is a temperature increase,
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also occurring after the MBs collapse induced by ultrasound exposure. Whereas the full
mechanism still remains to be elucidated, evidence indicates that the use of ultrasound alone
and ultrasound combined with MBs can enhance clot dissolution by creating microholes in
freshly formed thrombi [142, 143].
14. Conclusions
LNPs and MBs are examples of the successful transfer of basic and applied research into
commercial medicinal products. Biocompatibility and biodegradability of LNPs together with
versatility in modification and functionalization are features which put together favour their
application in medicine. Combinations of LNPs and MBs make best use of both technologies
to form new theranostic systems that could form the basis of future advanced therapeutics.
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1. Introduction
In the textile market industry, technical textiles are one of the fastest growing businesses. Part
of that industry consists of textiles for medical and healthcare applications and are responsible
for a continuous increase in its market potential [1]. Next to their need in hospital environ‐
ments, there is a growing demand in other sectors such as the food and hotel industry, due to
stricter hygiene regulations. In most cases biomedical textile meets a well-defined set of
requirements such as minimizing non-specific protein adsorption, drug delivery coatings or
the presence of active functional coatings and most importantly excellent biocompatibility
(blood-, tissue-or cyto-compatibility) [2]. In general there are very few materials meeting all
these characteristics, while at the same time offering the needed structural and mechanical
properties. Furthermore, depending on the application, the production process has to be cost-
effective and approved by local legislation.
In order to meet all these requirements, numerous modification techniques have been
developed in the past [3-5]. Most of these techniques lead to the incorporation of extra/new
functionalities and might lead to a change in surface free energy. For most biomedical
applications, the preservation of material bulk properties such as elasticity, strength, ductility,
structural integrity etc. is critical. For biomedical end-products, the use of solvents and
chemicals based surface treatment techniques are reduced to a strict list approved by local
legislation. Chemical-free techniques such as γ-radiation, UV treatments, corona discharges
etc. have led to some excellent results in the field of tissue engineering [6, 7]. One of those
solvent-free techniques that have been around for over a century, has more recently found its
way into the biomedical field: non-thermal plasma technology.
Over time, it has extensively been proven that non-thermal plasma technology can profoundly
change the surface properties of polymer films (PP, PET, PU, etc.) as well as material charac‐
teristics (adhesion, printability, dyeing etc.) of more complex substrates such as industrially
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
produced textile [8-14]. Alongside the growing interest in tissue engineering and the booming
of the electrospinning industry at the end of last century, non-thermal plasma technology
found its way into the biomedical field. Today non-thermal plasma treatment can be consid‐
ered as a well-established technique for the surface treatment of (bio)materials.
Before the start of the 21st century, the majority of contributions to scientific literature was
focussing on oxygen plasma treatments at low pressures and the corresponding response on
cell adhesion, growth and proliferation. Although today there is still a steady stream of
publications on these low pressure oxygen plasmas, there is a growing interest in atmospheric
pressure plasma treatments as they offer a number of practical advantages. In the next chapter
part, a detailed overview will be given on plasma technology in general and the different
treatments possible. After that, the chapter will continue on the use of plasma technology for
(bio)medical textiles, according to the application. At the end there will be a critical conclusion
and a look forward to the possible future of plasma technology for the biomedical textile
industry.
2. Non-thermal plasma technology
2.1. History and definitions
A plasma is a gaseous mixture of ions, radicals, electrons and neutrals. Plasma is often referred
to as the fourth state of matter, as its properties fundamentally differ from solids, liquids and
gasses and the change of state can be obtained by adding energy to a gas, similar to the
transition from solid to liquid to gas. In 1929, Langmuir was the first to actually define a plasma,
but already in the 19th century plasma was used on an industrial scale for the generation of
ozone (Siemens) [15].
Plasma itself can be divided up into two categories: 1) thermal or equilibrium and 2) non-
thermal or non-equilibrium plasma. Thermal or hot plasmas have temperatures of 4000 K or
higher and are considered to be in a thermal equilibrium, meaning that both heavy ions and
electrons have the same temperatures. Well known applications include plasma spraying,
wide arc spraying, and thermal plasma chemical vapour deposition (TPCVD), thermal plasma
synthesis of fine powders (nm), thermal plasma (toxic) waste destruction, thermal plasma
densification of powders, thermal plasma metallurgy, thermal plasma extractive metallurgy
etc. For non-thermal or cold plasma, only the electrons are accelerated via e.g. an applied
electrical field, causing a thermal inequilibrium between the electrons and the heavy particles.
This results in the formation of a plasma at lower temperatures. Due to this difference in
operating temperature between thermal and non-thermal plasmas, they are often referred to
as ‘hot’ and ‘cold’ plasmas respectively. Although referred to as cold plasma, temperatures of
up to 1000 K can be reached. For biomedical applications, non-thermal plasma treatments are
preferred with a degree of ionization of 1% or lower as this results in a discharge that can be
sustained at room temperature (290-330 K), thus avoiding thermal degradation of thermo-
sensitive materials. In the next paragraphs, the focus will be on the sources that are used to
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drive the discharge, as they are an excellent way to distinguish between the ways a plasma
can be generated, independent of the set-ups possible.
2.2. Plasma discharges
The different non-thermal or cold discharges discussed in the following parts have all proven
their usefulness as well as their limitations. Over time, applications have been found for each
different type of discharge in all branches of the industry: automotive, packaging, textiles,
aerospace, catalysis, waste treatment, (bio)medical etc. [9, 13, 16-18]. The number of plasma
reactor designs is nearly limitless and complete reviews have been written on that topic alone,
as design changes are made to optimize the plasma treatment for their specific application [19].
Most of the designs available today can be linked to one of the plasma sources discussed here.
2.2.1. Corona and silent discharge
A corona discharge reactor typically consists out of a cathode wire and an anode, which is
normally the material that needs treatment. The first developed systems were powered by a
DC source working in a pulsed mode and were operated at atmospheric pressure. When turned
on, the system generates a lighting crown build out of many streamers, hence the name corona
[9]. Pulses are used that are shorter than the time necessary to form an arc, thus avoiding the
transition to the spark regime. In the middle of 20th century, the first corona discharge systems
were patented for the incorporation into industrial textile production systems [20]. Later on,
the systems were adapted to work with high frequency sources (radio-frequency (RF),
microwave (MW) and AC) and today a number of commercial systems are available from
companies such as Tech Sales Company, Air Liquide, Acxys Technologies etc. These modern
high-tech set-ups are able to quickly and efficiently treat delicate structures such as electrospun
sheets. One of the main disadvantages of corona treatment is that the streamers always form
at the same sports, resulting in an inhomogeneous treatment of the exposed surfaces. To solve
this particular problem, there has been a shift to the usage of silent discharges [16].
A silent discharge, also known as a dielectric barrier discharge (DBD), is powered either via a
high frequency AC or an RF source. What makes the DBD stand out against other systems, is
its higher and broad pressure operating range (5-105 Pa) [21, 22]. In 1857, Siemens was the first
to use a DBD in a successful attempt to generate ozone and to this day it remains one of the
most important industrial applications of the DBD [15].
A DBD reactor typically consists of 2 electrodes, of which at least 1 is covered with a dielectric
material such as glass, ceramic or quartz. The voltage used to drive the discharge can start as
low as 0.5 kV and can be increased up to a few 100 kV. The generated plasma is a collection of
many small micro-discharges or streamers. The dielectric material is able to limit the discharge
current, giving cause to very short-lived micro-discharges (1-10 ns) that are distributed
homogeneously across the electrode. In some specific cases, the streamers can be avoided
altogether and a true glow regime can be obtained, which is considered the best case for
homogeneous treatments [9].
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DBD set-ups have one major advantage compared to most other systems: the possibility to
operate in a higher pressure range makes it possible to avoid extensive vacuum equipment.
This results in a lower operating cost and faster treatment cycles, thus allowing them to be
implemented in industrial surface modification processes. The low heat generation at elevated
pressures allows for a wider range of applications, including plasma chemistry, grafting,
polymerization, cleaning... These applications are not always as easily feasible in systems
powered with a different source.
It should be noted that occasionally in literature also the term corona discharge or corona
treatment is used in connection with DBDs, although most authors prefer to use this term only
for discharges between bare metal electrodes without dielectric.
2.2.2. DC discharge
Non-thermal plasmas generated via a DC discharge are in most cases formed in a closed set-
up between two electrodes at very low pressures (10-1 – 10 pa) [21, 22]. As the current is
increased, different types of discharges can be obtained. The Townsend discharge is a self-
sustaining discharge, typically characterized by a low current. A higher current results in a
drop of voltage and a glow discharge is generated. The glow discharge regime is the desired
regime for surface modifications, as it guarantees a homogeneous treatment al throughout the
reactor. Increasing the discharge current still further results in a fast increase of voltage until
an arc is formed, allowing for the charge to dissipate and the voltage drops almost completely.
One of the biggest advantages today of DC discharges, is that it is a well understood process,
allowing for a high control over the process and its different parameters.
The DC current can be driven through the system in a continuous manner, or it can be pulsed.
For biomedical applications in general, there are two advantages in doing the latter: first of,
higher discharge powers can be applied without the otherwise inevitable thermal damage
caused by the heating of the electrodes and secondly, if used for the coating applications, it
renders a more homogeneous coating. One of the main disadvantages of the DC driven systems
is the direct exposure of the electrodes to the plasma environment, making them prone to
corrosion if exposed to certain reactive monomers.
2.2.3. Radiofrequency and microwave discharges
Radiofrequency (RF) and microwave (MW) discharges are generated using high frequency
electromagnetic fields [21-23]. RF discharges have a relatively wide frequency operating range
between 1 – 100 MHz, but in most cases a fixed frequency of 13.56 MHz is applied. Concerning
the operating pressure, a wider range, compared to DC systems, (1-103 Pa) is possible, but with
the exception of a few, high-vacuum equipment is needed, which is expensive, drastically
increases treatment times and are hard to implement in continuous production processes. For
the treatment of biomedical materials, it is most likely the most applied discharge, as it is the
plasma treatment technique of choice for the popular oxygen plasma treatments and several
systems are commercially available.
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Microwave discharges are operated at a higher frequency range, usually fixed at 2.45 GHz.
The pressure range is more versatile compared to RF and DC discharges, with a range between
1 Pa and 105 Pa. Higher pressures lead in most cases to an increase of heat transfer from the
electrodes to the substrate, making it a less than ideal situation for the treatment of textiles and
nonwovens. This limitation results in the same treatment restrictions as the previously
discussed discharges.
2.2.4. Atmospheric pressure plasma jets
To finalize this chapter part on plasma technology, some special attention will be given to
atmospheric pressure plasma jets (APPJ’s). Operating a plasma in a confined space has certain
advantages when it comes to the control of the physics and chemistry taking place, but
sometimes there are cases where it would be more desirable if the plasma could be free from
any geometrical confinements. APPJ’s, also referred to as plasma plumes are an ideal solution
and are excellent tools for the treatment of geometrically larger and more complex surfaces
such as textile fibers [24].
APPJ’s can be powered with any of the sources discussed before, but all deal with the same
problem: how to avoid the transition from glow to arc. For DC sources this can either be
achieved via the use of hollow cathode discharges with sub mm dimension or the use of
resistive barrier discharges. For the DBD systems driven by high frequency AC sources, the
dielectric barrier itself is the solution, as it prevents the discharge current to increase to the
point of arcing. Under some special circumstances the DBD’s can generate an uniform diffuse
plasma that is filament free. For the RF powered APPJ, either a set-up similar to the DBD set-
up can be used, or the metal electrodes are left bare. For the latter, cooling of the electrodes is
required, as well as an excellent control of the flow rate in order to minimise the risk of arcing
[24]. Finally it is also possible to generate a plasma plume, using a microwaves to drive the
plasma, but it is limited to a strict set of geometrical parameters which has been described in
more detail by Park et al. [25].
It would be possible to give an extended description on the different set-ups available today,
but it would lead to far out of the scope of this chapter. Laroussi and Akan already wrote a
complete review on the different set-ups available. Also Shütze el al. wrote a compact review
on the physics behind several set-ups [22]. Since that time also a number of commercial systems
have become available on the market (crf Plasmatreat®, PlasmaSpot®, PlasmaStream®...). The
applicability of the APPJ for the treatment of biomedical textile will be covered in the following
chapter part 3: Plasma and textile: the biomedical applications.
2.3. Plasma-material interactions
In order to have an understanding of what is happening at the plasma-material interface, it is
critical to have a basic knowledge about the possible effects the different active species have
on a substrate exposed to them.
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2.3.1. Plasma cleaning and etching
During the production process and storage of (bio)materials, they can be exposed to a number
of solvents, greases, volatiles components etc. These contaminants will adsorb and accumulate
on the material surface over time, resulting in an altered, non-reproducible surface with a likely
reduced product performance. A typical example in the biomedical field, is the adsorption of
low molecular weight carbon species onto a pristine titanium sample, when exposed to
ambient air. When used as an implant material, this surface pollution results in a reduced cell
adhesion, proliferation and growth and in some cases even results in cell death [26, 27].
Any volatile surface contamination that is exposed to a non-thermal plasma, will be removed
in a few seconds [28]. Prolonged exposure to the plasma will not only result in the removal of
the adsorbed contamination but will cause etching of the top layers of the material surface
[29-32]. Depending on the density and hardness of the exposed material, more intense
discharges and/or extended exposure are required to obtain a notable effect. As (biomedical)
textiles are in most cases build out of relatively soft materials, the etching effect cannot be
overseen and will introduce a certain nano-roughness on the fiber surface. For in-vitro and in-
vivo applications this change in surface topography can have a benign effect, as it can amplify
the other effects plasma has on cell adhesion and proliferation [33-35].
2.3.2. Plasma activation
Plasma activation or plasma treatment is the exposure of a surface to the reactive particles
present in the plasma. This mixture of reactive particles will result in the incorporation of
radical sites on the surface, up to the depth of a few 10 nm. Depending on the gas used to
maintain the plasma, these sites will react (in)directly with other radicals present, recombining
into a broad variety of functional groups. These new functional groups have a high impact on
surface properties such as wettability and surface free energy, which in turn might have a
positive effect on material-material and material-cell interactions.
In most cases an increase in hydrophilicity is pursued to enhance the materials histological
performance. For some applications such as the surface of heart valves, the insides of needles
and tubes or artificial stents, any adhesion of cells and proteins is highly unwanted, as it can
lead to blockages resulting in premature failure of the biomedical device. Instead of using
typical gas feeds for plasma treatment (noble gasses, oxygen, dry air, nitrogen...), fluorinated
gasses such as CF4 are used which result in the formation of super hydrophobic surfaces with
water contact angles of 150° and higher. These fluorinated surfaces prevent cells and proteins
from effectively adhering on the surface and thus guaranteeing an optimal performance of the
implant material [11, 36, 37].
Plasma activation is definitely not the only technique available for the introduction of new
functional groups onto a surface, but as it is non-invasive and chemical-free, it guarantees the
preservation of even the most delicate structures.
2.3.3. Plasma grafting and polymerization
Non-thermal plasmas are not only applied for plasma treatments, but can also be used as an
initiation medium for radical polymerization, resulting in the deposition of a wide variety of
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performance. For some applications such as the surface of heart valves, the insides of needles
and tubes or artificial stents, any adhesion of cells and proteins is highly unwanted, as it can
lead to blockages resulting in premature failure of the biomedical device. Instead of using
typical gas feeds for plasma treatment (noble gasses, oxygen, dry air, nitrogen...), fluorinated
gasses such as CF4 are used which result in the formation of super hydrophobic surfaces with
water contact angles of 150° and higher. These fluorinated surfaces prevent cells and proteins
from effectively adhering on the surface and thus guaranteeing an optimal performance of the
implant material [11, 36, 37].
Plasma activation is definitely not the only technique available for the introduction of new
functional groups onto a surface, but as it is non-invasive and chemical-free, it guarantees the
preservation of even the most delicate structures.
2.3.3. Plasma grafting and polymerization
Non-thermal plasmas are not only applied for plasma treatments, but can also be used as an
initiation medium for radical polymerization, resulting in the deposition of a wide variety of
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thin films. In order to optimize the bonding between the thin film and the biomaterial, the
deposition process is preceded by a plasma treatment, introducing radical sites that allow
covalent bonding of the polymer to the substrate surface. The polymerization process itself
can happen via two different reaction pathways: plasma polymer grafting simply uses the
radical sites introduced via plasma treatment to initiate the chain reaction. In other words,
during the polymerization process itself, no plasma is used and the monomer is not exposed
to the plasma. This results in the incorporation of the monomer as such, thus preserving its
functional groups.
For plasma polymerization this is not the case. The plasma is used as an initiation medium
and remains active during the entire polymerization reaction. This has as a consequence that
the monomer is exposed to the reactive plasma, forming initiation sites on both the substrate
surface as well as on the monomer. In contrast to chemical initiation, plasma is not as specific
as to where the radicals are formed, using any functional groups of the polymer precursor as
well to initiate the chain reaction. This results in a highly cross-linked, pinhole free and
completely amorphous thin film that significantly differs from its traditional counterpart and
adheres to almost any surface. Varying the discharge power gives a high control over the
amount of functionalities preserved in the film. From a biomedical viewpoint this is an
interesting application, as functional group density plays a critical role in the growth and
proliferation of cells and differs for the type of cells used.
3. Plasma and textile: The biomedical applications
3.1. Wound dressing
Optimal modern wound dressings should assure a moisture wound bed, help drainage,
remove debris of the wound surface, provide optimal thermal stability, might be removed
without trauma of the wound bed and wound edge, be antiallergenic and without immuno‐
genicity [38]. Over the years wound dressings have experienced a continuous development
stimulated by a better understanding of wound healing and bacterial growth mechanisms. In
more recent years research has shifted to targeted therapy by including different pharmaceut‐
ical compounds (e.g., antiseptics, analgetics, or growth factors) in to wound dressings. The
continuous presence, or controlled release of active substances, can tremendously stimulate
the healing process.
Non-thermal plasma technology has been part of this development process in many different
aspects of wound healing treatments. The review of the literature dealing with the use of
plasma technology for the enhancement of wound dressings will be divided according to the
purpose of the treatment: wound monitoring, enhancement antimicrobial properties, inter‐
mediate bonding, and adhesion.
3.1.1. Antimicrobial properties
Successful wound treatment cannot be achieved without keeping its two major aspects in
mind: maintaining a decent hydrophilicity and a high antimicrobial efficiency.
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In two different papers Persin et al. compared a few different treatment methods on viscose
fibers to address both of these aspects [39, 40]. In a first reaction pathway, a two-step process
consisting of an oxygen plasma treatment, followed by the immobilization of AgCl particles,
is followed. The alternative pathway consists of a single-step treatment of the cellulose fibers
with an ammonia plasma. The single-step treatment resulted in a 30-fold increase in water
uptake while the immobilization of the silver particles only had a marginal effect. For the
antimicrobial properties of the wound dressings, the reverse trend was found. The single-step
treatment only had an effect on Gram-positive bacteria, while the steady release of silver ions
resulted in a quasi-complete destruction of both Gram-positive and Gram-negative bacteria.
The authors therefore suggest to use a different treatment for different wound-healing
applications, depending on the risk of infection. In a third paper from the same authors, a closer
look is taken on the ageing of the plasma treated surfaces and the effect on the water up-take
[35]. The study showed that 4 days after the treatment, the water contact angle increased with
15° and the oxygen concentration decreased with less than 1%. These numbers suggest that
there is a limited shelf-lifetime of the modified wound dressings. Hacker et al. followed an
alternative strategy for the immobilization of Ag particles by plasma polymerizing PEG onto
electrospun PU mats, followed by soaking in AgNO3 and UV treatment, resulting in the
incorporation of metallic silver [41]. Water-uptake tests revealed a significant increase of
hydrosorption after 24 hours. The steady release of silver particles had a detrimental effect on
the viability of both Gram-positive and –negative bacteria while at the same time no cytotoxic
effects were noted on the adhesion and proliferation of fibroblasts. Further on in the chapter,
other strategies will be discussed to obtain antibacterial properties for other applications, but
it is already clear that the incorporation of silver particles with the help of plasma technology
is a successful pathway for the improvement of wound dressings.
Figure 1. SEM micrographs (3000×) of the (a) plasma modified nonwoven, (b) AAc coated nonwoven, (c) PP-g-collagen
nonwoven, and (d) PP-g-collagen-g-PNIPAAm nonwoven [126].
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3.1.2. Adhesion and intermediate bonding
Next to increasing the hydrophilicity of surfaces, plasma are also known to promote the
adhesion between layers. Gajanan et al. published two papers where plasma technology was
used to improve the adhesion between an electrospun material and a woven support structure
[42, 43]. In the first article chitosan was used as a raw material for the electrospinning process.
In the second article, the chitosan was mixed with silk fibroin. For both cases a 100% cotton
gauze was used as support material. Out of the different DBD plasma treatments, using He
+1% O, the combination of a pre-and post-treatment gave the best results. Flex durability tests
showed that there was a 4-fold increase in adhesion between the electrospun material and the
cotton gauze. On top of that SEM images showed that the plasma treatment resulted in a
reduction of the fibers’ delamination after repetitive flexing.
As explained earlier in section 2.3, plasma can be used to graft new side chains on polymer
substrates. The goal of grafting can either be to introduce new functional groups and use their
properties as such, or to introduce them as intermediates that can be used in consecutive
reactions. In biomedical surface engineering the latter is quite popular as the list of products
that can be used is limited, meaning that in most cases there is a sub-optimal affinity between
coating and substrate. Chen et al. used a PP-non-woven as a substrate on which acrylic acid
was grafted. The newly introduced carboxylic acid functionalities were used to either cova‐
lently bond collagen or chitosan, on which the thermo sensitive polymer PNiPAAm was
immobilized of which each step is depicted in figure 1. Above 32° C, the wound dressing
becomes hydrophobic and releases the stored moisture, which in turn resulted in an enhanced
wound healing [44, 45]. Lin et al. used an oxygen low pressure plasma to activate a PE non-
woven substrate, followed by the grafting of N-isopropyl acrylamide [46]. This intermediate
was then used for the covalent bonding of bovine gelatin. In-vivo tests revealed that the
covered wound healed completely (reached the maturation phase) and much faster compared
to the PE control.
The results discussed above show that plasma technology can be a valid, solvent-free alterna‐
tive for the permanent fixation of technically advanced layers onto standard substrates. Most
of the studies on adhesion and intermediate bonding are relatively new and more research is
needed to see if the obtained results can be extrapolated to other materials and applications.
3.1.3. Wound monitoring
In modern society the development of ‘smart’ materials is a hot topic (crf smartphones,
smartwatches, smart-TV’s etc.). In the wound care industry similar developments are taking
place and several groups are doing research on so-called ‘smart bandages’. The idea behind
smart bandages is that they autonomously could monitor the wound and signal in case of
infection or other irregularities. A few groups working on biosensors have successfully
incorporated plasma technology in their biosensor production process.
Phair et al. used a corona discharge in ambient air to activate carbon fiber threads in order to
improve their electro-analytical performance [47]. Via a redox probe set, the ion exchange rate
was determined as a function of plasma treatment time. The results showed that the incorpo‐
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ration of carboxyl groups resulted in better electron transfer kinetics. Exposing the prototype
bandage to whole blood proved that they were capable of detecting urates.
Zhou et al. developed a biosensor based on self-quenching fluorocarbons [48]. These fluoro‐
carbons were stored in lipid vessels which were immobilized on a pp-non-woven that was
plasma coated with maleic anhydride using a commercial RF discharge system. Upon contact
with both Gram positive and negative bacteria, the lipid vessels released the fluorocarbons,
allowing for a visual infection detection mechanism. In combination with the simultaneous
release of antibacterial products using the same release system, they believe it is possible to
make a quasi-autonomous or ‘smart’ bandage.
The collection of reviewed papers shows that non-thermal plasma technology can play an
important role in the development of smart bandages, allowing for low-cost personalized
wound care treatment.
3.2. Antimicrobial functionality
Within the section on wound dressings already a part on antibacterial properties of plasma
treated fibers has been included, but the applicability of these modified textiles goes much
further than wound treatment alone and is highly wanted for other (bio)medical applications
such as surgical gowns, sutures etc. as well as in the food industry and catering business [49].
The study on antimicrobial finishes of fibers and meshes has been quite extensive and between
25 and 30 papers will be reviewed here. A wide variety of substrates has been modified, ranging
from natural-based products such as cellulose and wool to PP, polyesters, polysulfons,
polyamides, carbon composites etc.
3.2.1. Ag immobilization
As for the modification itself, a distinction can be made between alterations involving the
immobilization of metal nanoparticles (Ag, Cu) and all other treatments. To this day, the
controlled release of silver particles is by far the most effective technique to inhibit the
attachment and growth of both Gram positive and negative bacteria [50-65]. Most of the
research groups use a non-thermal plasma to increase the wettability and nano-roughness of
the textile substrate in order to enhance the uptake of silver nanoparticles (either via AgNO3
or Agn) or a plasma polymer coating with controlled release properties. Antibacterial tests
involving micro-organisms such as E. Coli, S. Aureus and C. Albicans show in most cases a
bactericidal efficiency of more than 99.9%.
3.2.2. Plasma activation, grafting and intermediate bonding
Other research groups followed less known pathways with mixed success. Yao et al. did an
Ar low pressure plasma pretreatment of PVDF-HFP/PU fibrous membranes, followed by the
UV grafting of 4-vinylpyridine and a quaternization of the introduced pyridine group using
hexyl bromide [66]. Anti-bacterial essays showed a killing efficiency of 99.9999 % for both E-
Coli and S. Aureus strains (See figure 2). Despite the excellent performance of the fibers, the
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commercial applicability remains limited due to relatively expensive production process in a
competitive business environment.
Different research groups did a plasma pretreatment on cotton and polyproplyne (PP)
nonwovens respectively, followed by the immobilization of natural products [67-69]. Vaideki
et al compared the uptake of neem leaf extract before and after RF air plasma treatment and
found that both the increase in wettability as well as the surface etching resulted in a superior
adsorption of the extract [67]. Nitkyakalyani et al made a mix of herbal plant parts that were
dried and grinded after which they were dissolved so the PP could be soaked in it [68]. A wide
variety of both Gram positive and negative bacteria were tested and excellent antimicrobial
activity was noted. Although the use of natural products is a pro in some cases, it is difficult
to obtain a certain consistency in the production process and there is always a certain risk of
product pollution. Strnad et al. treated cellulose fibers with an RF O2 plasma to increase the
adsorption of chitosan [69]. The antimicrobial tests revealed a modest effect against S. Aureus
and no effect against E-Coli. Antifungal tests using several fungi strings resulted in modest
antifungal behavior.
Some groups simply applied a plasma treatment as such, using reactive gasses such as CF4
and hydrazine to obtain the desired antimicrobial effect. Uygun et al. did a pretreatment of
chitosan powder using a RF hydrazine plasma [70]. Chemical analysis shows a significant
increase in the number of primary amines present. Using the modified chitosan for the
electrospinning of nano-fibers results in a nonwoven that has a better moisture uptake and an
enhanced antibacterial effect for Gram-positive bacteria. Canal et al. and Virk et al. used an
Ar-CF4 post discharge plasma with mixed results. The treatment of wool, polyamide and
Sontara® resulted in a heightened bacterial resistance, while the treatment of cotton had no
effect at all [71, 72].
Just as described in the intermediate bonding paragraph of the wound treatment section,
plasma is used for the grafting of intermediate layers that are used for the immobilization of
antibacterial components. Degoutin et al. used a low pressure RF Ar plasma to graft acrylic
acid onto a PP nonwoven [73]. The carboxylic acid functionalities were used for the immobi‐
lization of gentamicin, which is known to be 99% bactericidal as was confirmed by the testing
with E. Coli. Gawish et al. used a He plasma for the grafting of glycylmethacrylate, which was
used for the covalent bonding of cyclodextrines [74]. These macromolecules are known for the
controlled release of active components, in this case biocides with antimicrobial and insect
repellent properties. These experiments confirm that plasma grafting is a versatile technique
that forms the basis for subsequent reactions.
In general it can be concluded that the incorporation of silver micro-and nano-particles is still
the golden standard for the production of antibacterial textiles. Non-thermal plasma technol‐
ogy can be a useful tool for the immobilization of the metal particles and plasma deposited
coatings are ideal for the controlled release. Plasma treatments as such can generate highly
antimicrobial surfaces, as was proven, amongst others, by Yao et al. [66], but only after the
right selection of precursors and discharge gasses.
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Figure 2. SEM images of (a) and (d) filter paper (control), (b) and (e) pristine, and (c) and (f) modified PU fibrous mem‐
branes after immersed in PBS suspension of (a)–(c) S. Aureus, or (d)–(f) E. Coli at 107 cells/mL for 4 h. PU fibrous mem‐
branes were electrospun from 10% (w/v) solutions in THF and DMF (1:1, v/v) [127].
3.3. Cell culture and soft tissue engineering
Technical textiles for tissue engineering applications are one of the youngest branches in the
textile industry, but in a just a few decades they have become a major player on the biomedical
market and the number of publications dealing on the theme of tissue engineering applications
has exponentially grown. The idea behind tissue engineering is that (stem) cells are extracted
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from a patient with a malfunctioning organ. The retrieved healthy cells are seeded on a culture
plate and grown to a full culture [3, 4, 75]. Once enough cells can be harvested, they are seeded
onto a 3D nanofibrous scaffold. After a certain incubation period, allowing the cells to grow
and differentiate into the scaffold, the nonwoven is implanted into the patient in order to
restore the organ functionality or replace the organ as such. By treating patients with their own
cells, immuno-response can be reduced to an absolute minimum and it is considered to be a
constructive solution for the transplant waiting list issue.
In this specific chapter part, both the enhancement of cell culture applications as well as soft
tissue engineering will be discussed together, as they are closely related and in some cases
even overlap. This chapter part will therefore be subdivided into a first section dealing with
plasma treatment as such and its effect on cell growth, adhesion, proliferation and differen‐
tiation and a second section handling plasma grafting and polymerization, talking in more
detail about adhesion and homogeneity of the deposited coatings as well as the histological
properties.
3.3.1. Plasma treatment
The most widely used polymer collection for the production of nonwoven scaffolds for tissue
engineering is the biodegradable polymer family. Polylactic acid(PLLA), polylactic-glycolic
acid (PLGA), Polycaprolacton (PCL)... are well established biomaterials due to the fact that
after implantation they get broken down by the body in harmless end products (ideally CO2
and H2O) that can be secreted by the body, making a second surgery no longer necessary [13,
76]. The mechanical and structural properties of these materials are sufficient for their field of
applications. The biocompatibility and bioactivity on the other hand are mediocre at best and
often inhibit the migration and differentiation of cells into the textile scaffold structure [77,
78]. The surface treatment of these scaffolds is rather complicated, as the pore size limits the
infiltration efficiency of (wet)-chemical treatments and often degrade the structural stability
of the delicate nano-fibers. Gas-based treatments such as non-thermal plasmas are promising
to penetrate more easily into the electrospun scaffold structure and are at the same time known
for the fact that they only alter the surface without affecting the bulk, guaranteeing the
mechanical and structural integrity of the modified biomaterial [14, 79].
The contact angle of PCL electrospun scaffolds lies between 120° and 140°, indicating a
hydrophobic surface, which is not well liked by most cells. After treatment with either air, Ar,
NH3 or O2 plasmas, all research groups were able to reduce the contact angle to less than 5°
[80-85]. The XPS results reveal an increase in the oxygen content with the incorporation of a
mixture of C-O, C=O and O-C=O functional groups. Prabhakaran et al. seeded neurolemmo‐
cytes (or Schwann) cells onto the nanofibrous scaffolds and found an increase in proliferation
rate at all times, with a maximum of 17% compared to the untreated material after 10 days,
compared to the untreated scaffolds [80]. They claim that the treatment is as effective as a
collagen coating, making it a cost-effective alternative for nerve cell regeneration applications.
Yan et al. found that after plasma treatment with NH3+O2 had no influence on the mechanical
properties of the non-woven. After seeding with MC3T3 osteoblasts a 2-3 times increase in cell
adhesion was found in the first 24 hours and after 7 days the proliferation was increased by a
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factor of 6, making the plasma treatment an excellent tool for the introduction of osteo-
inductive properties [81, 84]. Martins et al. came to the same conclusions after treating their
PCL nano-textile scaffolds both with Ar and O2 plasma [82]. Seeding 3 different cell lines (L929,
ATDC5 and Saos-2) covering a wide variety of cell-types, resulted in a significant increase in
both adhesion and proliferation for all cells. Min et al. tested the O2 plasma treated PCL nano-
textile with primary astrocytes and noted an increase in adherence and viability in the first 24
hours [83]. Jeon et al. used a nano-sized template to enhance the nano-roughness introduced
by the plasma [85]. After seeding MG63 osteoblasts a dramatic increase in cell adhesion and
proliferation were noted as well as an elongated morphology compared to both untreated PCL
and PCL treated without the nano-sized template, showing that both the surface chemistry
and topography have a significant influence on the histological performance of the PCL
electrospun scaffolds. Finally Blackstone et al. used a CF4 plasma to further increase the contact
angle of the non-woven in order to obtain a superhydrophobic scaffold [86]. After seeding a
mixture of fibroblasts, keranocytes and MCF-7 cancer cells, they were able to sort out the cancer
cells by applying a fixed amount of stress to the textile. The recovered cancer cells did not
change in morphology, allowing for post-sorting analysis, making the development of a low
cost cancer detection device possible.
Figure 3. Photographs of water droplets taken immediately after contacting (a) non-treated, (b,c) oxygen plasma-treat‐
ed and (d,e) ammonia plasma-treated PLGA nanofibers. Treatment time was varied from (b,d) 30 to (c,e) 180 s [128].
PLLA and PLGA both exhibit the same hydrophobic properties as PCL non-woven, giving
water contact angles situated between 130° and 150°. After a plasma treatment with the typical
discharge gasses (O2, Ar, NH3...) a decrease in contact angle was found to a minimum, ranging
between 20° and 45° as depicted in figure 3 [87-89]. XPS reveals that PLLA is less robust
compared to PCL as the initial increase in oxygen content is reversed when the substrate is
over-treated, resulting in etching/degradation of the polymer structure [88]. Both Park et al.
and Dolci et al. seeded fibroblasts (NIH 3T3 and MEF) after NH3 and air treatments respectively
and similar results for the increase in viability and elongated morphology were found [88,
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90]. Liu et al. did a study on the adhesion behavior before and after O2 plasma treatment of
pMSC cells in the first hour after seeding [89]. Results revealed that both the adhesion and cell
morphology were greatly improved as can be seen from figure 4. These results show that
plasma treatment is indeed a valid option for the culturing of stem cells.
As PLLA, PLGA and PCL all show similar histological effects after exposure to a wide variety
of plasmas, it is no surprise that blends of PLLA and PCL exhibit similar behavior. Chanda‐
sekaran et al. exposed such a co-polymerized fiber mesh to an air plasma treatment and studied
the effects on fibroblast growth and proliferation [91]. In both cases a significant increase was
noted and stimulation of extra cellular matrix formation was found, opening up the possibility
for skin tissue regeneration applications.
Figure 4. SEM images of pMSCs on Plasma treated PLLA nanofibers (NFS) and pristine PLLA NFS. (A–D) pMSCs on
PLLA NFS after cultured for 10 min, 20 min, 30 min,60 min, respectively; (E–H) pMSCs on P-PLLA NFS after cultured
for 10 min, 20 min, 30 min,60 min, respectively; (a–h) higher magnification for (A–H) [129].
The biodegradability of the textile scaffold material is not required in every case and sometimes
has to be avoided all together (tissue culture ‘plates’, vascular grafts...) as the loss of the
mechanical framework would result in the permanent failure of the implant. A polystyrene
electrospun scaffold was treated by Baker et al. with a low pressure Ar plasma, followed by
the seeding of smooth muscle cells [92]. The in-vitro tests revealed a significant increase in cells
and an alignment with the electrospun material. The excellent results show that the polystyr‐
ene electrospun scaffold could be a valid alternative for 2D tissue culture plates. Zandén et al.
treated a PU fiber mesh with an oxygen plasma in an attempt to improve the interaction with
red blood cells [93]. SEM images showed that prolonged exposure to the plasma resulted in a
reduction of the fiber diameter and finally the degradation of the structure. As was the case
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with PLLA and PCL, a significant increase in hydrophilicity was noted due to the incorporation
of polar functional groups. The in-vitro tests revealed that there was no significant difference
between the adhesion of red blood cells before and after treatment. This shows that not all
plasma treatments have a positive effect on biocompatibility and that the treatment gas and
operation parameters should be carefully selected.
The final paragraph of this chapter part on plasma treatment for tissue engineering will go
over the possibilities to use non-thermal plasmas to stimulate the formation of apatite on
flexible scaffold structures. Yang et al. immersed an Ar plasma treated PCL fiber structure in
an SBF 10 solution for a period of 7 days [94]. In the first 24 hours, already a CaP coating had
grown on the fibers, consisting of nano-apatite and dicalcium phosphate dehydrate. After 7
days a structure closely resembling bioapatite was found. Luo et al. performed the same
analysis on air plasma treated PEEK (reinforced with carbon fiber) and whereas the untreated
PEEK resulted in no apatite formation, a fully grown apatite layer could be found on the treated
nonwoven scaffold [95]. Other research groups made a solution of PCL mixed with hydrox‐
yapatite/CaCO3 which was electrospun, resulting in a composite nano-textile which was
followed by an oxygen/air plasma treatment [96, 97]. After seeding hFOB osteoblasts, a
significant proliferation rate was noted, as well at the first signs of mineralization similar to
human bone as depicted in figure 5. These papers show that plasma activation of polymeric
nonwoven scaffolds is an excellent tool for the promotion of apatite growth.
Figure 5. Mineralization of hFOB on PCL/HA-P nanofibrous scaffolds at different magnifications: (a) mineral deposi‐
tion 5000× (6 days), (b) mineral deposition 10000× (6 days), (c) mineral deposition 15000× (6 days), (d) apatite-like mor‐
phology of natural bone 15000× (10 days) [130].
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In general it can be concluded that non-thermal plasma treatments, both at lower and elevated
pressures, are excellent tools for the stimulation of the histological properties of a wide variety
of cells seeded onto flexible scaffolds for tissue culture and tissue engineering applications.
3.4. Plasma grafting, polymerization and immobilization
The tissue engineering nanofibrous scaffold materials subjected to plasma grafting and plasma
polymerization are, in the majority of the papers reviewed, more or less the same ones used
for plasma activation, PCL being the most popular one. A minority of papers investigated less
obvious material choices that are inherently not (sufficiently) biocompatible, but once coated
exhibit sufficient bioactive properties, as will be discussed in the last paragraph of this chapter
part.
Guex et al. coated a PCL mesh using a combination of ethylene and CO2 in an Ar discharge in
order to restore the functionality of damaged myocardium [98]. After seeding extracted
mesenchymal stem cells onto the modified electrospun scaffold, it was implanted in a rodent
model. Post-mortem analysis revealed a stabilized cardiac functionality as well as an attenu‐
ated dilation. Zander et al. covalently bonded lamilin proteins onto an air plasma treated PCL
scaffold [99]. PC12 neuron-like cells were seeded onto the modified substrate and analysis
showed a positive correlation between the neuron outgrowth and the concentration of the
immobilized proteins. Xie et al followed a similar strategy, immobilizing dopamine [100]. The
dopamine coating itself was then used to immobilize fibronectin, which significantly stimu‐
lated the attachment, spreading and cytoskeletal development of NIH 3T3 cells. Furthermore
it was proven that the coatings could be used for the controlled release of active substances.
Ma et al. used a combination of air plasma and wet carboiimide chemistry to graft gelatin onto
both random and aligned PCL fiber meshes [101]. The spreading and proliferation of endo‐
thelial cells was greatly enhanced and the cells aligned themselves along the fibers, which was
not the case for the untreated material. Finally Hegeman et al. performed a degradation study
of PCL nanofibrous scaffolds coated with amine containing polymers and showed that the
incorporation of oligomers in the deposited films can leach out, causing cell death [102].
Storage of the coated nano-textiles in liquid media removed the low molecular weight residue,
solving the problem. Overall, the literature shows that PCL nonwoven scaffolds, either
activated or coated, can be used for a wide variety of tissue engineering applications, exhibiting
excellent bioactive properties. It is essential though to use the right set of parameters and avoid
the inclusion of unreacted products as this can have a detrimental effect on the histological
performance of the 3D electrospun scaffold.
Several research teams used non-thermal plasmas to immobilize bioactive macromolecules
(collagen, cRGD peptides and heparin respectively) onto a PLLA nano-textile scaffold, after
which they were seeded with either BOECs, hMSC or endothelial cells [78, 103-106]. In all cases
a positive influence was found on the scaffold’s histological properties. Park et al. also obtained
an increase in adhesion and proliferation after seeding NIH 3T3 fibroblasts onto PLLA nano-
textile scaffolds that were grafted with an acrylic acid coating using a low pressure O2 plasma
[107]. He et al and Chan et al. performed a similar procedure compared to Feng et al. to
immobilize collagen onto PLLA-PCL electrospun scaffolds [108, 109]. The first group success‐
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fully seeded hCAEC’s, showing the possibilities for vascular grafts (see figure 6), while the
Chan et al. studied the enhancement of the adsorption properties of MSC cells in the first hour
after seeding, proving that coated nonwoven scaffolds are more efficient than plasma treated
samples, which in turn are more effective then untreated samples.
A rather large number of publications can be found on a variety of other biomaterials that are
not always biodegradable such as PDMS, PU, PET, silk fibroin, cellulose, PHBV... Most of these
textile scaffolds get coated with well-known bioactive macromolecules such as collagen,
galactose, lamilin, peptides, or polymer films containing functional groups that are well-liked
by cells, such as primary amines or carboxylic acids [92, 110-118]. A whole spectrum of cells
is seeded on the coated textile scaffolds, ranging from osteoblasts and fibroblasts to endothelial
cells, nerve cells and even stem cells. Discussing all of them again would lead to far, especially
as the effects are similar to the histological performance of the coated PCL and PLLA textiles.
Therefore the results have been summarized in table 1.
Figure 6. Fluorescent micrographs of HUVECs cultured on PU (A and B), plasma treated PU (P-PU) (C and D), P-PU/
PLGA (E and F), and plasma treated (P-PU/PLGA) films for 3 s (G and H). Cells were stained with Texas-Red Malei‐
mide C2 for cell membrane and nuclei were stained with Hoechst33258. Images are 40× (A, C, E, and G) and 400× (B, D,



































Chien et al. [112]
Advances in Bioengineering134
fully seeded hCAEC’s, showing the possibilities for vascular grafts (see figure 6), while the
Chan et al. studied the enhancement of the adsorption properties of MSC cells in the first hour
after seeding, proving that coated nonwoven scaffolds are more efficient than plasma treated
samples, which in turn are more effective then untreated samples.
A rather large number of publications can be found on a variety of other biomaterials that are
not always biodegradable such as PDMS, PU, PET, silk fibroin, cellulose, PHBV... Most of these
textile scaffolds get coated with well-known bioactive macromolecules such as collagen,
galactose, lamilin, peptides, or polymer films containing functional groups that are well-liked
by cells, such as primary amines or carboxylic acids [92, 110-118]. A whole spectrum of cells
is seeded on the coated textile scaffolds, ranging from osteoblasts and fibroblasts to endothelial
cells, nerve cells and even stem cells. Discussing all of them again would lead to far, especially
as the effects are similar to the histological performance of the coated PCL and PLLA textiles.
Therefore the results have been summarized in table 1.
Figure 6. Fluorescent micrographs of HUVECs cultured on PU (A and B), plasma treated PU (P-PU) (C and D), P-PU/
PLGA (E and F), and plasma treated (P-PU/PLGA) films for 3 s (G and H). Cells were stained with Texas-Red Malei‐
mide C2 for cell membrane and nuclei were stained with Hoechst33258. Images are 40× (A, C, E, and G) and 400× (B, D,



















































































Baker et al. [92]







Ma et al. [116]








PDMS L929 Cytocompatibility Arjun et al. [118]
Table 1. Overview of papers on the histological performance of plasma coated 3D electrospun scaffolds (no PCL and
PLLA)
3.5. Sutures
Of all the textiles for biomedical applications, sutures are probably the most low-tech. The
amount of research conducted to improve the performance of surgical sutures is therefore not
as extensive. Traditionally sutures were either non-biodegradable, requiring removal after‐
wards or biodegradable, but lacking the necessary mechanical strength and flexibility [49].
Eventually glycolide and lactide polymers such as PLLA and PLGA found their way into the
suture market, introducing the required mechanical properties combined with biodegrada‐
bility. Yet, as has been discussed earlier in the chapter, these biodegradable polymers do not
always exhibit the wanted bioactive surfaces. A small number of research groups have
investigated if non-thermal plasma technology can help to further improve the performance
of medical sutures, of which a brief overview will be given.
Loh et al. performed a study, using both activation and deposition, analyzing the hydrolytic
degradation rate of commercially available synthetic absorbable sutures [119, 120]. Dexon
(PGA), Vicryl (PGLA), PDS11 (PpDO) and Maxon were either coated with parylene or treated
by a number of different plasma gasses. Using the right set of plasma treatment parameters
significantly increased the degradation rate of Vicryl and PDS11, while for Dexon and Maxon
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only marginal differences were found. The plasma coating process, using parylene, resulted
in an increase in tensile strength, most likely due to the hydrophobic character of the coating.
Saxena et al. published 3 papers on plasma grafting of PP sutures [121-123]. In all the articles
an RF O2 plasma was used to activate the monofilament, followed by the immersion in an
acrylic acid solution. The introduced carboxylic acid groups were then used to successfully
immobilize chitosan. While the first 2 articles elaborates on the preservation of the mechanical
properties and the surface chemical characterization, the second article focusses more on the
antimicrobial, in-vitro and in-vivo properties. The viability of both E. Coli and S. Aureus were
reduced with more than 90%. The in-vitro studies revealed excellent adhesion and prolifera‐
tion of MC3T3 cells and the in-vivo use in a rodent resulted in a better quality of tissue
integration and a minimal inflammatory response. The grafting of acrylic acid onto a mono‐
filament for improved antimicrobial functionality was inspired by Gupta at al. who grafted
acrylic acid onto PET monofilaments, obtaining similar antimicrobial results [124, 125].
 
Figure 7. Left: Zone of inhibition against E. Coli (a) control PP suture and (b) drug-loaded PP suture (degree of graft‐
ing, 5%). Middle: Zone of inhibition against K. Pneumonia (a) control PP suture and (b) drug-loaded PP suture (degree
of grafting, 5%). Right: Zone of inhibition against S. Aureus (a) control PP suture and (b) drug-loaded PP suture (de‐
gree of grafting, 5%) [132].
Albeit being a rather low-tech application, plasma technology is still able to improve the
performance of medical sutures. If the results found for tissue engineering applications would
be applied for monofilament applications, it is beyond doubt that the biomedical properties
could be further enhanced.
4. Conclusion
In this chapter a broad range of applications has been reviewed where non-thermal plasma
technology could play a beneficial role in the biomedical performance of technical textiles.
Albeit being more limited in the number of functional groups that can be incorporated and the
limited stability over time, plasma activation still leads to improvements in cell viability,
adhesion, proliferation and differentiation as well as better adsorption and chemical bonding
of bioactive and bactericidal macromolecules. Plasma grafting and polymerization is equally
able to do all of the above, while having access to a wider variety of functional groups and
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results in more stable surfaces. The incorporation of low molecular weight species into the
coatings has to be avoided at all costs as they can have a detrimental effect on the cells viability.
Up to now, the low pressure systems are by far the most used treatment systems, as the physics
behind the process are well understood and multiple systems are commercially available. In
the last decade there has been a growing interest in atmospheric pressure systems as they are
more low-cost and can be more easily incorporated in textile production systems and it is our
personal believe that atmospheric pressure systems such as the plasma jets will become the
most prominently used set-ups. All in all it can be concluded that non-thermal plasma
technology has earned its place in the (bio)medical textile market and will continue to do so
in the future.
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1. Introduction
Vital information monitoring has become an indispensable part of the next generation
healthcare technologies. Remote monitoring of the vital health information facilitates personal
in-home care, reduces the cost and time of frequently going to the hospitals and minimizes the
difficulties of monitoring the health of the elderly persons. Recent research on contemporary
implantable and wearable sensors for monitoring various physiological parameters as well as
improvement of wireless technology have led to the development of all-inclusive patient
monitoring systems such as Wireless Body Area Network (WBAN) and Body Sensor Network
(BSN). One of the integral parts of these networks is implantable sensor. Applications of
implantable sensors include (but not limited to) monitoring of blood glucose level for diabetic
patients, continuous in vivo monitoring of lactose in the bloodstream or tissues, pressure
monitoring of blood vessels and electronic interfaces to monitor the nervous system. Moni‐
toring of physiological parameters such as pH level in tissues, glucose and lactose in blood‐
streams, heart rate and respiration rate not only improves the quality of life of the patients but
also increases their lifespan. Even though astounding advancements have been made in
medical electronics and instrumentation, invasive medical devices such as small lancets are
still used to collect samples from human body for testing and diagnostic purposes. These
devices increase the risk of infection in human body. For a diabetic patient the discrete
measurements provided by the lancets are not sufficient for monitoring of blood glucose level.
In order to get an idea of the blood glucose trend line, continuous monitoring of glucose level
is highly desirable and minimally invasive implantable sensors are ideal fit for this application.
The most important concern related to the use of implantable sensor is the health safety of the
patients. The true success of an implant depends on the proper functioning of the sensor
without having any adverse effect on the tissues surrounding the implant.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
2. Implantable sensors for biomedical applications
Recent developments in biomedical sensors and state-of-the-art CMOS technologies have led
to the realization of minimally invasive implantable biomedical sensors for continuous
monitoring of the patients. A continuous monitoring system allows the doctors to investigate
the medical data of the patient online and thus provides savings in both time and money. The
data acquired by the sensor from frequent monitoring also helps the hospital to efficiently
record the medical history of a patient for future references. Figure 1 represents a detailed
implantable sensor system with the combination of different biosensors and integrated circuits
(ICs) which are designed to be implanted underneath the skin. Sub-micron CMOS technologies
offer various advantages such as small form factor and reliable operation which make them
very suitable for implantable medical applications. Biosensors on this platform include
glucose, lactose, oxygen and pH sensors, etc. The state of the art research on implantable
biosensor system focuses on its small form factor and light-weight for easy integration and
biological safety [1]. Even though the development of deep sub-micron CMOS processes has
significantly brought down the overall chip area, still the power unit such as lithium ion battery
takes up a substantial area of the overall system. Therefore elimination of the battery as the
power source can potentially reduce the system area significantly. Batteries also impose a
potential risk of leakage which might result in serious health hazards to the patient and require
periodic replacement. An eco-friendly solution of this potential problem involves the devel‐
opment of more efficient wireless powering methods or the design of low-power ICs. In
contrast to a battery operated system, wireless powered system eliminates the hassle of
frequent replacement of the power source and can be considered as a minimally invasive
option with no risk of infection [1] [2]. Previously reported works present the use of inductive
coupling (i.e. inductive link) [1] and optical coupling (i.e. solar cells) [2] as potential wireless
powering approaches. A noninvasive, reliable, and efficient power supply along with a reliable
data communication interface is a potentially important feature that an implantable sensor
must possess.
A biosensor usually consists of an electrochemical sensor which generates an electrical signal
that corresponds to the concentration of a particular electrolyte. Readout electronics such as
potentiostats (amperometric or voltametric electrochemical sensors) help maintain a constant
potential difference between two electrodes to facilitate the chemical reaction to take place and
provide output in the form of a current (amperometric) or a voltage (voltametric) signal. A
typical potentiostat consists of three electrodes: a working electrode (WE), a counter electrode
(CE), and a reference electrode (RE). The potential difference between the working and the
reference electrodes stimulates the chemical reaction and the counter electrode provides the
corresponding output current signal, which is then delivered to the signal processing unit
(SPU). The SPU modulates the data so that it can be transmitted outside of the body wirelessly
to a receiver, which can be a smart phone or a similar electronic device. Peripheral ICs such as
power supply units, sensor activation circuits etc. are also integrated together to realize this
scheme on a system-on-a-chip (SoC) platform.
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Figure 1. Implantable biosensor system (inside the dashed red rectangle) [3].
3. Low-power circuit design techniques
Even though the amplitude of the signal generated by the implantable biosensors depends on
the concentration of various physiological parameters, nonetheless the signal needs to be
amplified and converted to a digital signal for further processing. Low-voltage and low-power
circuit design techniques are required to be employed in the design of the signal processing
circuitry of the implantable devices for long-term reliable operations. Depending on the
application the most appropriate circuit topology needs to be chosen to meet the design
challenges. Various innovative low-power circuit design methodologies have appeared in
literatures to meet the requirement of long term operations. Their working principles are
discussed in the following sections.
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From the perspective of a circuit designer, employing of short-channel transistors is an
appealing and efficient method to reduce the SoC chip area. The added advantage of these
transistors is that the power supply voltage also downscales proportionally with the reduction
of the transistor channel length. Thus hot electron effect and time-dependent dielectric
breakdown (TDDB) [4] do not deteriorate the robustness and reliability of the devices.
However, the threshold voltage, VT of the MOSFET does not scale down as aggressively as the
channel length or the power supply voltage [5], which puts a constraint on the number of
transistors that can be cascaded in a given process. Some of the techniques for low-power
circuit design include bulk-or body-driven technique, floating gate technique, subthreshold
biasing scheme of the transistors etc. The following sections summarize various low-power
circuit design techniques reported in literature.
3.1. Bulk-driven technique
The bulk (or body-)-driven scheme is a technique that allows circuit designers to implement
ultra-low voltage and ultra-low power system. In the bulk-driven circuit design scheme, the
bulk or the body terminal of a MOSFET is enabled as an AC input. The gate of the device is
kept at a certain potential so that the transistor is ‘on’ during the entire operation. This
technique eliminates the threshold voltage limitation mentioned earlier and helps achieve
ultra-low supply voltage requirement while cascading a good number of transistors. Circuit
designers have used this technique to design a low-voltage, low-power amplifier with a supply
voltage of as low as 1 V [3]. A major drawback of this approach is the lower body transcon‐
ductance (gmb). In addition, the bulk-driving voltage needs to be kept within a certain range
so that the body diodes of the MOSFET are reverse-biased during the variation of the AC input
signal of the body terminal. Therefore, this technique can only be applied to a limited number
of applications [6].
3.2. Floating gate technique
Although the implementation of the floating gate technique is mostly seen in the integrat‐
ed  memory  cell  applications,  it  can  also  be  used  for  designing  low-power  circuits  for
implantable sensors. Floating gate is the polysilicon gate of the MOSFET that is surround‐
ed by silicon dioxide (SiO2). Once the charge has been deposited on the floating gate, it can
be  stored permanently.  Therefore  this  technique  is  suitable  for  flash  memory cells.  The
amount of  this charge can be adjusted by an ultraviolet  (UV) light or a large gate volt‐
age. The stored charge on the floating gate can be used to reduce the threshold voltage of
the transistor. Thus this technique helps reduce the DC supply voltage requirement as well
as the total power consumption [7].
3.3. Subthreshold design technique
Another method that is being used to implement the low-power circuit is the subthreshold
design technique. In subthreshold region (or weak inversion region) design, the gate-to-source
voltage of the MOSFET is biased below the threshold voltage (VGS ≤ VTH) of the transistors. This
level of gate-to-source voltage can weakly invert the transistor channel underneath the gate.
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This process of inversion of the channel is also known as weak inversion. Previously it was
assumed by the researchers that this condition put the MOSFET in to cut-off region and
therefore no current flows through the device. Now, it is well known that there is actually a
small current that flows through the channel of the MOSFET mostly due to the diffusion of
electrons from the drain to the source. A common expression for this subthreshold current of




( VGS-VTHnUT ) (1)
Where ID0 is the current that flows when the gate-to-source voltage is equal to the threshold
voltage, n is a technology specific slope parameter, and UT is thermal voltage (UT ≈ kT/q ≈ 26
mV at room temperature where k is the Boltzmann constant, T is the temperature in Kelvin and
q is the charge of an electron which is equal to 1.6×10-19 coulomb). The exponential relationship
between the drain current and the gate-to-source voltage causes subthreshold biased circuits
to be extremely sensitive to noise and matching. In comparison with the strong inversion circuit
design technique that requires the gate-to-source voltage of the transistor to be much higher
than the threshold voltage, this technique can achieve higher transconductance efficiency for
the same level of current. Combined with rational circuit design and layout approach, this
method can be used for implementing low-power analog circuits for implantable sensors.
4. Wireless interface for implantable sensor
For tether-less operation and to avoid skin infections, the data signal from the signal processor
needs to be wirelessly transmitted to the outside environment. Several research works have
been reported in recent years to meet the design requirements of wireless operation in
biomedical applications. These systems should be miniaturized, light-weight, low-power and
reliable for long term operation. The radiated power needs to be less than the limit set by FCC
(Federal Communications Commission) for wireless telemetry. Wireless communication is one
of the most prevailing means of data transmission for biomedical sensors. Wireless transmit‐
ters and receivers can be found everywhere from short-distance medical endoscopic applica‐
tions [8] to long-distance cell phone communication. Technological advances in silicon
manufacturing have made it possible to design low-power, low-cost integrated circuit for
biomedical sensing application. Examples include electroencephalography (EEG), electrocar‐
diography (ECG) and biometric information sensing for early detection of diseases such as
tumor, cancer, and Alzheimer. Most of these applications require low data rates of a few Hz
to a few kHz. ECG monitoring typically needs 12-bit resolution of ADC with 250 Hz data
sampling rate for a transmission data rate of 3 kbps [9]. However the minimum energy per bit
requirements for implantable sensor put a constraint on the transmitter power consumption
to extend the battery life time. Since it would not be feasible to change the battery of the sensor
often for an implantable sensor, low-power circuit design is an essential requirement. Con‐
sidering most of the power harvesting techniques as well as battery storage capacities, a power
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budget of only 100 μW could be available for each sensor node [10]. Although one can relax
the power constraints by larger battery/energy-harvester size, the importance of a low-power
communication scheme cannot be overlooked for a compact design of the sensor node. Despite
the urge for the design of a low-power low-data rate transceiver with traditional narrowband
architecture, the best transceiver design in this domain for implantable sensors still consumes
about 500 μW of power [11].
The first demonstration of a fully customized mixed-signal silicon chip that had most of the
attributes required for a wearable or implantable BSN was described in [12]. The system blocks
include low-power analog sensor interface for temperature and pH sensing, a data multiplex‐
ing and conversion module, a digital platform based around an 8-b microcontroller, data
encoding for spread-spectrum wireless transmission, and an RF section requiring very few off-
chip components as shown in Figure 2. A programmable direct-sequence spread-spectrum
(DS-SS) transmitter is integrated into the SoC in order to improve the reliability of the wireless
transmission [13]. The transmitter is comprised of a data encoder and an RF section. The
minimum data rate from the encoder is approximately 3.67 kbps. The amplification stage of
the RF section is designed to be a near-class-E RF power amplifier driven by the digital output
of the encoder. The gain budget of the amplifier enables it to maintain high gain and linearity
while limiting the total current. The on-chip RF section uses a relatively low frequency carrier
for modulation. An 800μm × 300μm on-chip spiral inductor transmits the signal that is
detectable at a range of 0.5 m in air using a Winradio receiver with a conventional whip antenna
at a data rate of up to 5 kbps. Even though the on-chip inductor is less efficient than an external
antenna, it demonstrates the feasibility of integrated antennas on silicon [14], [15]. A data-























Figure 2. Schematic diagram of the system-on-chip architecture for body sensor networks [12].
An integrated CMOS ultra-wideband, high duty cycled,  non-coherent wireless telemetry
transceiver for wearable and implantable medical sensor applications was reported in [16].
A prototype wireless capsule for endoscopy was designed using the proposed transceiver
and it demonstrated in vivo image transmission of 640 × 480 resolution at a frame rate of
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Figure 2. Schematic diagram of the system-on-chip architecture for body sensor networks [12].
An integrated CMOS ultra-wideband, high duty cycled,  non-coherent wireless telemetry
transceiver for wearable and implantable medical sensor applications was reported in [16].
A prototype wireless capsule for endoscopy was designed using the proposed transceiver
and it demonstrated in vivo image transmission of 640 × 480 resolution at a frame rate of
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2.5 fps with 10 Mb/s data rate. This transceiver supports scalable data rate of up to 10 Mbps
with energy efficiency of 0.35 nJ/bit and 6.2 nJ/bit for transmitter and receiver, respective‐
ly. The block diagram of the transmitter is shown in Figure 3. The transceiver uses On/Off
keying (OOK) modulation scheme where a binary “1” is represented by a short pulse and
binary “0” is represented by no pulse transmission. For improved performance of anten‐
nas with miniaturized size, UWB frequency band in 3–5 GHz is selected. The UWB pulse
is generated by a fast on/off voltage-controlled oscillator (VCO) controlled by the TX data.
A driving amplifier provides voltage amplification and isolation between the VCO and the
antenna.  Both the VCO and the driving amplifier  consume power during pulse genera‐
tion only. At the receiver end, the weak signal is first amplified by a variable gain low-
noise amplifier (LNA) followed by a squarer performing the energy detection. A variable
gain amplifier (VGA) amplifies the squarer output further and a slicer digitizes the final
signal.  The  digital  baseband  provides  synchronization,  error  correction  coding,  and
interfaces with the external sensors. The transceiver chip consumes a die area of 3 mm × 4
mm when designed in a standard 0.18 μm CMOS process. The transmitter draws an average
power of 0.35 mW with the energy per bit of 0.35 nJ/bit for up to 10 Mbps. The receiver
average power consumption is as low as 6.1 mW with duty cycling under 1 Mbps data rate


















Figure 3. Block diagram of the ultra-wideband wireless telemetry transceiver [16].
Cleven et al. [17] presented a novel fully implantable wireless sensor system implanted into
the femoral artery with computed tomography angiography intended for long-term monitor‐
ing of hypertension patients. The system was employed to measure intra-arterial pressure at
a sampling rate of 30 Hz and an accuracy of ±1.0 mmHg over a range of 30–300 mmHg, and
consumed up to 300μW power. The implant consists of two functional components: the
pressure sensor tip and the transponder unit for communicating with the external readout
station. Both the components are linked by a data cable. The full length of the sensor system
is approximately 22 cm. The telemetric unit has a diameter of approximately 2 cm and a
thickness of approximately 4 mm. The telemetry chip schematic including external compo‐
nents necessary for telemetric mode is presented in Figure 4. The analog output signal from
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the pressure sensor ASIC is digitized by the sensor readout block. At the same time, the
bidirectional data pads provide the offset and the gain settings. The digital component of the
chip, a state machine, provides the protocol for data transmission of the measured values. The
HF front-end controls the telemetry components while generating the controlled supply
voltage required for sensor readout. Using a transmission frequency of 133 kHz, the digitalized











Figure 4. Schematics of transponder ASIC and external circuitry for long-term monitoring of hypertension patients [17].
A transcutaneous two-way communication and power system for wireless neural recording
was reported in [18]. Figure 5(a) shows a schematic of the power and bidirectional data transfer
system. Wireless powering and 1.25 Mbps forward data transmission (into the body) are
achieved using a frequency-shift keying modulated class-E converter. The carrier frequency
for reverse telemetry (out of the body) is generated using an integer-N phase-locked loop
which provides the necessary wideband data link to support simultaneous reverse telemetry
from multiple implanted devices on separate channels. The physical arrangement of the coils
is illustrated in Figure 5(b). For the implanted device, coil 1 (L1) represents the external power
coil, coil 2 (L2) is the implanted power coil, coil 3 (L3) is regarded as one of the external
differential data coils, and coil 4 (L4) is the implanted data coil. A large AC current is generated
in coil 1 using a class-E converter to transfer power to the implant. An AC current proportional
to the coupling coefficient between the external and the implanted power coils is induced in
coil 2. The resulting AC voltage is rectified and supplied to the application-specific integrated
circuit (ASIC) to power it up. Frequency-Shift Keying (FSK) modulation of the 5 MHz power
carrier at a data rate of 1.25 Mbps is performed to achieve forward data transfer and to send
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control data to the ASIC. The reference clock is multiplied up by an integer-N PLL in the ASIC
circuitry to generate a reverse telemetry carrier between 50 and 100 MHz. The reverse telemetry
uses either Amplitude-Shift Keying (ASK) or Binary-Phase-Shift Keying (BPSK) modulation
scheme. To generate the reverse telemetry signal, the on-chip driver circuitry induces current
in coil 4. Data is received by one of the two external differential data coils, coil 3. The purpose
of a differential coil configuration is to cancel both the large power signal at its fundamental
frequency and harmonics generated by the class-E converter that fall within the frequency
range of the reverse telemetry.
Class E Converter 
&
FSK Modulator


































Figure 5. (a) Schematic of bidirectional data transfer system for wireless neural recording, (b) Physical diagram of dual
inductive link coils [18].
Cao et al. prototyped a device for gastroesophageal reflux disease (GERD) monitoring in [19].
The system consists of an implantable, battery-less and wireless transponder with integrated
impedance and pH sensors and a wearable, external reader that wirelessly powers up the
transponder and interprets the transponded radio-frequency signals. The total size of the
transponder implant is 0.4 cm × 0.8 cm × 3.8 cm and it harvests radio frequency energy to
operate dual-sensor and load-modulation circuitry. The system is designed in a way that it can
store data in a memory card and/or transmit data to a base station wirelessly. Figure 6 shows
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the block diagram of the sensor system. The coil antennas and the tuning capacitors form the
resonant circuits. Relaxation oscillators are used as the frequency converters in the transpond‐
er. The system is designed to operate at 1.34 MHz since the recommended maximum permis‐
sible exposure of magnetic fields is the highest in the frequency range of 1.34 MHz to 30 MHz
[20]. A coil antenna is made using a 34-AWG magnet wire wound around the printed circuit
board. The energy harvesting circuit consists of a series of diodes and capacitors (100 pF) in a
voltage multiplier circuitry that builds up the DC voltage from the received RF signals [21],


























Figure 6. Block diagram of the gastroesophageal reflux disease (GERD) monitoring system [19].
Cheong et al. [24] presented an inductively powered implantable blood flow sensor microsys‐
tem with bidirectional telemetry. The microsystem is comprised of silicon nanowire (SiNW)
sensors with tunable piezoresistivity, an ultra-low-power application-specific integrated
circuit (ASIC), and two miniature coils that are coupled with a larger coil in an external
monitoring unit to form a passive wireless link. The implantable microsystem operates at 13.56-
MHz carrier frequency. It receives power and command from the external unit and backscat‐
ters digitized sensor readout through the coupling coils. Cheong et al. fabricated the ASIC in
a standard 0.18-μm CMOS process and the chip occupied an active area of 1.5 × 1.78 mm2 while
consuming only 21.6 μW of power. The overall system architecture consisting of an implant‐
able wireless sensor microsystem and an external hand-held device is shown in Figure 7. The
ASIC consists of a sensor interface circuit, an analog-to-digital converter (ADC), a digital
baseband (DBB), a low-dropout (LDO) regulator, and front-end circuits for wireless powering
and bidirectional telemetry. The external monitoring unit needs to be placed in close proximity
to the implant microsystem to initiate the passive sensing operation. The RF power is trans‐
mitted by the external unit through the carrier at 13.56 MHz. The parallel resonant LC tanks
and the rectifiers convert the received RF signal to a DC signal, and the LDO regulator powers
the ASIC with regulated DC supply. Following the demodulation of the incoming modulated
carrier, it is de-spread by the DBB to configure the system parameters such as integration time,
amplifier gain, selection between two sensors, resonance tuning, and modulation index. At
the same time, the clock is extracted from the incoming carrier and is provided to the DBB.
Once the system parameters are set according to the received commands, the sensing operation
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ensues. A successive approximation register (SAR) ADC converts the analog voltage output
from the sensor interface circuit into digital data. The digital data is spread and formatted by
the DBB and is sent to the load modulator that backscatters the incoming RF carrier according





















































Figure 7. Architecture of the implantable blood flow monitoring system [24].
The above discussion presents an overall picture of the recent evolution in wireless technology
for implantable sensors for monitoring of various physiological parameters. The background
information and the current trends for the design of a wireless transmitters and receivers are
also discussed. For a low-power, non-invasive and unobtrusive performance of an implantable
sensor, wireless power transfer is mandatory. In the following sections, a brief discussion on
various wireless power transfer and energy scavenging techniques are presented in terms of
application requirements, available resources and radiation constraints.
5. Wireless power transfer
Previously, transcutaneous power cables were used in clinical implantable applications [25]
at the expense of the introduction of a significant possibility for infection. Another alternative
for power cables is an implanted battery. The use of batteries is usually intended to be avoided
in implantable biomedical sensors as battery replacement is cumbersome and there is always
a probability of leakage which can have serious health consequences. For this reason, various
energy harvesting schemes and wireless powering techniques are employed in implantable
sensors for battery-less operation. Energy harvested from body heat, breathing, arm motion,
leg motion or from the motion of other body parts during walking or any other activity can be
converted into a usable voltage to power up the sensor.
There are several possible sources of energy for sensorsincluding kinetic and thermal energy
harvesters such as piezoelectric and pyroelectric transducers, photovoltaic cells etc. A sum‐
mary is provided in the following table highlighting their sizes, produced energy or power
and respective applications [26].
Electronic Sensor Interfaces With Wireless Telemetry
http://dx.doi.org/10.5772/59754
161
Method Density Advantage Disadvantage
Piezoelectric 200 μW/cm3 No energy required from outside Dependent on movement
Thermoelectric 60 μW/ cm3 No material to be replenished Low efficiency less than 5%




Harvesting energy from ambient EM
wave
Depends on EM wave
availability
Visible light *100 mW/cm2 Free
Not available at night and in
cloudy days.
Temperature variation 10 μW/ cm3 No material to be replenished
Low efficiency, Energy storage
required
Airflow *1 μW/cm2 No material to be replenished Implantation is difficult
Heel strike *7 W/cm2 Good source of energy Dependent on movement.
* Energy Density per Unit Area
Table 1. Comparison of Different Sources of Energy
All the above methods presented in Table 1 have their benefits as well as disadvantages. The
method which is free of most of these disadvantages is the wireless power transfer (WPT).
WPT is clean, controllable, independent of patient’s movement, always available and more
efficient than all the sources of energy that have been mentioned in Table 1. Although WPT
has lower efficiency compared to the battery, it does not have the risk factors that are associated
with a battery. Especially for sensors that come in direct contact with blood, any leakage can
cause chemical burning, poisoning etc. and may eventually lead to death. A battery usually
lasts for 5 to 7 years and then surgical procedure is required for its removal and replacement.
On the other hand, WPT usually lasts for 15 to 20 years and consequently it is much cheaper
than the batteries.
WPT is a technique for supplying energy from the source to the destination without any
interconnecting wires. Nicola Tesla first demonstrated WPT using his resonant transformer
called ‘Tesla coil’. In this design, resonant inductive coupling was used to excite the secondary
side of a transformer. With the passage of time, many researchers came up with different
applications for the use of WPT and now WPT is used when a wire interconnection is incon‐
venient, risky or impossible. WPT is now used in induction heating coils, wireless chargers for
consumer electronics, biomedical implants, radio frequency identification (RFID), contact-less
smart cards etc. Several types of wireless power transfer techniques have been briefly dis‐
cussed in the following section.
5.1. Classifications of wireless power transfer
There are two major methods for wireless power transfer – electromagnetic induction and
electromagnetic radiation. Electromagnetic induction can be subdivided into three categories
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– electrodynamic, electrostatic and evanescent wave coupling. Electromagnetic radiation such
as microwave power transfer and laser are also used for transferring power wirelessly. Figure
8 illustrates various types of wireless power transfer techniques.
Wireless Power 
Transfer







Microwave Power Transfer Laser
Figure 8. Types of wireless power.
Electromagnetic Induction
By varying the magnetic field an electromotive force can be produced across a conductor. This
is called electromagnetic induction. The three possible ways to achieve that are summarized
below:
a. Inductive coupling: This is achieved via near field radiation which causes coupling of
energy between two inductors (coils) and is also known as the electrodynamic or magnetic
coupling.
b. Electrostatic or capacitive coupling: This is the propagation of electrical energy through a
dielectric medium. High voltage and high frequency alternating current gives rise to the
electrical field for this form of WPT. Unintended parasitic capacitance (e.g. capacitance
between two adjoining wires or PCB traces) can cause noise and has to be taken into
account for high frequency circuit design.
c. Evanescent wave coupling: In this process, an exponentially decaying electromagnetic field
is used to transmit the electromagnetic waves from one medium to another.
Electromagnetic Radiation
After an electromagnetic radiation is emitted, it can be absorbed by some charged particles.
This type of radiation can propagate through vacuum at the speed of light. It has a time varying
electric field component as well as a magnetic field component, which oscillates perpendicu‐
larly to each other and perpendicularly to the direction of energy and wave propagation. Two
ways in which wireless power transfer using electromagnetic radiation can be accomplished
are:
a. Microwave power transmission: It is the transmission of energy using electromagnetic waves
with wavelengths ranging from 30 cm down to 1 cm or equivalently a frequency range of
1 GHz to 30 GHz. It is used for directional power transmission to a remote destination.
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b. Laser: In this technique electricity is first converted into a laser beam which is then directed
towards a photovoltaic cell. The receiver is an array of photovoltaic cells designed to
convert the light back to a usable electrical energy. This method is also known as optical
coupling.
Since inductive link is the most commonly used wireless power transferring technique for




Figure 9. Basic inductive link caused by alternating electromagnetic field.
5.2. Inductive link
An inductive link comprises of a loosely coupled transformer consisting of a pair of coils as
shown in Figure 9. An alternating source (AC) drives the primary coil and generates the desired
electromagnetic field. A portion of the generated magnetic flux links the secondary coil and
according to Faraday’s Law of electromagnetic induction, the temporal change of magnetic
flux induces a voltage across the secondary coil. The voltage induced in the secondary coil is
proportional to the rate of change of magnetic flux in the secondary coil and the number of
turns in that coil.
 C1 L1 L2 C2 RL
 M
Figure 10. Schematic of basic inductive link based on series parallel resonance.
Figure 10 illustrates a basic inductive link based on series-parallel resonance. The maximum
value of the mutual inductance, M that can possibly be achieved between the two coils of
inductance of L1 and L2 is (L1L2)1/2 and this occurs when all the flux generated in the primary
coil links with all the turns in the secondary coil. The ratio of mutual inductance to its maximum
value is called the coupling coefficient k, which is a dimensionless quantity ranging from 0 to
1 and can be determined using the following equation:
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The performance of the inductive link is dependent on the link efficiency, which is defined as
the ratio of the power delivered to the load to the power supplied to the primary coil. For a
parallel resonant circuit, the link efficiency of the secondary side can be written as [46],
η =  
k 2Q1Q2
(1 + Q2α + k 2Q1Q2)(α +  1Q2 )
 (3)
For a series resonant circuit, the link efficiency of the secondary side turns out to be,
η =
k 2Q1α
(1 + 1Q2 + k 2Q1)(α +  1Q2 )
 (4)
In both Equation 3 and 4, Q1 is the quality factor of the primary coil, Q2 is the quality factor of
the secondary coil, k is the coupling factor between the coils, α is a unit-less constant which is
equal to ωC2RL, where ω is the angular frequency, C2 is the capacitance of the secondary coil
and RL is the load resistance.
Inductive link is a common method for wireless powering of implantable biomedical elec‐
tronics and data communication with the external world. WPT and data telemetry using
inductive link have been demonstrated for various biomedical applications including visual
prosthesis, cochlear implant, neuromuscular and nerve stimulator, cardiac pacemaker/
defibrillator, deep-brain stimulator, brain machine interface, gastrointestinal microsystem and
capsule endoscopy[27-37]. A summary of various inductive link wireless power transfer
applications and their respective carrier frequencies is presented in Table 2:
Reference Applications Frequency Inductor Type
[28] Neural prosthetic Implant 2-20 MHz Ferrite core
[29] Cochlear Implant -- --
[37] Retinal prosthesis 1 MHz Litz wire
[36] Biomedical implant 5/10 MHz --
[35] Neural implant 4 MHz Copper magnet wire
[32] Endoscope 1.055 MHz Litz wire
[33] Gastrointestinal microsystems 58.418 KHz Copper wire
[38] Neural recording 4 MHz Litz wire
[39] Implantable system 13.56 MHz On-chip
[40] Neural prosthesis 25 MHz Wire
[41] Implantable prosthesis 1 GHz Bond wire
[42] Neuroprosthetic implantable device 13.56 MHz PCB
[43] Neural recording 2.64 MHz Off-chip power, on-chip data
[44] Neural recording <10 MHz Wire
Table 2. Wireless Power Transfer for Different Biomedical Implants
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The design of an inductive link is required to meet the power requirement of any of the above
mentioned applications. There are several parameters which play key roles in determining the
performance of an inductive link. A qualitative analysis of these key factors is presented in the
following section.
5.2.1. Performance dependence on different factors
The factors that affect the performance of an inductive link wireless power transfer are as
follows:
a. Diameter of coils: The diameters of the receiver and the transmitter coils are important
parameters affecting the voltage gain of an inductive link [28]. Both the self inductance
and the mutual inductance are proportional to the diameters of the coils. Therefore
increasing the diameters boosts the link efficiency. In case of an implantable system, due
to the constraint on the size of the implant there are more stringent limitations on the
receiver coil size compared to those of the transmitter coil.
b. Number of turns: The number of turns is another important factor since the mutual
inductance is proportional to the product of the number of turns in the transmitter and
the receiver coils. Therefore increasing the number of turns will improve the performance.
c. Spacing and alignment: Spacing between the primary and the secondary coils and their
alignment also significantly affect the coupling between them. Therefore the position of
the implantable sensor in terms of the external wireless power transferring module is an
important factor that needs to be taken in to account. Compared to an exact coaxial
alignment, similar or even better performance can be achieved if the receiver coil is present
within the circumference of the transmitter coil [28]. In case of implantable sensors, any
movement of the patient can cause misalignment between the transmitter and the receiver
which in turn can alter the mutual inductance and the link gain. Two types of misalign‐
ment that affect the link efficiency are lateral misalignment and angular misalignment [25]
as illustrated in Figure 11. After a certain lateral or angular misalignment, the performance


























Figure 11. Indcutive coupling bewtween two coils with lateral misalignment and angular misalignment.
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d. Quality Factor: Higher Quality factors (Q) of the primary and the secondary coils can
significantly improve the link efficiency of an inductive link [27], [47]. Therefore designing
coils with high Q values at the desired frequency of operation is required to achieve a
satisfactory power transfer. Another disadvantage of low Q circuit is that it makes the
output voltage susceptible to load changes [45].
e. Operating frequency: The maximum power allowed to penetrate through human tissue
depends on the operating frequency. It also dictates the size of the coil, the mutual
impedance and the voltage transfer ratio. Since the quality factor depends on the operating
frequency, the efficiency and the bandwidth of the link are influenced as well. Thus, the
frequency of operation plays an important role in the design of wireless power transfer.
f. Other relevant factors: The primary coil of an inductive link is usually driven by low-loss
switching amplifiers. It is necessary to have a high driver efficiency to ensure satisfactory
power transfer efficiency of an inductive link. With a tuned amplifier load, the drive
transistor only draws current when there is no voltage across it [48], improving the overall
system efficiency significantly in the process. Different topologies for the amplifier have
been reported in literature: class-C [27], [48], class-D [45], [50], class-E [35], [37], [49] and
class-CE [47]. Sokal et al. reported a class-E amplifier with a very high efficiency and
insensitivity to small timing errors [51]. Variation in output impedance has a pronounced
effect on class-E amplifiers. When the power demand of the implantable sensor or the
coupling factor between the coils changes the equivalent load seen by the driver amplifier
also varies. Lastly, as far as implantable biomedical applications are concerned, the overall
system gain and the efficiency also depend on the physical configuration of the two coils
and the surrounding materials.
There are some major challenges associated with the implementation of an efficient wireless
power transfer system in implantable sensors. The next section summerizes the major
limitations.
5.3. Limitations of wireless energy transfer
There are several factors that impose serious limitations on the widespread use of wireless
energy transfer for implantable sensors. First of all, it is not often possible to scale the trans‐
mitter or the receiver down to a small enough size to make it suitable for its implementation
in a miniaturized system. Secondly, the range of energy transfer has not yet been demonstrated
to exceed a few meters, which poses a major challenge for its practical implementation.
Ongoing research is focused on finding more compact solution for wireless energy transfer
covering a greater range. Another problem with wireless energy transmission is that its typical
efficiency varies between 45% and 80% falling short of a conventional battery or wire based
technology. Future innovations resulting in the reduction in size as well as increase in
efficiency and operating range will undoubtedly make wireless energy transfer suitable for
plenty of new potential sensor applications.
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6. Health issues related to wireless power transfer
While designing wireless power transfer system for biomedical applications, the associated
health risks have to be taken into consideration. Since RF energy can quickly heat up the
biological tissues due to the thermal effect, the exposure to very high levels of RF radiation
can be harmful. Since attenuation increases with frequency, most of the existing work in
Wireless Body Area Networks (WBAN) considers only the Medical Implant Communication
System (MICS) band (402-405 MHz) or sub-gigahertz bands. Federal Communications
Commission (FCC) regulates the time and the amount of exposure of the electromagnetic
radiation to human tissues at various frequencies [52]. American National Standard Institute
(ANSI) standard C95.1-1982 sets the electromagnetic field strength limits for frequencies
between 300 kHz and 100 GHz [53], [54]. For frequencies below 300 MHz, the electric and the
magnetic fields have to be accounted for separately. The ANSI standard C95.1-1991 sets the
electric and the magnetic field strength limits for the general public for the frequency range of







Power Density, S (mW/cm2) Averaging Time
|E|2 , |H|2 (minutes)E-field H-field
0.003-0.1 614 163 100 1E6 6
0.1-3.0 614 16.3/f 100 10000/f2 6
3-30 1842/f 16.3/f 900/f2 10000/f2 6
30-100 61.4 16.3/f 1 10000/f2 6
100-300 61.4 0.163 1 6
300-3K -- -- f/300 6
3K-15K -- -- 10 6
15K-300K -- -- 10 616000/f1.2
Table 3. IEEE Standard C95.1-1991: Limit of Maximum Permissible Exposure at Controlled Environment on Human
Body [55].
An important parameter that is used to measure the effect of radio frequency exposure on
human is SAR (specific absorption rate). SAR is a quantity that is used to measure the amount
of energy absorbed by a body which is exposed to radio frequency (RF) electromagnetic field.
It is defined as the power absorbed per mass of the tissue with units of watts per kilogram (W/
kg) or milliwatts per gram (mW/g) and can be expressed as,
SAR = ∫ σ
(r )|E (r )|2
ρ(r )  dr  (5)
Here σ is the electrical conductivity of the sample, E is the RMS electric field and ρ is the sample
density. In case of whole-body exposure, a standing human adult can absorb a maximum RF
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radiation rate of approximately 80 MHz to 100 MHz. As a result, RF safety standards are often
most stringent for these frequencies. SAR has to be within an acceptable range for biological
tissues [56], [57]. A whole-body average SAR of 0.4 W/kg has been set as the restriction that
provides adequate protection for occupational exposure [58]. An SAR level of 1.6 W/kg has
been set as the FCC limit for public exposure from cellular telephones [59]. Two areas of the
body, the eyes and the testicles, are particularly vulnerable to RF heating due to the relative
lack of available blood flow to dissipate the excessive heat. The detrimental effects of RF
exposure which does not cause significant heating (referred to as ‘non-thermal’ effects) are still
unproven.
7. Biocompatibility issues related to implantable sensor
Since there is direct contact between the implanted device and biological tissue, a compatibility
assessment of the sensors needs to be performed prior to being deployed inside the human
body. This biocompatibility assessment is defined in [60] as, ‘‘the ability of a material to
perform with an appropriate host response in a specific application’’. Some of the major
characteristics of the bulk and surface materials which can possibly influence host response
and some of the important characteristics of host responses are listed in [61]. The biocompat‐
ibility of an implantable sensor depends on parameters such as the part of the human body
where the implant is deployed and the surface material of the sensor itself. Also the shape and
size of the sensor also have to be optimum to make the sensor compatible with human body.
Surface chemistry and composition of the outer material also need to be kept in mind so that
it does not react with the tissue and blood that come in contact with the implant. Finally,
sterility issues, contact duration and degradation of the material that surrounds the sensor
need to be taken into account while designing a biocompatible implantable sensor [62–63].
Several protocols related to the biocompatibility issues that are scrutinized thoroughly before
an implantable device could be used in the human body have been developed by the U.S. Food
and Drug Administration (FDA). Materials appropriate for long-term reliable implantable
devices according to [61] include a) titanium alloys for dental implants, femoral stems,
pacemaker cans, heart valves, fracture plates, spinal cages, b) cobalt-chromium alloys for
bearing surfaces, heart valves, stents, pacemaker leads, c) platinum group alloys for electrodes,
d) nitinol for shape memory applications, e) stainless steel for stents and orthopedic implants,
f) alumina for bearing surfaces, g) calcium phosphates for bioactive surfaces, h) polyurethane
for pacemaker lead insulation, i) PMMA for bone cement, intraocular lenses, j) silicone for soft
tissue augmentation, insulating leads, ophthalmological devices. On May 28, 2014 FDA
approved the first implantable wireless device with wireless monitoring feature to measure
pulmonary artery pressure for heart patients [64]. With the ongoing research on finding
biocompatible materials it can be easily inferred that there will be numerous implantable
devices in the global market in near future.




In summary, the chapter includes the discussion on various implantable sensors that are
currently being used in biomedical applications. Various low-power low-voltage signal
processing schemes to convert the signal from the sensors into usable data signal have been
discussed as well. This is followed by an analysis of current state-of-the-art research on wireless
telemetry for implantable sensors. Different power management schemes have been explored
at the later part of the chapter. Finally, the chapter concludes with a brief discussion on
biocompatible issues related to implantable sensors.
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1. Introduction
1.1. Sensor definition and classification
Sensors are very critical components in all devices and measurement systems. They have been
widely used in a lot of fields such as science, medicine, automated manufacturing, environ‐
mental monitoring, and so on. Some cheap sensors are finding their ways applying into all
sorts of consumer products, from children’s toys, dishwashers to automobiles. To some extent,
sensors are multidisciplinary and interdisciplinary field of endeavor. This chapter introduces
sensor’s basic definition and features, biomedical sensors, equivalent components in circuit,
signal filters and amplifiers, biomeasurement systems and design.
There are a lot of terms which are often used for sensors including transducer, meter, detector,
and gage. Defining the term sensor is a very difficult task. At present, there is not a uniform
definition which is agreed by all of us. The most widely used definition is that which has been
applied to electrical transducer by the Instrument Society of America(ANSI MC 1, 1975):
“Transducer —A device which provides a usable output is in response to a specified measur‐
and.” Furthermore, national standard of China points out that sensors consist of sensing
component, converting device and electronic circuit. A transducer is more generally defined
as a device which converts energy from one form to another. Output of sensor can be an optical,
electrical, chemical, or mechanical signal. In the field of electrical engineering, the measurand
is physical, chemical, or biological property or condition measured; hence output of biological
signal should be an electrical signal, too.
The words sensor and transducer are both commonly used in the context of measurement
systems, and often in an interchangeable manner. Transducer is used more in the United States,
and sensor has great popularity in Europe and China. The blurring of lines between the exact
meaning of sensors and transducers leads to a degree of confusion. Most but not all sensors
are transducers, employing one or more transduction mechanisms to produce an electrical
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
output signal. According to the basic sensing principle, sensors are classified into mechanical
sensors, electrochemical sensors, biosensors, optical sensors, semiconductor sensors, magnetic
sensors, and thermal sensors. From different viewpoints, there are different classifying
methods. According to the physical parameters measured by sensors, sensors are classified
into resistance displacement sensor, inductive displacement sensor, capacitive displacement
sensor, piezoelectric pressure sensor, laser interferometer displacement sensor, bore gagging
displacement sensor, ultrasonic displacement sensor, optical encoder displacement sensor,
optical fiber displacement sensor, optical beam deformation sensor, flow sensor, imaging
sensor, temperature sensor, intelligent sensor and chemical ingredient sensor. Biomedical
sensors are used to gain the information on body and pathology, which is a branch of bio‐
medical engineering. Biomedical sensors are classified into physical sensor, chemical sensor
and biosensor. Physical sensor could be employed to measure blood pressure, body temper‐
ature, blood flux, blood viscosity, biological magnetic field, etc. Chemical sensor is utilized to
detect the ingredient and concentration of body liquid such as PH value, Ca+ concentration,
glucose concentration, etc. Biosensor is used to sense enzyme, antigen, antibody, hormone,
DNA, RNA and microbe. In nature, biosensor is a kind of chemical sensor, which is mainly
used to detect biological signals.
1.2. Sensor package and specifications
Packaging of certain biomedical sensor is an important consideration during the design,
fabrication, and use of the device. Obviously, the biomedical sensor has to be safe, soft, and
reliable for biomedical sensors often touch the body skin or inner organs of patients. In the
development of implantable biosensor, an additional key issue is to consider the biocompati‐
bility of sensor and operational lifetime in body. When a biomedical sensor is implanted into
the body, it inevitably contacts with body fluids. Then body will affect the function of bio‐
medical sensor, or sensor will affect the site that it is implanted. For example, protein absorp‐
tion and cellular deposition can alter the permeability of sensor packaging that is designed to
both protect sensor and allow free chemical diffusion of certain analytics between body fluids
and the biosensor. Unsuitable packaging of implantable biomedical sensor could lead to drift
and a gradual loss of sensor sensitivity and stability overtime. Furthermore, inflammation of
tissue, infection, or clotting in a vascular site could produce some harmful or adverse effects
on biomedical sensor. Hence, the material used in the construction of sensor’s outer body must
be biocompatible because they play a crucial pole in determining an overall performance and
longevity of implantable biomedical sensor. One convenient method is to utilize various
polymer covering material and barrier layers to prevent the toxic sensor components from
coming into body. It’s very important that packaging material of biomedical sensor must
prevent the chemical diffusion of harmful ingredient between biomedical sensor and outer
body.
Accurate medical diagnostic procedures require the stringent specifications on the design and
use of biomedical sensor. Depending on the intended applications, the performance specifi‐
cations of biomedical sensor may be evaluated to ensure that the measurement meets the
design specifications.
Advances in Bioengineering178
output signal. According to the basic sensing principle, sensors are classified into mechanical
sensors, electrochemical sensors, biosensors, optical sensors, semiconductor sensors, magnetic
sensors, and thermal sensors. From different viewpoints, there are different classifying
methods. According to the physical parameters measured by sensors, sensors are classified
into resistance displacement sensor, inductive displacement sensor, capacitive displacement
sensor, piezoelectric pressure sensor, laser interferometer displacement sensor, bore gagging
displacement sensor, ultrasonic displacement sensor, optical encoder displacement sensor,
optical fiber displacement sensor, optical beam deformation sensor, flow sensor, imaging
sensor, temperature sensor, intelligent sensor and chemical ingredient sensor. Biomedical
sensors are used to gain the information on body and pathology, which is a branch of bio‐
medical engineering. Biomedical sensors are classified into physical sensor, chemical sensor
and biosensor. Physical sensor could be employed to measure blood pressure, body temper‐
ature, blood flux, blood viscosity, biological magnetic field, etc. Chemical sensor is utilized to
detect the ingredient and concentration of body liquid such as PH value, Ca+ concentration,
glucose concentration, etc. Biosensor is used to sense enzyme, antigen, antibody, hormone,
DNA, RNA and microbe. In nature, biosensor is a kind of chemical sensor, which is mainly
used to detect biological signals.
1.2. Sensor package and specifications
Packaging of certain biomedical sensor is an important consideration during the design,
fabrication, and use of the device. Obviously, the biomedical sensor has to be safe, soft, and
reliable for biomedical sensors often touch the body skin or inner organs of patients. In the
development of implantable biosensor, an additional key issue is to consider the biocompati‐
bility of sensor and operational lifetime in body. When a biomedical sensor is implanted into
the body, it inevitably contacts with body fluids. Then body will affect the function of bio‐
medical sensor, or sensor will affect the site that it is implanted. For example, protein absorp‐
tion and cellular deposition can alter the permeability of sensor packaging that is designed to
both protect sensor and allow free chemical diffusion of certain analytics between body fluids
and the biosensor. Unsuitable packaging of implantable biomedical sensor could lead to drift
and a gradual loss of sensor sensitivity and stability overtime. Furthermore, inflammation of
tissue, infection, or clotting in a vascular site could produce some harmful or adverse effects
on biomedical sensor. Hence, the material used in the construction of sensor’s outer body must
be biocompatible because they play a crucial pole in determining an overall performance and
longevity of implantable biomedical sensor. One convenient method is to utilize various
polymer covering material and barrier layers to prevent the toxic sensor components from
coming into body. It’s very important that packaging material of biomedical sensor must
prevent the chemical diffusion of harmful ingredient between biomedical sensor and outer
body.
Accurate medical diagnostic procedures require the stringent specifications on the design and
use of biomedical sensor. Depending on the intended applications, the performance specifi‐
cations of biomedical sensor may be evaluated to ensure that the measurement meets the
design specifications.
Advances in Bioengineering178
In order to understand sensor’s performance characteristics, it is very important to learn some
of the common terminology associated with sensor specifications. The following definitions
are commonly used to describe sensor characteristics and select sensor for particular applica‐
tions.
(1) Measurement range
The range of sensor corresponds to the minimum and maximum operation limits that sensor
is expected to measure accurately. For example, a pressure sensor may have a nominal
performance over the operating range from 0 Pa to 10MPa.
(2) Sensitivity
Sensitivity refers to the ratio of output change for a given input change. Another way to define
sensitivity is to find the slope of calibration line relating the input to the output, as illustrated
in figure 1.A high sensitivity implies that a small change in input causes a large change in
output.
For example, a pressure sensor may have a sensitivity of 0.4V / Pa ; that’s to say, the output of
this sensor will change 0.4V for 1Pa change in input pressure. If the calibration curve is linear
seen in figure 1 (a), then sensitivity of sensor will be constant, whereas the sensitivity of sensor
will vary with the input when the calibration is nonlinear, as in figure 1 (b). Alternatively,
sensitivity can be defined as the smallest change in input that will result in a detectable change
in sensor output.
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Accuracy refers to the difference between the true value and the actual value measured 
by sensor. Classically, accuracy is expressed as a ratio between the preceding difference and 
the true value; it is specified as a percent of full-scale readings. Here, note that the true value 
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Precision refers to the degree of measurement reproducibility under the same conditions. 
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Figure 1. Input versus output calibration curve of a typical sensor
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When the input is increased from some arbitrary nonzero value, the output of a sensor will
not change until a certain input increment is exceeded. Accordingly, resolution is defined as
the smallest distinguishable input change that can be detected with certainty.
(6) Reproducibility
Reproducibility describes how close measurements are when same input is repeatedly exerted
into same sensor under same conditions. When the range of measurement is small, the
reproducibility is very high. For example, a temperature sensor may have a reproducibility of
±0.1V/℃ for a measurement range from 20℃ to 80℃. Here, what need to be noticed is that
reproducibility can vary depending on the measurement range. In other words, readings can
be highly reproducible over one range and less reproducible over a different operating range.
(7) Offset
Offset refers to the output value when input value is zero, seen in figure 1 (a) and (b).
(8) Linearity
Linearity of sensor also called nonlinear error of sensor’s characteristic curve; it is a measure‐
ment of the maximum deviation between calibration curve and fitting curve. Usually, linearity
of sensor is expressed as a percent of full-scale readings or a percent of the actual readings.
Linearity could be expressed as the following equation:
max
.




Here, σLinearity ——linearity of sensor; ΔL max =max(Vcal −V fit), ΔL max is the maximum error
between calibration line and fitting line; Y F .S  is the full-scale meaning value of sensor,
Y F .S =Ymax −Yo, Ymax is the maximum deviation of output, Y0 is the deviation without any input
value.
(9) Response time
The response time indicates that the time it takes a sensor to reach a percent of its final steady-
state value when input of sensor is changed. For example, it takes 10 seconds for pressure
sensor to reach 95 percent of its maximum value when a change in pressure of 1Pa is measured.
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Drift refers to the change in sensor reading when the input keeps constant. Drift is divided
into temperature drift and zero point drift. Zero point drift refers to the output without any







Temperature drift refers to the change of output with the change of temperature. It means the







Here, ΔT  is the change of temperature.
(11) Hysteresis
In some sensors, the input-output characteristic follows a different nonlinear trend, depending
on whether input increase or decrease, as in figure 2. For example, a certain pressure sensor
could produce a different output voltage when the input pressure varies from zero to full scale
and then back to zero. When the measurement is not perfectly reversible, the sensor will show
its hysteresis. If a sensor exhibits hysteresis, the input-output relationship is not unique, but
depends on the direction change to the input value of sensor.
Figure 2. Input versus output response of a sensor with hysteresis
1.3. Special features of biosensor
Biosensor is a kind of device which senses biomaterial and its concentration, and which
converts the biosignal into electrical signal. Biosensor has the function of acceptor and
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converter, which configuration is seen in figure 3. In biosensor, the physicochemical change
of the biologically active material resulting from the interaction with the analyte must be
converted into an electrical output signal by an appropriate converter. Biosensor’s sensing
components mainly have enzymes, cells, antibodies, DNA (Deoxyribonucleic acid), chemical
electrode, microbe and other biologically active agents in analytical devices. In the course of
detecting the parameters of analytes, biomaterial should be always immobile. In order to
develop biosensor, some biotechnology has to be studied and applied, such as DNA biosensor,
PH sensor, microelectrode, and so on.
The special features of biosensor are the following:
1. Biological active material immobilized is used as catalyst, and expensive reagents could
be repeatedly used to detect same biological parameters.
2. Biosensor has intensive specificity. Biomaterial only senses definitive ingredient and it is
not affected by color and concentration of measured material.
3. Biosensor could quickly analyze the result of the measurand.
4. Biosensor’s accuracy is very high, which relative error could reach one percent.
5. Biosensor’s analyzing system is very simple.
6. The cost of biosensor is very low.
According to biological sensing component, biosensor may be divided into five classes:
enzyme sensor, microbe sensor, cell sensor, tissue sensor, and immune sensors. According to
the signal converter of biosensor, biosensor may be also divided into five classes: bioelectrode
sensor, semiconductor biosensor, optical biosensor, piezoelectric biosensor and thermal
biosensor. According to the interaction between sensing component and measured material,
biosensor can be divided into two classes: affinity biosensor and catalytic biosensor.
Figure 3. Common configure of a biosensor
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1.4. Biomedical sensor’s application
In biomedical field, main applications of biomedical sensor are as follows:
1. Detecting the information of clinical chemistry. In the field of medical clinic and basic
research, the biology’s information needs to be detected to ensure the present state of given
biology. For example, before operating on a patient, a doctor needs to know the body
temperature and blood pressure. Under this condition, clinic thermometer and blood
sensor has to be employed to help doctor quickly detect body temperature and blood
pressure of patient.
2. Continuously monitoring some parameters of biology outside and inside. In biomedical
field, heart frequency has to be monitored continuously by heart sound sensor for a few
days after operation. In military, some viruses need to be found by biosensor to hold back
the attacking from enemy.
3. Control. In medicine, people usually utilize some parameter detected by biomedical
sensor to control or adjust physiological course of body. In the food industry, biomedical
sensor could be utilized to measure some enzyme and its concentration to control the
process of fabricating food and to analyze the nutritional ingredient of food. In military,
biomedical sensor could be employed to detect the situation of battle field to adjust the
strategy of spying or attacking enemy.
Of course, biomedical sensor such as PH sensor could be also employed to detect our atmos‐
phere and condition to improve our living situation.
2. Biomedical sensors
2.1. Biomedical sensor classification
Many different kinds of sensors can be used in biomedical application. According to the
sensing principle in biomedical application, biomedical sensors can be classified into physical
sensors and chemical sensors, seen in table 1.
It’s possible to categorize all sensors as being physical or chemical. In the case of physical
sensors, quantities such as geometric, mechanical, thermal, and hydraulic variables are
measured. In biomedical applications these variables can include things such as muscle
displacement, blood pressure, core body temperature, blood flow, cerebrospinal fluid pres‐
sure, and bone growth velocity. Two types of physical sensors deserve special mention with
regard to their biomedical application: sensors of electrical phenomena in the body, usually
known as electrodes, play a special role as a result of their diagnostic therapeutic applications.
The most familiar of these are sensors used to pick up the electrocardiogram, an electrical signal
produced by the heart. The other type of physical sensor that finds many applications in
biology and medicine is optical sensor. These sensors can utilize light to collect information,
and, in the case of fiber optic sensors, light is the signal transmission medium as well.
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The second major classification of sensing device is chemical sensors. In this case sensors are
concerned with the chemical quantities such as identifying the presence of chemical composite,
detecting the concentration of various chemical species, and monitoring the chemical activities
in the body for diagnostic and therapeutic application. A wide variety of chemical sensors are
classified in many ways. Chemical sensors are used to detect chemical components being
measured and chemical composition measured in the gas phase. Electrochemical sensors are
utilized to measure chemical concentration, or more precisely, activities based on chemical
reactions that interact with electrical systems. Photometric chemical sensors are optical devices
that detect chemical concentrations based on changes in light transmission, reflection or color.
Other types of physical chemical sensors such as the mass spectrometer utilize various physical
methods to detect and quantify chemicals associated with biologic systems.












Other physical chemical methods
Biopotential electrodes
Body surface biopotential electrode
Metal plate










Table 1. Classifications of biomedical sensor
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Although bioanalytic sensors are essentially chemical sensors, they are often classified as a
separate major sensor category. These devices incorporate biologic recognition reaction such
as enzyme-substrate to identify complex biochemical molecules. The use of biologic reactions
gives bioanalytic sensors high sensitivity and specificity in identifying and quantifying
biochemical substances.
2.2. Oxygen and carbon dioxide sensor for blood
Measurements of arterial blood gas (pO2 and pCO2) and pH are frequently performed by on
critical patients in both the operating rooms and intensive care unit. They are selected and used
by the physician to adjust mechanical ventilation or administer pharmacological agents. Such
measurement could provide information about the respiratory and metabolic imbalance in the
body and reflect the change of blood oxygen increment and carbon dioxide(CO2) elimination.
Noninvasive sensors for measuring O2 and CO2 in arterial blood are based on the discovery
that gases such as O2 and CO2 can easily diffuse from body skin. Diffusion occurs due to a
partial pressure difference between the blood in the superficial layers of the skin and the
outermost surface of the skin. Such idea has been used to develop two types of noninvasive
electrochemical sensors pO2 and pCO2. The discovery that blood changes its color depending
on the percent of oxygen has led to the development of several optical methods to measure
the oxygen saturation in blood.
2.2.1. Oxygen sensor for blood
The method for measuring blood oxygenation is very great important in assessing the
circulatory and respiratory condition of a patient. The blood from the lungs to the tissues in
two distinct states transports oxygen. Under normal physiological conditions, approximately
2% of the total amount of oxygen carried by the blood is dissolved in the plasma. This amount
is proportional to the blood pO2.. The 98% remain is carried inside the erythrocytes in a loose
reversible chemical combination with hemoglobin (Hb) as oxyhemoglobin (HbO2). Thus, there
are two methods for measuring the blood oxygenation: either using polarographic pO2 sensor
or measuring oxygen saturation (the relative amount of hemoglobin dioxide HbO2 in the
blood) by means of an optical oximeter.
A pO2 sensor, also widely known as a Clark electrode, is used to measure the partial pressure
of O2 gas in a sample of air or blood. This sensor is categorized as an amperometric sensor and
requires an external polarization bias source. The measurement is based on the principle of
polarography as illustrated in figure 4. The electrode utilizes the ability of oxygen O2 molecules
to react chemically with H2O in the presence of electrons to produce hydroxyl (OH-) ions. This
electrochemical reaction, called an oxidation/reduction or redox reaction, generates a small
current and requires an externally applied constant polarizing voltage source of about 0.6V.
Oxygen is reduced (consumed) at the surface of a noble metal (such as platinum or gold)
cathode (this electrode is connected to the negative side of voltage source) according to the
following the chemical reaction:
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O2 + 2H2O + 4e↔4OH
−
In this reduction reaction, one O2 molecule takes four electrons and reacts with two water
molecules, generating four hydroxyl ions. The resulting OH- ions migrate and react with a
reference Ag/AgCl anode (this electrode is connected to the positive side of voltage source),
causing a two-step oxidation reaction as follows:
Ag↔Ag + + e
Ag + + Cl −↔AgCl ↓
Figure 4. Sensing principle of Clark-type pO2 sensor
In this oxidation reaction, silver from the anode electrode is firstly oxidized to silver ions, and
electrons are liberated to the anode. These silver ions are immediately combined with chloride
ions to form a kind of compound precipitant silver chloride AgCl  which precipitates on the
surface of anode. The transient current between the anode and the cathode in the external
circuit produced by this reaction is directly proportional to the number of O2 molecules
constantly reduced on the surface of the cathode. The electrodes in the polarographic cell are
immersed in an electrolyte solution of potassium chloride and surrounded by an O2-permeable
or polypropylene membrane that permits gases to diffuse slowly into electrode. Thus, by
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measuring the change in current between the cathode and the anode, the amount of oxygen
that is dissolved in the solution can be determined.
2.2.2. Carbon dioxide sensor for blood
Electrodes for measuring partial pressure of carbon dioxide CO2 in blood are based on
measuring the pH as illustrated in figure 5. The measurement is based on the observation that
it forms a weakly dissociated carbonic acid (H2CO3) that subsequently forms free hydrogen




As a result of this chemical reaction, the pH of the solution is changed. This change generates
a potential between the glass pH and a reference electrode that is proportional to the negative
logarithm of the concentration of the carbon dioxide pCO2 in the plasma.
Figure 5. Sensing principle of a pCO2 electrode
2.3. Heart sound sensor
The expansion and shrinkage of heart necessarily lead to the vibration of artery that is formed
by blood turbulence in vein. When the vibration of artery is transported to the surface of
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thoracic cavity, heart sound will take place. Heart sound is very valuable for doctor to diagnose
many kinds of diseases in our body.
The range of heart sound is from 20Hz to 200Hz. Low limit frequency of heart sound could
reach about 4Hz and high frequency limit is greater than 1000Hz. There are many kinds of
medical heart sound sensors that are divided into two classifications: air conduction heart
sound sensor and direct conduction heart sound sensor. Air conduction heart sound sensor
consists of air chamber and common sensor. Such sensor has obvious defects: low sensitivity
and easy disturb by surrounding circumstance. Hence, in clinic application, the most sensors
applied are direct conduction heart sound sensor.
2.3.1. Piezoelectric heart sound sensor
The sensing structure of piezoelectric acceleration sensor is illustrated in figure 6. Such sensor
is used to measure heart sound. Its structure is very simple, which consists of vibration mass
block and piezoelectric crystal. A stress spring is utilized to exert a certain stress on vibration
mass block between top shell and mass block. Such method could timely adjust the linear
characteristic of sensing component. This sensor’s gravity is less than 30g, and is used to detect
heart sound and buffeting from body organisms.
Figure 6. Sensing structure of piezoelectric acceleration sensor
2.3.2. Fetus heart sound sensor
Detecting fetus heart sound is very important in clinic application for doctor sometimes needs
to grasp the present body status of fetus. PVDF piezoelectric thin film sensor is utilized to be
fit for the measurement of fetus’s heart sound as illustrated in figure 7. Its piezoelectric
coefficient is the following:
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sound sensor and direct conduction heart sound sensor. Air conduction heart sound sensor
consists of air chamber and common sensor. Such sensor has obvious defects: low sensitivity
and easy disturb by surrounding circumstance. Hence, in clinic application, the most sensors
applied are direct conduction heart sound sensor.
2.3.1. Piezoelectric heart sound sensor
The sensing structure of piezoelectric acceleration sensor is illustrated in figure 6. Such sensor
is used to measure heart sound. Its structure is very simple, which consists of vibration mass
block and piezoelectric crystal. A stress spring is utilized to exert a certain stress on vibration
mass block between top shell and mass block. Such method could timely adjust the linear
characteristic of sensing component. This sensor’s gravity is less than 30g, and is used to detect
heart sound and buffeting from body organisms.
Figure 6. Sensing structure of piezoelectric acceleration sensor
2.3.2. Fetus heart sound sensor
Detecting fetus heart sound is very important in clinic application for doctor sometimes needs
to grasp the present body status of fetus. PVDF piezoelectric thin film sensor is utilized to be
fit for the measurement of fetus’s heart sound as illustrated in figure 7. Its piezoelectric




d33 = − (5~8)×10
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In this structure, silicon rubber converts the vertical motion of itself into the radial motion of
PVDF piezoelectric thin film and then corresponding dynamic charge produced by PVDF thin
film is proportional to the externally transient force. The voltage along thickness direction is
output. Obviously, its work mode is d31 work mode. For both thin film and silicon rubber are
very soft, they could well touch the skin of body belly. Then fetus heart sound is gained to
judge fetus heart. Design requirement of PVDF heart sound sensor is as follows:
1. In the same piezoelectric thin film, one part is used as driving electrode; another is utilized
as receiving the sound wave from heart sound.
2. Dynamic response characteristics on the surface of belly should be considered to well mate
belly skin and sensor.
Figure 7. Sensing structure of PVDF piezoelectric acceleration sensor
With the development of sensing technology, more and more heart sound sensors are
appearing in our life. Although they have different sensing principle, their functions are alike.
2.4. Blood flow sensor
If oxygen and nutrients are to reach tissues, the flow of blood must be maintained in body.
Cardiac output flow is often measured as an index of cardiac performance, blood flow through
arterial graft is used to ensure that a graft has been successfully inserted during surgery, or
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the blood flow in peripheral arteries and veins may be measured to assess vascular diseases.
There are usually two kinds of measuring methods: one method is direct measurement, sensor
is inserted into the blood pipe to sense transient blood flow; another one is indirect measure‐
ment, sensor is placed outside vein and senses blood flow by the parameter related to the blood
flow. Here, an electromagnetic flow sensor as an example is introduced to demonstrate the
measurement of blood flow.
Figure 8. Sensing principle of electromagnetic flow sensor (a) Relation diagram between electrode and magnetic field
intensity; (b) Three dimension diagram
Blood flow through an exposed vessel could be measured by means of electromagnetic flow
sensor. Electromagnetic flow sensor can be used in biomedicine and science research studies
to measure blood flow in major blood vessels near the heart. Such sensor requires that the
tested vein must be peeled off and placed into the magnetic gap of sensor. According to the
output voltage of sensor, the mean velocity of vein can be calculated and known. And then in
terms of the section area tested of vein, the blood flow could be gained finally. According to
above idea, the sensing principle of electromagnetic flow sensor is illustrated in figure 7.
Magnetic field intensity B is exerted along the direction vertical to vein, two electrodes are
installed at both sides of vein, and then potential between two electrodes could be tested:
V =2aBva
Here, B is the magnetic induction intensity at the magnetic gap; a is the radius of tested vein;
υa is the mean velocity of vein during given test time; V  is the output potential between two
electrodes EE’.
Practically, this device consists of a clip-on probe that fits snugly around the blood vessel, as
illustrated in figure 8. The probe contains electrical coils to produce an electromagnetic field
that is transverse to the direction of blood flow. This coil is usually excited by an AC current.
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A pair of very small biopotential electrodes is attached to the housing and rest against the wall
of blood vessel to pick up the induced potential. The flow-induced voltage is an AC voltage
at the same frequency as the excitation voltage. Utilizing AC method instead of DC excitation
could help to remove any offset potential error due to the contact between the vessel wall and
the biopotential electrodes.
Certainly, ultrasonic wave could be also used to detect blood flow of artery. In biomedical
application, there are four kinds of ultrasonic wave blood flow sensors according to specific
sensing principle and methods: (1) pulse time difference; (2) voice beam deflection; (3) phase
shift; (4) Doppler frequency shift. Readers could research biomedical engineering handbook
to learn more information.
2.5. Respiration sensor
Respiration measurement often includes two classes: physiological parameter measurement
and gas ingredient from respiration system. What sensor the former utilizes is physical sensor,
and what sensor the latter employs is chemical sensor and biological sensor. Here, respiration
sensor which belongs to the first class is only introduced and explained. The measurement of
respiration system is important basis of clinic diagnosis, and it is necessary for patients in the
fields of surgery, baby and critically ill patient’s monitoring, sports medicine, and medical
research. The measurement of respiration system could be classified into three classes of
parameters: respiration frequency, respiration flow and lung respiration volume.
In biomedical research or clinic monitoring, respiration frequency of patient needs to be
sometimes detected to record the physiological status. Figure 9 illustrates a kind of sensor for
respiration frequency based on thermistor sensing principle. Thermistor is mounted to the
front-end of binder. When binder clamps the nares, airstreams from body flows through the
surface of thermistor. According to the change of thermistor value, the respiration frequency
would be measured.
Figure 9. Electromagnetic blood flow sensor
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Figure 10. Thermistor sensor for respiration frequency (a)structure diagram, (b)measurement diagram
Of course, elastic strain instrument could be also utilized to detect the respiration frequency.
Its sensing principle is such: resistance wire is fixed to the surface of elastic plastic pipe. And
then mercury or other electrolyte is sealed into the elastic plastic pipe. After elastic plastic pipe
is adhered to the front of breast, respiration would lead to the length change of elastic plastic
pipe. Such length change causes the change of resistance wire which could show the change
of respiration frequency. When resistance wire is introduced into a detecting circuit, the
respiration frequency will be sensed and measured.
2.6. Blood pressure sensor
If blood circulation is to be maintained in the body, tissues are to be perfused with oxygen.
Then correct pressure measurement has to be applied in the vascular system. The usual blood
pressure methods have: liquid coupling direct measurement, pipe-end sensing measurement,
indirect blood pressure sensing measurement. Liquid coupling direct measurement means
that the pipe filled with liquid is inserted into the measured part and that the pressure is
measured by liquid coupling of pipe end position in the body, which is the simplest method.
Pipe-end sensing measurement employs pipe-end sensor to measure blood pressure. Pipe-end
sensor which can convert the pressure signal into electronic signal is placed on the measured
part. And then the electronic signal measured is transmitted to the external wire. Such method
could avoid the distortion of signal of blood pressure. Pipe-end sensing measurement has a
lot of advantages, but such method needs to activate the skin and relative sensors have to been
placed into the body. Hence indirect blood pressure measurement is noted by people and
continuously explored. Blood-pressure meter is a classic example of indirect blood pressure
measurement, which is shown in figure 10.
In figure 10, the sensing principle is based on Coriolis sound. Gas is filled into cuff to hold back
the arterial blood flow. And then gas in cuff is sent out slowly to monitor whether there appears
arterial blood flow at the downstream of arterial blocking point. Here, the employed sensor is
common mercury pressure meter. And such method is up to the actual experience of staff.
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When coriolis sound is heard, namely when blood flows through artery blood pipe, blood
pressure in cuff is shrinking pressure in artery pipe. When blood flows recover normal level,
blood pressure in cuff is diastolic pressure of artery. Systole pressure and diastolic pressure
are recorded as blood pressure. Such method is not harmful to the skin or organ in the body.
2.7. Electrochemical electrode
Biopotential measurements are made using different kinds of specialized electrochemical
electrodes. The function of electrodes is to couple the ionic potentials generated inside the body
to an electronic instrument. Biopotential electrochemical electrode is classified either as
noninvasive (e.g. skin surface) or invasive (e.g. microelectrode, wire electrode) electrodes.
When a metal is placed in an electrolyte solution, a charge distribution is created next to the
metal/electrolyte solution interface as illustrated in figure 11. The localized charge distribution
causes an electronic potential by electrochemical electrode, called half-cell potential, to be
developed across the interface between metal electrode and electrolyte solution.
The half-cell potentials of several important metals are listed in table 2. Here, a point needs to
be pointed out that hydrogen electrode is considered to be a standard electrode against which
the half-cell potentials of other metal electrodes are measured.
Figure 11. Sensing principle of indirect blood pressure measurement
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Silver and zinc electrodes are immersed in an electrolyte solution. And then we may calculate
the potential drop between two electrodes. From table 2, the half-cell potentials for silver and
zinc electrodes are 0.799V and -0.763V respectively. Hence, the half-cell potentials between
two electrodes are equal to the following value:
0.799-(-0.763) =1.562V
Typically, utilizing the electrochemical electrodes composed of the same metals could measure
the half-cell potentials. Hence, the two half-cell potentials for these electrodes would be equal
in magnitude. Some common electrodes are introduced here, which is utilized as a sensor.
2.7.1. ECG electrodes
A typical flexible biopotential electrode for ECG (electrocardiogram, ECG) recording is
composed of certain polymers or elastomers which are made electrically conductive by the
addition of a fine carbon or metal powder. These electrodes as illustrated in figure 13a are
available with prepasted AgCl gel for quick easy application to the skin using a double-sided
peel-off adhesive tape. The most common type of biopotential electrode is the silver/silver
chloride electrode (Ag/AgCl), which is formed by electrochemically depositing a very thin
layer silver chloride onto the surface of silver electrode as illustrated in figure 13b. These
electrodes are recessed and imbedded in foam that has been soaked with an electrolyte paste
to provide good electrical contact with the skin. The electrolyte saturated foam is also known
to reduce motion artifacts which are produced during stress testing when the layer of the skin
moves relative to the surface of the Ag/AgCl electrode. This motion leads to the large inter‐
ference in the recorded biopotential and, in the extreme cases, could severely degrade the
measurement.
Figure 12. The charge distribution at a electrolyte/metal interface
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Primary Metal and Chemical Reaction Half-cell Potential
Al → Al3++3e- -1.706
Cr → Cr3++3e- -0.744
Cd → Cd2++2e- -0.401
Zn → Zn2++2e- -0.763
Fe → Fe2++2e- -0.409
Ni → Ni2++2e- -0.230
Pb → Pb2++2e- -0.126
H2 → 2H++2e- 0.000(stand by definition)
Ag → Ag++e- +0.799
Au → Au3++3e- +1.420
Cu → Cu2++2e- +0.340
Ag+Cl → AgCl+2e- +0.223
Table 2. Half-cell Potentials of Important Metals
Fe              →            Fe2++2e- -0.409 
Ni              →            Ni2++2e- -0.230 
Pb              →            Pb2++2e- -0.126 
H2              →            2H
+
+2e
- 0.000(stand by definition) 
Ag              →            Ag++e- +0.799 
Au              →            Au3++3e- +1.420 
Cu              →            Cu2++2e- +0.340 
Ag+Cl           →            AgCl+2e- +0.223 
A typical flexible biopotential electrode for ECG (electrocardiogram, ECG) recording is composed of 
certain polymers or elastomers which are made electrically conductive by the addition of a fine carbon or 
metal powder. These electrodes as illustrated in figure6.12a are available with prepasted AgCl gel for quick 
easy application to the skin using a double-sided peel-off adhesive tape. The most common type of 
biopotential electrode is the silver/silver chloride electrode (Ag/AgCl), which is formed by 
electrochemically depositing a very thin layer silver chloride onto the surface of silver electrode as 
illustrated in figure6.12b. These electrodes are recessed and imbedded in foam that has been soaked with 
an electrolyte paste to provide good electrical contact with the skin. The electrolyte saturated foam is also 
known to reduce motion artifacts which are produced during stress testing when the layer of the skin 
moves relative to the surface of the Ag/AgCl electrode. This motion leads to the large interference in the 





(a) Flexible Mylar electrode (b) Disposable snap-type Ag/AgCl electrode 
Figure6.12 Biopotential skin surface ECG electrode 
2) EMG electrodes 
Electrochemical electrodes are also used to record electromyography (EMG) signals from different 
muscles in the body. The body and size of the recorded EMG signals depends on the electrical property of 
these electrodes and the recording location. For invasive recordings, proper skin preparation, which 
normally involves cleaning the skin with alcohol or the application of a small amount of an electrolyte 
paste, helps to minimize the impedance of the skin-electrode interface and improve the quality of recording 
signal considerably. The most common electrodes used for the surface EMG recording and nerve 
conduction studies are circular discs, about 1 cm in diameter, that are made of silver or platinum. For direct 
recording of electrical signals from nerves and muscle fibers, a variety of percutaneous needle electrodes 
are available as illustrated in figure6.13. The most common type of needle electrode is the concentric 
bipolar electrode as illustrated in figure6.13a. This electrode is made from the thin metallic wires encased 
inside a larger canola or hypodermic needle. The two wires serve as the recording and reference electrodes. 
Figure 13. Biopotential skin surface ECG electrode
2.7.2. EMG electrodes
Electrochemical electrodes are also used to record electromyography (EMG) signals from
different muscles in the body. The body and size of the recorded EMG signals depends on the
electrical property of these elec rodes and the r cording location. For invasive rec rdings,
proper skin prepara ion, which normally involves cleaning the skin with alcohol or the
application of a small amount of an electrolyte paste, helps to minimize the impedance of the
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skin-electrode interface and to improve the quality of recording signal considerably. The most
common electrodes used for the surface EMG recording and nerve conduction studies are
circular discs, about 1 cm in diameter, that are made of silver or platinum. For direct recording
of electrical signals from nerves and muscle fibers, a variety of percutaneous needle electrodes
are available as illustrated in figure 14. The most common type of needle electrode is the
concentric bipolar electrode as illustrated in figure 14a. This electrode is made from the thin
metallic wires encased inside a larger canola or hypodermic needle. The two wires serve as
the recording and reference electrodes.
Figure 14. Intramuscular biopotential electrode:(a)bipolar electrode, (b)unipolar configuration
Another type of percutaneous EMG electrode is the unipolar needle electrode as illustrated in
figure 14b. This electrode is made of a thin wire that is most insulated by a thin layer near the
distal tip. Unlike bipolar electrode, this type of electrode requires a second unipolar reference
electrode to form a closed electrical circuit. The second recording electrode is normally placed
either adjacent to the recording electrode or attached to the surface of our skin.
2.7.3. EEG electrodes
The most commonly used electrode for recording electroencephalographic (EEG) signals from
the brain are cup electrodes and subdermal needle electrodes. Cup electrodes are made of
platinum or tin and are approximately 5-10mm in diameter. The cup electrodes are filled with
an electrolyte gel and can be attached to the scalp with an adhesive tape.
Recording the biopotentials from the scalp is very difficult because hair and oily skin hold back
the good electrical contact. Hence, clinicians sometimes prefer to use subdermal needle
electrodes (EEG electrodes) instead of the metal surface electrodes for EEG recording. These
electrodes are both fine platinum or stainless-steel needle electrodes about 10mm long by
0.5mm wide, which are inserted under the skin to provide a better electrical contact.
2.7.4. Microelectrodes
Microelectrodes are biopotential electrodes with ultra-fine tapered tip that can be inserted into
biological cells. These electrodes play a very important role in recording action potentials from
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single cells and are used in neurophysiologic studies to comprehend the course of biological
information conversion and transmission in our body. The tip of these electrodes must be very
small with respect to the dimensions of the biological cell to avoid cell damage and at the same
time sufficiently strong to penetrate the cell wall. The electrode which is applied to microbe
studies is called microelectrodes. Generally, there are three types of microelectrodes: (1) glass
microelectrodes, (2) metal electrodes, and (3) solid-state microprobes.
For glass microelectrodes, when the tip of such electrodes is inserted into an electrolyte
solution, such as the intracellular cytoplasm of a biological cell, ionic current can flow through
the fluid junction at the tip of the microelectrode. Such mode could establish a closed electrical
circuit between two Ag/AgCl wire electrodes inside the microelectrode and biological cell. For
metal electrode, when the tip of such microelectrodes is usually sharpened down to a diameter
of a few micrometers by an electrochemical etching process. The wires are then insulated up
to its tip.
Solid-state microfabrication techniques commonly used in the production of the integrated
circuits can be used to produce microprobes for multichannel recordings of biopotentials or
for electrical stimulation of neurons in our brain or spinal cord. Most of solid-state micro‐
electrodes are microsensor actually. Such probe consists of a precisely micromachined silicon
substrate with four exposed recording sites. One of main advantages of microfabrication
techniques is the ability to mass produce very small and highly sophisticated microsensors
with highly reproducible electrical and physical properties.
2.8. Enzyme sensor and microbial sensor
Enzyme constitutes a group of more than 2000 proteins having so-called biocatalytic proper‐
ties. These properties give the enzymes the unique and powerful ability to accelerate chemical
reactions inside biological cells. Most enzymes react only with specific substrates even though
they can be contained in a complicated mixture with other substances. It is important that
soluble enzymes are very sensitive both to temperature and pH variations, and they can be
inactivated by many chemical inhibitors. For practical biosensor applications, these enzymes
are normally immobilized by insolubilizing the free enzymes via entrapment into an inert and
stable matrix such as starch gel, silicon rubber, or polyacrylamide. This process is very
important to ensure that the enzymes retains its catalytic properties and can be reusable.
The action of specific enzymes may be utilized to form a range of different biosensors. A typical
example of enzyme-based sensor is a glucose sensor that uses the enzyme glucose oxidase.
Glucose plays an important role in metabolic process. Currently, available glucose sensors are
based on an immobilized enzyme, such as glucose oxidase, which acts as a catalyst. Glucose
is detected by electromechanically measuring either the amount of gluconic acid or hydrogen
peroxide (H2O2) produced or by measuring the percent of oxygen consumed according to the
following chemical reaction:
Glucose + O2 + H2O ↔
glucose oxidase
gluconic acide H2O2
Biomedical Sensor, Device and Measurement Systems
http://dx.doi.org/10.5772/59941
197
A glucose sensor is similar to a pO2 sensor and is shown in figure 15. Glucose and oxygen enter
through outer membrane to interact with glucose oxidase enzyme. The remaining oxygen
penetrates through the second oxygen-permeable membrane and is measured by the oxygen
electrode.
Figure 15. Sensing principle of glucose sensor
Biocatalytic enzyme-based sensors generally consist of an electrochemical gas-sensitive
converter or an ion-selective electrode with an enzyme immobilized in or on a membrane that
serve as the biological mediator. The analyte diffuses from the bulk sample solution into the
biocatalytic layer where an enzymatic reaction takes place. The electroactive product that is
formed (or consumed) is usually detected by an ion-selective electrode. A membrane separates
the basic sensor from the enzyme if a new gas is produced (such as CO2 or NH3) or consumed
(such as O2). Although the concentration of the bulk substrate drops continuously, the rate of
consumption is usually negligible. The decrease is detected only when the test volume is very
small or when the area of enzyme membrane is large enough. Thus this electrochemical
analysis is nondestructive, and the sample is reused. Measurements are usually performed at
a constant pH and temperature either in a stirred medium solution or in a flow through
solution. In order to control biochemical process including some enzyme sensors, a number
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of microbial sensors have been continuously developed and applied to various environment,
agriculture, food and pharmaceutical.
Microbial sensors typically involve the assimilation of organic compounds by microorganisms,
followed by a change in respiration activity(metabolism) or the production of specific electro‐
chemically active metabolites, such as CO2, H2, or NH3, that are secreted by the microorganism.
A microbial sensor is composed of immobilized microorganisms that serve as specific recog‐
nition elements and an electrochemical or optical sensing device that is used to convert the
biochemical signal into electronic signal that can be processed. The operation of a microbial
sensor can be described by the following five-step process:
1. The substrate is transported to the surface of the sensor;
2. The substrate diffuses the membrane to the immobilized microorganisms;
3. A reaction occurs at the organism;
4. The products formed in the reaction are transported through the membrane into the
surface of detector;
5. The product is measured by the detector.
Here, an example of a microbial sensor is given to demonstrate the detecting course of
microbial sensor including ammonia (NH3) and nitrogen dioxide (NO2) sensors that utilize the
nitrifying bacteria as the biological sensing component. A NH3 biosensor can be constructed
on the base of nitrifying bacteria that uses ammonia (NH3) as a source of energy and oxidizes
ammonia as follows:
Figure 16. Sensing principle of a NO2 microbial biosensor
N H3 + 1.5O2 =
Nitrosomonas
N O2 + H2O + H
+
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This oxidation process proceeds at high rate, and the amount of oxygen consumed by the
immobilized bacteria can be measured directly by a polarographic oxygen electrode placed
behind the bacteria.
Nitric oxide (NO) and NO2 are two principal pollution gases of nitrogen in the atmosphere.
The principle of a NO2 biosensor is shown in figure 16. When a sample of NO2 gas diffuses
through the gas-permeable membrane, it is oxidized by the nitrosomonas bacteria as follows:
2N O2 + O2 =
Nitrosomonas
N O3
Similar to an ammonia biosensor, the consumption of oxygen O2 around the membrane is
determined by an electrochemical oxygen electrode.
3. Charge, current, voltage, power and energy
Many biomedical instruments utilize a sensor to convert a signal created by the body into an
electrical signal. In medicine, the electrical circuits and electrical components are often utilized
to detect the biomedical signal by sensor. After basic electrical components and biomedical
sensors are connected together, a bioinstrumentation is then formed. Hence, describing a
bioinstrumentation could begin with charge, current, voltage, power and energy. In this
section, these basic variables will be introduced and explained.
3.1. Charge and its conversion
In our life, there are two kinds of charge, negative and positive, and they are carried by the
protons and electrons, respectively. The negative charge, qe, carried by the electron is the
smallest amount of charge that exists and is measured in unit called coulombs(C):
qe = −1.6×10
−19C
The symbol, q(t), is used to represent the charge that change with time, and the symbol, Q, is
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Figure 17. A simple circuit illustrating current flowing around a closed loop
In addition to the above definition, current also depends on the direction of flow, as illustrated
in figure 17 Current is defined as positive if
a. A positive charge is moving in the direction of arrow;
b. A negative charge is moving in the opposite direction of arrow.
Figure 18. A sample current waveform and its electrical circuit
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Since these two cases cause the same outcome, there is no need to be concerned as to which is
responsible for the current. In electrical circuits, current is carried by electrons in metallic
inductors.
Consider the waveform in figure 18, with the current entering into terminal1 in the circuit on
the right, the current in the time interval 0 to 1.5 second, is positive and enters terminal1. The
current in the time interval 1.5 to 3 second, is negative and enters terminal2 with positive value.
If there are no current changes in the time interval 0 to 3s, the curve of current will be a line.
Then the electrical circuit in figure 18 is constant which is called direct current (DC) indicating
that it does not change with time. We denote a time-varying current with lowercase letter, such
as i or just i(t).
Kirchhoff’s Current Law
Current can only flow in a closed circuit. Kirchhoff’s current law is used to ensure the rela‐
tionship among every branch of circuit at same point. For current is continuous, any a point
in circuit can not accumulate charge. Hence, at any time and any node, the sum of the currents
which flow same node is equal to the sum of the currents which outflow from same node. This
principle is known as Kirchhoff’s current law (KCL).
In circuit as illustrated in figure 19, the current at the node, a, can be written as:
I1 + I2 = I3
or, above formula is adjusted into the following equation:
I1 + I2 − I3 =0
Namely,
∑ I =0
At any time, the algebraic sum of the currents at a node is equal to zero. It should be clear for
all currents whether they are all leaving or entering the node.
Figure 19. Node of circuit
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Figure 20. Voltage and current convention
In describing a circuit, we define its characteristics with terms node, branch, path, closed path,
and mesh as follows:
• Node: A point at which two or more circuit elements have a common connection.
• Branch: A circuit element or connected group of circuit elements. A connected group of
circuit elements usually connect nodes together.
• Path: A connected group of circuit elements in which none is repeated.
• Closed Path: A path that starts and ends at the sam node.
• Mesh: A closed path that does not contain any other closed paths within it.
• Essential Node: A point at which three or more circuit elements have a common connection.
• Essential Branch: A branch that connects two essential nodes.
Kirchhoff’s current law could be also applied to any closed surface surrounding a part of the
circuit. It’s understood that the closed surface does not intersect any of the circuit elements.
3.2.2. Voltage
Voltage represents the work per unit charge associated with moving a charge between two




The unit of measurement for voltage is the volt (V). A constant voltage source is denoted by
the letter V, while a time-varying voltage is denoted by the lowercase letter v(t), or just v. In
figure 20, the voltage, υ between two points (A and B) is the amount of energy required to
move a charge from point A to point B.
Kirchhoff’s Voltage Law
Kirchhoff’s voltage law is utilized to ensure the voltage relationship at any branch of circuit.
Starting from any point of circuit, the sum of potential drop at the closed branch along the
clockwise or counterclockwise direction is equal to the sum of potential rise.
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Figure 21. Circuit loop
In figure 21, the reference direction of electromotive force, current and branch voltage is
marked. Cycling one circle along virtual line given in circuit, the following equation could be
listed out:
U1 + U4 =U2 + U3
Above equation could be also written into the following equation:
U1−U2−U3 + U4 =0
Namely, ∑U =0
According to above voltage equation, the algebraic sum of branch voltage is equal to zero along
any a closed branch circuit. If it is stipulated that potential drop is negative, potential rise is
positive.
Kirchhoff’s laws are applied in electrical circuit analysis to determine unknown voltages and
currents. Each unknown variable has its distinct equation. To solve for the unknowns using
MATLAB, we create a matrix representation of the set of equations and solve them using the
matrix calculation techniques.
3.3. Power and energy







dt =ui = i
2R
Where, the letter, p, is power measured in watts(W), and the letter, w, is energy measured in
joules(J). Power is usually determined by the product of voltage across a circuit element and
the current through it. By convention, we assume that a positive value for power indicates that
power is being delivered (or absorbed or consumed) by the circuit element. A negative value
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for power indicates that power is being extracted or generated by the circuit element which
could be considered as a battery.
Figure 22. Polarity references for four cases of current and voltage. Cases (a) and (d) result in positive power being
consumed by the circuit element. Cases (b) and(c) result in negative power being extracted from the circuit element.
Figure 22 illustrates the four possible cases for a circuit element’s voltage and current config‐
uration. According to the convention, if current and voltage are positive, with the arrow and
polarity shown in figure 22, energy is absorbed. If either the current arrow or the voltage
polarity is reserved, as in (b) and (c), energy is supplied to the circuit. If both the current
direction and voltage polarity are reserved together as in figure 22(d), energy is absorbed.
Figure 23. Basic symbol for independent source
A passive circuit element is defined as an element whose power is always positive or zero,
which is dissipated as heat (resistance), stored in an electric field (capacitor), or stored in
magnetic field (inductor). We define an active circuit element as one whose power is negative
and capable of generating energy. Energy is given by the following equation:






In circuit, the basic source symbol is listed in figure 23.
4. Resistance, inductors and capacitors
4.1. Resistance and its combination
4.1.1. Resistance
In figure 24, the direction of current and voltage is the same. According to Ohm’s law, the
following formula could be given:
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uR 
This parameter is called resistance which has the property of holding back the current in 
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applied at very high voltage and current. Some electrically materials have a very small range 
of currents and voltages where they exhibit linear behavior. In reality, some material is linear 
only within a range of values. Outside this range, resistance is not linear. In circuit, we 
define:(1) having a 0V voltage drop when R=0;(2)having a 0current through resister when R=
∞.
Each material has a property called resistivity(ρ) that indicates the resistance of the 
material. Conductivity is the inverse of resistivity, and conductance (G) is the inverse of 
resistance. Conductance is measured in unit called siemens(S) and has the unit of A/V. In 
terms of conductance, ohm’s law could be written as: 
Gui 
Figure 24. Resistance and its symbol
u = iR
The parameter of resistance is gained: R = ui
This parameter is called resistance which has the property of holding back the current in circuit.
And it is denoted with the symbol in figure 24b. Here, this relations ip could be applied t
very high voltage and current. Some electrictronic materials have a very small range of currents
and voltages where they exhibit linear behavior. In reality, some material is linear only within
a range of values. Outside this range, resistance is not linear. In circuit, we define:(1) having a
0V voltage drop when R=0;(2)having a 0current through resister when R=∞.
Each material has a property called resistivity(ρ) that indicates the resistance of the material.





In circuit, the basic source symbol is listed in figure 23.
4. Resistance, inductors and capacitors
4.1. Resistance and its combination
4.1.1. Resistance
In figure 24, the direction of current and voltage is the same. According to Ohm’s law, the
following formula could be given:
Figure6.22 Basic symbol for independent source 
A passive circuit element is defined as an element whose power is always positive or 
zero, which is dissipated as heat (resistance), stored in an electric field (capacitor), or stored 
in magnetic field (inductor). We define an active circuit element as one whose power is 




In circuit, the basic source symbol is listed in figure6.22. 
6.4. Resistanc , inductors nd capacitors 
6.4.1 Resistance and its combination 
1) Resistance 
In figure6.23, the direction of current and voltage is the same. According to Ohm’s law, 
the following formula could be given: 
(a)resister component (b) Ideal resister with the Resistance 
Figure6.23 Resistance and its symbol 
iRu 
The parameter of resistance is gained: i
uR 
This parameter is called resistance which has the property of holding back the current in 
circuit. And it is denoted with the symbol in figure6.23b. Here, this relationship could be 
applied at very high voltage and current. Some electrically materials have a very small range 
of currents and voltages where they exhibit linear behavior. In reality, some material is linear 
only within a range of values. Outside this range, resistance is not linear. In circuit, we 
define:(1) having a 0V voltage drop when R=0;(2)having a 0current through resister when R=
∞.
Each material has a property called resistivity(ρ) that indicates the resistance of the 
material. Conductivity is the inverse of resistivity, and conductance (G) is the inverse of 
resistance. Conductance is measured in unit called siemens(S) and has the unit of A/V. In 
terms of conductance, ohm’s law could be written as: 
Gui 
Figure 24. Resistance and its symbol
u = iR
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And it is denoted with the symbol in figure 24b. Here, this relations ip could be applied t
very high voltage and current. Some electrictronic materials have a very small range of currents
and voltages where they exhibit linear behavior. In reality, some material is linear only within
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0V voltage drop when R=0;(2)having a 0current through resister when R=∞.
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Conductivity is the inverse of resistivity, and conductance (G) is the inverse of resistance.
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Conductance is measured in unit called siemens(S) and has the unit of A/V. In terms of
conductance, ohm’s law could be written as:
i =Gu
For formula u = iR, if current is produced by both sides of this equation and they are integrated,






This formula demonstrates that electrical energy is all consumed by resister component. And
the energy is converted into thermal energy, that’s to say, resister is a consuming-energy
component.
4.1.2. Series and parallel combination of resistance
If the same current flows from one resister to another, the two are said to be in series. If these
two resisters are connected to the third and the same current flows through all of them, then
the three resistors are in series. Consider figure 25 with three resisters in series, an equivalent
circuit can be derived through Kirchhoff’s Voltage Law as follows:
Figure 25. A series circuit
−Vs + I R1 + I R2 + I R3 =0
Above equation can be also rewritten as:
Req = R1 + R2 + R3 =
Vs
I
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Where, the equivalent resistance, Req, is the sum of three resister in figure 25 which is called
equivalent resistance. In general, if there are N  resisters in series, their equivalent resistance





Figure 26. A parallel circuit
Two or more resisters are said to be parallel if the same voltage is across each of resisters.
Consider the three parallel resisters as illustrated in figure 26, a equivalent circuit for figure 26
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A capacitor in figure 27 is a device that stores energy in the electrical field by charge separation
when appropriately polarized by the voltage. Simple capacitors consist of parallel plates of
conducting material that are separated by a gap filled with a dielectric material. Dielectric
materials that are air or mica contain a large number of electric dipoles that become polarized
in the presence of electric field. The charge separation caused by the polarization of the
dielectric is proportional to the external voltage and given by the following equation:
q(t)=Cu(t)
Where the symbol, C , represents the capacitance of element. The unit of measurement for
capacitance is the farad or farads (F).
1F =106μF =1012pF






This equation is given on the base of the same direction of current and voltage; otherwise there
should be a negative symbol in this equation.
The capacitance of capacitor is determined by the permittivity of the dielectric, ε, that fills the
gap between the parallel plate, the size of the gap between the plates, d , and the cross-section




When a constant voltage is exerted on the both sides of capacitor and its current is zero, this
capacitor is considered as an open circuit or DC circuit. In physical structure, capacitor consists
of two conducting surfaces that store charge, separated by a thin insulating material that has
a very large resistance.
For the equation idt =Cdu, if voltage is produced by both sides of this equation, the following









Above equation demonstrates that the electric energy increases with the increase of voltage
on the capacitor, and in the course, the capacitor component acquires electric energy from
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electric source. Formula 12 Cu
2 is the electric energy in the capacitor. When voltage reduces on
the capacitor, electric energy reduces. Namely, capacitor releases electric energy to electric
source. Hence, capacitor is an energy storage element in circuit.
Figure 27. Circuit with a capacitor
Figure 28. Circuit with inductor





idt , or u(t)= 1C ∫t0
t
idt + u0(t0)












The initial voltage in above equation, u0(t0), is usually defined with the same polarity as u,
which means u0(t0) is a positive quantity. If the polarity of u0(t0) is in the opposite direction,
then u0(t0) is negative.
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4.3. Inductor
An inductor in figure 28 is a passive element that is to store energy in magnetic field and is
made by winding a coil of wire around a core that is a insulator or a ferromagnetic material.
A magnetic field is established when current flows through the coil. The symbol 
is utilized to represent the inductor in a circuit. The unit of measurement for inductance is the




The convention for writing the voltage drop across an inductor is similar to that of a resistor.
Physically, current cannot change instantaneously through a inductor since an infinite voltage
required. Mathematically, a step change in current through an inductor is possible by applying
a voltage. For convenience, when a circuit has just DC currents (or voltages), the inductors can
be replaced by short circuits, since voltage drops across the inductors are zero.










Above expression demonstrates that magnetic energy increases with the increase of current
through inductor component. In this course, electrical energy could be converted into magnetic
energy, namely inductor acquires energy from the source. Formula 12 L i
2 is the magnetic
energy of inductive element. When current decreases, magnetic energy decreases and then is
converted into electric energy, namely inductor releases energy to the source. Hence, inductor
is not a dissipative element, but a energy storage element, too.





Ldi, or, i(t)= 1L ∫t0
t
u(t)dt + i(t0)
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The initial current in above equation, i(t0), is usually defined with the same polarity as i, which
means i(t0) is a positive quantity. If the polarity of the initial current i(t0) is in the opposite
direction, then i(t0) is negative.
5. Signal filters and operational amplifiers
Biosignals are recorded as potentials, voltages, and electrical field strengths generated by
nerves and muscles. The measurements involve voltages at very low levels, typically ranging
from 1μV to 100mV, with high source impedances and superimposed high level interference
signals and noise. The signals need to be amplified to make them compatible with devices such
displays, recorders, or A/D converters for computerized equipment. Amplifiers adequately to
measure these signals have to satisfy very specific requirements. They have to provide
amplification selective to the physiological signal, reject superimposed noise and interference
signals, and guarantee protection from damages through voltage and current surges for both
patient and electronic equipment. Amplifiers featuring these specifications are known as
biopotential amplifiers.
5.1. Basic signal amplifier
The basic requirements that a biopotential amplifier has to satisfy are:
1. The physiological process to be monitored should not be influenced in any way by the
amplifier.
2. The measurement signals should not be distorted.
3. The amplifier has to provide protection of patient from any hazard of electrical shock.
4. The amplifier itself has to be protected against damages that might result from high input
voltages as they occur during the application of defibrillators or electrosurgical instru‐
mentation.
A typical configuration for the measurement of biopotentials as illustrated in figure 29. Three
electrodes, two of them are used to pick up the biological signal and the third providing the
reference potential, connect the subject to amplifier. The input signal to the amplifier consists
of five components:(1) the desired biopotential, (2)undesired biopotential, (3) a power line
interference signal of 60Hz (50Hz in some countries) and its harmonics, (4)interference signal
generated by the tissue/electrode interface, and (5) noise. Proper design of the amplifier
provides rejection of a large portion of the signal interferences. The main task of designing
deferential amplifier is to reject the line frequency interference that is electrostatically or
magnetically coupled into subject. The desired biopotential appears as a voltage between two
input terminals of differential amplifier and is referred to as the differential signal. The line
frequency reference signal shows only small differences in amplitude and phase between the
two measuring electrodes, causing approximately the same potential at both inputs, and thus
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appears only between the inputs and ground and is called common mode signal. Strong
rejection of the common mode signal is one of the most important characteristics of a good
biopotential amplifier.
In order to provide optimum signal quality and adequate voltage level for further signal
processing, amplifier has to provide a suitable gain range and needs to maintain a possible
signal-to-noise ratio. The presence of the high level interference signals not only deteriorates
the quality of the physiological signals, but also restricts the design of the biopotential
amplifier. For example, electrode half-cell biopotentials limit the gain factor of the first
amplifier stage since their amplitude can be several orders of magnitude larger than the
amplitude of physiological signal. To prevent the amplifier from going to saturation, this
component has to be eliminated before the required gain be provided for physiological signal.
Figure 30. Schematic design of the main stages of a biopotential amplifier. Three electrodes connect the patient to a
preamplifier stage. After removing DC and low frequency interference, biological signal is connected to an output low-
pass filter through an isolation stage which provides electrical safety to the patient, prevents patient loops, and reduces
the influence of interference signals.
A typical design of the various stage of a biopotential amplifier is shown in figure 30. The three
electrodes which provide the transition between the ionic flow of currents in biological tissue
Figure 29. Typical configuration for the measurement of biopotentials
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and electronic flow of currents in amplifier represent a complex electrochemical system. To a
large extent, these electrodes determine the composition of the measured signal. The pream‐
plifier represents the most critical part of a amplifier since it sets the stage for the quality of
the biosignal. With proper design, the preamplifier can eliminate, or at least minimize, the
most signal interfering with the measurement of biopotentials. In addition to electrode
biopotentials and electromagnetic interference, noise which is generated by the amplifier and
the connection between biological source and amplifier has to be taken into account when
designing a preamplifier.
(a) One-order low-pass filter for its circuit and logarithmic amplitude-frequency characteristics 
(b) One-order high-pass filter for its circuit and logarithmic amplitude-frequency characteristics 
(c) Band-pass filter principle diagram (d)Band elimination filter priciple diagram 
Figure6.30 Four types of filters and its amplitude-frequency characteristics 
After biosignals is preamplified, some unuseful signal has to be eliminated or filtered to 
highlight the useful biosignal. Such function can be realized by all kinds of filters. In circuit, 
according to the frequency range of signals there are four classes of filters: low-pass filter 
(LPF), high-pass filter (HPF), band-pass filter (BPF) and band elimination filter (BEF). These 
four types of filters are shown in figure6.30. 
Figure 31. Four types of filters and its amplitude-frequency characteristics
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After biosignals are preamplified, some unuseful signal have to be eliminated or filtered to
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5.2. Operational amplifiers
Operational amplifiers play an important role that they amplify a weak signal and adjust
voltage or current in detecting circuit. An operation amplifier is an electronic device that
consists of plenty of transistors, resistors, and capacitors. Fully understanding its operation
requires that people have the knowledge of diodes and transistors. Circuit involving opera‐
tional amplifier forms the cornerstone of any bioinstrumentation, from amplifiers to filters.
Amplifiers used in biomedical applications have very high-input impedance to keep the
current down from the system being measured. Most body signals have small magnitudes.
For example, ECG has a magnitude in millivolts and the EEG has a magnitude in microvolt.
Analog filters are often used to remove noise from a signal, typically through frequency
domain analysis to design the filter.
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Performance
characteristics
∎ Realize inverse proportional operation.
∎ Cite parallel voltage negative
feedback.
∎ Virtual ground, low common-mode
input voltage.
∎ Low input and output resistance.
∎ Realize noninverse proportional
operation.
∎ Cite series voltage negative
feedback.
∎ Virtual short, but not virtual
ground, high common-mode input
voltage.
∎ High input resistance and low
output resistance.
∎ Realize subtract operation.
∎ Virtual short, but not virtual ground,
high common-mode input voltage.
∎ Low input and output resistance.
∎ High requirement of component
symmetry.
Table 3. Comparison of three types of scaling operation circuits
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The operational amplifier is an amplifier, but when it is combined with other circuit elements,
it may integrate, differentiate, product, divide, sum, and subtract. In circuit, there are three
basic types of proportional operation amplifiers: inverse scaling operation circuit, noninverse
scaling operation circuit, and differential scaling operation circuit. These three types of
operation circuit are compared as illustrated in table 3.
According to the information listed in table 3, we could know that operational amplifier is
drawn with the symbol in figure 32. The input terminals are labeled the no inverting input (+)
and inverting input (-). The power supply terminals are labeled V+ and V−, which are frequently
omitted, since they do not affect the circuit behavior except in saturation conditions. Most
people shorten the name of operational amplifier to the “op amp”.
Figure 32. Circuit element symbol for the operational amplifier
Figure 33 shows an ideal mode of op amp, focusing on the internal behavior of input and
output terminals. The input-output relationship is the following:
Figure 33. An internal mode of the op amp
uo = A(Vp −Vn)
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Since the terminal resistance is very large, we may replace it with an open circuit to simplify
analysis, leaving us with the op amp model shown in figure 34.
With the replacement of the internal resistance in an open circuit, the input current is zero
(ip = in =0A). In addition, the output current (iA) of the op amp is not zero. Because the output
current (iA) is not known, seldom is KCL applied at the output junction. In solving the op amp
problems, KCL is always applied at input terminals.
Example problem 1
Find the output voltage uo for the following circuit.
Solution
Using the op amp model shown in figure 33, we may apply KCL at the inverting terminal and
gain the following:
i1 + i2 =0








Multiplying by R1R2 and collecting like terms, we could gain:
R2Vs =(R1 + R2)Vn −R1Vo
Now Vo = A(Vp −Vn), and since the no inverting terminal is connected to the ground, Vp =0,
Figure 34. Idealized mode of the op amp
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Vo = − AVn
Substituting Vn into the KCL inverting input equation gives
R2Vs =(R1 + R2)(− VoA )− R1Vo










Interestingly, with A going to infinity, output voltage Vo remain finite due to the resistor
R2.This happens because a negative feedback path exists between the output and the inverting
input terminal through resistor R2. This circuit is called the inverting scaling operation circuit.
Of course, similar circuits have differential circuit, integrating circuit, summing circuit, index
circuit, logarithmic circuit and dividing circuit. These circuits could be found and read in the
analog circuit textbook.
5.3. Bioinformation acquisition
Biological signals are often very small and typically contain some unwanted noise or interfer‐
ence. Such interference could determine the effect of obscuring relevant information that may
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be available in the measured signal. Noise can be extraneous in nature, arising from sources
outside the body, such as thermal noise in sensors or noise in the electronic components of the
acquisition system. Noise can be intrinsic to the biological media, meaning that it can arise
from adjacent tissues or organs. ECG measurement from the heart can be affected by bioelectric
activity from the adjacent muscles.
In order to extract the meaningful information from biological signals, sophisticated bioinfor‐
mation acquisition techniques and equipment are commonly utilized and explored. Equip‐
ments with high-precision low-noise are very necessary to minimize the effect of unwanted
noise. Basic components include sensors, amplifiers, analog signal conditioner, data acquisi‐
tion, data storage and display, digital signal processing circuit. The bioinformation acquisition
procedure is shown in figure 35.
Figure 35. Procedure of obtaining biological information
In figure 35, sensors feel the biological signal that is being observed into an analog signal
conditioner to adapt the requirement of data acquisition system. Here data acquisition system
converts the analog signals into a calibrated digital signal that can be stored. Digital signal
processing techniques are employed here to reduce the noise and extract additional informa‐
tion that can improve understanding of physiological meaning of original parameter.
Throughout the data acquisition shown in figure 35, it’s very critical that the information and
structure of original biological signal of interests be faithfully preserved. Because these signals
are often used to help people diagnose the pathological disorder. The procedure of analog
signal conditioner, data acquisition system, analog amplifying and signal filtering, and A/D
conversion should not generate misleading or untraceable distortion. Signal distortion would
lead to an improper diagnosis on biological body.
In bioinstrumentation, after biological signal has been detected with an appropriate sensor, it
is amplified and filtered. Operational amplifiers are electronic circuits that are used to adjust
the amplitude or size of biological signal. Analog filter may be used to remove the noise hiding
in biological signal or compensate for distortions caused by sensors. Amplification and
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filtering of biological signal may be necessary to meet the requirement of hardware specifica‐
tions of signal conversion procedure. Continuous signal needs to be limited to a certain band
of frequencies before signal can be digitized with an analog-to-digital converter, prior to
storing in a digital computer.
6. Biomeasurement system and instrumentation
6.1. Biomeasurement system constitution
The biomeasurement system is shown in figure 36 to measure some biological signals such as
quantity, property, or condition which are bioelectrical signal generated by muscles or the
brain, or a chemical or mechanical signal that is converted into an electrical signal. Biomea‐
surement system is composed of sensor, analog processing circuit, A/D conversion, digital
signal processing, output display, and data storage. A/D conversion is used in bioinstrumen‐
tation to acquire the enough system gain.
Figure 36. Basic biomeasurement system using sensors to measure a biological signal with data acquisition, storage
and display capabilities, data transmission, along with control and feedback
With the invention of telephone and with appearance of internet, signal can be required with
a device in one location, perhaps in patient’s home, and transmitted into another device for
transmission or storage. For example, if a biological signal from bioinstrumentation system in
rural area could be transmitted into a diagnosis center in hospital, doctor would quickly judge
some diseases to make patients gain an accurate treatment or diagnosis in time.
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Two other components play important roles in bioinstrumentation system. The first is the
calibration signal. A signal with known frequency and amplitude is applied to the bioinstru‐
mentation system at sensor’s input. The calibration device permits the system components to
be adjusted so that it’s known that the output and input have a certain linear relationship.
Without such information, it’s impossible to convert the output of an instrument system into
a meaningful representation of the measurand.
Another important component, a control or feedback element, is not a part of all instrument
systems. These parts include pacemakers and ventilators that could stimulate the heart and
lungs. Some feedback devices collect physiological data and stimulate a response— a beat or
breath—when needed or are part of biofeedback systems in which patients are made aware of
a physiological instrument, such as blood pressure, and uses conscious control to change the
physiological response.
6.2. Biomeasurement circuit
Figure 36 shows the basic elements which constitute basic bioinstrumentation system. Circuits
play a very important role in bioinstrumentation system. If a bioinstrumentation needs to be
developed or improved to be fit for new condition, function circuits in different blocks from
figure 36 have to be respectively designed to form bioinstrumentation system with relative
indexes. Among all kinds of circuits, amplifiers and A/D converters are very important
component for detecting the biological signal. Hence, amplifying circuits will be only intro‐
duced here in detail, and other function circuits could be read or utilized in relative books.
• Bioelectric amplifier
In order to record the bioelectric potential from the body, biological amplification is always
required. The simplest form is shown in figure 37 which uses a single-input amplifier. Here
amplifier only amplifies one input signal which is applied in the input and the reference
“earth” or “ground”.
In this amplifier, the resistor R1 is required to allow the “bias current” to flow into the non-
inverting (+) input of the operational amplifier and the resistor R2 is required to balance the
resistor R1 so that the bias currents do not produce a voltage difference between the two inputs
of the amplifier. If there is no capacitor in the positive input, amplifier in figure 37 will become
a voltage follower, that’s to say, the bioelectric input signal could be transmitted completely
to the output. Namely, the following equation is given:
uin+ =uout
Unfortunately, in circuit shown in figure 37, the resistor R1 defines the maximum input
impedance of the amplifier. The input impedance is an important consideration in bioelectric
amplifiers because it can cause attenuation of a signal which is derived from electrodes with
high impedances. For example, if the two electrode impedances were 10kΩand the input
impedance of the amplifier was 1MΩ, then 1% of the signal would be lost by attenuation of
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two electrodes. The impedance presented by electrodes is termed the source impedance which
has to be very much less than the input impedance of amplifier. Source impedance is very
important when we consider differential amplifier shortly.
Figure 37. A simplest single-input amplifier
Figure 38. A differential amplifier
There is also capacitor introduced in figure 37 in series with the input signal. Capacitor C  blocks
any DC (direct current) signal by acting as a high-pass filter with the resistor R1. This function
is usually referred as AC (alternative current) coupling. AC coupling will also cause some
attenuation of the signal which may be important. We could determine the attenuation of
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If capacitor C is 1μF and resistor R1 is 1MΩ, then the attenuation of a 1Hz signal will be 1.25%.
This is perhaps a significant attenuation for ECG which has considerable energy at 1Hz.
Unfortunately, even with capacitor C added, this type of amplifier is not suitable for recording
small bioelectric signal because of interference from external electric fields. An electric
electrode has to be connected to the amplifier via a wire and this wire is exposed to interfering
signals. However, the interference will only appear on the input wire to the amplifier and not
on the “ground” wire which is held at zero potential. An elegant solution to this problem is to
utilize differential amplifier as shown in figure 38. The input of the type of amplifier has three
connections marked ‘+’, ‘-’ and ‘ground’.
• Differential amplifier
In figure 38, the signal which we wish to record is connected between the ‘+’ and ‘-’ points.
Now both inputs are exposed to any external interfering electric fields so that the difference
between the ‘+’ and ‘-’ input will be zero. This will not be quite true because the electric fields
experienced by the two input wires may not be exactly the same, but if the wires are run close
together then the difference will be small. Differential amplifier is not perfect in that even with
the same signal applied to both inputs, with respect to ground; a small output signal can
appear. This imperfection is specified by the common mode rejection ratio or CMMR. An ideal
differential amplifier has zero output when identical signals are applied to the two ‘+’ and ‘-’
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In practice, common-mode voltage Ucm can be as large as 100mV or even more. In order to
reject this signal and record a signal Vin as small as 100μV, a high CMMR is required. If we
wish the interfering signal to be reduced to only 1% of output voltage then


















Hence, the required CMMR could be given as:







In fact, it’s not always easy to achieve a CMMR of 100dB. As we have known, electrode source
impedances have a very significant effect on CMMR and hence electrode impedance affects
noise rejection.
Of course, in detecting biosignals, the AC coupling shown in figure 37 and figure 38 degrades
the performance of the amplifiers. If the input impedance and bias current of amplifiers is
sufficiently high, then they can be connected directly to the input electrodes, without produc‐
ing electrode polarization. Furthermore, DC offset will occur from the electrode contact
potentials, but if the amplifier gain is low (<10) DC offset will be not a significant problem. The
offset can be removed by AC coupling at later stage.
However, there are some safety arguments against the use of DC coupling. If a fault arises in
the operational amplifier, then it’s possible for the power supply to be directly connected to
the patient and so give rise to a hazard. DC currents will cause electrolysis and result in tissue
necrosis. AC coupling could avoid this problem and is often used. Nonetheless DC coupling
is also often used in biomedical field.
6.3. Bioinstrumentation design
The purpose of using bioinstrumentation is to monitor the output of a sensor or sensors and
to extract some useful information from signals that are produced by sensors.
Acquiring discrete-time signal and storing this signal in computer memory from a continuous-
time signal is accomplished with analog-to-digital (A/D) converter. After analog signals have
been processed which are based on analog filters such as low-pass or high-pass filters, A/D
converter uniformly samples the continuous-time waveform and transforms it into a sequence
of numbers, one every tk  seconds. The A/D converter also transforms the continuous-time
waveform into a digital signal, which is converted into computer words and stored in
computer memory. To adequately capture the continuous-time signal, the sample frequency
has to be carefully selected to ensure any signal information is not lost. The minimum sampling
frequency is twice the highest frequency content of the signal based on the sampling theorem
from communication theory. In reality, we often adopt the sampling frequency from five to
ten times the highest frequency content of the signal so as to achieve better accuracy by
reducing aliasing error.
• Biological signal categories in human body
The electrical, chemical and mechanical activity that occurs during this biological event often
produces signals that could be detected and analyzed. Biological signals are the record of a
biological event such as a beating heart or a contracting muscle. Hence, biological signals
contain useful information which could reflect human’s activities and physiology, that’s to






In fact, it’s not always easy to achieve a CMMR of 100dB. As we have known, electrode source
impedances have a very significant effect on CMMR and hence electrode impedance affects
noise rejection.
Of course, in detecting biosignals, the AC coupling shown in figure 37 and figure 38 degrades
the performance of the amplifiers. If the input impedance and bias current of amplifiers is
sufficiently high, then they can be connected directly to the input electrodes, without produc‐
ing electrode polarization. Furthermore, DC offset will occur from the electrode contact
potentials, but if the amplifier gain is low (<10) DC offset will be not a significant problem. The
offset can be removed by AC coupling at later stage.
However, there are some safety arguments against the use of DC coupling. If a fault arises in
the operational amplifier, then it’s possible for the power supply to be directly connected to
the patient and so give rise to a hazard. DC currents will cause electrolysis and result in tissue
necrosis. AC coupling could avoid this problem and is often used. Nonetheless DC coupling
is also often used in biomedical field.
6.3. Bioinstrumentation design
The purpose of using bioinstrumentation is to monitor the output of a sensor or sensors and
to extract some useful information from signals that are produced by sensors.
Acquiring discrete-time signal and storing this signal in computer memory from a continuous-
time signal is accomplished with analog-to-digital (A/D) converter. After analog signals have
been processed which are based on analog filters such as low-pass or high-pass filters, A/D
converter uniformly samples the continuous-time waveform and transforms it into a sequence
of numbers, one every tk  seconds. The A/D converter also transforms the continuous-time
waveform into a digital signal, which is converted into computer words and stored in
computer memory. To adequately capture the continuous-time signal, the sample frequency
has to be carefully selected to ensure any signal information is not lost. The minimum sampling
frequency is twice the highest frequency content of the signal based on the sampling theorem
from communication theory. In reality, we often adopt the sampling frequency from five to
ten times the highest frequency content of the signal so as to achieve better accuracy by
reducing aliasing error.
• Biological signal categories in human body
The electrical, chemical and mechanical activity that occurs during this biological event often
produces signals that could be detected and analyzed. Biological signals are the record of a
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into bioelectric signals, biomagnetic signals, biochemical signals, biomechanical signals,
bioacoustic signals and biooptical signals.
Nerve and muscle cells generate bioelectric signals that are the result of electrochemical
changes within and between cells. When plenty of cells are stimulated, an electric field is then
generated that propagates through biological tissues. These changes in extracellular potential
may be measured on the surface of tissue or organism by using surface electrodes. The
electrocardiogram (ECG) is an example of this phenomenon. Different organs in body,
including the heart, brain, lungs, and liver, also generate weak magnetic fields that could be
detected with magnetic sensors. The strength of magnetic field is much weaker than the
corresponding physiological bioelectric signal. Magnetic sensors could be used to detect
biomagnetic signals. Magnetocardiography (MCG) is a specific example of such phenomenon.
Biochemical signals contain information about changes in the concentration of various
chemical agents in the body. The concentration of various ions such as calcium and potassium
in cell can be measured and recorded. Oxygen sensor is used to detect oxygen concentration
in body. Mechanical functions of biological systems, including motion, displacement, tension,
force, pressure and flow, also produce measurable biological signals. Blood pressure sensor is
a measurement of the force that blood exerts against the walls of blood vessels. Change in
blood pressure can be recorded as a waveform by blood pressure sensor. Bioacoustics’ signals
are a special subset of biochemical signals which involve vibrations. Many biological events
could produce acoustic noise. For example, the flow of blood through the valves in the heart
can be used to determine whether motion is operating properly. Besides these, the respiratory
system, joints and muscles could also produce bioacoustic signals that propagate through the
biological medium and can be often measured at the skin surface by acoustic sensors. Bioop‐
tical signals are generated by the optical or light induced attributes of biological systems.
Biooptical signals can occur or be introduced to measure a biological parameter with an
external light medium such as the measurement of health of a fetus by red and infrared light.
• Noise
Measurement signals are always corrupted by noise in the bioinstrumentation system.
Interference noise occurs when unwanted signals are introduced into systems by external
sources such as telephone magnetic wave, power line and transmitted radio. Interference noise
needs to be effectively reduced by careful attention to the circuit wiring configuration to
minimize coupling effect.
Interference noise is introduced by power lines, fluorescent lights, AM/FM radio broadcasts,
computer clock oscillator, laboratory equipment and cellphone. Electromagnetic energy
radiating from noise source is injected into the amplifier circuit or into the patient by capacitive
or inductive coupling. Even action potentials from nerve conduction in the patient generate
noise at the sensor/amplifier surface. Filters are also used to reduce the noise and to maximize
the signal-to-noise(S/N) rate at the input of the A/D converter.
Low frequency noise could be eliminated by high-pass filter with the cutoff frequency set above
the noise frequency. High frequency noise could be reduced by low-pass filter with the cutoff
frequency set below the noise frequency and above the frequency of biological signal which
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is being monitored. Power line noise is a very difficult problem in biological monitoring
because the 50-or-60-Hz frequency is usually at the range of biological signal which could be
monitored. Band-stop filters are commonly used to reduce the power line noise. The notch
frequency in the band-stop filters is set to the power line frequency of 50 or 60Hz with the
cutoff frequency located a few Hertz to either side.
The second type of noise is called inherent noise. Inherent noise arises from random processes
that are fundamental to the operation of circuit’s elements and thus is reduced by a good circuit
design practice. While inherent noise is reduced, it can be never eliminated. Low-pass filters
are used to reduce high-frequency components. However, noise signals within the frequency
range of biological signals being amplified cannot be eliminated by this filtering approach.
• Computer
Computer is a main device which is used to display the biological signals being monitored.
However some low or high level languages such as machine language, FORTRAN, visual C+
+, MATLAB or LabView, have to be used to realize the operation on the acquisition data from
biological body. When computers are used to acquire physiological data, programming
instruction tell computer when acquisition data should begin, how often samples should be
taken from how many sensors, how long acquisition data should continue, and where the
digitized data should be stored. The rate at which a system acquires sample depends on the
speed of computer clock’s frequency and the number of computer instruction that could be
completed in order to realize a sample. Of course, some computers are utilized to control the
gain on the input amplifiers so that biological signals could be adjusted during data acquisition.
In other systems, the gain of data acquisition has to be adjusted.
7. Chapter summary
In this chapter, main biomedical sensors, devices and biological measurement systems are
introduced to make readers understand present bioinstrumentation in market. The common
biomedical sensors are narrated here to make readers grasp their basic sensing principle such
as heart sound sensor, blood flow sensor and enzyme sensor. Furthermore, basic charge,
current, voltage, power and energy used in biomedical engineering are explained to design
some detecting circuits. Besides above, signal filters and operational amplifiers are also
described and some advice or opinions are given out to give readers some available references.
The basic detecting blocks of biomeasurement system are provided to quickly design relative
bioinstrumentations. Readers need to carefully learn the content of biomedical sensors, signal
filters, operational amplifiers for bioinstrumentation.
Suggested reading
[1] Wang Baohua. Biomedical measurement and instrument [M]. China Fudan press, shanghai,
January, 2009.
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1. Introduction
The rapid development of high brightness light emitting diodes (LEDs) makes feasible the use
of LEDs, among other light sources (such as laser, intense pulse light and other incoherent light
systems), for medical treatment and light therapy. This chapter provides an overview of LED
application in human health and the results in healing and cell rejuvenation [1].
The technique of LEDs used in tissue treatments is called LED Therapy and from now on we
will treat it this way. With the use of electronic converters that supply the high brightness LEDs
it is possible to control the spectral composition, allowing to obtain the wavelengths desired
to apply the human tissue to obtain efficacy in phototherapy. High brightness LEDs can be
easily integrated in digital control systems for the purpose of providing a variation in spectral
composition over a phototherapy treatment stage. The colors emitted by the high brightness
LEDs operate differently, i.e. depending on which layer of the human tissue that will be applied
to light and which type of which will combat disease. In the skin, the red light has restorative
action, healing and analgesic, while blue has a bactericidal action [19]. The intensity of the
beams of light emitted by LEDs on the skin is lower, since its cells maintain a good interaction
with the light [2, 21]. The high brightness LEDs respond effectively in the therapeutic appli‐
cation and can be used a variety of electronic converters that control the output current, output
power, the duty cycle and other parameters that directly interfere in luminous efficiency and
length of wave offering a positive response in phototherapy treatments.
LED Therapy is gaining ground every day in various areas, including in medicine, dentistry,
physical therapy and aesthetics [20]. Biomedical engineering has made great strides in their
research on the application of LEDs in the treatment of pre-malignant lesions and malignant,
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in the treatment of rejuvenation and acne, hair loss, skin lesions, wound healing in post-
operative incisions in the patient's psychological recovery, where the lights are applied to the
environment and on other fronts of medicine. In dentistry the development of modern
photopolymerizable materials represents a great advance for restorative dentistry because
they allow excellent aesthetics, ease in handling and control of the clinical time [3, 23].
Advances in the medicine are encouraging and research in the area grows every day, the intent
of this chapter is to present a study and results in healing and cell rejuvenation.
2. Action of LED Therapy in human tissues
The photobiostimulation caused by irradiation with LEDs has a number of outcomes such as
increasing cell proliferation rate, the production rate of fibroblasts and collagen synthesis. LED
Therapy is known for its anti-inflammatory and healing properties and it can be used as an
independent procedure of the conventional treatments of clinical medicine, but it should
always be accompanied by a health professional with knowledge of the tissue pathology, cell
rejuvenation and photobiostimulation cell. Different applications of LED Therapy may be
performed as a function of wavelength (nm) of light penetration in tissue (mm). The relation‐
ship between these parameters demonstrates that the penetration depth of light into tissue, as
shown in Figure 5.
2.1. Light penetration in human tissues generated by the action of high brightness LEDs
arrangements
The processes of refraction and reflection of light emitted by LEDs in human tissues are
responsible for the dispersion of light, as shown in Figure 5. However, the action of light is
peculiar because the response to these processes can vary from person to person undergoing
therapy.
Despite the high dispersion, the degree of penetration is significant, approximately 50% of the
incident radiation to reach the substrate directly below the skin of the patient [4]. The fabric
layers to be submitted to receive a red light portion scattered radiation given where a small
tissue area can absorb light in the dermis and epidermis. This is due to the presence of
photoreceptor layers that can be constituted of amino acids, melanin, and other acids. Typically
each type of photoreceptor is sensitive to a particular wavelength.
Thus, light can be absorbed by the tissue which depends on the color and wavelength. For
example, red light, near infrared, easily penetrates the fabric because this light radiation is not
blocked by blood and water as other wavelengths.
Wavelengths less than 630nm, such as yellow, blue and green are significantly blocked by
hemoglobin in the blood, so that they do not penetrate deeply [5].
Wavelengths greater than 900nm are blocked by the liquid portion of the skin and connective
tissues. Many wavelengths can emit a large amount of energy above the infrared range and
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cannot be seen by the human eye; this type of radiation may produce a certain amount of heat
to interact with human tissue [5].
2.2. Action of light emitted by high-brightness LEDs in human tissue
The blue is in the range of 430 to 485nm. The green is in the range of 510 to 565nm. The yellow
is between 570 to 590nm. The red is in the range of 620nm to 700nm, to the point that it does
not become visible anymore in the range of 740nm. Some companies that manufacture LEDs
say that the yellow light helps remove wrinkles. There is also some interesting research, which
emphasizes that the application of blue light helps in the elimination of a bacteria that causes
some forms of acne [20].
The phototherapy with the narrow band blue light seems to be a safe treatment and one
additional effective therapy for treatment of mild and moderate acnes. Some researchers
suggest that the green LED light can help against cancer, but this color cannot penetrate more
than the skin. Figures 1, 2, 3 and 4 show prototypes that emit light in the red, blue, green and
amber colors.
2.2.1. Action of red light emitted by high brightness LEDs
Red light emitted by high brightness LEDs (in the range of 630nm wavelength) promotes
increased cellular energy synthesis (ATP) restructuring fibroblast collagen and elastin fibers
stimulating the production of new fibers. It also assists in enhancing the flow of blood and
oxygen to the skin and capillaries, increasing cellular metabolism and strengthening the walls
of the capillaries. The red light is also an excellent treatment for scarring, inflammation and
hard-to-heal ulcers. The red light emitted by high brightness LEDs when in contact with tissue
injury has regenerative and major impact on healing characteristics. Patients with physiolog‐
ical difficulties of tissue healing can get great results with this therapy.
Figure 1. Arrangement of high brightness LEDs that emit red light.
High Brightness LEDs Supplied by Electronics Converters Used in Tissue Healing and Cell Rejuvenation
http://dx.doi.org/10.5772/59817
233
2.2.2. Action of blue light emitted by high brightness LEDs
Blue light emitted by high brightness LEDs (in the range of 470nm wavelength) acts as a
bactericide because its wavelength reaches the surface of the skin (epidermis) producing
oxygen and generating oxidative stress destroying bacterias such as those that develop acne.
The action of blue light emitted by high-brightness LEDs is indicated for patients with
inflammatory acne, as this therapy reduces bacterial growth and reduces inflammation. LED
blue light therapy helps to kill the acne causing bacteria, reducing inflammation and providing
a general rejuvenation effect on the skin. Blue light emitted by high brightness LEDs can be
used to reduce cellulite and stretch marks and if combined with the red light the result will be
more significant.
The action of light acts directly on the excessive production of fat by inhibiting excessive
sebaceous secretion, oxygenation, aiding tissue regeneration, and stimulating the production
of collagen and elastic fibers.
Figure 2. Arrangement of high brightness LEDs that emit blue light.
2.2.3. Action of green light emitted by high brightness LEDs
Green light emitted by high brightness LEDs (in the range of 530nm wavelength) can be used
in the improvement of skin metabolism, pigmentation, and effects of aging. It provides a
control of melanin absorption, aids in whitening pigmentation spots and provides an overall
effect of hydration. It also prevents the formation of stains, freckles, and helps to reduce them.
It keeps the skin smooth and moisturized.
2.2.4. Action of amber light emitted by high brightness LEDs
The amber LEDs have a wavelength of 617nm. The irradiation of amber has both draining and
detoxifying properties, improving blood and lymph circulation, reducing edema, stimulating
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the presence of water and causing a calming effect in case of redness caused by rosacea or
sunburn.
For aging, the collagen fibers are presented densely packed together, to receive the amber light.
The enzyme releases ions receivers which immediately adhere to the cytoplasmic membrane
of the cells, creating a non-thermal thickening effect of collagen fibers. The reflection of light
by the tissues in these conditions gives a healthy expression to patients. It has a draining action,
stimulates blood and lymph circulation, and reduces swelling.
Figure 4. Arrangement of high brightness LEDs that emit amber light.
Figure 3. Arrangement of high brightness LEDs that emit green light.
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3. The importance of wavelength in the therapeutic application
The response to the treatment with LED Therapy depends on several factors, but the most
important is the wavelength and light penetration into the tissue beyond the physical, organic
and genetic characteristics of the patients, which may provide a more efficient biological
response one to another.
Some studies indicate that the wavelengths in the range of 620, 680, 760 and 820nm may be
most suitable for health treatments [6]. Commercially available LEDs emit light at certain
specific wavelengths, for example, 630, 660, 850 and 880nm. These values may not be accurate,
it is possible to have a small variation during the operation in real time where this change can
be due to temperature, input or output, electrical current and power dissipation. Currently the
electronic converters and the quality of manufacture of high brightness LEDs can considerably
reduce this variation. The wavelength of 630nm generated by certain LEDs can affect peak
620nm and 660nm wavelength generated by the LEDs is approaching the peak of 680nm, for
example [6]. When operating the LEDs with currents in milliampere range, you can improve
the input waveform of [20], this fact is important to have control of the desired wavelength.
To perform the therapy a medical evaluation is required to get the correct diagnosis and
indicate the most appropriate treatment and which wavelength should be applied.
3.1. Relationship between the penetration depth and the wavelength in human tissues by
applying light emitted by the high brightness LEDs
The light penetration into human tissue is directly connected to the wavelength, that is, the
larger the wavelength the longer is their penetration in the human tissue, as these wavelengths
are specific and are within the visible light spectrum [6, 22]. Therefore, the application of a
given wavelength is directly related to the color. Each color has a certain wavelength respecting
the chromaticity diagram. The color used depends on the type of treatment to be applied. The
electronic converters can control the wavelength through duty cycle, which facilitates the
relationship between the depth of penetration with the desired wavelength.
3.2. Cell photobiostimulation
There are areas of medicine and veterinary where the LED Therapy has an important role to
play, as shown in Figure 6. These are: (i) wound healing, tissue repair, prevention of tissue
death; (ii) the relief of inflammation, chronic diseases and injuries, with their pain and edema
associated; (iii) relieving the pain and neurogenic some neurological disorders [7].
One of the photobiology principles is that visible light can have an effect in a living biological
system. Photons must be absorbed by electronic absorption bands belonging to some molec‐
ular chromophore or photoreceptor. Figure 6 depicts the biological response as a function of
wavelength, frequency, or energy of the photons and should resemble the absorption spectrum
of the photoreceptor molecule [24].
The fact that a structured action spectrum can be built on the hypothesis of cell photoreceptors
and absorption pathways stimulated by light.
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Figure 5. Action of color and depth of penetration in human tissue. Optical penetration depth.
Figure 6. Schematic representation of the main areas of application of LED Therapy.
One should take into consideration some optical properties of tissues. Both the absorption and
scattering of light in tissue are wavelength dependent (both much higher in the blue region of
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the spectrum than the red), chromophores (hemoglobin) has bands of high absorption and the
wavelength less than 600nm [7]. For these reasons they are called "optical window".
The water begins to absorb wavelengths longer than 1150nm and acts tissue at wavelengths
in the range of red and NIR, wherein the tissue penetration becomes maximized (Figure 7).
Furthermore, blue, green and yellow light may have significant effects on the cells because its
therapeutic interaction is proven every day.
Figure 7. Optical window in tissue due to reduced absorption of red and NIR wavelengths (600-1200 nm) by tissue
chromophores.
4. Electronic converters used to supply high brightness LEDs
The application of electronic converters switched to supply high brightness LEDs is critical
because these converters have higher efficiency than linear converters. Thus, there are several
possibilities of implementing converters DC/DC insulated and not insulated. The converters
that are chosen must attend all the control and the power delivery to the high brightness LEDs
[8]. Resonant converters help to reduce the peak power; they have low switching losses and
low electromagnetic interference. Therefore, these topologies are useful for LED applications.
Depending on the characteristics of the electronic converters applied to LEDs more favorable
characteristics should be observed to its applicability. Several converters can be used to supply
the LEDs, preferably those that have a natural control over the output current.
DC/DC converter for high brightness LEDs should have a current source characteristic at its
output, which already limits the inrush current, acting as an inherent protection circuit. To
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minimize the variations current it is preferable that its output current is not pulsed, which also
minimizes the filter output current and allows the use of capacitors with longer life.
4.1. Converters not isolated commonly used for supplying high brightness LEDs
Buck converter, shown in Figure 8, is widely used in power high brightness LEDs. The current
source attribute in the output makes this very interesting electronic converter, essentially
because its output current can be continuous. Thus, the output capacitor C may have a small
value and is unnecessary to use an electrolytic capacitor, which has the characteristic of a
considerably short lifetime.
The output inductance L can be designed to provide a small ripple current, maintaining stable
optical characteristics and the temperature of the LED junction.
Figure 8. Buck converter.
If the output capacitor is removed from this type of DC/DC converter, the current on the LEDs
is no longer purely DC because it contains a pulsating component. If the converter is a Boost
or Buck-Boost converters, LED load is powered by an almost square with a sufficiently high
reactance wave. The electronic converter CUK, in its basic structure consists of a fusion of two
converters (Boost and Buck) in series using only a controlled switch. The union in series of
these two converters permits the entry and exit can operate in continuous conduction mode
and the static gain of the converter is the same Buck-Boost converter. Buck converter output
enables obtaining a low current ripple in the LED, even for a small amount of C. ZETA
converter comprises a Buck-Boost converter in series with an input Buck converter output.
Similarly the CUK converter, the Buck converter on the output allows to obtain a low ripple
current on the LED. SEPIC converter is composed of a Boost converter at the input, in series
with a Buck-Boost converter output. All of these topologies may be used to supply the high
brightness LEDs, some have more positive characteristics for the LEDs, such as the control of
the output current.
4.2. Converters isolated commonly used for supply high brightness LEDs
Currently there is a considerable range of converters that can be used to supply LEDs, such as
that with galvanic isolation. This sort of application employs the Flyback, Push Pull, Forward
and Resonant converters [9]. The Figure 9 shows a system that supplies power to the LEDs
using galvanic isolation.
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Figure 9. Representation of a LEDs supply the galvanic isolation system.
4.3. Topologies used in research
After reviewing several possible topologies for using as a power source for high-brightness
LEDs two converters were chosen, one with galvanic isolation, the Flyback, and one without
galvanic isolation, the Buck.
Flyback converter is more robust and has the advantage of being isolated, but it may show
some noise in the output. Buck converter controls the output current better and offers a good
response, but it has the disadvantage of not being isolated.
In summary, these two converters have been selected because their characteristics are more
suited to supply the arrangements proposed by LEDs. The expected results should be quite
satisfactory [9, 20].
4.3.1. Flyback converter
The Flyback converters of levels below 100W of power are widely used for the several
applications and also for lighting with LED, normally, operating in discontinuous mode. This
mode of operation is appropriate to control the current. The proposed topology is observed
on Figure 10 and it was developed to supply the array of LEDs, which produce red light [9].
The red color has a greater wavelength (in the range of 647 to 780nm) and penetrates more
deeply into the tissue. Thus, it is indicated for healing and recovering deep tissues [9].
The Flyback converter employed in the experiments owns a universal voltage input and its
maximum output voltage is 5V.
The maximum output current is 2A. His frequency of switching is 100kHz.
The proposed arrangement of red LED contains 90 high-intensity LEDs of 5mm, with wave‐
length in the range of 400 to 730nm. The current in each LED is around 20mA.
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The source was designed to support up to 100 LEDs.
These tests are being conducted in patients with proper authorization and with the participa‐
tion of five doctors, two surgeons, and three dermatologists, at Hospital Regional do Oeste in
Chapecó, SC - Brazil.
The voltage produced on the LED was 4.1V and current of the LEDs around 570mA. The values
obtained were close to the simulation and design [12, 13].
4.3.2. Buck converter
The second converter developed has the Buck configuration as shown in Figure 11, with the
following characteristics: Input Voltage DC-13V (after one stage rectified by with a Flyback
converter) and the output voltage reaches 6V and maximum output current reaches 1A [20].
The frequency of switching is 52kHz. The source has total isolation, even in short-circuit
conditions in its terminals [10].
Figure 11. Buck converter.
This topology has the same versatility of a Flyback converter and supplies the array of LEDs.
Figure 10. LEDs powered by a Flyback converter.
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The voltage produced on the LED was 3.8V and current of the LEDs around 580mA. The values
obtained were close to the simulation and design [11].
5. LED Therapy automation using an embedded system integrated with a
control software
The main goal here was to provide a control interface of the therapy between the healthcare
professional and the patient, giving them the possibility to monitor the phototherapy ses‐
sions progress and to treat the patient in a simple and effective way.
There are already lots of resources available in the market that use LEDs for skin disease
treatment, like skin cancer or even aesthetic purposes, among others. When a new treatment is
discovered, the creation of a new essay is necessary and therefore a new product is created. This
project proposes a solution for this problem integrating hardware with control software. With
the control software acting over the embedded system, it’s possible to program new assays for
each treatment; acting directly over the LED’s, and dynamically minimizing the costs over new
products every time a new treatment is discovered
5.1. System overview
The system is divided into two parts: the embedded system and the control. The embedded
system contains a microcontroller, a LED board and an Ethernet Module for communication
with the application [12]. The control consists of a database server and an application, as shown
in Figure 12.
Figure 12. Automation of phototherapy with high brightness LEDs using an embedded system integrated with a soft‐
ware control.
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Through the control application, it is possible to register a patient or start a treatment session.
The treatments are mapped to the database as essays that determine the variable values for
each pathology. The variables are: the colors and the time of firing the LED arrays [25]. The
communication between Embedded System and Application control is possible through the
Ethernet Protocol [16].
5.2. System model
In this section the prototype details will be shown, such as: the application operation, embed‐
ded system operation and the database server details [16].
5.2.1. Application
The control application was written in JAVA language. The application aims to perform the
user interface with the proposed system. Through the application the user can perform the
following tasks:
• Register new patients, which are going to be stored in the database;
• Visualize the stored patients in the database;
• Connect the patient to a treatment; and
• Initiate a new session of the treatment.
The application stores the results of each treatment session.
5.2.2. Embedded system
The embedded system purpose is to communicate with the application and to execute the
treatment over the patient. The embedded system is based on the Atmega328p AVR micro‐
controller present in the Arduino UNO board. It also has a LED board and an Ethernet Module
ENC28J60 and resistors. The Figure 13 shows the prototype schematics. The database server
aims to store all the patient data and the treatments as well. It’s in the database that the LED
treatment sequence is also stored. The chosen Data Base Management System (DBMS) was the
PostgreSQL version 9, because it doesn’t have license costs and it’s capable of storing all the
needed data [13, 14, 16].
Tree arrays were assembled on a phenolite board with tree blue, yellow and red LED colors.
Each array has thirty LEDs of the specified color which are powered by the corresponding
Arduino pin and a common ground.
Where, (A) Ethernet ENC28J60 module, (B) Resistors, (C) Arduino UNO and (D) LEDs array.
The LEDs board is composed by three arrays of high brightness LEDs with the following
characteristics:
• Red array: The red light emitting LED array contains 30 high brightness LEDs of 5mm, with
wavelength between 725nm and 730nm. Operates at 3, 3V and 20mA.
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• Blue array: The blue light emitting LED array contains 30 high brightness LEDs of 5mm,
with wavelength between 465nm and 470nm. Operates at 4V and 25mA.
• Yellow array: The blue light emitting LED array contains 30 high brightness LEDs of 5mm,
with wavelength between 585nm and 590nm. Operates at 3, 6V and 22mA.
Figure 13. Prototype schematics.
Figure 14 shows the prototype used in the laboratory.
Figure 14. Numerous tests were performed with the prototype before manufacturing the device.
Advances in Bioengineering244
• Blue array: The blue light emitting LED array contains 30 high brightness LEDs of 5mm,
with wavelength between 465nm and 470nm. Operates at 4V and 25mA.
• Yellow array: The blue light emitting LED array contains 30 high brightness LEDs of 5mm,
with wavelength between 585nm and 590nm. Operates at 3, 6V and 22mA.
Figure 13. Prototype schematics.
Figure 14 shows the prototype used in the laboratory.
Figure 14. Numerous tests were performed with the prototype before manufacturing the device.
Advances in Bioengineering244
6. Types of treatment and response to therapy
The concentration of light coming from the LED bulb can concentrate light to a certain point of
light that can have a high ratio in millicandelas, but passing through the skin undergoes a
dispersion of its light concentration. The rate control devices are important because the total
light energy emitted by the LED or energy in Watts per square centimeter in units of mW/cm2
is essential [15].
If the designer decides to use his knowledge to choose a less expensive way to manufacture
power supply, then the power converter should be about 2 or 3 times more than the total of its
light energy. The maximum light output of the output device is the source of half the power (W
= Volt x Amps) of the transformer. The mW/cm2 is the total light energy in mW divided by the
length and breadth of the array of LEDs in cm.
6.1. Criteria, control and response to treatment of the patients who were treated by red and
blue light emitted by high-brightness LEDs
Patients who are subject to the treatment will be properly classified with the criteria establish‐
ed by the doctors who assist in the implementation of therapy. Among them, age, sex, physi‐
cal condition and mental health. The therapy was performed with LEDs Hospital Regional do
Oeste in the city of Chapecó/SC, Brazil.
The first case is from a patient who had put breast prosthesis. The prothesis were large and a
few days later, streaks appeared (Figures 15 and 16). Stretch marks are linear atrophies which
arise due to the disruption of elastic fibers that support the middle layer of the skin. General‐
ly, this breakup is from mechanical stress, such as excessive stretching of the skin, or physiolog‐
ical stress, stimulated by hormones. When the fibers are broken, they are filled with blood,
becoming primarily redish, but over the time they acquire a white color. This patient under‐
went a medical evaluation and its treatment was approved. 15 sessions were held in 44 days.
The application time for each session was 40 minutes. After the treatment the reduction was
95% (Figures 17 and 18). The use of LED Therapy is completely painless and leaves no sequel.
The Figures 19 and 20 show the results of treatment.
Figure 15. Patient with stretch marks on breasts before application of therapy.
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Figure 16. Patient developed stretch marks after placing silicone breast.
Figure 17. Application of therapy with LEDs that emit blue and red lights.
Figure 18. Application of the array of LEDs during treatment.
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Figure 19. Result after treatment.
Figure 20. The striations were eliminated.
The second case is a patient who had stretch marks on her hip in the region of the buttocks.
She underwent a medical evaluation and the treatment was initiated. 20 sessions were held
for 49 days. Each session was 40 minutes long. A reduction of 87% of the hips as shown in
Figure 21 has occurred.
In this procedure the Buck converter, which is supplied by the LEDs, was used that emit red
and blue light.
All patients who underwent treatment fulfilled all requirements and recommendations of the
medical staff. All International Laws and National research in human beings were observed.
All protocols required by the Brazilian Ministry of Health and the Ethics Committees of
Hospital Institutions.
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Figure 21. Outcome of treatment for stretch marks.
The Figure 22 shows some prototypes that were manufactured to perform the therapy.
Figure 22. Prototypes that are being manufactured.
7. The future of LED therapy
The application of high brightness LEDs in human tissue has been growing every day. Several
scientific institutions have explored this theme. Many researches are underway on the use of
therapy with the LED in order to improve their application and to determine if there are other
applications which may be used. The therapy is applied within the visible light spectrum and
each color has its application and its therapeutic purpose.
The red color that is in a range of 600-700 nanometers, is effective in human tissues and shows
excellent results in wounds and sores. The higher wavelengths, including infrared, are more
sharp and can reach the bone. Studies also suggest that the spectrum between 400 to 500
nanometers, in the range of blue color, can be effective in the treatment of skin disorders,
including acne, stretch marks, cellulite, skin blemishes and scarring.
Advances in Bioengineering248
Figure 21. Outcome of treatment for stretch marks.
The Figure 22 shows some prototypes that were manufactured to perform the therapy.
Figure 22. Prototypes that are being manufactured.
7. The future of LED therapy
The application of high brightness LEDs in human tissue has been growing every day. Several
scientific institutions have explored this theme. Many researches are underway on the use of
therapy with the LED in order to improve their application and to determine if there are other
applications which may be used. The therapy is applied within the visible light spectrum and
each color has its application and its therapeutic purpose.
The red color that is in a range of 600-700 nanometers, is effective in human tissues and shows
excellent results in wounds and sores. The higher wavelengths, including infrared, are more
sharp and can reach the bone. Studies also suggest that the spectrum between 400 to 500
nanometers, in the range of blue color, can be effective in the treatment of skin disorders,
including acne, stretch marks, cellulite, skin blemishes and scarring.
Advances in Bioengineering248
Probably in the next few years, LED Therapy will be the main treatment for wounds, such
as  post-surgical  wounds  and  unhealed  as  diabetic  ulcers.  Scientists  seek  to  test  the
technology of  LED Therapy in other clinical  situations,  such as spinal  cord injuries  and
treatment  of  Parkinson's  disease,  cerebrovascular  accidents,  brain  tumors  and  regenera‐
tion of tissues and organs [17].
With the advancement and development of new applications of LEDs in health, manufacturers
of these devices will increasingly improve these devices that every day demonstrate its
usefulness and its application to human health.
8. Conclusion
The application of LEDs in interaction with the human tissues shows a great interest of
manufacturers and researchers. The correct use of LEDs in this context directly depends on
the tissue nature where it wants the light to interact [10].
Several parameters are important for satisfactory results, such as wavelength, the kind of color,
temperature control of the LED, the characteristics of the used converter, control the brightness,
output current, duty cycle and all the observations made in the previous sections of this work.
This is because a small spectral change can lead to a major shift in the lighting characteristics.
LEDs are increasingly becoming a great option to help cure various diseases and to prevent
others [18].
Thus,  this  work  contributed  to  the  development  of  LED  application  in  human  tissues
showing that the effect of the emission of light through the high brightness LEDs offers a
new treatment option for opening new ways of therapeutic technique LED Therapy applied
to human tissues [20].
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1. Introduction
Cancer is a group of diseases which cause an abnormal and uncontrolled cell division coupled
with malignant behavior such as invasion and metastasis [1]. World Health Organization
(WHO) estimates that in 2012, the total number of cancer deaths in the European Union (EU)
was 1283101 [2]. For the treatment of cancer various methods have already been discovered
and many others are in the process of discovery e.g. chemotherapy (alkylating agents,
antimetabolites and natural products - as plant products and micro-organisms), hormonal
therapy (with steroids, hormones, anti-estrogens, anti-androgens, gonadotropin releasing
hormones analogues, non-steroidal aromatase inhibitors), immunotherapy (interferon,
growth factor inhibitors, vaccines, interleukin-2) and different therapies: radiation therapy,
photodynamic therapy, surgery, chemotherapy and some traditional therapies [3]. But the
anticancer drugs can fail to kill cancer cells for various reasons, the transport of the anticancer
drug being governed by physiological and physicochemical properties of the target cell and
of the drug itself [4]. These properties include pressure, charge, size, configuration, electro‐
chemical properties, hydrophilicity, etc. For the therapeutic agents delivery to the tumor cells,
the following problems can be addressed, as follows:
a. Drug resistance at the tumor levels (non cellular based mechanisms);
b. Drug resistance at cellular level (cellular based mechanisms);
c. Pharmacokinetic properties of the anticancer agent in the body [5].
The concept of the nanoparticles which permits higher absorption of the drugs in a specific
tissue, and this concept has been applied for hyperthermia, radiation therapy, photodynamic
therapy, etc. [6]. Meanwhile, the nanoparticles opened new horizons for drug delivery and
bringing the term nanomedicines. Nanomedicine is the medical application for diagnosis and
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
treatment of different human diseases by means of small particles, known as nanoparticles
with sizes of 2-100 nm.
The nanoparticles are known by their large surface area, high reactivity, high solubility,
reduced side effects and low toxicity [7-9]. The main nanoparticles applied in nanomedicine
are: polymeric nanoparticles, liposomes and lipid nanoparticles, micelles, microcapsules,
magnetic particles, and carbon nanoparticles (fullerenes, carbon nanotubes, carbon nanofibers,
etc) and the nanoassemblies [10-12].
Photodynamic therapy (PDT) as a part of photochemotherapy, is a concerted method where,
in addition to light and an administered drug, oxygen is required. PDT represents a concerted
action of light, with a sensitizers and an oxygen active specie (singlet oxygen) which prefer‐
entially actions on tumor cells and not on healthy cells. The administered drug is generally a
substance which can efficiently photosensitize the formation of singlet oxygen (or other
reactive species derived from oxygen), and such species react with different biological targets,
and cause cellular damage and finally, the cellular death. Activation of the photosensitizers
by light is an essential condition for a successful PDT. Doses of light energy applied in PDT
are commonly within 60-200 J/cm2, though doses may vary from 25 to 500 W/cm2 depending
on indications, tissues and light sources [13].
Under such circumstances, this chapter offers the most up–to–date coverage of photodynamic
therapy including information on how nanosensitizers, have evolved within the field of cancer
therapy and more recently for drugs controlled release in this field, by using personal data
correlated with literature reports.
2. Short history
Photodynamic therapy is dating from ancient time, the Indian civilizations reported from the
first time the combined action of psoralens with sunlight to treat vitiligo [14].
Niels Fiensen used UV light to treat small pox, pustular infections eruptions, cutaneous
tuberculosis, and for its results he obtained the Nobel Prize in Medicine in 1903. Similar results
obtained Niels Raab in 1905, by using eosin as sensitizer and combining his results with
Jesionek and J.Prime results for skin tumors and epilepsy generated by light induced dermatitis
[17]. Meyer-Betz was the only experimentalist who tested this method on himself, by injecting
haematoporphyrin, reporting the observed effects: oedema, erythema and light sensitivity
[18]. Later, Campbell and Hill studied the PDT effects on microcirculation, reporting the
thrombosis and vascular shutdown [19].
Lipson in 1966 went on to treat a patient with a large cancer of the breast following an
injection of  a  derivative of  haematoporphyrin (HpD).  The modern era of  photodynamic
therapy  was  established  by  Dr.  T.J.Dougherty,  at  the  Division  of  Radiation  Biology  at
Roswell Park Memorial Institute, Buffalo, USA, who reported that a systematically injected
porphyrin  on  activation  with  red  light  caused  complete  eradication  of  transplanted
experimental tumors [20].
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3. Mechanism of photodynamic effect
The photodynamic effect mainly results from energy and/or electron transfer of the lowest
excited triplet state T1 of the photosensitizer to an organic substrate or molecular oxygen. In
the photodynamic therapy occur three types of mechanisms:
• type I mechanism – electron transfer (eT) where the photosensitizer excited state generates
a radical species, for example by electron transfer from (or to) a substrate, or by hydrogen
atom abstraction from a substrate. The radical species then reacts with ground state oxygen
so that the overall reaction is a photochemically initiated autoxidation:
(Sens = sensitizer; A = biomolecule; 3O2 = triplet excited state of oxygen)
Sheme 1. The type I mechanism of PDT
• In type II mechanism - energy transfer (ET) an energy transfer occurs from the excited
photosensitizer to molecular oxygen, to give the sensitizer in its ground state and singlet
oxygen. In this mechanism electronic excitation energy is transferred from the excited triplet
T1 of the sensitizer (generated by intersystem crossing isc from the ecited singlet S1) to triplet
molecular oxygen, to give the sensitizer in its ground state S0 and singlet oxygen 1O2.
Sheme 2. The type II mechanism of PDT
Major biological targets are membranes that undergo rupture and the cells are destroyed
through the membranes around the mitochondria and the lysosomes. These organelles induce
subsequent cellular destruction by necrosis or apoptosis [21-24].
Except these two types of mechanisms, there is another one: type III mechanism, which take
place when the oxygen is absent in the system.
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Sheme 3. The type III mechanism of PDT (a)AH = porphyrin; B = quinone (b)Don = donor (cysteine); A = porphyrin;
Acc = acceptor (methyl viologen)
4. Photosensitizers
4.1. Conventional photosensitizers
All the sensitizers could be natural or synthetic compounds, with proper absorption properties
from a light source. They should be pure compounds, soluble in body fluids, with high capacity
to be incorporated in malignant cells. Also, they should be fluorescent and able to generate
singlet oxygen, which is the excited state of oxygen efficient on malignant cells [25]. Taking
into account all these criteria and knowing the compatibility with human body, the porphyrins
are known as ideal sensitizers for photodynamic therapy.
The general chemical structure for some porphyrins and phthalocyanines as PDT agents are
represented in Figure 1.
First Generation Photosensitizers, includes Photofrin® and HpD and exist as complex
mixtures of monomeric, dimeric, and oligomeric structures. At 630 nm, their effective tissue
penetration of light is small, 2–3 mm, limiting treatment to surface tumors. Although Photo‐
frin® has a low εmax (at 630 nm~3000 M−1 cm−1), generate singlet oxygen with high quantum
yield, ΦΔ = 0.89. In spite of its safe applications in bladder, esophageal and lung cancers,
Photofrin tends to be applied to head human part and thoracic part affected by cancer [26].
The Second Generation Photosensitizers, includes porphyrins and related compounds
(porphycenes, chlorins, phthalocyanines, so on), many of them being under clinical tests. From
the porphyrins family, meta-tetra(hydroxyphenyl)porphyrin (m-THPP) and 5,10,15,20-
tetrakis(4-sulfanatophenyl)-21H,23H-porphyrin (TPPS4) are the most used second generation
PDT sensitizers (Figure 2). m-THPP, however, caused skin phototoxicity, and was 25 to 30
times more potent than HpD in tumor photonecrosis when irradiated at 648 nm [27]. TPPS4
exhibited lower photochemical efficiency than meso-substituted porphyrins containing fewer
sulphonated groups [28].
Except the free-bases, the porphyrins can be chelated with a variety of metals, the diamagnetic
ones enhancing the phototoxicity. Paramagnetic metals are shortening the lifetime of the triplet
state and as result can make the dyes photoinactive [21]. The presence of axial ligands to the
centrally coordinated metal ion is often advantageous, since it generates some degree of steric
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The Second Generation Photosensitizers, includes porphyrins and related compounds
(porphycenes, chlorins, phthalocyanines, so on), many of them being under clinical tests. From
the porphyrins family, meta-tetra(hydroxyphenyl)porphyrin (m-THPP) and 5,10,15,20-
tetrakis(4-sulfanatophenyl)-21H,23H-porphyrin (TPPS4) are the most used second generation
PDT sensitizers (Figure 2). m-THPP, however, caused skin phototoxicity, and was 25 to 30
times more potent than HpD in tumor photonecrosis when irradiated at 648 nm [27]. TPPS4
exhibited lower photochemical efficiency than meso-substituted porphyrins containing fewer
sulphonated groups [28].
Except the free-bases, the porphyrins can be chelated with a variety of metals, the diamagnetic
ones enhancing the phototoxicity. Paramagnetic metals are shortening the lifetime of the triplet
state and as result can make the dyes photoinactive [21]. The presence of axial ligands to the
centrally coordinated metal ion is often advantageous, since it generates some degree of steric
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hindrance to intermolecular aggregation, without impairing the photophysical properties of
the dye [21].
Phthalocyanines (Pc) are currently recognized as one of the best sensitizers used in PDT, have
a long-wavelength band with a large extinction coefficient (~ 105 M-1 ⋅ cm-1) and generally a
low dark toxicity [29-32].
Their absorption maxima are in the region 670-700 nm, with very high molar coefficients. A
representative compound is aluminium phthalocyanine tetrasulphonated AlPcS4, commer‐
cially known as Photosens, in spite of its skin sensitivity, proper absorption maxima at 676 nm,
it is well applied in Russian clinics for stomach, skin, oral and breast cancers [33].
Another clinical phthalocyanine is silicon phthalocyanine 4 (Pc4) which was successful tested
in different skin cances (pre-malignant - actinic keratosis, Bowen disease) or even in malgnant
forms of cutaneous cancers [34,35,36].
The central metal ions play an important role in the photophysical properties of phthalocya‐
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more ring substituents or both. When a diamagnetic ion is in the center of the ring (e.g., Zn,
Al, Ga), the phthalocyanine generally possesses a high triplet state yield (φT > 0.4) with a long
lifetime (τT > 200 μs) and enough energy (110-126 kJ/mol-1) to generate 1O2 (94.5 kJ/mol-1 is
required) [37-40]. Silicon phthalocyanine allows two appropriate axial ligands, which forbid
the ring staking which decrease the clinical efficiency [41-44]. The triplet-state lifetimes of an
axially substituted silicon phthalocyanine typically vary from 100 to 200 μs and the yields from
0.2 to 0.5 [43]. Some synthetic silicon phthalocyanine and naphthalocyanine (Figure 2) have
been used in some laboratory experuiments on K562 culture cellk with excellent results [45, 46].
Third generation photosensitizers contains available drugs that are modified them with
antibody conjugates, biologic conjugates, etc.[47,48]. These terms are still being used although
not accepted unanimously and dividing photosensitizing drugs into such generations may be
very confusing. The nanostructures are increasingly being used as carriers for the development
of 3rd generation PS, as the most important drug delivery systems used as carriers for PS in the
field of anticancer PDT.
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- ‘Hard nanoparticles’ - inorganic materials that keep unchanged their original shape and size,  
- ‘Soft nanoparticles’ - organic materials that could be functionalized capacity, with versatile size and shape under 
different conditions; pH, T, pressure. Nanoparticles have unusual properties that can improve the drug delivery.  
HARD NANOPARTICLES:
Inorganic Nanoparticles is the generic term for several nanoparticles including for example metal oxide- and non-oxide 
ceramics, metals, gold and magnetic nanoparticles.  
Ceramic nanoparticles: Ceramic-based nanoparticles have some advantages over organic carriers: particle size, shape, 
porosity, and mono-dispersibility. They are water-soluble, extremely stable, and known for their compatibility in biological 
systems without being subjected to microbial attack. For conventional drug delivery, the carrier vehicle should release 
the encapsulated drug at the target tissue. The works done by Prasad’s group is one of the few examples for the 
application of ceramic nanoparticles to PDT [49]. Their silica-based nanoparticles (diameter ca. 30 nm) have been 
entrapped with the hydrophobic photosensitizing anticancer drug 2-devinyl-2-(1-hexyl-oxyethyl) pyropheophorbide via a 
controlled hydrolysis of triethoxyvinylsilane in micellular media. The resulting silica- based nanoparticles were 
monodispersed with uniform particle size. By irradiation with suitable wavelengths: 532 or 650 nm, silica nanoparticles 
with porphyrin embedded, could be efficiently taken up by tumor cells and lead to cells death. 
Silica nanoparticles (SiO2), with the following advantages: 
1. chemically inert, avoiding interactions with other molecules in the body.  
2. available for their synthesis, allowing precise control their particles size, shape, porosity and polydispersity 
during the preparation.  
3. allow to incorporate small molecules encapsulated within the own particle or covalently attached to the surface. 
4. These interesting properties have made silica nanoparticles the most studied nanoparticle-based PDT systems. 
The delivery of photosensitisers embedded in porous silica nanoparticles has many advantages: 
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extremely stable, and known for their compatibility in biological systems without being
subjected to microbial attack. For conventional drug delivery, the carrier vehicle should release
the encapsulated drug at the target tissue. The works done by Prasad’s group is one of the few
examples for the application of ceramic nanoparticles to PDT [49]. Their silica-based nano‐
particles (diameter ca. 30 nm) have been entrapped with the hydrophobic photosensitizing
anticancer drug 2-devinyl-2-(1-hexyl-oxyethyl) pyropheophorbide via a controlled hydrolysis
of triethoxyvinylsilane in micellular media. The resulting silica- based nanoparticles were
monodispersed with uniform particle size. By irradiation with suitable wavelengths: 532 or
650 nm, silica nanoparticles with porphyrin embedded, could be efficiently taken up by tumor
cells and lead to cells death.
Silica nanoparticles (SiO2), with the following advantages:
1. chemically inert, avoiding interactions with other molecules in the body.
2. available for their synthesis, allowing precise control their particles size, shape, porosity
and polydispersity during the preparation.
3. allow to incorporate small molecules encapsulated within the own particle or covalently
attached to the surface.
4. These interesting properties have made silica nanoparticles the most studied nanoparticle-
based PDT systems.
The delivery of photosensitisers embedded in porous silica nanoparticles has many advan‐
tages:
• almost any type of photosensitiser can be used. Second, the concentration of photosensitiser
can be modulated as needed (increasing or decreasing it).
• the silica surface offers the possibility for further functionalisation.
• When the photosensitisers are incorporated on to silica nanoparticles trough covalent bonds,
it is possible to avoid the eventual release of the compounds in the media, and the conse‐
quent lost of efficacy or the appearance of side effects.
Gold nanoparticles: Gold nanoparticles have been targeted to breast cancer cells by incorporat‐
ing a primary antibody to the ir surface in addition to a zinc phthalocyanine photosensitiser
and a bioavailability and solubility enhancer, with promising results [50,51]. Gold particles
with various diameters and uniform size distribution have been demonstrated to have novel
and fascinating properties. The goal of the synthesis methods is to produce size controllable
gold nanoparticles. Many methods are based on the reduction of tetrachloric acid (HAuCl4) to
form gold nanoparticles. The formation and stabilization of nanosized colloidal metal particles
demands careful attention to the preparation conditions and to the presence of stabilizers.
Nanoparticles of silver, gold, platinum, and copper have been prepared by various methods,
but most of their shapes have been limited to spheres [52,53].
Magnetic nanoparticles: The magnetic nanoparticles offer the possibility of being directed
towards a specific target in the human body and remaining eventually localised, by means of
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an applied magnetic field. Iron coated nanoparticles are therefore appropriate to be used as
magnetic carriers of medical drugs, magnetic resonance imaging contrasts, biological labels
etc, adsorbed into the carbon surface. As one of the most important materials, magnetite
(Fe3O4) nanoparticles have attracted a lot of attentions for their interesting magnetic properties
and potential applications in the fields of biology, pharmacy and diagnostics [54]. The
magnetite Fe3O4 with oleic acid nanoparticles analyzed by TEM showed a spherical shape with
a narrow size distribution. Figure 3 shows Fe3O4 nanoparticle surrounded by TPPS4, AFM for
TPPS4 and Fe3O4.
Figure 3. Fe3O4 nanoparticle surrounded by TPPS4 (left), AFM for TPPS4 (right, up) and for Fe3O4 (right, down)
Organic Nanoparticles is the generic term for several nanoparticles including for example
porphyrins, phthalocyanines and related sensitizer nanoparticles. The general trend in current
research from nanomedicine is the application use of photosensitizers for PDT by development
of photoactive nanoparticles and to modify photosensitizers to improve effect of photody‐
namic therapy. PS can be modified by encapsulated them in delivery agents such as liposomes
[93], micelles [81], ceramic based nanoparticles [49], and polymer nanoparticles [57, 67]. Some
examplification will be shown bellow.
5.2. Soft nanoparticle
5.2.1. Polymeric carriers for drug delivery
The polymeric carrier are divided into three groups:
1. Biodegradable polymers. These degrade under biological conditions to nontoxic products
that are eliminated from the body.
2. Drug-conjugated polymers (Natural polymers). The used polymers are dextran, polya‐
crylamides and albumins, and offer a targeted drug controlled releasing by drug-polymer
cleavage at the proper site.
3. Nondegradable polymers. These are stable in biological systems, and used as components
of implantable devices for drug delivery.
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Macromolecular complexes of various polymers can be divided into the following categories
according to the nature of molecular interactions: complexes formed by interaction of oppo‐
sitely charged polyelectrolytes, charge transfer complexes, hydrogen-bonding complexes and
stereocomplexes. Both synthetic and natural polymers could be used for the production of
nanosystems. These polymers may be used alone or in combination to develop nanoparticles.
Several fabrication techniques are developed and can generally be subdivided into two
categories. The first category includes solvent evaporation or diffusion, ionotropic gelation, so
on. The second one includes emulsion, interfacial polymerization and polycondensation [66].
5.2.2. Biodegradable polymers
Polymer nanoparticles involve natural or biocompatible synthetic polymers as: polysacchar‐
ides, poly lactic acid, poly lactides, poly acrylates, poly alkyl cyano acrylates, poly alkyl vinyl
pyrrolidones or acryl polymers. The most important seems to be Poly(lactic-co-glycolic acid)
(PLGA) which has shown several advantages over other biodegradable polymers that are
routinely used for photosensitiser delivery [49] and has become the most popular polymer for
PDT. The size of PLGA 50:50 nanoparticles with m-THPP as photosensitiser influences their
photodynamic activity (bigger size, lower activity), but it also affects their interaction with the
biological environment (protein absorption, cellular uptake or tissue distribution) [56].
Another important polymer - poly(vinyl alcohol) (PVA) - seems to have certain affinity for the
p-THPP photosensitiser, inducing the adsorption of PVA on to the surface of the nanoparticle
and leading to higher clearance of the complex [57, 76]. Many sensitizers from the second
generation have been encapsulated into polymer nanoparticles, for example PLGA, the final
size of the new system being 285 nm, with a polidispersity index of 0.12 and a relatively reduced
toxicity. A specific example is bacteriochlorophyll encapsulated into PLGA prepared by
solvent evaporation method. This yielded to spherical particles of about 660 nm size with an
encapsulation efficiency of 69% and higher singlet oxygen production (ϕ= 0.26) [58]. Another
porphyrin sensitizer, a synthetic one, 5,10,15,20-tetrakis(4-methoxyphenyl) porphyrin (TMPP)
has been tested on chick embryo chloroallantoic membrane model, showing a longer retention
time when is encapsulated into nanoparticles and an improvement of the vascular effects after
light irradiation [59], due to the fact that the pathological tumoral vasculature is "leaky", most
probably due to the pore size 100-780 nm and to the accumulation in the interstitial tumor
tissue [60,61]. Also, pheophorbide a and chlorin e6 have been encapsulated in PLGA nano‐
particles [63,64]. Similar results have been registered in choroidal neovascularization associ‐
ated with AMD [62], where the lipophilic porphyrins show photothrombic effect and leakage
from blood vessels.
5.2.3. Natural polymers
The naturally-occurring polymers of particular interest for delivery of some drugs could be
the polysaccharides that include chitosan, hyaluronan, dextran, cellulose, pullulan, chondroi‐
tin sulphate and alginate, and polymers as casein and gelatin. They are nontoxic, biocompat‐
ible, biodegradable and hydrophilic.
Examples of the natural polymers used to prepare drugs-loaded nanoparticles are:
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Dextran sulphate is a polysaccharide that consist from linear 1,6-linked D-glucopyranose units
with 2.3 sulphate groups per glucosyl residue, is non-toxic, water-soluble and biodegradable.
Because it wears negatively charges, it is used for nanoparticle insulin delivery system based
on complexation with oppositely charged polymers [65].
Alginate/chitosan nanoparticles  may form complexes  with  cationic  β-cyclodextrin  poly‐
mers  [66].  Some  polyphenols  have  been  entrapped  in  calcium  alginate  beads  and  to
investigate their encapsulation efficiency and in vitro release [67]. Addition of 0.25-1% CS
in  coagulation  fluid  determined  an  improvement  of  encapsulation  efficiency.  This  is
probably due to increased ionic interactions between the carboxylate groups in the alginate
and the protonated amine groups in the chitosan during gelation. In the presence of more
chitosan, the process will go faster [68]. In vitro polyphenols released of prepared beads
was carried out both in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF).
The  total  polyphenols  release  rate  in  SGF  was  between  40.7%  -  93.6%  and  in  SIF  was
between 3.7  -  15.4%,  and the  highest  content  of  polyphenols  was  released in  SGF.  The
release rate (RR) of polyphenols from microcapsules is influenced by the concentration of
alginate,  this phenomenon is in agreement with the previous study where it  is  reported
that the release rate was quicker for beads prepared in low concentration of alginate but
slower  for  beads  prepared  in  high  concentrations  [69].  For  microcapsules  prepared  by
adding  chitosan  in  coagulation  fluid  the  best  encapsulation  efficiency  (85.2%)  was  ob‐
tained with 0.5% CS (w /  v).  Weak interactions  between polyphenols  and calcium algi‐
nate have allowed most of the polyphenols to be released in SGF. With the addition of CS
in the coagulation fluid is observed a slight increase of polyphenols released in SIF.
Alginate is a linear copolymer composed of β-D-mannuronic acid and α-L-guluronic acid
joined by a 1-4 glycosidic bond. The composition is highly dependent on the used polysac‐
charide. The most common source of alginate is the cell wall of brown algae. Alginate is
biocompatible, biodegradable and non-toxic polymer and has many biomedical applications
due to the reactivity of its carboxylate side groups and its capacity to form spontaneous gelation
when exposed to divalent cations such as calcium [70] and specific drug delivery [71]. Some
nanoparticles were prepared by the ionotropic pre-gelation of alginate with calcium chloride
followed by complexation between alginate and chitosan [69].
Chitosan (CS) is a copolymer consisting of β (1 →  4)-linked 2-acetoamido-2-deoxy-β-D-
glucopyranose (Glc-NAc; A-unit) and 2-amino-2-deoxy-β-D-glucopyranose (GlcN; D-unit)
[70]. The primary amine groups make chitosan very useful in pharmaceutical applications [72].
CS nanoparticles proved cytotoxic properties on various tumor cell lines [73]. Moreover, this
polysaccharide had been used as immunoadjuvant in laser immunotherapy with positive
effects in the treatment of experimental tumors [74]. CS proved antioxidant properties.
5.2.4. Nanovectors
Polymeric micelles have many advantages such as small size (10 to 200 nm) for passive
accumulation in solid tumors by enhanced permeation and retention (EPR), improved
stability, biodegradability and high flexibility for structural and chemical modifications
[75,76]. Micelles polymers are usually formed into core shell structures by spontaneous
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that the release rate was quicker for beads prepared in low concentration of alginate but
slower  for  beads  prepared  in  high  concentrations  [69].  For  microcapsules  prepared  by
adding  chitosan  in  coagulation  fluid  the  best  encapsulation  efficiency  (85.2%)  was  ob‐
tained with 0.5% CS (w /  v).  Weak interactions  between polyphenols  and calcium algi‐
nate have allowed most of the polyphenols to be released in SGF. With the addition of CS
in the coagulation fluid is observed a slight increase of polyphenols released in SIF.
Alginate is a linear copolymer composed of β-D-mannuronic acid and α-L-guluronic acid
joined by a 1-4 glycosidic bond. The composition is highly dependent on the used polysac‐
charide. The most common source of alginate is the cell wall of brown algae. Alginate is
biocompatible, biodegradable and non-toxic polymer and has many biomedical applications
due to the reactivity of its carboxylate side groups and its capacity to form spontaneous gelation
when exposed to divalent cations such as calcium [70] and specific drug delivery [71]. Some
nanoparticles were prepared by the ionotropic pre-gelation of alginate with calcium chloride
followed by complexation between alginate and chitosan [69].
Chitosan (CS) is a copolymer consisting of β (1 →  4)-linked 2-acetoamido-2-deoxy-β-D-
glucopyranose (Glc-NAc; A-unit) and 2-amino-2-deoxy-β-D-glucopyranose (GlcN; D-unit)
[70]. The primary amine groups make chitosan very useful in pharmaceutical applications [72].
CS nanoparticles proved cytotoxic properties on various tumor cell lines [73]. Moreover, this
polysaccharide had been used as immunoadjuvant in laser immunotherapy with positive
effects in the treatment of experimental tumors [74]. CS proved antioxidant properties.
5.2.4. Nanovectors
Polymeric micelles have many advantages such as small size (10 to 200 nm) for passive
accumulation in solid tumors by enhanced permeation and retention (EPR), improved
stability, biodegradability and high flexibility for structural and chemical modifications
[75,76]. Micelles polymers are usually formed into core shell structures by spontaneous
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assembly when its concentration is above critical micelle concentration (CMC). They have a
number of unique features, including nano size, easy modification of the surface chemistry,
core functionalities, and also, the and also, they serve as carriers and delivery systems [77].
They have been tested for solubilizing some anti-cancer drugs as: docetaxel (DOC), paclitaxel
(PTX), camptothecin [78 -80]. Due to their hydrophilicity, the polymer micelles play an
important part in RES recognition and in the blood circulation of drugs.
Porphyrins could be encapsulated into micelles as Triton X-100 at a critical concentration
2.7x10-4  M.  Above  this  concentration,  porphyrins  and  micelles  coexist  in  a  dynamic
equilibrium.
Also, from geometrical considerations, two possibilities can occur, i.e. the case of an oblate
ellipsoid or that of a prolate ellipsoid. The model of an oblate ellipsoid is supported by
energetically considerations, although the second model can't be neglected as beeing that of a
host molecule for the porphyrin. The fluorescence lifetimes of porphyrins are in the range 13-17
ns in micelles and 9-12 ns in organic solvents, which means that the electron transfer should
be available for about 10-9s before the excited molecule decays spontaneously back to its
ground state. The lifetimes of all the porphyrins in Triton X-100 micelles could be attributed
to the monomeric forms and are larger than the values obtained in pure solvents.The increasing
of the porphyrins lifetime in micelles can be ascribed to the reduction in the diffusion-limited
fluorescence quenching by oxygen in micellar samples (Figure 4).This could be an explanation
for the low rate photodegradation of all these porphyrins [81].
Figure 4. The fluorescence quenching of TPP-Mg in benzene (A) and Triton X-100 (B)
Liposomes are known as vesicles with clinical applications, formed by hydratation of phos‐
pholipids at higher temperature than their transition temperature. They have sizes of 100 nm
and allow some drugs to be contained in the lipid space between bilayers. Liposomes are stable
microscopic vesicles formed by phospholipids and similar amphipathic lipids. Liposome
properties vary substantially with the composition, size, surface charge, and the preparation
method. Liposomes are nanoconstructs (approximately 100 nm in diameter) with bilayered
membrane structures composed of phospholipids with hydrophilic heads and hydrophobic
anionic or cationic long chain tails [82]. Moreover, the hydrophobic membrane can encapsulate
hydrophobic drug molecules and prevent leakage of hydrophilic agents from within the core.
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Based on their size and number of bilayers, the liposomes are divided into three classes.
1. Small unilamellar vesicles are surrounded by a single lipid layer and are 25–50 nm in
diameter.
2. Large unilamellar vesicles as heterogeneous group of vesicles surrounded by a single lipid
layer.
3. Multilamellar vesicles formed by several lipid layers separated from each other by a layer
of aqueous solution.
Liposomes are used as pharmaceutical carriers due to their unique abilities to efficient
encapsulate both hydrophilic and hydrophobic therapeutic agents, to offer protection to the
encapsulated drugs from undesired effects of external conditions, because they can be
functionalized with specific ligands that can target specific cells, tissues, and organs of interest,
and because they could be coated with inert and biocompatible polymers such as polyethylene
glycol (PEG), in turn prolonging the liposome circulation half-life in vivo. They can form
desired formulations with needed composition, size, surface charge, and other properties [83].
Liposome vesicles are interesting and useful drug carriers because they can carry both
hydrophilic molecules in their aqueous core and hydrophobic drugs among the fatty acid
chains in the phospholipid bilayers [84]. Liposomes are vesicles which consist of one to several,
chemically-active lipid bilayers. Some drug molecules can be encapsulated and/or solubilised
within the bilayers according to their hydrophilic/lipophilic balance. Due to their hydrophobic
properties, photosensitizers being poorly soluble in aqueous phases and due to their aggre‐
gation property have limited delivery in active form to the desired target [85,86]. Additionally,
many photosensitizers have a low affinity to tumor sites inducing some damages of normal
tissue following PDT in patients. Nanotechnology based formulations of photosensitizers are
attractive systems for improved delivery of photosensitizers [87]. Liposomes are artificial
vesicles composed of a lipid bilayer usually used for the formulation and delivery of all kind
of drugs. The benzoporphyrin derivative monoacid ring A (BPD-MA) has been used for
antiangiogenic PDT encapsulated in polycationic liposomes modified with cetyl-polyethyle‐
neimine. The encapsulated photosensitiser was better internalised by human umbilical vein
endothelial cells and was found inside the nucleus and associated with mitochondria [88]. The
commercial liposomal preparation of the same photosensitiser (Visudyne; Novartis) is active
against tumours in sarcoma -bearing mice [89]. Photofrin loaded into PEG modified liposomes
presents enhanced phototoxicity compared to the free drug or when embedded in the same
non-PEGylated liposomes [90]. Although the presence of the PEG inhibited the uptake of the
nanoparticles by the tumour cells, it decreased the release of the photosensitiser from the
liposome. Another porphyrin derivative (2,3-dihydro-5,15-di(3,5-dihydroxyphenyl)porphyr‐
in (SIM01)) in dimyristoyl-phosphatidylcholine liposomes (DPPC) also yields better results in
PDT than the photosensitizer alone, mainly due to a major accumulation in the tumour cells
(human adenocarcinoma in nude mice) [91]. Liposomal TPP is effective in PDT of human a
melanotic melanoma in nude mice; after being intravenously administered, authors demon‐
strated that their use can totally disintegrate tumours [92]. Also, TPP, TNP and ChL could be
used in E.Coli destroying by PDT treatment (Figure 5), [93].
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X=control; Δ=E.Coli+ TPP in DPPC; Ο= E.Coli + ChL in DPPC; □= E.Coli + TNP in DPPC
Figure 5. The destroying kinetics of E.Coli during PDT process with porphyrins
5.3. Hydrogels and their applications in drug delivery
Hydrogels are a desired material for biomedical and pharmaceutical applications due to their
unique swelling properties and hydrated structure. Gels are macromolecular material with an
intermediate material between a solid and liquid material. These gels are made up of a
combination of local cross-linked polymer chains, noting that the junction zones are of size
reduced. The structure of these gels is their property associated with swelling by incorporating
a solvent. When the solvent comprises water in a proportion higher to 20 %, the gel will be
called hydrogel. Hydrogels are elastic in nature due to the presence of the reference configu‐
rations, stored in the hydrogel, which will in turn even after the been distorted over a period
of time. The natural polymers chitosan and alginate has been the most studied, for the
manufacture of the hydrogel nanoparticles. Among synthetic polymers based nanoparticles,
remember poly (vinyl alcohol) PVA, poly (ethylene oxide) PEO, poly (ethylene imide) (PEI),
polyvinylpyrrolidone (PVP), poly (N-isopropyl acrylamide), which were used in order to
release molecules incorporated.
Hydrogels are crosslinked polymeric networks that are insoluble in water but swell to an
equilibrium size in the presence of excess water or biological fluids [94]. Research on hydrogels
started in the 1960s with a landmark paper on poly(hydroxyethyl methacrylate) (PMMA) [95].
Due to the unique swelling properties and biocompatible structure, these materials have been
extensively studied for biomedical and pharmaceutical applications, such as contact lenses,
biosensors, artificial hearts, artificial skin and drug delivery devices [96]. Among them,
hydrogels from poly (vinyl alcohol) are especially important due to their advantages of being
water soluble, non-toxic, non-carcinogenic and biodegredable. Hydrogels based on poly (vinyl
alcohol) (PVA) is characterized by transparency, in a three-dimensional polymeric structure
and a water absorption capacity greater volume, without dissolving therein. Poly (vinyl
alcohol) has a semi-crystalline nature with applications for encapsulation and controlled
release of the porphyrins, especially in cancer therapy. Hydrogel loading procedure with
5,10,15,20-tetra-sulfonato-phenyl porphyrin (TPPS4), sorption experiments, the retention
efficiency of porphyrins on the PVA hydrogel, and controlled release of TPPS4 from the PVA
hydrogel have been achieved and altready reported [97].
PVA becomes more porous and its pores become more larger after porphyrin retention. This
observation is more stronger for TPPS4 than for the other porphyrins with smaller sizes [98,
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99, 100]. SEM analysis showed a porous structure of the hydrogel, evidencing interconnected
pores with a size distribution in the range of 80-950 nm, Figure 6. The retention efficiency










where: mPorphyrin_ initial is the initial amount of porphyrin to be found in the solution, and
mPorphyrin_retained is determined from the difference between the initial and the remaining amounts
of porphyrin after retention. Release experiments were carried out by using a TPPS4-loaded
PVA hydrogel, rinsed thoroughly after loading with distilled water, and then placed in the
appropriate quantity of medium (distilled water). The sorption mechanism of the porphyrins
onto the PVA hydrogel can be interpreted as having two components: physisorption and
chemisorption. In physisorption, the porphyrin is encapsulated in the pores of the nanostruc‐
tured hydrogels. This mechanism is mainly controlled by diffusion. The diffusion mechanism
is not ideal (Fickian), but rather Stephan diffusion, because of the anisotropic porous structure
of the gel [101]. The chemisorption mechanism consists of the hydrogen bonding between the
–OH groups of the poly(vinyl alcohol) and the pyrrolic nitrogen of the porphyrin molecule.
The nature and the intensity of the chemisorption depends largely on the conformation of the
porphyrin molecule and the solvent used.
Figure 6. Aspect of PVA hydrogel with (left) and without TPPS4 hydrogel (right)(up), SEM images of PVA 90 hydrogel
(TPPS4) before (left) and with TPPS4 (right) (middle) and kinetics of TPPS4 loading in PVA hydrogel (left) and kinetic of
TPPS4 release from the PVA hydrogel (normalized to encapsulated TPPS4 amount)(right) (down)
Advances in Bioengineering266
99, 100]. SEM analysis showed a porous structure of the hydrogel, evidencing interconnected
pores with a size distribution in the range of 80-950 nm, Figure 6. The retention efficiency










where: mPorphyrin_ initial is the initial amount of porphyrin to be found in the solution, and
mPorphyrin_retained is determined from the difference between the initial and the remaining amounts
of porphyrin after retention. Release experiments were carried out by using a TPPS4-loaded
PVA hydrogel, rinsed thoroughly after loading with distilled water, and then placed in the
appropriate quantity of medium (distilled water). The sorption mechanism of the porphyrins
onto the PVA hydrogel can be interpreted as having two components: physisorption and
chemisorption. In physisorption, the porphyrin is encapsulated in the pores of the nanostruc‐
tured hydrogels. This mechanism is mainly controlled by diffusion. The diffusion mechanism
is not ideal (Fickian), but rather Stephan diffusion, because of the anisotropic porous structure
of the gel [101]. The chemisorption mechanism consists of the hydrogen bonding between the
–OH groups of the poly(vinyl alcohol) and the pyrrolic nitrogen of the porphyrin molecule.
The nature and the intensity of the chemisorption depends largely on the conformation of the
porphyrin molecule and the solvent used.
Figure 6. Aspect of PVA hydrogel with (left) and without TPPS4 hydrogel (right)(up), SEM images of PVA 90 hydrogel
(TPPS4) before (left) and with TPPS4 (right) (middle) and kinetics of TPPS4 loading in PVA hydrogel (left) and kinetic of
TPPS4 release from the PVA hydrogel (normalized to encapsulated TPPS4 amount)(right) (down)
Advances in Bioengineering266
Endothelial cell line, HUVEC, as adherent cells line and photodynamic therapy model, were
grown on the surface of hydrogels mentioned, and monitorized by microscopic techniques,
following the cellular membrane integrity. Also, the influence of TPPS4 forms on hydrogel
properties are analyzed. For this purpose HUVEC cells pre-incubated with TPPS4 were
illuminated with red light. PDT led to a dramatic change in the morphology of these endo‐
thelial cells. The photosensitizer accumulated in mitochondria and its fluorescence emission
is detected in red region (~590 nm), before (left) and after PDT protocol. A deformation of the
cells, as a sign of the cellular death, is observed after PDT (right) (Figure 7).
Figure 7. Laser scanning confocal microscopy of HUVEC before (left) and after (right) the PDT protocol with TPPS4
hydrogels
5.4. Non–biodegradable nanoparticles for photodynamic therapy
Compared to biodegradable polymeric carrier systems, non-biodegradable nanoparticles have
several advantages: they are very stable to fluctuations in temperature and pH [102], taking
into account that the particle size, shape, porosity and mono-dispersibility can be controlled
during their preparation [103]; they are not subject to microbial attack [104]; and the tiny pores
in the ceramic particle, which are 0.50 – 1.00 nm in diameter, are too small to allow the drug
to escape the matrix but are large enough to enable efficient oxygen diffusion to and from the
particle [105]. Biodegradable polymer nanoparticles degrade readily to release the photosen‐
sitizers, whereas the shells in non-biodegradable particles are difficult to collapse. However,
the efficiency of PDT is only attributable to the production of 1O2; it is unnecessary to release
the loaded photosensitizers, but it is essential that the oxygen can diffuse in and out of the
nanoparticles. The lifetime of singlet oxygen is able to induce PDT-induced oxidative damage
around few miliseconds in aqueous media [106]. The nanoparticles size is under 100 nm and
have a negligible effect on the delivery of 1O2. The use of non-biodegradable nanoparticles has
some advantages with respect to their degradable counterparts. As the nanoparticle keeps its
integrity, the photosensitizer has a permanent protection from the environment; besides, it is
possible to use the nanoparticles as platforms to incorporate additional functionalities and they
can be of smaller size. These nanoparticles kept their integrity over several months and were
effective with just 5 minutes of irradiation. 5,10,15,20-tetrakis(1–methyl-4-pyridino)porphyrin
tetra(p-toluenesulfonate) (TMPyP), has also been encapsulated in polyacrylamide -based
nanoparticles. Its phototoxicity with two photon IR radiation was demonstrated in vitro by
modulating the time of exposure to light [106]. The main difference between classic PS and
nano-PS is their relative size (Figure 8).
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Figure 8. Comparison of the approximate sizes of a porphyrin and C60 nanoparticles
However, several strategies have now been developed to encapsulate photosensitizer into
nanoparticles and also improve delivery to the required area and many formulations have
been described whereby the nanomaterials have an additional active intermediary role in the
photodynamic process [107]. Recent trends in the use of fullerene derivatives in medicine are
related to development of nanoplatforms that contain drugs with different composition able
to carry out selective delivery of them to some human organs. The main medicinal targets are
cancer cells of different types. It is believed that in this aspect the fullerenes are of great interest
because of their opportunity to participate in the composition of such nanoplatforms in several
roles: cytotoxic agent as well as, conversely, an antioxidant (these roles may change depending
on accumulation in different organs and tissues) ones; as transporter of drugs; as photo- or
radiosensitizer (or protector). Recently, the conjugates of C60 with meso-aryl-porphyrins with
long chain substituents were obtained for using in PDT, Figure 9, [108]. Apoptosis without
participation of caspase-3 was observed when the human lymphoblast cell line (K562) was
treated by TPP/PVP/C60 [109]. TPP generates singlet oxygen with high quantum yield (0.63)
[110]. Three types of interactions were registered in this dyad: electrostatic, hydrogen bonds
and the donor acceptor bonds between fullerene and other components [111]. Here the high
ability of these compounds to the formation of photo-induced state with divided (isolated)
charges was first noted. Cell survival was dependent on illumination rate and the phototoxic
effect persisted even in an atmosphere of argon. Depending on the microenvironment of the
sensitizer site localization, the tissue is damaged either through the mechanism of 1O2 -
mediated photoreaction process or through ROS attack at a low concentration of oxygen.
Apoptosis by caspase-3-dependent pathway (58% of apoptotic cells) has been replaced by
predominant necrotic phenomena in anaerobic conditions. Starting from the characteristics of
fullerene compounds, we tried to study in vitro C60 fullerene and some functionalized
derivatives (C60 complexes with PVP (poly-vinyl-pyrrolidone) and with the oxo-dimer (TPP-
Fe)2O experimental models in vitro with normal and tumor cells and investigation of their
toxicological profile, in order to identify novel anti-neoplasic therapeutic devices.
However, the complexity of the problem is that until now there is no predictive model of action
of fullerene derivatives under concrete conditions for a specific cell type. Moreover, the set of
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possible mechanisms of the effect of fullerenes on the signaling pathways of apoptosis varied
and depends on many factors that are difficult to administrate. However, the success of some
fullerene derivatives against HIV, the selectivity to certain lines of cancer cells without
damaging normal tissue, the possibility of using in theranostics suggest promising perspec‐
tives of fullerenes in the field of nanomedicine.
6. Study of the photodynamic effects of selected photosensitizers on human
biological samples
6.1. Incorporation of nanoparticles in human blood
Significant nowadays research efforts are focused on finding new photosensitizers with
antineoplastic activity and an acceptable toxicological profile. Although consistent informa‐
tion exists regarding PDT in solid tumors, relatively few data are available for PDT of blood
cancers. Therefore, we carried out a comparative study on lymphoblastic K562 cells and human
normal peripheral blood mononuclear cells (PBMC) treated at a density of 2 x 105 cells/mL
with 5,10,15,20-tetra-sulphophenyl-porphyrin (TPPS4) and then irradiated with He-Ne laser
light (λ = 632.8 nm). The following cell functions were investigated: viability, multiplication,
RNA synthesis, total RNA levels and apoptosis. Human normal PBMC subjected to TPPS4
loading and laser-irradiation develop a different cellular response, their viability and prolif‐
erative capacity not being altered by experimental PDT. Accordingly, it appears that TPPS4 is
a non-aggressive compound for cellular physiology and becomes cytotoxic only by irradiation;
moreover laser-activated TPPS4 affects only cells that have a tumoral pattern [112].
There are several differences between lymphocytes obtained from healthy donors undergoing
artificial activation in vitro and genuinely leukemic cells. The cells membrane structure is
different in healthy and malignant cells, resting and stimulated cells can be compared using
fluorescence spectroscopy [27]. In the concentration range 10–100 μg/mL, TPPS4 loaded for
24h in normal PBMC does not significantly alter cell viability (Figure 10).
Figure 9. The proposed structure of C60-(TPP-Fe)2O
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Figure 10. The viability of human normal PBMC loaded with various concentrations of TPPS4 for 24h
Irradiation of K562 cells, either loaded or not loaded with TPPS4, drops off cellular viability
(assessed by the Trypan Blue exclusion test 4hrs after irradiation) for both tumor cells and
normal PBMC (Figure 11). TPPS4-loaded K562 cells are almost similarly affected by irradiation
as the corresponding control. TPPS4 alone has no significant effect on cell viability.
Figure 11. The viability of K562 cells and human normal PBMC at 4h post-irradiation (assessed by the Trypan Blue
exclusion test). C/TPPS4 = non-irradiated cells; Ci = irradiated unloaded cells; TPPS4i = irradiated loaded cells.
Human normal PBMC react differently at the PDT procedure than tumor cells. Their viability
and capacity to incorporate uridine are not altered by laser-activating of TPPS4 loaded into
cells (Figure 12).
4-5 ml of human peripheral blood were fast collected. Blood mononuclear cells (PBMC) were
separated by gradient dental equipment screened using Histopaque 1077 (Sigma), washed
twice with RPMI 1640 culture medium (Sigma) and then normalized to 105 cells / ml RPMI
1640 culture medium. Samples containing cell lines loaded with various concentrations of
TPPS4 24h were investigated in flow cytometry fluorescence recorded at wavelengths above
670nm. Increasing the concentration of TPPS4 fluorescence intensity increases cell suspension
directly proportional both total fluorescence and fluorescence maximum. In flow cytometry,
the regions of lymphocytes, granulocytes and monocytes are clearly distinguished. The
fluorescence of sample can be measured by using properly chosen filter. Fluorescence is
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analyzed separately for each type of cells. A flow cytogram represents the graphical repre‐
zentation of light scattering vs. right angle scattering and help to determine lymphocytes and
granulocytes. The aspect of flow cytometry (mean fluorescence intensities) could offer data
about dye aggregation or dye interaction with cellular membrane [41,113, 114]. The number
of stained cells decrease from 91.02% (for control cells), to 89,27% for 10 μg/ml TPPS4, 87,80 %
for 20 μg/ml TPPS4 and 86.93% for 40 μg/ml TPPS4 (Figure 13.)
Figure 13. The flow cytometry results for the PMBC cells incubated with TPPS4 at different concentrations
Ion [115] and Frackowiak [27] evaluated the incorporation of sulphonated porphyrin TPPS4,
which is better incorporated in cells by comparison with the non-sulphonated ones, most
probably due to the spatial forms of J-aggregated forms (helical forms) able to penetrate the
membrane and recovering to the monomeric forms after penetration. It is shown that during
irradiation cells are actively destroyed (Figures 14-17), [116].
Figure 12. The viability and multiplication rate of normal PBMC at 24h post-irradiation. C = non-irradiated unloaded
cells; TPPS4 = non-irradiated loaded cells; Ci = irradiated unloaded cells; TPPS4i = irradiated loaded cells.
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Figure 14. The absorption and emission properties of TPPS4
Figure 15. The aggregation equilibrium of TPPS4
For a longer photodynamic activity it is important to correlate the photophysical activity (the
lifetimes of the excited states) with photochemical activity (singlet oxygen efficiency and the
photodegradation rate. The aggregated forms (J-aggregates) of porphyrins favor the penetra‐
tion of the membranes. The porphyrins incorporation in cells is well correlated with singlet
oxygen generation capacity. In monomeric forms the non-sulfonated porphyrins are better
incorporated than the sulfonated ones which are better incorporated in leukocytes than in
granulocytes (Figures 18,19), [113].
The non-sulphonated porphyrins (TNP and TPP) in DMSO-water mixture (0.05% DMSO) exist
as monomeric and J-aggregated (dicationic - aggregated forms), the last ones with comparable
fluorescence properties with the monomers [117].
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Figure 14. The absorption and emission properties of TPPS4
Figure 15. The aggregation equilibrium of TPPS4
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tion of the membranes. The porphyrins incorporation in cells is well correlated with singlet
oxygen generation capacity. In monomeric forms the non-sulfonated porphyrins are better
incorporated than the sulfonated ones which are better incorporated in leukocytes than in
granulocytes (Figures 18,19), [113].
The non-sulphonated porphyrins (TNP and TPP) in DMSO-water mixture (0.05% DMSO) exist
as monomeric and J-aggregated (dicationic - aggregated forms), the last ones with comparable
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Figure 16. The flow cytometry of different forms of TPPS4
Figure 17. The flow cytometry of leukocytes and granulocytes incorporated with TPP and TNP
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Figure 18. Emission properties of TPP and TNP in DMSO:water and in lymphocytes
Figure 19. The correlation graphic of absorption and emission for TPP and TNP
6.2. Application of B2 Vitamin in liposomes for ophthalmologic diseases
After PDT treatment was possible to see by angrography a rapid and complete vasooclusion
(Figure 20), because the vessels were filled with erythrocytes and due to platelet aggregates.
Another observed effects are: vacuolization of mitochondria and endoplasmatic reticulum
(ESR), clumping of nuclear chromatin and finally, a subconjunctival hemrrhage, chemosis and
cyanotic color of the neovascular areas (Figures 21 and 22).
Figure 20. Fluorescein angiography after PDT treatment with Riboflavin on rabbit. Dark area delimitates the irradiated
sites where hypofluorescence indicates vascular occlusion
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Figure 21. Angiofluorography for a patient with malignant melanoma before PDT treatment with Rb (left), and 6
months (right) after PDT treatment with Riboflavin.
From Figure 21 could be observed the dissapearance of peritumoral neovascularization and
complete dissapearance of tumoral neovascularization and tumoral atrofia (6 luni). Angiog‐
raphy showed an immediate and complete vasooclusion (Figure 22).
Before PDT: VPD=1/8 fc, VOS =1/6 fc; 2 months after PDT: VOD=1/6 fc; VOS=1/12 fc; 4 months after PDT: VOD=1/10 fc;
VOS = 1/8 fc; 10 months after PD: VOD=1/15 fc; VOS=1/20 fc
Figure 22. Macular degenerescence for a patient with neovascular membrane for right eye and atrofic pseudotumoral
form at left eye
6.3. Dermatological applications
PDT produces cytotoxic effects through photodamage of cellular organelles and biomolecules.
It is known that PDT mediates tumor destruction by three mechanisms: direct cell killing,
tumor vasculature damage and immune response activation. The combination of the three
mechanisms is required to obtain long-term tumor control [122].
Actinic keratosis (AK) is the most common skin lesion with malignant potential, with a
prevalence ranging from 11% to 25% in the Northern Hemisphere and from 40% to 50% in
Australia [123]. There are some factors responsible for skin lessions (squamous cell carconoma
(SCC)) as follows: UV light, heat and pollutants resulted from carbon processing. The most
sensitive persons are Fitzpatrick I and II phototype and men by comparison with women [124].
In time, these lesions could remain unchanged, could spontaneously regress or could progress
to SCC and further developing on the support of pre-existing actinic keratosis.
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In our experimental approach, we have obtained from untreated skin biopsies a mean of
2.8x106 keratinocytes/cm2 skin with a mean of 65% viability. After therapy from the same skin
region and from the same surface isolated keratinocytes were less than half compared to the
control skin, displaying as well a lower viability (Figure 23).
Figure 23. Primary keratinocytes isolated from normal human skin before (control) and after PDT with TPPS4 (viability
and proliferative capacity)
Primary keratinocytes were further cultivated until the culture could not be maintained. The
proliferation capacity of primary keratinocytes extracted from PDT skin biopsies was signifi‐
cantly lower compared to control skin (Figure 23). Annexin-V and propidium iodide labelling
of isolated keratinocytes after in vivo PDT compared to control keratinocytes yielded to the
following values: control = 100 %; An-PI- = 10 %; An+PI- = 18 %; An+PI+ = 65 %.
The tested TPPS4 showed an effective in vivo destructive effect on keratinocytes in the patient
with actinic keratosis doubled by a good clinical response (Figure 24).
Figure 24. The aspect of the skin with AK before PDT (left) and after PDT (right) with TPPS4
7. Conclusions
Photodynamic therapy is a recognized alternative used in successful cancer therapy, in a
society when the clinicians are seeking new and efficient methods for saving people. There is
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no doubt that the long scientific efforts of photodynamic therapy will allow useful patient
treatments in the future.
The main benefits of PDT are the following:
a. The patients can avoid surgery.
b. PDT patients usually don't even need to check into the hospital.
c. PDT can be repeated, unlike radiation and chemotherapy.
d. PDT can work in places where surgery would not be feasible, such as the trachea, the
major airway leading from the voice box to the lungs.
e. The photosensitizing agent will selectively accumulate in cancer cells and not in sur‐
rounding normal tissues. Hence, cancer cells can be selectively destroyed while most
normal cells are spared.
f. The treatment occurs only in the presence of light.
g. PDT might be applied in many cases where surgery, chemotherapy and X ray radiation
are contra-indicated.
Side effects, limitations could be registered, especially for photosensitivity or sensitivity to light,
the pain of PDT, which is usually mild to moderate, easily controlled with some drugs.
However, there are many problems for the clinical application of existing photosensitzers.
a. Most PS molecules are hydrophobic and can aggregate easily in aqueous media, decreas‐
ing its quantum yield. Moreover, the aggregated PS cannot be simply injected intrave‐
nously.
b. Selective accumulation of the PS molecules in deceased tissues is required to avoid
collateral damage to healthy cells. Although third generation PS based on nanomaterials
have been prepared for selective targeting, their selectivity is not high enough for clinical
application.
c. Nanomaterials (organic or inorganic) are more promising because they are hydrophilic,
possess enormous surface areas, and their surface can be modified with functional groups
possessing a diverse chemical or biochemical properties;
d. Owing to their sub-cellular and sub-micron size, nanoparticles can penetrate deep into
tissues through fine capillaries, and are generally taken up efficiently by cells.
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1. Introduction
Nowadays, implantable devices developed for electrically interfacing to the brain are of great
interest. Such devices, also known as brain-machine interfaces (BMI), are expected to revolu‐
tionalize so many aspects of the human life, such as the way we interface with the external
world, and how we cure deseases and disabilities such as the Parkinson’s desease, paralysis,
and blindness. General concept of intra-cortical neural recording using implantable microsys‐
tems along with an example of such systems is illustrated in Figure 1. In a wide variety of
applications for such systems, there is a need for recording neural activities from a certain
region of the brain with enough spatial resolution. To be able to come up with meaningful
information from the region of interest in the brain, implantable neural recording devices are
typically designed to record from tens to hundreds of recording sites [1-3].
1.1. General building blocks
A neural recording system, in general, comprises two parts: a neural recording implant, and
an external setup. Implantable cortical neural recoding microsystems (the implant) typically
consist of three main parts:
• neural recording front-end; This module is in charge of sensing extracellular neural
activities, and consists of a recording microelectrode array followed by analog signal
preconditioning circuitry. A 4-site silicon probe fabricated based on the Michigan approach
[4] is shown in Figure 2 [5].
• neural signal processing module; This is where most of the signal handling and signal
processing tasks take place, e.g., analog signal processing, analog/digital conversion, and
digital signal processing.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
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• wireless interface module; This module is used for data exchange with the external setup
and in some cases for supporting power telemetry from the outside to the implant.
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data through a wireless link is also a design bottleneck. This is simply due to the fact that an
implantable neural recording device needs to transmit the recorded neural information to the
external world through wireless connection, and the frequency band used for wireless
communication is not unlimited. One of the efficient ways to overcome this problem is to either
compress the data being telemetered or at least to extract and transmit only the useful
information needed for the target application.
2. Spike reporting
An intra-cortically-recorded neural signal, in general, comprises three major components:
action potentials (also known as neural spikes or simply spikes), local field potential (LFP), and
background noise. It is believed that most of the important information in neural signals is
reflected in the occurrence rate of neural spikes. As a result, in some applications (e.g.,
prosthetic applications) only the occurrence of spikes is detected and reported to the external
world. In some other applications (e.g., neuroscientific research), however, researchers and
scientists need more information on how or where the neural activities occur.
Recording the entire neural signal (action potentials superposed with background noise) is the
maximum function expected from a general neural recording system, which allows for
studying different components of a neural signal including the background noise. For multi-
channel wireless neural recording implants, because of the limited bandwidth available for
transmitting the neural data, the number of recording channels will be limited if the entire
signal is intended to be telemetered. In many applications, the rate of spike occurrence is the
most important information that is expected from a neural recording system to provide. Hence,
it will be much more bandwidth-efficient if the spikes are detected by the implanted recording
system and only the occurrences of the spikes are reported to the external host rather than
transmitting the entire neural signal.
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In addition to the small action potentials with the amplitude of around 100~500μV, a neural
signal contains background noise and probably low-frequency baseline variations. To prepare
the neural signal for spike detection, it is amplified with a gain of around 40~60dB and also its
low-frequency (below 1~10Hz) and high-frequency (above 7~10kHz) contents are filtered out
[7], [2]. Then, this preconditioned signal is delivered to a spike detector.
There are various spike detection approaches that can be classified into two major categories:
feature-based spike detection methods, and spike detection by hard thresholding. In the
former, a preprocessor searches the input neural signal for certain features of a spike to occur,
while in the latter, a threshold level is defined and a spike is detected when the neural signal
goes beyond the threshold.
Feature-Based Approaches. Only a few years after artificial neural networks (ANN’s) were
introduced as an efficient tool to implement artificial intelligence, due to the feature extraction
capability that certain types of ANN’s had, they showed to be attractive candidates for
automatic spike detection either by themselves or in conjunction with preprocessors [8-9].
Kohonen and Grossberg networks with unsupervised learning, and Multi-Layered Perceptron
network with “error back-propagation” as a supervised learning algorithm have been used to
perform spike detection. Although there are cases where the raw neural signal is fed to the
ANN for spike detection [9-10], it is mostly preferred to use a preprocessor for extracting
certain spike features first, and then use an ANN for processing them and detecting the spikes,
as illustrated in Figure 3. Because of their relatively large area- and power-consuming














Figure 3. Employing neural networks for spike detection
Spike Detection Based on Nonlinear Energy Operator (NEO). Traditional spike detectors
(explained above) usually need prior information about action potentials, which is usually not
available before recording the neural signals in real applications. In contrast with these
methods, which are mostly based on the amplitude or time-domain features of the neural
signal, detection of action potentials, i.e., spikes, can also be performed based on the energy
content of the signal. Direct square of the signal, absolute value operator, and variance
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estimator are the energy-based operators commonly used for the detection of bio-potentials.
The nonlinear energy operator (NEO), also called the Teager energy operator (TEO) is one of
the unsupervised action potential detectors exhibiting satisfactory performance in the case of
low signal-to-noise ratio (SNR) for the neural signal and also convincing speed for the
alignment of spikes in the real time. In its original form, continuous-time NEO is defined as:
ψ(x(t))= ( dx(t )dt )2 - x(t)( d 2x(t )dt 2 ). (1)
which is sensitive to signal with short time interval and at a high-frequency band [11]. An
efficient hardware implementation for an NEO neural signal processor employing custom
OTA1-C analog circuits was reported in [12].
2.2. Hard thresholding
Four possible ways of spike detection by hard thresholding are illustrated in Figure 4. Spike
detection is mostly performed to detect either positive (Figure 4 (a)) or negative (Figure 4
(b)) spikes [7], [2], [13]. Having such a fixed pre-assumption for the polarity of the spikes limits
the operation of the system. Recognition of both positive and negative spikes, i.e., bi-phasic
spike detection, can be realized in two major ways, illustrated in Figure 4 (c) and (d). In Figure
4 (c), the spike detector returns a logical “1” on the Spike Occurrence (S.O.) output upon the
detection of a spike, no matter if it is positive or negative. This is a bandwidth-efficient way of
bi-phasic spike detection, which requires almost the same bandwidth as the uni-phasic
methods, but pays the price by losing the spike polarity. The simplest realization of this idea
is to filter out the DC component of the input signal, find its absolute value, and then detect
the spikes using one comparator and one threshold [14] as shown in Figure 5(a). Aside from
the need for a precise full-wave rectifier in this realization, the fact that both the positive and
the negative spikes are compared with the same threshold level might be considered as a
drawback. Figure 5 (b) shows another realization of bi-phasic spike detection with no polarity,
which uses two comparators and an OR gate and also allows for comparing positive and
negative spikes with separate threshold levels. This approach is used in [7],[13] with positive
and negative thresholds, VTH,P and VTH,N, defined by a threshold value (THR) and a threshold
offset (ThrOS), as shown in Figure 6.
The circuit shown in Figure 5 (b) can also be used with minor modifications to realize the
complete bi-phasic spike detection method illustrated in Figure 4 (d), which returns two bits
per detected spike. These two bits can be either Spike Occurrence (S.O.) and Spike Polarity
(S.P.) as shown, or one bit assigned to detected positive spikes and the other to detected
negative spikes.
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There is a variety of methods for generating the thresholds required for spike detection. The threshold 
can be either statically defined by the user [2], [13] or automatically set by the internal circuitry. 
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There is a variety of methods for generating the thresholds required for spike detection. The
threshold can be either statically defined by the user [2], [13] or automatically set by the internal
circuitry.
Automatic Threshold Setting. The 32-channel spike detector ASIC reported by [7] uses a
straightforward approach for automatic threshold generation. In this method, the average
(AVG) and the standard deviation (SD) of the neural signal is calculated, and then the two
thresholds required for bi-phasic spike detection are set above and below the average value as:
THR=AVG ± k.SD (2)
where k is a constant. Typical value for k varies from 3 to 7 depending on the signal-to-noise
ratio (SNR) of the recorded neural signal. Functional block diagram of this spike processor
implementing the above method in digital domain is shown in Figure. Thirty two channels of
preconditioned neural signals, which are already time-division multiplexed on four lines in
analog domain by a recording front-end (not shown), are delivered to the spike detector ASIC.
The four multiplexed inputs each carrying 8 channels of neural signals are first converted to
digital by four A/D converters simultaneously. The Sample Distributor, which is synchronized
with the time-division multiplexer on the recording front-end, demultiplexes the amplitude
samples into 32 digital neural channels. Then, the digital spike detector computes the averages
and standard deviations of the 32 channels separately and accordingly calculates their
threshold values. After the Threshold Calculation program is executed, the Spike Detection
program is run. The amplitude sample of each channel is compared to the associated threshold,
and if it is beyond the threshold level, it is considered as a detected spike. As long as a channel
is active, its amplitude samples are tagged with the associated channel address, and put in a
buffer to be sent to a wireless interface.
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Figure 9. shows another idea in analog spike detection, in which two OTA-based low-pass
filters with different cut-off frequencies play the key role [17]. One filter has a higher cut-off
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Figure 9. shows another idea in analog spike detection, in which two OTA-based low-pass
filters with different cut-off frequencies play the key role [17]. One filter has a higher cut-off
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frequency to remove high frequency noise, and the other has a lower cut-off frequency to make
a local average. The difference between the high-pass filtered signal and its local average is
provided by an OTA, and is recognized by another OTA as a detected spike when exceeds a
certain reference value (Vref). This method is robust against changes in both noise level and the
input signal's DC offsets, both of which are likely to happen in long-term neural recording.
The OTAs operate in subthreshold region to reduce power. The τ bias voltages are set off chip
to enable adjustment of the cut-off frequencies after fabrication. In this circuit, the spike
detection threshold level is set by Vbias, which along with the other bias and reference voltages
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Figure 9. Schematic diagram of the analog spike detector of [16]
In both of the above analog approaches, there are device and circuit parameters that should
be set by the user for proper operation, which make these circuits inappropriate for implantable
applications.
3. Mathematical approaches
Mathematical transforms are among the most common methods of data compression.
Recently, the Discrete Wavelet Transform (DWT) has been successfully employed in neural
recording microsystems to compress the neural information, while preserving the wave shape
of action potentials [18-26]. The DWT transforms discrete signals from the time domain into
the time-frequency domain. One-level DWT for a given signal is achieved by convolving the
sign l samples through low-pass and high-pass decomposition filters [19,21]. The filtering is
then followed by sub sampling to obtain the approximation and detail coefficients. For multi-
level DWT, approximation coefficients should be fed to the same decomposition filters
recursively [27]. Characteristics of the filters are determined by the wavelet basis. For neural
Data Reduction Techniques in Neural Recording Microsystems
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signal compression, the optimal choice is a wavelet function that can approximate the action
potentials waveform with minimum DWT coefficients and error. It has been shown that by
proper selection of the wavelet basis, most of the spike energy is concentrated in a few large
coefficients, while many small coefficients carry insignificant information and are mainly
attributed to noise [19]. Therefore, in order to achieve higher data reduction rates, the DWT
coefficients are passed through a thresholding stage. In this block, data coefficients smaller
than desired certain threshold level are set to zero, while others are left unchanged. It is obvious
that the threshold value plays an important role in the overall data compression rate, and also
in the quality of the reconstructed signal. Hence, the threshold level should be set carefully
based on the requirements of the target application.
Due to power and size constrains in biomedical implants, VLSI implementation of DWT is of
great importance. In [20], it has been shown that from a signal compression standpoint,
symmlet4 wavelet basis is advantageous over other wavelet functions for neural recording
applications. It is believed that this is mainly because of the similarity of this function to the
general wave shape of action potentials. For hardware implementation of symmlet4 function,
lifting method is proposed in [21]. Furthermore, two different circuit designs, pipelined and
sequential, are presented and compared for the lifting scheme. It is demonstrated that for
single-level single-channel integer DWT, the pipelined approach consumes lower power, but
occupies more silicon area compared with the sequential implementation. On the other hand,
4-level multi-channel implementation of the two designs indicates that the sequential ap‐
proach requires significantly smaller chip area, while the power consumption of both is almost
the same. As a result, the sequential execution architecture is employed in [23] to design a
complete 32-channel compression system based on the 4-level symmlet4 DWT. The chip
consumes 3 mW of power and occupies only 5.75 mm2 in a 0.5-μm CMOS technology. Also,
with a sampling rate of 25 KSample/Sec per channel and 10-bits data samples, the system
provides data compression of more than 20 times, resulting in a total output bit rate of less
than 370 kbps.
In [26], a neural signal compression method based on the Discrete Haar Wavelet Transforms
(DHWT) is proposed. From the standpoint of data compression, Haar basis function may not
perform as efficient as complex functions such as high-order Daubechies and symmlet, but due
to its simple hardware implementation, it can be easily used for large number of neural
channels with less concern about power and area. As discussed in [26] for two-point DHWT,
data coefficients can be calculated by only a buffer, an adder, and a subtractor. Moreover, in
order to compare Haar and symmlet4 basis functions, they have been both designed for
processing a single channel with 8-bits data samples. Results indicate that before the thresh‐
olding stage, relative error (between the original signal and the corresponding reconstructed
signal) for the DHWT is only 0.01% larger than the symmlet4 case, which is obviously negligible.
On the other hand, hardware implementation of the DHWT shows around 83% saving in
number of transistors, and more than 90% in the occupied silicon area, when physically laid
out in a 0.13-μm CMOS technology. The complete 64-channel DHWT-based neural compressor
achieves a compression rate of 112 with an error of 2.22%. Additionally, the compressor circuit
consumes as low as 0.12 mW @1.2 V supply voltage, and occupies less than 0.1 mm2 in a 0.13-
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coefficients are passed through a thresholding stage. In this block, data coefficients smaller
than desired certain threshold level are set to zero, while others are left unchanged. It is obvious
that the threshold value plays an important role in the overall data compression rate, and also
in the quality of the reconstructed signal. Hence, the threshold level should be set carefully
based on the requirements of the target application.
Due to power and size constrains in biomedical implants, VLSI implementation of DWT is of
great importance. In [20], it has been shown that from a signal compression standpoint,
symmlet4 wavelet basis is advantageous over other wavelet functions for neural recording
applications. It is believed that this is mainly because of the similarity of this function to the
general wave shape of action potentials. For hardware implementation of symmlet4 function,
lifting method is proposed in [21]. Furthermore, two different circuit designs, pipelined and
sequential, are presented and compared for the lifting scheme. It is demonstrated that for
single-level single-channel integer DWT, the pipelined approach consumes lower power, but
occupies more silicon area compared with the sequential implementation. On the other hand,
4-level multi-channel implementation of the two designs indicates that the sequential ap‐
proach requires significantly smaller chip area, while the power consumption of both is almost
the same. As a result, the sequential execution architecture is employed in [23] to design a
complete 32-channel compression system based on the 4-level symmlet4 DWT. The chip
consumes 3 mW of power and occupies only 5.75 mm2 in a 0.5-μm CMOS technology. Also,
with a sampling rate of 25 KSample/Sec per channel and 10-bits data samples, the system
provides data compression of more than 20 times, resulting in a total output bit rate of less
than 370 kbps.
In [26], a neural signal compression method based on the Discrete Haar Wavelet Transforms
(DHWT) is proposed. From the standpoint of data compression, Haar basis function may not
perform as efficient as complex functions such as high-order Daubechies and symmlet, but due
to its simple hardware implementation, it can be easily used for large number of neural
channels with less concern about power and area. As discussed in [26] for two-point DHWT,
data coefficients can be calculated by only a buffer, an adder, and a subtractor. Moreover, in
order to compare Haar and symmlet4 basis functions, they have been both designed for
processing a single channel with 8-bits data samples. Results indicate that before the thresh‐
olding stage, relative error (between the original signal and the corresponding reconstructed
signal) for the DHWT is only 0.01% larger than the symmlet4 case, which is obviously negligible.
On the other hand, hardware implementation of the DHWT shows around 83% saving in
number of transistors, and more than 90% in the occupied silicon area, when physically laid
out in a 0.13-μm CMOS technology. The complete 64-channel DHWT-based neural compressor
achieves a compression rate of 112 with an error of 2.22%. Additionally, the compressor circuit
consumes as low as 0.12 mW @1.2 V supply voltage, and occupies less than 0.1 mm2 in a 0.13-
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μm CMOS technology. Therefore, it can be said that with this architecture, the gain in circuit
simplicity and the bit-rate improvement are much more significant than the penalty paid by
the noise added to the signal. However, it is worth mentioning that, in general, the appropriate
architecture should be selected based on the application.
4. Hardware approaches
To avoid adding extra power- and area-hungry signal processing blocks for data reduction,
and at the same time preserving important information of the neural signals, there is a different
category of data reduction techniques, known as hardware approaches. These are the approaches
focused on modifying the hardware of the recording system in such a way that considerable
bit-rate reduction can be achieved. Obvious advantages of these approaches are smaller silicon
area and power consumption as compared with the mathematical approaches explained in the
previous section.
To benefit from the advantages associated with digital signal processing and also digital data
communication (as opposed to their analog counterparts), neural recording devices are
commonly designed to convert neural signals into digital as the first step. As a result, analog-
to-digital converters (ADCs) are known as one of the key building blocks in such systems.
Recently some efforts are put on designing application-specific ADCs to efficiently utilize the
bandwidth allocated for wireless data telemetry. In this section, an efficient method for analog-
to-digital (A/D) conversion of neural signals is discussed. This method results in significant
reduction of data-rate for multi-channel cortical neural recording microsystems.
4.1. Anti-logarithmc quantization
Although linear ADCs are typically used to digitize neural signals in neural recording
microsystems, it is beneficial to design a nonlinear ADC for such specific signals. Choosing
the best-suited nonlinearity function for a specific signal requires recognition of the concen‐
tration of information along the signal amplitude range. As illustrated in the left side of Figure
10, in general, signals can be categorized into three types according to how the information
they carry is distributed along the amplitude range.
Type-I signals are named “Signals with Non-Concentrated Information (NCI)” due to their almost
uniform distribution of information concentration. Important information for Type-II signals
is concentrated at the lower side of the amplitude range. Audio signals are of this type, referred
to as “signals with Information Concentration at Low Amplitudes (ICLA)”. Conversely, for “signals
with Information Concentration at High Amplitudes (ICHA)”, i.e., Type-III signals, more informa‐
tion is present at higher side of the amplitude range, with neural signals as examples.
Figure 10 provides intuitive illustration of the choice of different quantization functions for
the three signal types discussed. With a constant slope (i.e., linear) quantization function, an
NCI signal is better digitized. Decreasing slope quantization functions such as logarithmic
function are recommended for ICLA signals. These functions put more emphasis on lower
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amplitudes, where more information is concentrated. For example, compressing/expanding
(companding) of audio signals in communications systems is based on logarithmic quantiza‐
tion, which increases the dynamic range and improves the SNR [28]. Whereas quantization
functions with increasing slope along the input amplitude range, such as the exponential
function, put more resolution in the quantization of the larger amplitudes and are preferred
for ICHA signals.
 
Figure 10. Selecting quantization function for NCI, ICLA, and ICHA signals 
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Figure 11. Neural signal composed of APs and B-Noise
Useful action potential 
to be digitized with 
high resolution
Non-useful background 




























Figure 12. Quantization of a neural signal with linear and nonlinear quantization steps
Basic Idea. As shown in Figure 11, in time domain a typical intracortically-recorded extracel‐
lular neural signal can be divided into two parts: action potentials (APs) and background noise
(B-Noise). In probability density function (PDF) domain, APs are concentrated at large
amplitudes while B-Noise is concentrated at small amplitudes. In a wide variety of neuro‐
scientific and neurophysiological studies, as well as in many neuroprosthetic applications, it
is the APs that carry the useful information embedded in neural signals. As illustrated in Figure
12, in implantable neural recording microdevices, neural signals are usually digitized using
linear ADCs, i.e., ADCs with linear quantization characteristics. This means that the non-useful
B-Noise is digitized with the same resolution as the useful APs are. In other words, when
telemetering a digitized neural signal, part of the outgoing bit-rate is wasted to carry the noise
content present in the neural signal. In [29] the idea of digitizing neural signals using an ADC
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with non-uniform quantization steps has been proposed. According to the classification
presented in the previous section, neural signals are categorized under Type-III (i.e., ICHA).
Hence, the best type of nonlinearity function for the quantization of neural signals is signals
with increasing slopes such as parabolic and exponential functions.
Digitizing neural signals using exponential ADC (exp-ADC) helps saving the bandwidth in
wireless data telemetry between the implanted device and the external host. Data reduction
for an 8-bit exp-ADC is 24% as compared with its linear counterpart. Along with data reduc‐
tion, anti-logarithmic quantization of neural signals significantly reduces the power consump‐
tion of the ADC, comparing with a standard linear ADC. This is due to less number of digital
code transitions for the exp-ADC. Moreover, anti-logarithmic quantization increases the SNR
of neural signal by reducing its noise content.
Converting Back to Analog. The transfer characteristics for conventional linear analog-to-
digital-to-analog (A/D/A) conversion process is a linear function, i.e., analog input signal is
digitized by a linear ADC and then is converted back to the analog domain using a linear DAC.
On the other hand, in a nonlinear A/D/A conversion process, analog input signal is digitized
by a nonlinear quantization function. As shown in Figure 13 to convert back to the analog
domain, digital signal should be passed through a nonlinear DAC with exact inverse charac‐
teristic. The resulted A/D/A conversion transfer characteristic is similar to that of a linear
A/D/A conversion process, except that the quantization steps are non-uniform. In the case of
anti-logarithmic A/D/A conversion, quantization steps are decreasing in length along the input
amplitude range.
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Figure 14. An FR-ADC designed to digitize neural signals using two HR-ADCs with exponential quantization function 
Dummy Text Covering the Full Range. Assuming that the neural signal is preamplified and positioned around a certain 
baseline level, as illustrated in Figure 14, the nonlinear quantization function needs to be defined in an odd symmetric 
form around the baseline of the signal. Therefore, the nonlinear ADC needed to cover the entire input signal range, full-
range ADC (FR-ADC), is realized using two complimentary half-range ADCs (HR-ADCs) each covering half of the input 
signal range. Hence, assuming that the basic nonlinear quantization function is used for the upper half-range ADC 
(UHR-ADC), fUHR(x), the quantization function used for the lower half-range ADC (LHR-ADC) will be: 
   LHR UHRf x =- f -x . (3) 
The nonlinear ADC discussed hereafter is assumed to be the ADC that covers the upper half of the input signal range, 
i.e., the UHR-ADC, unless otherwise stated. 
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where (bN-1...b1b0) is digital representation of analog input, vin, and VFS is the full-scale input range for the UHR-ADC. To 
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Figure 14. An FR-ADC designed to digitize neural signals using two HR-ADCs w th exponential quantization funct on
Covering the Full Range. Assuming that the neural signal is preamplified and positioned
around a certain baseline level, as illustrated in Figure 14, the nonlinear quantization function
needs to be defined in an odd symmetric form around the baseline of the signal. Therefore, the
nonlinear ADC needed to cover the entire input signal range, full-range ADC (FR-ADC), is
realized using two complimentary half-range ADCs (HR-ADCs) each covering half of the input
signal range. Hence, assuming that the basic nonlinear quantization function is used for the
upper half-range ADC (UHR-ADC), fUHR(x), the quantization function used for the lower half-
range ADC (LHR-ADC) will be:
( ) ( )LHR UHRf x =- f -x . (3)
The nonlinear ADC discussed hereafter is assumed to be the ADC that covers the upper half
of the input signal range, i.e., the UHR-ADC, unless otherwise stated.
Half-Range Characteristic Function. The input-output relationship for an N-bit HR-ADC with
exponential quantization function is:
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where (bN-1...b1b0) is digital representation of analog input, vin, and VFS is the full-scale input
range for the UHR-ADC. To satisfy the boundary conditions for minimum and maximum
values of vin it can be shown that:






Parameter a sets the curvature of the characteristic function. The smaller this parameter is, the
more rapid the exponential input-output relationship will be. Quantization steps along the
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for i=0,1,...,2N-1. The largest and the smallest quantization steps, LSBmax and LSBmin, are
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In general, dynamic range (DR) of a nonlinear ADC is defined to be the ratio of the full-scale
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The choice of the largest quantization step, VLSB,max, is perhaps the most critical decision in
forming the quantization function for the exp-ADC. This is because of its key role in the
reduction of the noise content of the neural signal. The largest LSB is responsible for the largest
quantization error. It is along the VLSB,max that variations of the input signal are intentionally
not seen and replaced with 0 (the baseline level in our design). By using this method, not only
the quantization error is not a disturbing phenomenon for the signal, but it also plays a
denoising role as it replaces the B-Noise around the baseline with 0. To achieve significant
reduction in the B-Noise power, VLSB,max is set to 3σ, where σ is the standard deviation of the
B-Noise PDF. This way, most of the B-Noise will be intentionally removed from the neural
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In general, dynamic range (DR) of a nonlinear ADC is defined to be the ratio of the full-scale
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The choice of the largest quantization step, VLSB,max, is perhaps the most critical decision in
forming the quantization function for the exp-ADC. This is because of its key role in the
reduction of the noise content of the neural signal. The largest LSB is responsible for the largest
quantization error. It is along the VLSB,max that variations of the input signal are intentionally
not seen and replaced with 0 (the baseline level in our design). By using this method, not only
the quantization error is not a disturbing phenomenon for the signal, but it also plays a
denoising role as it replaces the B-Noise around the baseline with 0. To achieve significant
reduction in the B-Noise power, VLSB,max is set to 3σ, where σ is the standard deviation of the
B-Noise PDF. This way, most of the B-Noise will be intentionally removed from the neural
signal during the digitization process.
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Noise Analysis. PDF of quantization noise (Q-Noise) for linear ADC is uniform along the input am-
plitude range. This can be shown by eq. (10) which formulates PDF of the Q-Noise associated with 
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advantage comes from the fact that NLADCs exhibit non-uniform Q-Noise distribution. In a Loga-
rithmic ADC, Q-Noise energy is shifted to large amplitudes. As a result, logarithmic ADC has widely 
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Figure 15. Q-Noise PDF for  (a) linear ADC and (b) exp-ADC; (c) Q-Noise for exp-ADC vs. B-Noise 










































































Figure 15. Q-Noise PDF for (a) logarithmic ADC and (b) exp-ADC; (c) Q-Noise for exp-ADC vs. B-Noise of a neural
signal
Noise Analysis. PDF of quantization noise (Q-Noise) for linear ADC is uniform along the input
amplitude range. This can be shown by eq. (10) which formulates PDF of the Q-Noise associ‐
ated with code n in an N-bit li ear HR-ADC [30]:
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(10)
Uniform distribution of Q-Noise along the input amplitude makes linear ADCs suitable for
digitizing NCI signals. For specific signals an NLADC might be useful in terms of SNR
improvement. This advantage comes from the fact that NLADCs exhibit non-uniform Q-Noise
distribution. In a Logarithmic ADC, Q-Noise energy is shifted to large amplitudes. As a result,
logarithmic ADC has widely been used in digitizing of ICLA signals, such as audio. PDF of
Q-noise associated with code n for an N-bit logarithmic HR-ADC is formulated in eq. (11) and
is illustrated in Figure 15(a):
,
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(11)
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In the case of the anti-logarithmic N-bit HR-ADC, the Q-Noise PDF associated with code n is
derived as:
,
1 1( ) ln 1 ln 1 .
2 2 2Exp HR N N
n nP n
k a a
é ùæ ö æ ö= +  +ç ÷ ç ÷ê úè ø è øë û
(12)
As shown in Figure 15(b), exp-ADC shapes the Q-Noise in such a way that most of its energy
concentrates at small amplitudes, making it suitable for digitizing ICHA signals. As an
example, in neural signals, APs with large amplitudes are quantized with higher SQNR as
opposed to the B-Noise with rather small amplitudes. Figure 15(c) illustrates that most of the
noise content of the signal (B-Noise) lies within the very first LSBs. The interesting point here
is that since it is some of the noise content of the neural signal that is lost during the quantization
process, not only the associated quantization error is not undesirable, but it is also welcomed
as it leads to noise-content reduction and consequently to significant improvement in the SNR
of the neural signal being digitized.
Noise-Content-Reduction Ratio, NCRR, is a measure of capability of an ADC in reducing the
noise content of the neural signal being digitized, and can be defined as [29]:
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average noise power @ inputNCRR (dB) 10log





where the average noise power at the input of the ADC is calculated as:
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In this equation, Pni(ni) is the probability density function for noise content of the neural signal,
ni(t). Similarly, the average noise power of the signal at the output of the ADC is derived to
be:
2 2( ) ( ) ( )
io o n i o




where no(t) is the noise content of the neural signal after passing through the ADC:
( ) ( ) ´ ùû= éë    .o in t n t ADC Characteristic Curve (16)
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Figure 16 illustrates how the B-Noise is reduced as it passes through the exp-ADC, already
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Figure 16. The process of B-Noise reduction as the signal passes through the NLADC, formulated by eqs. (14)-(16)





















b3 b1 b0 b2 
T7 T5 T6 T4 T3 T2 T1 
T5 T6 T4 T3 T2 T1 
T7-T1 
b3-b0 b7-b0 



















b3 b2 b1 b0 
Segment Selection 
































































Figure 17. Circuit schematic for the two-step SAR ADC designed to implement exp-ADC and its simplified timing dia‐
gram
Circuit Design. To realize the proposed exp-ADC with reasonable power and silicon area,
successive-approximation register (SAR) architecture was chosen [31]. In order to facilitate the
realization of the exponential quantization function needed for the ADC, a piecewise-linear
(PWL) approximation of the required function was implemented. As shown in the timing
diagram of Figure 17, the proposed ADC operates in three phases: sign detection (SD), offset
cancelation (OC), and conversion. In the SD phase, the analog input voltage, vin, is compared
with a certain threshold voltage, VTH, which is temporarily set to the baseline voltage, VBL. The
result of this comparison determines the half range in which the input voltage is located. In
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the OC phase, an ordinary offset cancellation technique is applied on the comparator and
buffers. In the conversion phase, successive approximation algorithm first finds the segment
of interest, encoded by b6b5b4, in 3 clock cycles. These 3 bits are converted to a 7-bit thermometer
code, T7~T1, which will be used in the Segment Selection block to generate two analog voltages
associated with the endpoints of the segment of interest. An in-segment linear A/D conversion
process is then performed to determine the remained 4 LSBs, b3b2b1b0, in 4 clock cycles. Finally,
an end of conversion signal is generated to reset the ADC and prepare for the next conversion
cycle. A low-voltage band-gap reference (BGR) was designed to generate the required baseline,
reference and threshold voltages for the exp-ADC.
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Figure 18. Chip photograph of the proposed NLADC
Experimental Results. The presented exp-ADC was fabricated in a standard 0.18-μm CMOS
process. A chip photograph is shown in Figure 18, in which the chip occupies a total size of
220 ×230 μm2. The measured worst-case differential non-linearity (DNL) and integral non-
linearity (INL) are +0.8/-0.9 LSB and +4.3/-2.1 LSB, respectively. Table 1 summarizes the
specifications of the NLADC and compares it with some of the nonlinear and linear ADCs
reported in the literature.
A proof-of-concept prototype of a 4-channel neural recording system based on anti-logarithmic
quantization was reported in [6]. As shown in the block diagram of Figure 19, a time-domain
multiplexer (TDM) shares an anti-logarithmic ADC (AL-ADC) between 4 channels (each
sampled at 20kSps). The output digital codes are then packed by the data packaging block to
be transmitted to the outside world via a wireless link. At the external host, received signal is
first recovered and then converted back to analog via a PC software. This inverse conversion
is performed using a logarithmic DAC. Quantization characteristic function for the DAC is an
exact inverse for that of the NLADC used in the recording system. To evaluate the operation
of the system, neural signals recorded from the auditory cortex of a Guinea pig are used for
in-vitro tests. Figure 20 shows the input signal to one of the neural channels before entering
the nonlinear quantization process on the implant side along with the associated signal on the
external setup after reconstruction. To verify the concept of the noise reduction caused by
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the OC phase, an ordinary offset cancellation technique is applied on the comparator and
buffers. In the conversion phase, successive approximation algorithm first finds the segment
of interest, encoded by b6b5b4, in 3 clock cycles. These 3 bits are converted to a 7-bit thermometer
code, T7~T1, which will be used in the Segment Selection block to generate two analog voltages
associated with the endpoints of the segment of interest. An in-segment linear A/D conversion
process is then performed to determine the remained 4 LSBs, b3b2b1b0, in 4 clock cycles. Finally,
an end of conversion signal is generated to reset the ADC and prepare for the next conversion
cycle. A low-voltage band-gap reference (BGR) was designed to generate the required baseline,
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Figure 18. Chip photograph of the proposed NLADC
Experimental Results. The presented exp-ADC was fabricated in a standard 0.18-μm CMOS
process. A chip photograph is shown in Figure 18, in which the chip occupies a total size of
220 ×230 μm2. The measured worst-case differential non-linearity (DNL) and integral non-
linearity (INL) are +0.8/-0.9 LSB and +4.3/-2.1 LSB, respectively. Table 1 summarizes the
specifications of the NLADC and compares it with some of the nonlinear and linear ADCs
reported in the literature.
A proof-of-concept prototype of a 4-channel neural recording system based on anti-logarithmic
quantization was reported in [6]. As shown in the block diagram of Figure 19, a time-domain
multiplexer (TDM) shares an anti-logarithmic ADC (AL-ADC) between 4 channels (each
sampled at 20kSps). The output digital codes are then packed by the data packaging block to
be transmitted to the outside world via a wireless link. At the external host, received signal is
first recovered and then converted back to analog via a PC software. This inverse conversion
is performed using a logarithmic DAC. Quantization characteristic function for the DAC is an
exact inverse for that of the NLADC used in the recording system. To evaluate the operation
of the system, neural signals recorded from the auditory cortex of a Guinea pig are used for
in-vitro tests. Figure 20 shows the input signal to one of the neural channels before entering
the nonlinear quantization process on the implant side along with the associated signal on the
external setup after reconstruction. To verify the concept of the noise reduction caused by
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overlapping PDFs for B-Noise and Q-Noise, distributions of the measured quantization error

































Figure 19. Block diagram of the prototyped neural recording system
Specification This Work [34] [35] [36] [37]
Process (μm) 0.18 0.18 0.18 0.5 0.8
ADC Type Exp. Log. Linear Linear Linear
No. of Bits 8 7 8 10 10
Pdiss (μW) 87.2 9.7 7.4 100 17.9
Area (mm2) 0.036 0.003 0.04 0.15 0.8
Supply (V) 1.8 1.8 1.8 3.3 2.8
Input Range (V) 1 N/A 0.6 2.5 0.8
DR (dB) 64.1 80 39.1 N/A 50.5
fs (kS/s) 25 5 30 15 2.9
INL (LSB) +4.3/ -2.1 ±0.86 ±1 0.6 0.98
DNL (LSB) +0.8/ -0.9 ±0.44 N/A 0.6 0.67
Table 1. Performance Comparison
5. Conclusion
To overcome bandwidth limitation in the wireless telemetry of recorded neural data, a wide
variety of data reduction techniques has been reported. These techniques range from spike
reporting approaches such as spike detection and spike sorting techniques to mathematical
approaches such as the discrete wavelet transform. Although it is proven that spike reporting
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approaches contain enough information to actuate prosthetic devices [33], in some other
applications, such as neuroscientific studies, they are not satisfactory due to considerable loss
of important information, e.g., spike wave shapes. Mathematical approaches, on the other
hand, have been successful from the standpoint of data compression, while preserving wave
shape of the spikes. Nonetheless, increasing the number of recording channels can result in
the potential problems of these approaches: large silicon area and high power consumption.
In contrast with all of the mentioned techniques, hardware approaches are capable of data
reduction without adding any extra block to the microsystem. This is achieved by modifying
the present hardware of the implant. An implementation of one of these approaches focusing
on the ADC circuit of the system was presented and discussed in detail. The proposed method
results in considerable reduction of bit-rate in multi-channel neural recording microsystems.
Thus, efficient design of application-specific circuits for building blocks of neural implants
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Figure 20. Recorded neural signal and reconstructed neural signal
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Figure 20. Recorded neural signal and reconstructed neural signal
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Chapter 11
Multivariate Computing and Robust Estimating for
Outlier and Novelty in Data and Imaging Sciences
Michelle Yongmei Wang and Chris E. Zwilling
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/59750
1. Introduction
Data science is an evolutionary step in interdisciplinary fields incorporating computer science,
statistics, engineering, and mathematics. At its core, data science involves using automated
and robust approaches to analyze massive amounts of data and to extract informative
knowledge from them. Data science transforms traditional ways of analyzing problems and
creates powerful new solutions. Diverse computational and analytical techniques contribute
to data science. In this chapter, we review and also propose one type of data mining and pattern
recognition strategy that has been under development in multiple disciplines (e.g. statistics
and machine learning) with important applications ---- outlier or novelty detection [1-4].
In biomedical engineering, data science can make healthcare and medical imaging science not
only more efficient but also more effective for better outcomes and earlier detection. Outlier
and novelty detection in these domains plays an essential role, though it may be underappre‐
ciated and not well understood by many biomedical practitioners. From the healthcare point
of view, an outlier probably reflects the need for heightened vigilance, if not full-fledged
intervention. For example, an abnormally high glucose reading for a diabetic patient is an
outlier which may require action. In high-dimensional medical imaging, developing automat‐
ed and robust outlier detection methods is a critical preprocessing step for any subsequent
statistical analysis or medical research.
An exact definition of an outlier or novelty typically depends on hidden assumptions regard‐
ing the data structure and the associated detection method, though some definitions are
general enough to cope with varieties of data and methods. For example, outliers can be
considered as patterns in data that do not conform to a well-defined notion of “normal”
behavior, or as observations in a data set which appear to be inconsistent with the remainder
of that set of data. Figure 1 shows outliers in a 2-dimensional dataset. Since most of the
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
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observations fall into clusters N1 and N2, they are two “normal” regions; while points in region
O1 as well as points o2 and o3 are outliers (in red), due to their sufficiently far distance from
the “normal” regions. Identifying observations inconsistent with the “normal” data, or
detecting previously unobserved emergent or novel patterns is commonly referred to as outlier
detection or novelty detection [5, 6]. The distinction between novel patterns and outliers is that
the novel patterns are often incorporated into the “normal” model after being detected whereas
outliers are typically removed or corrected. This chapter aims to consider both detection
schemes and sometimes treat them interchangeably for some general purposes.
Figure 1. An example of outliers in a 2-dimensional dataset.
Figure 2. A 2-dimensional dataset with a multivariate outlier (lower right diamond in red).
Outlier and novelty detection methods can be divided into univariate and multivariate ap‐
proaches [7-10]. The early univariate methods typically assume a known data distribution, for
example, independently and identically distributed (i.i.d). In addition, many tests for detecting
univariate outliers further assume the distribution parameters and the outlier types are known.
However, these assumptions may be violated in real applications. Moreover, in many situa‐
tions multivariate outliers can not be identified when each variable is examined independently.
Multivariate analysis is usually required in these cases for precise outlier detection, which
Advances in Bioengineering318
observations fall into clusters N1 and N2, they are two “normal” regions; while points in region
O1 as well as points o2 and o3 are outliers (in red), due to their sufficiently far distance from
the “normal” regions. Identifying observations inconsistent with the “normal” data, or
detecting previously unobserved emergent or novel patterns is commonly referred to as outlier
detection or novelty detection [5, 6]. The distinction between novel patterns and outliers is that
the novel patterns are often incorporated into the “normal” model after being detected whereas
outliers are typically removed or corrected. This chapter aims to consider both detection
schemes and sometimes treat them interchangeably for some general purposes.
Figure 1. An example of outliers in a 2-dimensional dataset.
Figure 2. A 2-dimensional dataset with a multivariate outlier (lower right diamond in red).
Outlier and novelty detection methods can be divided into univariate and multivariate ap‐
proaches [7-10]. The early univariate methods typically assume a known data distribution, for
example, independently and identically distributed (i.i.d). In addition, many tests for detecting
univariate outliers further assume the distribution parameters and the outlier types are known.
However, these assumptions may be violated in real applications. Moreover, in many situa‐
tions multivariate outliers can not be identified when each variable is examined independently.
Multivariate analysis is usually required in these cases for precise outlier detection, which
Advances in Bioengineering318
allows for interactions over different variables to be taken into account within the class of data.
Figure 2 illustrates 2-dimensional data points, with the lower right observation (in red) a clear
multivariate outlier but not a univariate one. When analyzing each measure separately with
respect to the spread of values along the two dimensions, they are close to the center of the
univariate distributions. Therefore, the relationships between the two variables shall be
considered when testing for outliers, leading to multivariate methods that are the focus of this
chapter.
Another related topic is robust statistics for estimation that can handle outliers or at least is
less sensitive to the influence of outliers. Robust statistics perform well with data drawn from
a wide range of probability distributions, especially for distributions that are not normally
distributed. Robust statistical methods have been developed for many common problems,
such as estimating data properties including location and scatter or estimating model param‐
eters as in regression analysis [10, 11]. One motivation is to produce statistical methods that
are not unduly affected by outliers. Another motivation is to provide methods with good
performance when there are small departures from a parametric distribution. A typical
procedure or example of the former case is for multivariate estimation of location and
covariance as well as for multivariate outlier detection. In this case, as a first step, the ap‐
proaches often try to search for a minimum number of observations with a certain degree of
confidence being outlier-free. Based on this starting subset, location and covariance can be
estimated robustly. In a second step, outliers can be identified through computing the
observations’ distances with respect to these initial estimates.
In this chapter, we review and also propose statistical and machine learning approaches for
outlier and novelty detection, as well as robust methods that can handle outliers in data and
imaging sciences. In particular, robust statistical techniques based on the Minimum Cova‐
riance Determinant (MCD) are introduced in Section 2, which include a classical and fast
computation scheme of MCD and a few robust regression strategies. We present our newly
developed multivariate Voronoi outlier detection (MVOD) method for time series data and
some preliminary results in Section 3. This approach copes with outliers in a multivariate
framework via designing and extracting effective attributes or features from the data; Voronoi
diagrams allow for automatic configuration of the neighborhood relationship of the data
points, facilitating the differentiation of outliers and non-outliers. Section 4 reviews varieties
of machine learning methods for novelty detection, with a focus on probabilistic approaches.
In Section 5, we present some existing and new technologies related to outliers and novelty in
the area of imaging sciences. Section 6 provides concluding remarks of the chapter.
2. Robust statistical methods using Minimum Covariance Determinant
(MCD)
The Minimum Covariance Determinant (MCD) estimator is a highly robust estimator of
multivariate location and scatter. Since estimating the covariance matrix is the cornerstone of
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many multivariate statistical methods, the MCD has also been used to develop robust and
computationally efficient multivariate techniques.
2.1. MCD and its fast computing algorithm
Given a dataset consisting of p variables and n observations, i.e. a n × p data matrix, we can
represent this multivariate data as  X =(x1, …, xn)', where  xi, for i =1, …,  n, is the ith obser‐
vation and a p-dimensional vector. A classical distance measure, Mahalanobis distance (MD),
is given in Equation (1); it only depends on the sample mean (μ̂MD) and sample covariance
matrix (Σ̂MD), both of which are computed from the entire set of data.
MD(x)= (x - μ̂MD)'Σ̂MD-1 (x - μ̂MD) (1)
A point with a larger Mahalanobis distance will lie further away from the center of the data
cloud than a point with a smaller Mahalanobis distance. A robust distance (RD) measure is
achieved if we substitute the MCD estimate of mean (μ̂MCD) and covariance (Σ̂MCD) into
Equation (1), which yields Equation (2).
RD(x)= (x - μ̂MCD)'Σ̂MCD-1 (x - μ̂MCD) (2)
The classical estimates can be sensitive to outliers, while the MCD estimate is robust [8, 12,
13]. The MCD relies on a subset of the total observations. Choosing this subset makes the
algorithm robust because it is less sensitive to the influence of outlying points. Figure 3
illustrates the difference between these two estimates; it is a scatterplot of the distances for an
example dataset with 70 observations and 2 variables (i.e. n =70,  p =2). The two ellipses are two
outlier thresholds, determined by the 0.975 chi-square quantile with 2 degrees of freedom
when the classical and robust estimates are used, respectively. The dashed blue ellipse marks
off the 97.5% outlier threshold for the classical Mahalanobis distance, suggesting that two
observations lying beyond the ellipse are outliers. The 97.5% outlier threshold for the robust
distance measure is marked off by the solid red ellipse, suggesting ten points are outliers.
The MCD has a user-determined parameter,  h , which specifies the size of the subset of data
to base the estimate upon. It is constrained by (n + p + 1) / 2 ≤h ≤n. The h  observations are
chosen such that the determinant of the sample covariance matrix is minimal (but not mini‐
mized in the formal sense, because it relies on a sampling algorithm instead of a loss function).
The MCD is optimally designed for elliptically symmetric unimodal distributions, such as the
commonly encountered multivariate normal distribution. The MCD is most robust when
 h = (n + p + 1) / 2 . But this causes low efficiency [14] (at least for normal probability distribu‐
tions), which can be increased (while retaining high robustness) by applying reweighted
estimators [15, 16]. Robust statistical estimators are commonly evaluated both on their
breakdown value and influence functions. The MCD is a high breakdown estimator and its
influence function appears bounded, which is desirable. An alternative strategy that employs
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Delaunay triangulation to identify a robust outlier-free subsample in an adaptive way was
presented in [17].
Computing the exact MCD is possible but computationally difficult, as it requires the evalu‐
ation of all ( nh ) subsets of size h . Even though the MCD is a powerful robust estimator, it has
only become widely used since the development of the so-called Fast-MCD algorithm [18]
which we summarize below. Assume we have a dataset X =(x1, …, xn)' and let H1 ⊂ {1…n}
represent a h -subset of length constrained by (n + p + 1) / 2 ≤h ≤n. Denote this first h -subset as
H1 and it is randomly chosen from the entire dataset. Compute the mean μ̂MCD,1 and covariance
matrix Σ̂MCD,1 of H1, as well as the determinant of Σ̂MCD,1, denoted as  det(Σ̂MCD,1). Then compute
the distance of all n observations in the entire dataset (and not just the h  comprising the initial
subset) using Equation (2). Next, these distances are ordered from smallest to largest. Retain
an equivalent number of observations from this ordering as chosen in the initial h -subset; but
instead of being chosen arbitrarily as in the initial subset, these are chosen such that they have
the smallest distances as defined by the order statistics. Call this subset of observations H2,
and compute μ̂MCD,2, Σ̂MCD,2 and  det(Σ̂MCD,2). Now Equation (3) must be true:
det  (Σ̂MCD,2)≤  det(Σ̂MCD,1) (3)
Going from H1 to H2 is called a C-step for “Concentration step”, because the algorithm
concentrates on the h  observations with the smallest distances and det(Σ̂MCD,2) is more
concentrated (or equivalently, has a smaller determinant). This C-step is repeated numerous
or sufficient times, with each iteration using a different initial h -subset. The 10 subsets that
yield the smallest determinants overall are retained and further concentrated until conver‐
gence is met.
Figure 3. Outlier thresholds, as represented by ellipses, based on a classical and a robust scheme.
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2.2. Robust multivariate regression and Multivariate Least-Trimmed Squares (MLTS)
estimator
Section 2.1 introduced the robust MCD estimator and showed how the MCD can be computed
efficiently. In this section, we review different frameworks for applying the MCD estimator to
multivariate regression. These methods offer robust alternatives to standard multiple regres‐
sion analysis.
We first look at robust multivariate regression in [19]. Suppose we have a full dataset of
predictors and responses containing no outliers; computing the regression parameter esti‐
mates from the full dataset using a least squares procedure will yield accurate results. With
outliers present in the dataset, the MCD is used to search for a subset of size h  whose covariance
matrix has the smallest determinant with h  constrained by (n + p + q + 1) / 2 ≤h ≤n, where p and
q are respectively the numbers of variables for the predictor and response matrices, and n is
the number of observations. Then, using this subset h , the sample mean and covariance
estimates are calculated, which would allow for accurate estimation of the regression coeffi‐
cients and covariance matrix of the errors in the presence of outliers.
Different from the above robust multivariate regression, the multivariate least trimmed
squares (MLTS) estimator in [20] first fits a regression model to the subset of data and then
calculates the covariance matrix of the residuals. The estimator is defined by minimizing a
trimmed sum of squared Mahalanobis distances, and can be computed by a fast algorithm. Let
us consider the classical multivariate regression framework. Assume we have a sample of data
defined as Zn ={(xi, yi); i =1, …, n} and let X =(x1, …, xn)' denote the design (or predictor)
matrix and Y =(y1, …, yn)' denote the response matrix. The regression model is:
Y = Xβ + ε (4)
The classical least squares estimator for the regression parameter is given by:
β̂ LS =(X 'X )-1X 'Y (5)
and the classical estimator of the scatter matrix is:
Σ̂LS =
1
n - p (Y - X β̂ LS )'(Y - X β̂ LS ) (6)
These classical least squares estimators are sensitive to outliers. A robust alternative to these
estimators based on the residuals is achieved as below. For any β∈ℝ p+q, let ri(β)= yi - β 'xi denote
the residuals from the fitted regression model. Furthermore let ℋ={H ⊂ {1, …, n}| # H =h } be
the collection of all subsets of size h . For any H ∈ℋ denote β̂ LS (H ) the least-squares fit solely
on the observations {(x j, y j); j ∈ H }. In addition, for all H ∈ℋ and β∈ℝ p+q denote the cova‐
riance matrix of the residuals with respect to the fit β, belonging to subset H as:
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cov(H , β)= 1h ∑
j∈H
(r j(β) - r̄ H (β))(r j(β) - r̄ H (β))' (7)
where r̄ H (β)=
1
h ∑ j∈H r j(β). If we let Σ̂LS (H )=  cov(H , β̂ LS(H )) for any H ∈ℋ, the MLTS estimator
is defined as:
β̂MLTS (Zn)= β̂ LS (Ĥ ) (8)
where Ĥ ∈argmin
H∈ℋ  det Σ̂LS (H ). The covariance of the errors can be estimated by
Σ̂MLTS (Zn)=cαΣ̂LS (Ĥ ) (9)
where cα is a consistency factor. The observations corresponding to the residuals with the
smallest determinant of the covariance matrix can then be used to give robust results for the
regression parameters.
Using the MLTS as a means to estimate the parameters of the Vector Autoregressive (VAR)
Model was presented in [21]. The VAR model is popular for modeling multiple time series.
Estimation of its parameters based a typical least squares method is unreliable when outliers
are present in the data. Development of robust procedures for multiple time series analysis is
more crucial than for univariate time series analysis due to the data correlation structure.
Experimental results in [21] show that applying the reweighted MLTS procedure to the VAR
model leads to robust multivariate regression estimators with improved performance.
3. Multivariate Voronoi Outlier Detection (MVOD) for time series
In order to better analyze multivariate time series data, we have recently proposed a general
outlier detection method based on the mathematical principles of Voronoi diagrams. It is
general because different attributes or features can be extracted from the data for Voronoi
diagram construction. These attributes or features can be designed based on the nature of the
data and the outliers. This has the potential to increase the accuracy and precision of outlier
detection for specific application problems.
3.1. Background on Voronoi diagram
Our new method requires a Voronoi diagram, which is composed of Voronoi cells [22]. A
Voronoi diagram is a way of dividing space into regions. Assume we have a set S  of n points,
p1, …, pn in the Euclidean plane. Let V (pi) denote a Voronoi cell, which is a subdivision of the
plane where the set of points q are closer or as close to pi than to any other point in S . This is
expressed formally in Equation (10):
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V (pi)= {q |dist(pi, q)≤dist(p j, q), ∀ j ≠ i} (10)
where dist is the Euclidean distance function. The set of all Voronoi cells for all n points
comprises a Voronoi diagram.
Figure 4 shows part of a Voronoi diagram, assuming Euclidean distance between the points.
If one used a different distance metric, the Voronoi diagram would be configured differently.
The plane is decomposed into n convex polygonal regions, one for each pi. Vertices (or nodes)
are called Voronoi vertices and are equidistant to three or more sites. Voronoi edges are the
segments defined as the boundaries between two Voronoi cells and contain all the points in
the plane equidistant to the two nearest sites. The boundaries of a Voronoi cell V (pi) cannot
exceed n - 1 edges. Three important theorems apply to Voronoi diagrams:
Theorem 1: Every nearest neighbor ofpi defines an edge of the Voronoi polygonV (pi).
Theorem 2: Every edge of the Voronoi polygonV (pi) defines a nearest neighbor ofpi.
Theorem 3: Forn ≥3, a Voronoi diagram onnpoints has at most 2n - 5 vertices and3n - 6 edges.
Figure 4. A subset of Voronoi cells from a Voronoi diagram.
3.2. Our proposed MVOD method
The Voronoi Outlier Index (VOInd) used in our Multivariate Voronoi Outlier Detection
(MVOD) method is based upon the Voronoi notion of nearest neighbors. For a point pi of set
S , the nearest neighbors of pi defined by the Voronoi polygon V (pi) are the Voronoi nearest
neighbor of pi, denoted as V NN (pi). In Figure 4 the nearest Voronoi neighbors to point p1 are
p2, p3, p4, p5 and p6. For each point in the data set, our method uses the nearest neighbors to
compute an index (i.e. VOInd) of how likely that point is an outlier. It is multivariate because
it aggregates information across all individual time series, thus retaining features which might
be common to the entire interlocking set of variables.
Our method is based upon the geometric principles of Voronoi diagrams for defining the
neighborhood relationship of the data points and this facilitates the assignment of group or
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data membership (i.e. outliers and non-outliers). Construction of a two dimensional Voronoi
diagram requires two coordinates for each data point. Based on the nature of the data and the
nature of the outliers to be identified, we can embed their attributes into the coordinates via
extracting different valid features from the data. Here, we present one such case of the MVOD
framework for feature extraction; but many others are also possible, including nonparametric
forms. Figure 5 overviews the process and the rest of this subsection explains the steps in more
detail.
Figure 5. Flow chart of our MVOD procedure for outlier detection.
Feature Set 1 (feature value for the x-coordinate): In order to determine how a single obser‐
vation (at the same time point, across all time series under consideration) affects the covariance
matrix (which is a measure of inter-relationship among the individual time series), we remove
a given point from the data set and then use Multivariate Least Trimmed Squares (MLTS)
introduced in Section 2.2, which computes a determinant of the covariance matrix without that
point, to yield a single feature value. Removing one observation at a time is not part of the
original MLTS method; we introduced this modification into the procedure to show the effect
of removing that observation from all the time series. This determinant is known as the
generalized variance and can be interpreted as a volume. If we have outlying observations,
the volume will be larger. But if we remove those outlying observations, the volume will be
smaller.
Feature Set 2 (feature value for the y-coordinate): This is a two-step process. In Step 1, we
take the absolute value of all time series points for all variables, which provides some infor‐
mation about the total magnitude each time series contributes. However, sometimes, magni‐
tude alone is not sufficient for outlier detection as some data may have less extreme values
than those data with the largest magnitudes but are actually outliers for the data [23]. One way
to address this issue is by using the residual to calculate the feature value for the y-coordinate.
So Step 2 consists of fitting an appropriate model to the multivariate time series data and then
computing the residuals. Here, we estimate the parameters for a Multivariate Vector Auto-
Regressive (MVAR) model because our simulated data are generated from this type of model.
Once these residuals are obtained for each time series, they are squared and then summed
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across all time series. Finally, the feature value for the y-coordinate is determined by multi‐
plying together the results of Step 1 and Step 2. Specifically, let yi denote the ith observation
of the time series of length n, and ri denote the residual after fitting the MVAR model for each









Although a regression model is used here in Step 2 to extract the feature value, in fact, our
method does not require this model. With either Step 1 or Step 2 alone, we will have a
corresponding nonparametric or parametric basis, both of which could be suitable for different
applications or datasets.
Voronoi Outlier Index (VOInd): Given the two feature sets (from the above procedures) that
can be used as the x-coordinates and y-coordinates for the data, we construct the Voronoi
diagram based on Section 3.1 and compute a Voronoi Outlier Index (VOInd) for each time
series point. The VOInd for point pi has as its numerator the sum of the Euclidean distance
(dist) between each point and all its nearest neighbors. This is divided by the denominator
term which is the number of nearest neighbors, yielding an average density, as expressed in
Equation (12):
VOInd(pi)=∑O∈V NN ( pi) dist(pi, o) /  |V NN (pi)| (12)
Note that a Voronoi outlier factor is used in [24] as the index which, however, was completely
univariate in nature, since the x-and y-coordinates were based on a univariate time series. One
of our primary motivations for this study is to create a novel and general MVOD method,
which can detect outliers in time series data in a multivariate framework with multiple,
interlocking sets of variables.
3.3. Experimental evaluation and results
Simulation Setup and Data Generation: For each analysis, 5 multivariate autoregressive time
series, each containing 100 observations, were simulated 25 times using published Matlab code
[25]. The time series were generated using a Gaussian process with mean 0 and standard
deviation 1. The variance/covariance matrix contained all 1’s on the diagonal and all 0’s on the
off-diagonals. A total of 12 different unique multivariate time series were constructed, each
with differing numbers of outliers and strength/magnitude of the outliers. 5, 10 or 15 outliers
were introduced into a time series and the magnitude of those outliers was 1, 2, 3, 4 or 5. All
combinations of number of outliers and outlier magnitude were constructed; but they were
never mixed. For instance, if we introduced 5 outliers of magnitude 3 into a simulated time
series, only 5 outliers of magnitude 3 were used for all 25 simulated time series in that set. The
observation to which the outliers were introduced into the time series was always determined
randomly. Once the observations had been selected for outlier introduction, the same number
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of outliers for the given magnitude was added or subtracted (if the original observation was
negative) to each of the five components of the multivariate time series.
Validation Criteria and Procedure: We validated and compared the performance of our new
Voronoi Outlier Detection (MVOD) method with the MLTS, using True and False Positive
Rates (TPR and FPR) as defined in Table 1.
Outlier in data?
(Gold Standard)
Definition of TPR and FPR
True Positive Rate (TPR)
= TP / (TP + FN)Yes No
Detected
Outlier?
Yes TP FP False Positive Rate (FPR)
= FP / (FP +TN)No FN TN
Table 1. Definition of True (TPR) and False (FPR) Positive Rate.
The alpha parameter in the MLTS method determines both the size of the subset to use as well
as a critical value in a chi-square distribution. If an observation is greater than this threshold
in the chi-square distribution, then the MLTS method flags the observation as an outlier.
However, it is critical to note that a one-to-one correspondence does not exist between the
alpha value chosen, and the number of outliers flagged. For instance, one could set alpha at
0.10 but only have 2 out of 100 observations flagged as outliers. Partly for this reason we
considered a range of alpha values and then averaged across this range to fairly compare with
the MVOD method. For all simulated time series, we considered alpha between 0.01 and 0.20.
True Positive Rate False Positive Rate
Number of Outliers Number of Outliers







MVOD 0.52 0.52 0.54 0.037 0.065 0.094
MLTS 0.21 0.37 0.32 0.012 0.028 0.047
2
MVOD 0.91 0.79 0.78 0.025 0.041 0.056
MLTS 0.63 0.61 0.73 0.002 0.012 0.011
3
MVOD 0.96 0.83 0.86 0.023 0.037 0.045
MLTS 0.93 0.78 0.80 0.004 0.006 0.005
4
MVOD 0.96 0.86 0.88 0.023 0.034 0.042
MLTS 0.97 0.87 0.85 0.002 0.002 0.003
5
MVOD 0.96 0.86 0.90 0.023 0.034 0.039
MLTS 0.96 0.90 0.87 0.002 0.002 0.002
Table 2. True and False Positive Rates for MVOD and MLTS with 5, 10, or 15 outliers of magnitudes 1, 2, 3, 4, or 5.
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In the results presented next, we obtained the TPR and FPR for the two methods in the
following way. For a given number of outliers with a specific outlier magnitude, we averaged
a total of five cases. The five cases averaged always included the threshold (MVOD) or alpha
value (MLTS) corresponding with the number of outliers, but also contained the preceding
four cases as well. For instance, in the 10 outlier case, we took the results for threshold=10
(MVOD), as well as thresholds of 9, 8, 7 and 6. In the corresponding MLTS case, we would
have taken alpha=0.10, 0.09, 0.08, 0.07 and 0.06. The TPR and FPR for each of these five cases
for each method were averaged to obtain the values shown in Table 2.














Figure 6. True Positive Rate (TPR, y-axis) for MVOD and MLTS for 5 outliers (top panel), 10 outliers (middle panel),
and 15 outliers (bottom panel) with outlier magnitudes of 1, 2, 3, 4 or 5 (x-axis).
Results:Table 2 and Figure 6 show that in terms of the TPR, our method outperforms the MLTS
when the outlier strength is low (i.e. magnitudes of 1 and 2) and has slightly better performance
than the MLTS for medium outlier strength (i.e. magnitude of 3), while the two approaches
are comparable when the outlier strength is high (i.e. magnitude of 4 and 5). As evident from
Table 2, for the FPR, the two methods have similar behavior, with negligible difference on the
order of 10-2. Additionally, the number of outliers (5, 10 or 15) does not have an obvious effect
on either of the methods. In summary, the experiments demonstrate that our MVOD method
can work effectively and accurately in detecting the outliers from the multivariate time series
data. Compared to MLTS, the MVOD is more sensitive in detecting the small magnitude
outliers, which are often difficult for an outlier detection algorithm. Furthermore, both our
MVOD and the MLTS work reasonably well for a wide range of contamination levels. That is,
both methods are quite robust to the number of outliers in the dataset.
4. Machine learning methods for novelty detection
Novelty detection can be considered as the task of classifying test data that differ in some
respect from the data that are available during training. This may be approached within the
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framework of “one-class classification” [3], in which a model is built to describe “normal”
training data. Novelty detection methods can be categorized into several areas such as
probabilistic, distance-based, reconstruction-based, domain-based, and information-theoretic
techniques. In this section, we mainly introduce the first category of probabilistic approaches,
and briefly summarize the others.
4.1. Probabilistic approaches
Probabilistic approaches to novelty detection are based on estimation of the generative
probability density function of the data, which may then be used to define thresholds for the
boundaries of “normality” in the data space and test whether or not a test sample is from the
same distribution. Statistical hypothesis tests are the simplest statistical techniques for novelty
detection [5]. Among the different statistical tests for novelty detection, here we concentrate
on more advanced statistical modeling methods involving complex, multivariate data
distributions. Techniques for estimating the underlying data density from multivariate
training data broadly fall into parametric and nonparametric methods. The former imposes a
restrictive model on the data, leading to a large bias when the model does not fit the data; the
later builds up a very flexible model with fewer assumptions but requires a large sample size
for a reliable fit of all free parameters when the model size becomes large.
In parametric approaches, the widely used distribution form for continuous variables is
Gaussian. The involved parameters are estimated from the training data via maximum likelihood
estimates (MLE), for which a closed-form analytical solution is available for a Gaussian
distribution. More complex data distribution forms can be modeled through mixture models
(e.g. Gaussian Mixture Models, or GMMs for short), or other mixtures of different types of
distributions (e.g. the gamma, the Poisson, the Student’s t, and the Weibull distributions) [26,
27]. When the form of the data distribution is not available, Gaussian distribution is usually
taken due to its convenient analytical properties. The parameters of the GMMs can be
estimated with maximum likelihood methods (using optimization algorithms including
conjugate gradients or expectation-maximization, EM) or with Bayesian methods (e.g.
variational Bayes) [26]. Besides the requirement of large numbers of training examples in
estimating model parameters, another limitation of parametric methods is that the chosen data
distribution form and the model generating the data may not match well. Despite the limita‐
tions, GMMs have been a popular scheme for novelty detection. The other strategy for novelty
detection is to utilize time-series approaches, for example, the stochastic process of Autore‐
gressive Integrated Moving Average (ARIMA), which can be used to predict the next data point
and determine whether or not it is artefactual [28]. State-space models are also typically used
for novelty detection in time-series data, assuming there is some underlying hidden state that
generates the observations and this hidden state evolving through time [29]. The Hidden
Markov Model (HMM) and the Kalman filter are two common state-space models for novelty
detection.
Non-parametric methods do not assume a fixed structure of a model; the model grows in size
as necessary to fit the data and accommodate the data complexity. A common non-parametric
approach for probabilistic density estimation is the kernel density estimator [26], which
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estimates the probability density function with a large number of kernels over the data space.
The kernel density estimator places a kernel (e.g. Gaussian) on each data point and then sums
the contributions from a localized neighborhood of the kernel. This is the so-called Parzen
windows estimator [30], which has been used for novelty detection in a number of applications
including mammographic image analysis [31]. One-class classification based on Gaussian
Processes (GPs) has been developed and used recently [32]. This technique also takes a point-
wise approach to novelty detection, which divides the data space into regions with high and
low supports depending on whether those regions are close to those occupied by “normal”
training data, or not. A related way of detecting novelty is based on the well-established area
of changepoint detection [33], with the goal of determining whether the generative distribution
of a sequence of observations has remained stable or has undergone some abrupt change. Here
in addition to detecting whether a change has occurred or not, another aim is to estimate the
time that the change has occurred. When applied in a batch or online setting, the idea of
changepoint detection to the retrospective problem is identifying a test statistic suitable for
testing the hypothesis that a change has occurred versus the one that no change has occurred.
A likelihood ratio statistic, as well as others [33, 34], would be appropriate.
4.2. Other categories
Distance-based approaches, such as clustering or nearest-neighbor methods [35-37], are
another types of techniques that can be used for classification or for estimating the probability
density function of data. The underlying assumption is that “normal” data are tightly clus‐
tered, while novel data occur far from their nearest neighbors. These methods use well-defined
distance metrics to compute the distance (e.g. similarity measure) between two data points.
Reconstruction-based methods involve training a regression model with the training data [3,
38, 39]. The distance between the test vector and the output of the system (i.e. the reconstruction
error) can be related to the novelty score, which would be high when “abnormal” data occurs.
For instance, neural networks can be used in this way and show many of the same advantages
for novelty detection as they do for typical classification applications. Another type of
reconstruction-based novelty detection is subspace-based techniques. They assume that data
can be projected or embedded into a lower dimensional subspace, which makes better
discrimination of “normal” and “abnormal” data easier.
Domain-based methods often aim to describe a domain that contains “normal” data through
a boundary around the “normal” class following the distribution of the data without explicitly
providing a distribution [40, 41]. These techniques are usually insensitive to the specific
sampling and density of the interested class. The location to the boundary is the criterion for
determining the class membership of unknown data. Novelty detection support vector
machines (SVMs) are the “one-class SVMs”, which set the location of the novelty boundary
only based on the data lying closest to it in the transformed feature space. That is, the novelty
boundary is determined without considering the data that are not support vectors.
Information-theoretic methods calculate the information content of a dataset with measures
such as entropy, relative entropy, and Kolmogorov complexity, etc. [42, 43]. The key idea is
that novel data alter the information content in a dataset significantly. A common procedure
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is: metrics are computed using the entire dataset and then the subset of points whose elimi‐
nation from the dataset causes the largest difference in the metric are identified. The data
contained in this subset is then assumed to be novel data.
5. Robust estimator and outlier detection in high-dimensional medical
imaging
The statistical analysis of medical images is challenging, not only because of the high-dimen‐
sionality and low signal-to-noise ratio of the data, but also due to varieties of errors in the
image acquisition processes, such as scanner instabilities, acquisition artifacts, and issues
associated with the experimental protocol [44]. Furthermore, populations under study
typically present high variability [45, 46], and therefore the corresponding imaging data may
have uncommon though technically correct observations. Such outliers deviating from
normality could be numerous. With emergence of large medical imaging databases, develop‐
ing automated outlier detection methods turns out to be a critical preprocessing step for any
subsequent statistical analysis or group study. In addition, medical imaging data are usually
strongly correlated [47]; outlier detection approaches based on multivariate models are thus
crucial and desirable. Procedures using the classical MCD estimator are not well-suited for
such high-dimensional data.
In [48], several extensions to the classical outlier detection framework are proposed to handle
high-dimensional imaging data. Specifically, the MCD robust estimator were modified so that
it can be used for detecting outliers when the number of observations is small compared to the
number of available features. This is achieved through introducing regularization in the
definition and estimation of the MCD. Three regularization procedures were presented and
compared: l1 regularization (RMCD - l1); l2 regularization or ridge regularization (RMCD - l2);
and random projections (RMCD - RP). The idea of RMCD - RP  is to run the MCD estimator on
datasets of reduced dimensionality, and this dimensionality reduction is done by projecting
to a randomly selected subspace. In addition, the parametric approach of the regularized MCD
estimators is compared to a non-parametric procedure, the One-Class SVM algorithm (see
Section 4). Experimental results on both simulated and real data show that l2 regularization
performs generally well in simulations, but random projections outperform it in practice on
non-Gaussian, and more importantly, on real neuroimaging data. One-Class SVM works well
on unimodal datasets, and it has a strong potential if their parameters can be set correctly.
Outlier detection methods described above can serve as a statistical control on subject inclusion
in neuroimaging. However, sometimes it is controversial regarding whether or not outliers
should be discarded, and, if so, what tolerance to use. An alternative strategy is to utilize
outlier-resistant techniques for statistical inference, which would also compensate for inexact
hypotheses including data normality and homogeneous dataset. Robust techniques are
especially useful when a large number of regressions are tested and assumptions cannot be
evaluated for each individual regression, as with neuroimaging data.
Both individual subject and group analyses are required in neuroimaging. At a typical single
subject level, a multiple regression model is used for the time series data at each voxel [49,
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50], and outliers (or other assumption violations) in the time series would impact the model
fitness. Robust regression can minimize the influence of these outliers. At the group level, after
spatial normalization, a common strategy is to first save the regression parameters for each
subject at each voxel and then perform a test on the parameter values. Robust regression used
at this level can minimize the influence of outlying subjects. Wager et al. [51] used simulations
to evaluate several robust techniques against ordinary least squares regression, and apply
robust regression to second-level group analyses in three real fMRI datasets. Experimental
results demonstrate that robust Iteratively Reweighted Least Squares (IRLS) at the second level
is computationally efficient; it increases statistical power and decreases false positive rates
when outliers are present. Without the presence of outliers, IRLS controls false positive rates
at an appropriate level. In summary, IRLS shows significant advantages in group data analysis
and in the hemodynamic response shape estimation for fMRI time series data.
6. Conclusions
Outlier and novelty detection is a primary step in many data mining and analysis applications,
including healthcare and medical research. In this chapter, statistical and machine learning
methods for outlier and novelty detection, and robust approaches for handling outliers in data
and imaging sciences were introduced and reviewed. Particularly, we also presented our new
method for outlier detection in time series data based on the Voronoi diagram (i.e. MVOD).
There are several key advantages of our method. First, it copes with outliers in a multivariate
framework by accounting for multivariate structure in the data. Second, it is flexible in
extracting valid features for differentiating outliers from non-outliers, in the sense that we have
the option of using or not using a parametric model. Lastly, Voronoi diagrams capture the
geometric relationship embedded in the data points. Initial experimental results show that our
MVOD method can lead to accurate, sensitive, and robust identification of outliers in multi‐
variate time series.
It is often difficult to reach a precise definition of outlier or novelty, and suggesting an optimal
approach for outlier or novelty detection is even more challenging. The variety of practical
and theoretical considerations arising in real-world datasets lead to the variety of techniques
utilized [52]. Therefore, there is no single universally applicable detection method due to the
large variety of considerations, which could include the application domain, the type of data
such as dimension, and the availability of training data, etc. Based on the application and the
nature of the associated data, developing suitable computational methods that can robustly
and efficiently extract useful quantitative information from big data is still a current challenge
and gaining increasing interest in data and imaging sciences.
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Chapter 12
Energy Transfer and Dissipation in non-Newtonian
Flows in non-Circular Tubes
Mario F. Letelier
Additional information is available at the end of the chapter
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1. Introduction
In general, physiological processes are basically isothermal and isobaric. Several mechanisms
contribute to keep constant pressure in systems such as blood vessels, among them diameter
distribution and peristaltic motion. In this, it is to be understood that pressure constancy refers
to time-averaged or extreme values.
Many pathologies make the human body develop fever, which raises temporarily body
temperature. It is common practice to use, in some cases, medicines that restore, albeit for a
given period of time, normal temperature. Fever is not the only cause of body heat-transfer.
This process also occurs with body adjustment to changes in ambient temperature, physical
exertion, metabolism acceleration due to food ingestion, drug effects, and others. During these
body changes, blood and other fluid vessels undergo heat-transfer processes that pose
considerable difficulties to physical modeling. Some pertinent variables are fluid composition,
vessel elasticity, peristaltic motion in some cases, unsteadiness, and complex vessel geometry.
Heat-transfer in tube-flow has been investigated for several decades. One main practical
driving force for such studies is the need to understand and design efficient heat-transfer
equipment, widely used in several industrial areas. Models of simple tube-flow heat-transfer
problems are now textbook´s standard contents.
These include laminar Newtonian steady flow in round tubes with simple boundary condi‐
tions. More recently, as it is reviewed in the next section, Newtonian and non-Newtonian flows
in tubes of geometry other then circular have been modeled and analyzed. One important
finding as to this chapter´s objective is the effect of the interplay between tube geometry and
non-linear viscoelasticity.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
Such coupling leads to the development of secondary flows, or helicoidal flows, that increase
the transversal transport capacity of the flow, a phenomenon that can be applied, or related,
to heat-transfer enhancement, or to other transversal transport processes, such as cross-
sectional transport of particles immersed in the fluid.
Especially in blood flow, cells and other components introduce viscoelasticity [1, 2] that
becomes relevant in smaller blood vessels. The understanding of its effect on the flow charac‐
teristics may become very relevant in cases such as heart arteries, and when artificial implants
affect the blood flow. Also blood plastic effects appear is smaller vessels due to the aggregation
of red blood cells at low shear rates, which develop a yield stress to be overcome for the flow
to ensue.
Drawing on the above results, in this chapter it is presented a summary of relatively new
analytical findings that may be useful for the better understanding of heat-transfer and
complex flow phenomena in vessels that share some characteristics with biological vessels,
particularly when these work under abnormal conditions. Also it is analyzed the effect of
geometry in energy dissipation. This chapter is closely related to [3].
2. Mathematical models
Non-linear viscoelasticity and fluid plasticity are related in the following to heat- transfer and
energy dissipation processes. Next are presented the mathematical models to be considered
together with some remarks as to the corresponding state-of-the art, and relevant develop‐
ments with related references.
2.1. Viscoelastic flow
The physical model considered is a straight tube of arbitrary cross-sectional shape, in which a
non-Newtonian fluid moves along the axial coordinate z impelled by a pressure gradient,
which can be a function of t =  time. Secondary flows are induced when the necessary conditions
operate. The flow is assumed laminar, incompressible and with constant properties. Consid‐
ering Cartesian coordinates, the velocity field can be expressed as (u, v, w) in which the velocity
components align with the (x, y, z) axes respectively. The temperature and velocity fields are,







Figure 1. Definition diagram
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Two well-known problems are here relevant, i.e.,
1. Flow with constant wall heat-flux, in which the wall temperature is assumed constant at
any cross-section, with prescribed axial variation.
2. The “Graetz problem”, in which the flow is assumed isothermal up to a point z =0, from
which on a different constant temperature is applied at the wall, so that the fluid is
progressively heated or cooled.
Experimental findings concerning heat-transfer characteristics of aqueous polymer solutions
flowing in straight tubes point at considerable enhancement as compared to its Newtonian
counterpart driven by the same conditions and in the same geometry. Specifically it is reported
that heat-transfer results for viscoelastic aqueous polymer solutions are considerably higher
in flows fully developed both hydrodynamically and thermally, as much as by an order of
magnitude depending primarily on the constitutive elasticity of the fluid and to some extent
on the boundary conditions, than those found for water in laminar flow in rectangular ducts
[4, 5]. Heat-transfer phenomena in laminar flow of non-linear fluids has not been the subject
of many investigations with the exception of round pipes, and the case of inelastic shear-
thinning fluids in tubes of rectangular cross-section, in spite of the widespread use of some
specific contours in industry such as flattened elliptical tubes.
This statement is true for all cross-sectional shapes for both steady and unsteady phenomena
including quasi-periodic flows. Heat-transfer with viscoelastic fluids has been declared to be
a new challenge in heat-transfer research in the early nineties [6], but progress has been limited
since that time. The physics of the phenomenon has not been entirely clarified.
Highly enhanced heat-transfer to aqueous solutions of polyacrylamide and polyethylene of
the order of 40–45% as compared to the case of pure water in flattened copper tubes was
observed by Oliver [7] and later by Oliver and co-workers as early as 1969. Recent numerical
investigations in rectangular cross-sections of Gao and Hartnett [8, 9], Naccache and Souza
Mendes [10], Payvar [11] and Syrjala [12] establish the connection between the enhanced heat-
transfer observed and the secondary flows induced by viscoelastic effects. The former
researchers as well as Naccache and Souza Mendes predict for instance viscoelastic Nusselt
numbers as high as three times their Newtonian counterparts. Gao and Hartnett [8, 9].report
numerical results in rectangular contours which provide evidence that the stronger the
secondary flow (as represented by the dimensionless second normal stress coefficient Ψ2) the
higher the value of the heat-transfer (as represented by the Nusselt number Nu) regardless the
combination of thermal boundary conditions on the four walls. Constant heat flux is imposed
everywhere on the heated walls in their numerical experiments with the remaining walls being
adiabatic. The combination of boundary conditions plays some role in the enhancement
reported with the largest enhancement occurring when two opposing walls are heated. Despite
these efforts heat-transfer characteristics of viscoelastic fluids in steady laminar flow in
rectangular tubes remains very much an open question (quoted from Siginer and Letelier [13]).
Coelho et al [14] presented an analytical solution for the Graetz problem for the MPTT fluid
for a circular tube, steady flow, including several computations for negative heat flux (flow
cooling). Valko [15] published a solution of the Graetz problem using a power-law fluid model;
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he determined the influence of the Brinkman number for several flow conditions in circular
tubes. Kin and Özisik [17] published work on transient laminar forced convection of a power-
law fluid in ducts with sudden change in wall temperature. In these and related references it
is reflected the actual state-of-the-art in this subject.
Concerning numerical analysis, there is only one available commercial package for viscoelastic
fluid flow computations, POLYFLOW. However POLYFLOW cannot handle even relatively
high Weissenberg number flows and although convergent, gives erroneous results of the order
of 400% as compared to analytical test cases, Filali et al. (2012). In addition it cannot handle
heat-transfer in steady viscoelastic fluid flow in tubes. Thus to study problems of this type a
numerical algorithm has to be built from scratch and tested for stability (Hadamard-type).
Numerical analysis is not considered in this chapter.
Two well-known models of non-linear viscoelastic fluids are next described:
Modified Phan-Thien-Tanner (MPTT)
2ηmD =(1 + 0ληm0 tr  τ)τ + λ(V ∙∇τ -φτ - τφ T ) (1)
Giesekus
τ + λτ̌ + αλη0 τ ∙τ =η0D
τ̌ = - ((∇  V )T ∙τ + τ ∙∇V )
(2)
In the following, the MPTT model is applied to the flow field analysis. For the purposes of this
presentation, there is some evidence [17] that both models lead to qualitatively similar results.
The applicable equation of motion for 3-D, steady and incompressible flow are, in cylindrical
coordinates:
Continuity
∇ ∙V =0 (3)
Momentum
V ∙∇V =∇ ∙σ (4)
or, in expanded form
















∂ z (rσ zr)) - σθθr (5)
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In the above, u,  v,  w are the radial, tangential and axial velocity components, σ is the stress
matrix and P  is the piezometric pressure. Scale factors applied are a (base radius) for r ,  w0 for
the velocity components, and ηN w0 / a for the stress components, in which ηN  is the Newtonian
viscosity.
The MPTT model of viscoelastic fluid is next expressed, in dimensional variables, through the
following equations, i.e. [18].
σ = - PI + 2ηN D + τ (8)
2ηmD = f (ε0, trτ)τ + λτ∇ (9)
τ∇= ∂ τ∂ t + V ∙∇τ - (∇V T - ξD)τ - τ(∇V T - ξD)T (10)
where D is the rate of deformation tensor and τ is the non-Newtonian component of the shear
stress.
Defining
φ =∇ ∙∇V T -  ξD (11)
then, a more compact form of (10), is
τ∇=V ∙∇τ -φτ -  τφ T (12)
In this ηm is a viscosity, ε0 ,  ξ are material parameters, and λ is the relaxation time.
The function f, as defined in the MPTT model can be simplified for small values of ε0, yielding
f (ε0, trτ)= exp
( ε0ληmo trτ) = ∑
n=0
∞ 1
n ! ( ε0ληmo trτ)n =1 + ε0ληmo trτ + O(ε02) (13)
where from
2ηmD =(1 + ε0ληm0 tr  τ)τ + λ(V ∙∇τ -φτ - τφ T ) (14)
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For this constitutive equation the viscosity is defined as
ηm =ηm0
1 + ξ(2 - ξ)λ 2κ 2
(1 + λ 2κ 2)(1-m)/2 (15)
in which
κ = 2trD 2 (16)
and where ηm0,  and m are additional material parameters. If m=1, then (15) reduces to
ηm =ηm0 1 + λ
2ξ(2 - ξ)κ 2 (17)
Coming back to dimensionless variables and parameters (14) becomes
2(1 + 2ξ(2 - ξ)Wi2trD 2)D =(1 + ε0 Wi trτ)τ + Wi τ∇ (18)




By combining equations (18), (8) and (5-7), it is obtained the set of working equations in full,
i.e.
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in which the functions Fr ,  Fθ and Fz are the viscoelastic forcing functions that determine the
transversal flow. For developed flow, all derivatives with respect to z, excepted for the
pressure, must be put equal to zero.
The explicit expressions for the extra forcing terms are:
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For steady flow of an incompressible fluid with constant properties, the energy equation, in
terms of the temperature T can be written as
ρ0Cp
DT
Dt =Φ + ∇ ∙ (k∇T ) (26)
Where ρ0 is the density, Cp is the specific heat at constant pressure, ϕ is the dissipation function,
and k is the thermal conductivity coefficient. Further, it is assumed negligible dissipation and
constant k. Under these assumptions (26) becomes







Viscoplastic fluids are fluids that exhibit yield stress, which must be overcome before the
material develops deformation. As already mentioned plasticity appears in small blood vessels
due to red cell aggregation.
Also, many industrial fluids exhibit yield stress, and are found in areas such as mining
(slurries), food (pastes), construction (concrete and mud), cosmetics, etc. Flow and heat-
transfer description in tubes and other configurations is compounded by their geometry, which
brings in non-linear constitutive equations, except for very simple shapes. Some recent
research in this field include flow around a cylinder by Tokpavi et al. [19] particle sedimenta‐
tion, Yu and Wachs [20], flow in an eccentric annular tube, Wachs [21], and Walton and
Bittleston [22],a general analysis for flow in non-circular ducts, Letelier and Siginer [23] and a
preliminary analysis of the velocity field in non-circular pipes, Letelier, et al. [24]. Other
pertinent references can be found in the previous ones.
The constitutive characteristics of viscoplastic flow determine complex structures of velocity
and shear fields in tube flow when the tube cross-sectional contour differs from circular. This
is true even for the case of the Bingham model of viscoplastic fluid, which is one of the simplest
mathematical expressions for this kind of fluids.
Plasticity implies existence of fluid yield stress, which may induce both plug zones and
stagnant zones within the tube cross-section, when in there the tube geometry determines
zones of shear stress below the value of the yield stress. Such solid regions of the flow make
it necessary to apply greater pressure gradients in order to keep a given rate of flow which, in
turn, leads to greater energy dissipation and heating inside the fluid.
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In the following Bingham´s model of fluid is used. Simple plastic flows in straight non-circular
tubes do not develop secondary flows. The flow is, therefore, parallel when the motion is
laminar, and only the axial component of the velocity exists. Under these conditions, the











The constitutive relations are
τrz = - (1 + NI ) ∂w∂ r (29)
τθz = - (1 + NI ) 1r ∂w∂θ (30)
in which
I = ( ∂w∂ r )2 + ( 1r ∂w∂θ )2
1
2 (31)
is an invariant related to the rate of deformation matrix. Also
N = aηw0 τy (32)
where τy is the dimensional yield stress. The parameter N is a dimensionless yield stress that
greatly influence the flow characteristics.








τnz = N -
dw
dn (34)
In the above, n is a coordinate normal to isovels and ρ= radius of curvature of isovels




dn =τn(τn - N ) (35)
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3. Analysis of secondary flows and their effect on heat-transfer
The equations of motion and energy are next solved by using a double perturbation method,
as follows. First, and for all boundary conditions, the tube cross-section boundary is defined
by
G =1 - r 2 + εr nsin nθ =0 (36)
In which G is here labeled as a “shape factor”, that can describe a wide array of shapes
according to the given values of the parameters n and ε [1]. The shape perturbation parameter
is ε, which can take values in between 0 and a limiting values for the curve (36) staying closed.
The parameter n must be given integer values in order to get regular shapes.
Next all velocity components are expanded in series in terms of the Weissenberg number, i.e.
u =Wi u1 + Wi
2u2 + ...
v =Wiv1 + Wi
2v2 + ... 
w =w0 + Wi w1 + Wi
2w2 + ...
(37)
Complementarily, all velocity component, at any order, are defined as
V =G ( f 0 + ε f 1 + ε 2 f 2 + ...) (38)
where V is a generic velocity component, at any order in Wi, and f 0, f 1, ... are functions specific
for every V, to be determined by solving the momentum equations. Similarly, all other
dependent variables are expressed in series, i.e.
τ =τ0 + Wiτ1 + Wi
2τ2 + ... 
P = P0 + WiP1 + Wi
2P2 + ...
(39)
More details can be found in references [13, 25]. The velocity field is first found by substituting
(37-39) in (20-25) and related equations. For the axial velocity, the following expressions can
be determined, i.e.
w0 = p(1 - r 2 + εr nsin nθ)= pG (40)
p = - 14
∂ P
∂ z    (41)





3( 4(1 - ξ)0 - ξ(2 - ξ) (1 + r 2) + ξ(2 - ξ)(3n - 1) - 4(1 - ξ)(n 2 + 2n - 1)0(n + 1) rnsin(nθ))
(42)
Further, albeit more involved, exact solutions can be found for w3 and higher order terms in
Wi. In these results, since the parameter ε has a maximums value of 0,3849 for n=3, which
decreases as n increases, the series in ε shown in brackets in (38) were developed up to (ε)
yielding accurate results.
Computations show that up to 0(W i 2) the transversal velocity field is zero. Viscoelastic forcing
terms in (20-22) are non-zero from 0 (Wi3) upwards, which implies u1 =u2 =v1 =v2 =0.
At third order inWi, the viscoelastic forcing terms become non-zero. These are
Fr3 = (∇ ∙τ∇2)r
Fθ3 = (∇ ∙τ∇2)θ
Fz3 = (∇ ∙τ∇2)z
(43)
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At third order inWi, the viscoelastic forcing terms become non-zero. These are
Fr3 = (∇ ∙τ∇2)r
Fθ3 = (∇ ∙τ∇2)θ
Fz3 = (∇ ∙τ∇2)z
(43)






∂θ v3 = -
∂Ψ3
∂ r (44)







r∇4Ψ3 =8∈ (ξ - 2)ξ
2(n - 1)n(n + 4)p 4r n+1cos(nθ) (46)




2(2 - ξ)p 4 1 - r 2 + r nsin(nθ) 2 n
(n - 1)(n + 4)
(n + 1)(n + 2) r
ncos(nθ) (47)
Where from
u3(r , θ)= -
ξ 2(2 - ξ) p 4n 2(n + 4)(n - 1)w0
2r n-1sin(nθ)
4(n + 1)(n + 2)
v3(r , 0)=
ξ 2(2 - ξ)n(n + 4)(n - 1) p 4w0 n - (n + 4)r
2 r n-1cos(nθ)
4(n + 1)(n + 2)
(48)
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Plots of (47) are shown in figures 2, 3, 4 and 5
Figure 2. Characteristics plots of transversal streamlines for n=3 and ε=0.3849
Figure 3. Characteristics plots of transversal streamlines for n=3 and ε=0.33
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Figure 4. Characteristics plots of transversal streamlines for n = 4 and ε =0.25
Figure 5. Characteristics plots of transversal streamlines for n=4 and ε=0.2
It is to be noted that the vortical shape does not change with the slip parameter ξ, the pressure
coefficient p or the Weissenberg number. As these parameters change, the strength of the
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vortices change. Also, other parameters being equal, the strength of the vortices increases
significantly with ε, and thus transversal transport capacity. In all these cases the Reynolds
number is Re = 180. Similar results are found for n = 4, 5... in which the number of vortices is 2n.
In Figure 6 is shown the internal distribution of the normal axial shear stress for the case of
ε =0.3849
Figure 6. Characteristics plots of normal axial shear stress for n=3,  ε=0.3849,  Wi=0.3 and ξ=0.2
Curves are similar for all values of parameters, but the values of the normal axial shear stress
vary withWi, being of the order of 70% greater than the Newtonian counterpart for Re =180
and Wi =0,3.
The temperature field can be computed once the velocity field is known, through the energy
equation (27). To this end, the temperature T is expressed as
T =T0 + Wi T1 + Wi
2T2 + ...  (49)
In the following the temperature field and heat-transfer are computed for the case in which
there is a constant heat flux through de tube wall, so that the temperature difference between
de wall and the average temperature, i.e., Tw - Ta remains constant and also ∂Ta / ∂ z is constant.
This is problem 1 described in the section Mathematical Models.
The above leads to
∇2 T0 =a0Prw0 (50)
in which





T w - T a
∂T a
∂ z (51)




Applying the condition that the temperature, at all orders in Wi be zero at the tube contour,




2 - 3 + ε
(n - 3)
(n - 1) r
nsin nθ (53)
Higher order terms of T  can be found in similar way, but the expressions become very involved
and are omitted here.
Heat exchange is computed through the Nusselt number Nu, i, e.
Nu =
Dnh
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S = ∬ r  dr  dθ (57)
In the above p̄ is de contour perimeter and S is de cross-sectional area. A plot of Nu in terms





in which wa is the axial average velocity.
Numerical values related to Figure 7 are given in the following table, where they can be
compared with the Newtonian case
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in which wa is the axial average velocity.
Numerical values related to Figure 7 are given in the following table, where they can be
compared with the Newtonian case
Typical plots of temperature distribution appears in Figures 8 and 9.
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Figure 7. Please add caption
Table 1. Nusselt number values
Figure 8. Characteristics plots of isothermal curves for n = 3 and ε =0.3849
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Figure 9. Characteristics plots of isothermal curves for n=3 and ε=0.2
These results, as initially presented and discussed in [13, 25, 26] show that the Nusselt number,
i.e., the heat-transfer between fluid and wall, increases as the viscoelastic parameter Wi
increases, with an asymptotic trend, for a given value of the Reynolds number. As Re increases,
also Nu increases for a given value of Wi.
The relevance of these findings for biological flows may be related to vessel deformation due
to wall elasticity and peristaltic motion.
The preceding analysis shows that a very small deviation of the cross-section contour from the
circular geometry, as represented by the value of the parameter ε, may induce secondary flows,
and so increase the transversal transport capacity of biological flows. It seems to be an open
research area the study of physiological and morphological changes that, in this context, may
induce pathologies that accelerate heat transfer inside the human body. Such changes may
create conditions that improve or worsen transport processes that should lead to restore
normal physiological states.
Previous results associated to the flow of viscoelastic fluid in channels of axially-varying cross-
section [27] show also that axial change of geometry, as found in biological vessels, also
augment transport capacity.
4. Plastic flow
The velocity field and related variables for the flow of a Bingham fluid in non-circular tubes
is next found using a similar technique. The axial velocity is defined as
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w =w0 + εw1 + ε
2w2 + .. (59)
The constitutive equations (29, 30) can be expanded in series around the parameter ε by using
(58), where from [24]
τrz = N -
∂w0
∂ r - ε
∂w1
∂ r + 0(ε 2) (60)
τθz = -
ε





+ 0(ε 2) (61)
From the above the governing equation for w1 are found, i.e.
r  (r - N2 )( ∂2 w1∂ r 2 + 1r ∂w1∂ r ) + ∂
2 w1
∂θ 2 =0 (62)
which can be solved by separation of variables.
The dissipation function, in terms of the normal axial shear stress, is given in equation (35) and
can be computed, as an indicator of energy dissipation due to friction.
Typical results for the velocity field and dissipation function are shown in the following
figures.
Figure 10. Plots of isovels for n=3,   ε=0.3849 and N=0.2
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Figure 11. Plots of isovels for n=3,  ε=0.3849 and N=0.5
Figure 12. Plots of isovels for n=3,  ε=0.3849 and N=1.0
One significant feature of plastic flows are plug (or solid) and stagnant zones, which, as a
general rule, tend to decrease the rate of flow for a given pressure gradient, or require that
more energy by supplied in order to keep constant the rate of flow.
Figure 13 shows that energy dissipation is greatly affected by the tube geometry. The maximum
energy dissipation in the case of an equilateral triangle appears in the middle of the sides,
where the axial shear stress is maximum. Also the shear stress is zero at the corners, which is
a factor that determines stagnant areas close to such corners.
The plug zones are defined through the following joint conditions
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dw
dn =0   ;     w =const  (63)
which can be met up to certain value of N according to the cross-section shape.
Abnormal vessel geometries may occur in biological flow arising from many sources. Espe‐
cially in the case of stenosis, or geometry change due to solid deposition in artery walls, plastic
effects may lead to blood clotting in corners, when the arteries are small.
5. Concluding remarks
Some analytical results concerning the effects of fluid elasticity and plasticity, coupled with
tube cross-sectional geometry variation have been presented in this chapter.
The analysis is unified through some concepts that make it possible to explore, in a rather
general fashion, the mechanisms of transversal transport that arise with the coupling of
viscoelasticity and non-circular shape.
The circular shape is the most energy-efficient shape when only longitudinal mass transfer is
considered. However, this not the case when transversal motion becomes important, as in heat-
exchange processes, or in cases when also particle distribution is relevant.
General results indicate that viscoelasticity tends to increase transversal transport, which can
be demonstrated by analytical means. These in particular, show that starting at third order in
Wi, secondary flows appear when the fluid exhibits non-linear viscoelasticity, as prescribed by
the fluid models of Giesekus and Phan-Tien-Tanner. Such secondary, or transversal motions,
when coupled with the temperature, through the energy equation, determine a temperature
field that improve heat-transfer between the fluid and the tube wall.
Figure 13. Plots of the dissipation function (35) for n=3,  ε=0.3849 and N=0.5
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Plastic effects, on another perspective, do not induce transversal motion if the cross-section is
not circular. Rather plasticity increases energy consumption when maintaining a given rate of
flow is a priority. Shapes that include sharp corners lead to stagnant zones of fluids in the
vicinity of those corners, thus decreasing the flow. The analytical method herein applied can
be used for determining plug-zones of limiting values of the yield parameter N for which such
zones exist properly.
The application of these findings to biological flows have been commented in previous sections
of the chapter.
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Chapter 13
Quantifying Stress in Crabs
and Humans using Modified DFA
Toru Yazawa
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/59718
1. Introduction
Stress, which can be acute or chronic, is a term that has not been strictly defined, especially in
the field of neuroscience. Scientists have not yet fully characterized the complete set of
neuronal mechanisms that can explain stress. In this article, however, I use the term “stress”
because it is the most appropriate one.
Stress is a physiological reaction of an organism to an uncomfortable or unfamiliar physical
or psychological stimulus. Stress-inducing stimuli trigger reflex behavior, which results from
alteration in the activity of the autonomic nervous system (ANS) and hormones. Reflex
behavior includes a heightened state of alertness and increased heart rate. Acute stress is a
short-term response that lasts for seconds, minutes, or days. In this article, “stress” refers to
acute stress.
Scientists have not yet determined a method that can efficiently quantify stress. In fact,
scientists have difficulty objectively defining whether an organism is expressing stress in
response to stimuli. Through studies of crustacean hearts using electrophysiological methods,
I have discovered that stressful and non-stressful states can be distinguished by heartbeat
recordings: i.e., via electrocardiograms (EKGs). The methods used to measure stress in model
animals can be applied to humans because model animals and humans are fundamentally
similar in terms of autonomic nerve physiology. The autonomic cardio-regulatory function
can simply described as the combined action of acceleration and inhibition. In this article, I
present empirical results of stress observations in both model animals and humans. The
presented data provide convincing evidence that stress can be quantified.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
2. Brief history of crustacean heart physiology
Cardiac nerves—comprising accelerator nerves (CA) and inhibitory nerves (CI)—govern the
activity of the heart in an involuntary manner in both model animals and humans. CA and CI
are cardiovascular components of the ANS that transmit psychological information to the
heart. Alterations in the activity of these neurons can modulate momentary heart rate and
contractile force in a reflex manner in crustaceans as shown in Figures 1–3. Because the degree
of stress can be measured by monitoring heart rate variability, the heart can be called a
reflection of the neural activity of an animal.
However, the cardiac regulatory function of the human ANS is not clearly understood because
of the difficulty associated with recording ANS activity. Nevertheless, I have successfully
recorded ANS activity in crustaceans. Both CA and CI are active when the heart is beating.
This is evident in in situ recordings of nerve activity in hermit crabs in the 1970s (Figure 1,
unpublished data). In decapod crustaceans, only one pair of nerves, termed the cardiac or
regulator nerves, innervate the heart bilaterally. The crustacean system therefore appears
simpler than the human cardiac nervous system. However, appearances can be deceiving: the
fundamental mechanisms of the acceleration/inhibition functions are similar in humans and
crustaceans, and the ANS controls the cardiac region in both animals. It is evident in Figure
1 that three different impulses varying in size indicate discharging: small (not marked),
medium (shown by triangles), and large (not marked) impulses. A significant feature of Figure
1 is that the crab’s heartbeat stopped completely during the period when the large-sized
impulses were active, which is shown by a train discharge at a high frequency of approximately
50 or 60 Hz. Based on these observations, I was able to identify the neurons (in this case, the
large-sized impulses) that transmit inhibitory commands. CI and CA always function in
balance with each other. Figure 1 shows that the ANS dynamically controls the heart.
Healthy human hearts do not stop beating; only the rate of the heartbeat changes. However,
crustacean hearts can cease beating for a period of time (Figure 2). A key finding in my
crustacean study was that specimens showed a pattern of intermittent heartbeat cessation
under healthy, normal, non-stressed conditions. The cessation was induced by an intermittent
burst discharge of CI as mentioned above (Figure 1). An important observation was that the
presence of a human caused interruptions in this intermittency. In other words, stress from an
approaching human caused an alteration in ANS function: i.e., the intermittent pattern
changed to a continuous pattern [2] (Figure 3).
This intermittency was actually documented in the 1970s by Canadian crustacean heart
researchers, J. L. Wilkens and B. McMahon, though they did not mention the role played by
stress. (They found a strong relationship between cardiac and respiratory control.) The
physiology of the crustacean ANS has been studied throughout the 20th century by Carlson
(1900s), Alexandrowicz (1930s), Maynard (1950s, 1960s), Young [3], Field and Larimer [4], and
Yazawa and Kuwasawa [5]. However, these authors did not provide information on the
relationship between heartbeat and behavior of crustaceans.
Advances in Bioengineering360
2. Brief history of crustacean heart physiology
Cardiac nerves—comprising accelerator nerves (CA) and inhibitory nerves (CI)—govern the
activity of the heart in an involuntary manner in both model animals and humans. CA and CI
are cardiovascular components of the ANS that transmit psychological information to the
heart. Alterations in the activity of these neurons can modulate momentary heart rate and
contractile force in a reflex manner in crustaceans as shown in Figures 1–3. Because the degree
of stress can be measured by monitoring heart rate variability, the heart can be called a
reflection of the neural activity of an animal.
However, the cardiac regulatory function of the human ANS is not clearly understood because
of the difficulty associated with recording ANS activity. Nevertheless, I have successfully
recorded ANS activity in crustaceans. Both CA and CI are active when the heart is beating.
This is evident in in situ recordings of nerve activity in hermit crabs in the 1970s (Figure 1,
unpublished data). In decapod crustaceans, only one pair of nerves, termed the cardiac or
regulator nerves, innervate the heart bilaterally. The crustacean system therefore appears
simpler than the human cardiac nervous system. However, appearances can be deceiving: the
fundamental mechanisms of the acceleration/inhibition functions are similar in humans and
crustaceans, and the ANS controls the cardiac region in both animals. It is evident in Figure
1 that three different impulses varying in size indicate discharging: small (not marked),
medium (shown by triangles), and large (not marked) impulses. A significant feature of Figure
1 is that the crab’s heartbeat stopped completely during the period when the large-sized
impulses were active, which is shown by a train discharge at a high frequency of approximately
50 or 60 Hz. Based on these observations, I was able to identify the neurons (in this case, the
large-sized impulses) that transmit inhibitory commands. CI and CA always function in
balance with each other. Figure 1 shows that the ANS dynamically controls the heart.
Healthy human hearts do not stop beating; only the rate of the heartbeat changes. However,
crustacean hearts can cease beating for a period of time (Figure 2). A key finding in my
crustacean study was that specimens showed a pattern of intermittent heartbeat cessation
under healthy, normal, non-stressed conditions. The cessation was induced by an intermittent
burst discharge of CI as mentioned above (Figure 1). An important observation was that the
presence of a human caused interruptions in this intermittency. In other words, stress from an
approaching human caused an alteration in ANS function: i.e., the intermittent pattern
changed to a continuous pattern [2] (Figure 3).
This intermittency was actually documented in the 1970s by Canadian crustacean heart
researchers, J. L. Wilkens and B. McMahon, though they did not mention the role played by
stress. (They found a strong relationship between cardiac and respiratory control.) The
physiology of the crustacean ANS has been studied throughout the 20th century by Carlson
(1900s), Alexandrowicz (1930s), Maynard (1950s, 1960s), Young [3], Field and Larimer [4], and
Yazawa and Kuwasawa [5]. However, these authors did not provide information on the
relationship between heartbeat and behavior of crustaceans.
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Figure 1. Simultaneous recording of heartbeat (EKG) and cardiac nerve activity (ANS) of the hermit crab (Dardanus
crassimanus). Asterisks (*) indicate heartbeats.
Figure 2. Intermittent cessation of heartbeat shown in an EKG recording from a live saw tooth Gazami crab (Scyll serra‐
ta) specimen.
In summary, I recorded impulses of the cardiac nerves of crustacean hearts. I observed that CI
discharged a burst of impulses at a high-rate, ~60 Hz, and concomitantly, CA momentarily
Figure 3. Intermittent heartbeat cessation of a Japanese spiny lobster (Panulirus japonicus) was interrupted by an ap‐
proaching human shown in an EKG recording from a live specimen.
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ceased their impulse discharge [1]. During the CI burst period, the heart rate disappeared or
decreased significantly, although a rapid restitution of heartbeats occurred within one second.
These brief cessations of heartbeats occurred intermittently and somewhat regularly during
“stress-free” periods, for example, when the animal was hiding in a shelter. In contrast, the
stress-free behavior was not exhibited if the lobsters or crabs were approached by humans.
This response can be likened to the way cicadas stop singing when humans are in close
proximity. These findings suggest that crustaceans are incredible specimens because their
stress can be detected by electrocardiograms.
Crustacean and human hearts strongly resemble each other in structure and function. It is
known that homologous genes (e.g., Nkx2-5, the NK2 homeobox gene) function to form the
developing heart of all animals: [6]. In crustaceans and humans, both CA and CI connect
with the cardiac pacemaker cells, but CA further proceed to the ventricular muscles beyond
the pacemaker cells. Why do CA control the entire heart? The answer is that CA–muscle
connections can implement direct modulation of contractile force, whereas CI merely sup‐
press rhythm [5]. The resemblance between crustacean and human indicates that some
knowledge obtained from crustacean should be applicable to human. See Recent report by
Fossat et al.
(1) P. Fossat et al. “Anxiety-like behavior in crayfish is controlled by serotonin.” Science 344,
1293–1297 (2014).
(2) P. FOSSAT et al. “Anxiety-like behavior in crayfish is controlled by serotonin.” Society
for Neuroscience, Poster 655.18/UU43 - Motivation and Emotions: Rodent Anxiety Models
Tue, Nov 18, 1:00 - 5:00 PM 2014 Washington DC.
(3) OUTSIDE JEB. The Journal of Experimental Biology (2014) 217, 3389-3391
I studied electrocardiograms (EKG) of both animal models and humans and used modified
Detrended Fluctuation Analysis (mDFA) to calculate the scaling exponent (SI) (originally, Peng
et al., [7]). In this article, I show that the SI numerically is capable of distinguishing between
healthy and unhealthy hearts, and between “stressed” and “relaxed” hearts. Further, I propose
the mDFA to be a viable potential method for health/stress checking if incorporated into a
device that can quantify stress through EKGs.
3. Electrophysiology method
Human heartbeats were recorded using a PowerLab system (AD Instruments, Australia). A
set of three, ready-made Ag–AgCl electrodes (Vitrode V, Nihonkoden Co. Ltd. Tokyo) were
used for EKG monitoring. Permanently mounted metal electrodes were glued on the crusta‐
cean carapace for EKG recordings. These EKG signals were transferred to the PowerLab system
and PC. All subjects were treated according to the ethical regulations of Tokyo Metropolitan
University.
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4. Stress hormone measurement
The stress response of the lobster to approach by a human (Figure 3) may involve the contri‐
bution of stress hormones, but combined hormone and EKG measurements have not been
conducted. Therefore, I conducted micro-dialysis blood hormone measurements to determine
whether hormones are involved in crustacean stress responses. I prepared four different
HPLC-ECD (high performance liquid chromatography with electrochemical detection)
machines. These machines were respectively set up to separate biogenic monoamines (dopa‐
mine, adrenaline, serotonin and their breakdown products), acetylcholine and related
substances, amino acid neurotransmitters (glutamate, GABA, etc.), and peptide hormones.
Blood samples were collected using a micro-dialysis probe for all HPLC analyses (Figure 4).
Figure 4. The micro-dialysis (MD) probe placed on the dorsal carapace of lobsters (left panel). The tip of the MD probe
placed in the blood stream (right panel). H represents the heart chamber and arrows indicate the direction of flow.
Figure 5. HPLC chart indicating the detection of DOPAC (a breakdown product of dopamine) using the HPLC system
in a blood sample collected from a crayfish (Procambarus clarkii) specimen.
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Figure 6. HPLC chart indicating the detection of adrenaline (A) in a Japanese lobster (Panulirus japonicus) specimen.
Adrenaline release was induced by stress from human handling. Very little adrenaline was detected 20 min and 1.5
hour after the stress stimulus. Therefore, the adrenaline content measured at these times indicates the basal adrenaline
content in the blood. Note: noradrenaline (NA) was not detected.
Figure 7. EKG recording and MD experiment in a Japanese spiny lobster (Panulirus japonicus). A, a human approached
the lobster tank and conducted an MD experiment. B, continuous recording from A (note: the time scale is different).
Micro-dialysis HPLC (MD-HPLC) analysis detected a few substances in the blood samples
before, during, and after stress stimulation. EKGs were continuously recorded to check stress
responses. Figure 7 shows a lobster’s response to a human, observed through EKG recordings.
Significant features are evident in Figure 7. First, approach by a human interrupted the slow,
repetitive heartbeat pattern (Figure 7A). Second, the micro-dialysis experiment resulted in
continuous stress to the animal (MD period in Figure 7A). Third, the stressful reaction lasted
for approximately one day, the period shown by a white arrow (Figure 7B).
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Figure 8 shows the stress-induced release of dopamine. Blood samples were collected for 5
min and collection vials were exchanged every 5 min by an automatic solution-sampling
machine. A human entered the room containing the lobster for only a short time period (15
min); this period is indicated by the black bar. The human presence evidently irritated the
lobster, triggering a sharp increase in dopamine concentration, but this was followed by a rapid
decrease even though the stimulus was maintained for 15 min. The same stimulus also induced
adrenaline release, shown in Figure 6. The detection of stress-related hormones was confined
to dopamine and adrenaline and the breakdown product DOPAC. No other hormones that
directly correlated with stress behavior were detected—e.g., serotonin, noradrenaline, amino
acid neurotransmitters, and peptide hormones. Further details about these experiments can
be found in [8].
A characteristic feature revealed by the MD-HPLC experiments was that increased levels of
stress hormones are not maintained at a consistently high level even though the stress
stimulation was steadily maintained for 15 min (Figure 8). In conclusion, acute stress is
governed mainly by the functioning of the nervous system, whereas chronic stress more likely
relates to hormonal systems. Hormone release seems to be able to trigger a chain reaction in
biochemical pathways that results in a state of chronic stress.
Based on the results of the MD-HPLC examinations, I suggest that stress can be quantified by
measuring heartbeat rather than hormones. Stress can be determined using heartbeat fluctu‐
ation analysis; the method used was modified DFA (mDFA).
5. Modified DFA and DFA
In this article, I compare the methodologies of original and modified DFA. While most of the
computation sequences in DFA and mDFA are similar, there is one difference in the compu‐
tation process.
In DFA and mDFA, the scaling exponent (Peng used the Greek letter alpha) or scaling index
(SI) is calculated from time series data that obey the scaling law. Here, I use SI to refer to both.
In the mid-1980s, Goldberger pioneered the application of nonlinear dynamics to clinical
cardiology [9]. Thereafter, a voluminous literature appeared on chaos and nonlinear analysis
Figure 8. Micro-dialysis HPLC detection of dopamine in a Japanese spiny lobster (Panulirus japonicus) specimen. The
bar indicates a stimulation period of 15 min.
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in the life sciences [10]. The following literature provides information on nonlinear physics
with respect to heart physiology and DFA: Peng [11], Glass [12], Stadnistski [13], Stanley [14],
Goldberger [9], Katsuyama [15], Pérez [16], Liebovitch [17], Huikuri [18], Bigger [19], Scafetta
[20], and other work cited in these references. In addition, the scaling exponent, DFA, and
topics related to fractality research, for example, fractal, scaling, the Hurst exponent, and
power spectral density, are well explained by T. Stadnistski [13]. DFA is based on the concepts
of scaling and self-similarity [13]. Peng’s DFA [7] deals with critical phenomena. (Details of
the mathematics of DFA can be referenced elsewhere [9-19]). One DFA program, PhisoNet,
provided by Goldberger, Peng and others is available on the internet. However, there is no
web-based mDFA program available. Regardless, an mDFA program can be written with an
understanding of DFA and programming skills (I am a biologist and received programming
support from a graduate student, Katsunori Tanaka, who constructed an mDFA program
under my supervision using C++programming language).
While the genesis of DFA was long ago, no one has since constructed a useful device/instru‐
ment to quantify stress using it. In this article, I argue that implementing power law concepts
in DFA is a superior method for its practical use in biomedicine. In addition, I present the
results of our mDFA applied to real-world data. I anticipate that this literature will initiate a
public debate on whether to construct such a device/instrument, and hope that a functional
DFA device will be constructed as a result. This work is being performed in collaboration with
Symphodia Phil Confidential, Japan (President O. Takiguchi). Empirical data and the device
concept were previously presented at a conference of the Society for Chaos Theory in Psy‐
chology and Life Sciences in Milwaukee, Wisconsin, USA (August 2, 2014).
Although  DFA  is  not  a  recent  development,  the  technique  is  somewhat  difficult  to
understand. An important concept of DFA is that if data exhibit scaling characteristics and
self-similar fluctuations [11, 14], recorded signals and their magnified/contracted copies are
statistically similar. In general, statistical parameters such as the average and variance of
fluctuating signals can be calculated by taking the average and corresponding variance of
the signals across a certain section. In DFA and mDFA, however, the average is the squared
average of the data. The calculation of the statistical parameter thus depends on the size
of the section.
To use DFA as a practical tool for instantaneous determination of heart condition, the appro‐
priate section size, i.e. box size or number of heartbeats, needs to be determined. A practical
DFA tool should NOT be subject-specific. Rather, it should be constructed for general use
across the population. The section size, which is a restricted period of time, was determined
to range from 30 to 270 beats after conducting hundreds of tests.
6. EKG recording before mDFA
mDFA requires accurate heartbeat interval measurements without missing a single heartbeat.
Stable EKG recordings are needed for accurate detection of peaks in the data. If subjects move
(e.g., talk, touch, walk, squat, exercise, etc.) commercially available medical-EKG machines are
Advances in Bioengineering366
in the life sciences [10]. The following literature provides information on nonlinear physics
with respect to heart physiology and DFA: Peng [11], Glass [12], Stadnistski [13], Stanley [14],
Goldberger [9], Katsuyama [15], Pérez [16], Liebovitch [17], Huikuri [18], Bigger [19], Scafetta
[20], and other work cited in these references. In addition, the scaling exponent, DFA, and
topics related to fractality research, for example, fractal, scaling, the Hurst exponent, and
power spectral density, are well explained by T. Stadnistski [13]. DFA is based on the concepts
of scaling and self-similarity [13]. Peng’s DFA [7] deals with critical phenomena. (Details of
the mathematics of DFA can be referenced elsewhere [9-19]). One DFA program, PhisoNet,
provided by Goldberger, Peng and others is available on the internet. However, there is no
web-based mDFA program available. Regardless, an mDFA program can be written with an
understanding of DFA and programming skills (I am a biologist and received programming
support from a graduate student, Katsunori Tanaka, who constructed an mDFA program
under my supervision using C++programming language).
While the genesis of DFA was long ago, no one has since constructed a useful device/instru‐
ment to quantify stress using it. In this article, I argue that implementing power law concepts
in DFA is a superior method for its practical use in biomedicine. In addition, I present the
results of our mDFA applied to real-world data. I anticipate that this literature will initiate a
public debate on whether to construct such a device/instrument, and hope that a functional
DFA device will be constructed as a result. This work is being performed in collaboration with
Symphodia Phil Confidential, Japan (President O. Takiguchi). Empirical data and the device
concept were previously presented at a conference of the Society for Chaos Theory in Psy‐
chology and Life Sciences in Milwaukee, Wisconsin, USA (August 2, 2014).
Although  DFA  is  not  a  recent  development,  the  technique  is  somewhat  difficult  to
understand. An important concept of DFA is that if data exhibit scaling characteristics and
self-similar fluctuations [11, 14], recorded signals and their magnified/contracted copies are
statistically similar. In general, statistical parameters such as the average and variance of
fluctuating signals can be calculated by taking the average and corresponding variance of
the signals across a certain section. In DFA and mDFA, however, the average is the squared
average of the data. The calculation of the statistical parameter thus depends on the size
of the section.
To use DFA as a practical tool for instantaneous determination of heart condition, the appro‐
priate section size, i.e. box size or number of heartbeats, needs to be determined. A practical
DFA tool should NOT be subject-specific. Rather, it should be constructed for general use
across the population. The section size, which is a restricted period of time, was determined
to range from 30 to 270 beats after conducting hundreds of tests.
6. EKG recording before mDFA
mDFA requires accurate heartbeat interval measurements without missing a single heartbeat.
Stable EKG recordings are needed for accurate detection of peaks in the data. If subjects move
(e.g., talk, touch, walk, squat, exercise, etc.) commercially available medical-EKG machines are
Advances in Bioengineering366
not reliable because the EKG trace is frequently lost from the recorder chart or screen under
these conditions. Accurate identification of peak heartbeat times were a necessary condition
in this study. Therefore, I constructed a baseline-stable EKG recording amplifier with an input
time constant of 0.1 or 0.22 s (C=0.1 μF, R=1 MΩ, or C=0.22 μF, R=1 MΩ, respectively) and
amplification-gain of 2000 times. This made it possible to record baseline-stable EKGs. I used
a 1-kHz sampling rate. Based on my own electro-physiological observations, I knew that the
peak time of an action-potential always fluctuates in the order of milliseconds in response to
a stimulus. Therefore, I used a 1-kHz sampling rate (1000 dots per 1000 milliseconds). After
detecting peak heartbeat intervals, I constructed an inter-heartbeat interval time series (such
as the R-R peak interval of conventional medical EKGs). This time series was analyzed using
the mDFA program.
To conduct mDFA and obtain reliable scaling exponent (SI) values, a recording of ~2000
consecutive heartbeats was required; this number was used throughout my research. If a
dataset contained 4000 or 5000 heartbeats, these were divided into two data sets. The ideal
(minimum essential) number of heartbeats for use in an mDFA instrument would be ~2000. In
fact, various data lengths of EKGs, ranging from 700 to 5000 heartbeats are used. In this article,
analysis based on 2000 beats as well as shorter and/or longer data lengths are presented in
some figures. To obtain stable results in a practical health-determining device, a 30-min EKG
recording is ideal (here, 1900–2100 beats were used).
There are several ways to detect heartbeat timing; however, I prefer stable baseline EKGs. In
terms of a stable baseline, short and constant EKG recordings are superior to finger pulse and
light-sensor (infrared) blood flow recordings. However, consecutive R-R intervals of ~2000
beats are required irrespective of the type of recording used.
Several mDFA computations were performed simultaneously: scaling exponents in various
box sizes were computed (Figure 9). Initially (from 2004 to 2006), program A was used, which
Figure 9. Range in box sizes used for mDFA (i.e., the slope from one particular box size to another).
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included box-ranges [30: 60], [70: 140], [130: 270], and [30: 270]. These four ranges were
automatically and simultaneously computed. However, any box size range could be manually
computed if necessary. Then, program B was added in 2006, which included box-ranges [30:
70], [70; 140], [130: 270], [51; 100], [30; 140], [30; 270] (Figure 9). These automatic ranges were
arbitrarily determined. Until now, programs A and B have been used simultaneously. All
existing EKG-mDFA results were computed using both programs.
Program A computed 53 box points and program B computed 136 box points (Figure 10). This
increase in box number occurred because of an increase in the PC calculation speed due to a
Windows software improvement. A device requires relatively rapid computation of the scaling
exponent. An average scaling exponent was computed in each computation, calculated as the
average of the scaling exponents across the range of box sizes (see Figure 22 and 23).
mDFA calculations use recordings of approximately 2000 beats, digital recordings at a 1-KHz
sampling ratio, and a box size range of [30: 270] in the following sections of this article, unless
otherwise mentioned.
7. Box size
The mDFA program generated by K. Tanaka was based on an article by Scafetta and Grigolini
published in 2002 [20]. These authors pointed out that DFA does not reliably detect the
distribution of the Lévy time series [20]. The mDFA program is intended to observe the scaling
behavior over a wide range of SI values. DFA focuses on critical phenomena and an SI value
near 1.0, which is a Gauss distribution time series. In the current study, there were significant
differences in the computation results between the mDFA and Peng’s DFA, especially when
diseased hearts were examined. If mDFA was used instead of DFA, diseased hearts exhibited
a high SI (SI=~1.4, Table 1).
Figure 10. Box size (number of heartbeats) for the mDFA programs. Program A and Program B contained 53 and 136
boxes, respectively. Programming language C++.
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The idea of using a box in mDFA (and DFA) computations is presented in Figure 11 for 2000-
heartbeat interval time series obtained from a human subject. Seven clear irregular beats are
evident, i.e., so-called premature ventral contractions (PVCs) or ectopic heartbeat. The four
black bars indicate that the 2000-beat data set was divided into four boxes. Here, there are 500
beats in each box; therefore, the box size is 500. Every box always has an identical number of
beats in any mDFA/DFA computation. In mDFA (not DFA) computations using a PC, the box
size is changed cyclically from 10 to 1000 as shown in Figure 10.
Figure 11. Interval time series and boxes.
8. Arithmetic calculation and detrended data
Here, the mDFA procedures are briefly shown. First, one can obtain heartbeat interval time
series {Xi} and construct a “box” (Figure 12). Second, average heart rate <X> is computed
(Figure 13). Third, the values Xi-<X> are computed (Figure 14). All data fluctuate around the
zero line (see Figure 14).
Next, an integrated series (sigma) of all data fluctuating around the zero line qi = ∑
k=1
i
( xk -  x )
can be obtained (Figure 15). Note the random walk-like steps. A regression line is computed
for each box using a fourth order (biquadratic) polynomial (data not shown) (Figure 16). Then,
the procedure is detrended by computing si=qi-qj (Figure 17).
Figure 12. Heartbeat interval time series {Xi} and boxes. Ninety beats from 2000 beats are shown.
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Figure 13. Average heart rate, i.e., <X>; note the dotted horizontal line.
Figure 14. Average heart rate <X> is deduced from {Xi}, resulting in a time series fluctuation around zero.
Figure 15. An integrated series, qi.
Figure 16. Regression lines, qj.
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Figure 13. Average heart rate, i.e., <X>; note the dotted horizontal line.
Figure 14. Average heart rate <X> is deduced from {Xi}, resulting in a time series fluctuation around zero.
Figure 15. An integrated series, qi.
Figure 16. Regression lines, qj.
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Figure 17. Explanation of detrended computations, si=qi-qj.
Figure 18. Computation of mDFA.
Figure 19. Peng’s DFA showing the distance between each data point and the regression line.
Figure 20. An example of mDFA with a box size of 40.
Then, in mDFA (not DFA), the program calculates how many steps proceeded after traveling
within a box (Figure 18). This is an mDFA-exclusive computation, which is not used in Peng’s
DFA. Peng’s DFA program calculates the distance (zi) between random walk-like lines (yj) and
Quantifying Stress in Crabs and Humans using Modified DFA
http://dx.doi.org/10.5772/59718
371
regression lines (yv) (note the numerous vertical lines in Figure 19) as yj – yv. The data presented
in Figure 20 and 21 represent differences between mDFA and DFA with a box size of 40.
Figure 21. An example of Peng’s DFA with a box size of 40.
9. Scaling
Scaling graphs are constructed using the following procedures. The scaling exponent can be
determined using an integrated series (Figure 15). The important variables are the number of
boxes (N/n), where box size (n) and interval data number (N) are given by the integrated series.
The box size (n) can be changed from 10 to 1000 in mDFA computations (see Figure 10). In
addition, the variance, F(n) can be calculated for each box size (n). Then, the following graphs
can be drawn: Logarithm (n) vs. Logarithm F(n), and linear regression lines across various box
sizes (see Figure 22). These procedures was used to compute the scaling exponent SI (or Greek
letter alpha, α).
The equation used to determine the scaling exponent in Peng’s DFA program (source code
obtained from PhysioNet) is:
F (n) =  
∑
k =1
N ( yk - y 'k )2
n
  N  
   n  
,
(1)
where yk is the integrated series and y’k is the regression line.
In the mDFA program, however, the following equation is used to determine the scaling
exponent:
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where F(n), S(n), qi and q’i are the same as Peng, but different letters are used for comparison
between mDFA and DFA. Based on this equation, mDFA computations can be performed to
determine the scaling exponents for practical use (see Figure 18 and Figure 20).
First, a graph of variance vs. box size (Figure 22) can be constructed, followed by determination
of the scaling exponent (Figure 22 and Figure 23). For practical use of mDFA as a device, one
can use the slope of [30: 270] because the value is nearly always close to the average value. This
condition was applied to most of the empirical results presented below.
In summary, in Peng’s DFA, the SI is calculated from the variance, <(xi)2> and the random
walk-like steps are considered. However, in the mDFA presented here, SI is calculated as <(xi
+j – xi)2>. According to my physicist colleagues, the mDFA idea originates from a structure and
function distribution and deals with scaling.
Figure 22. Determining SI in mDFA. Various SI values were computed simultaneously.
Figure 23. Examples of SIs.
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10. Stress quantification using mDFA
Lobster EKGs are presented in Figure 24. The data presented in Figure 24A were recorded
when specimens were in a non-stressful state when no human was present in the room. The
data presented in Figure 24B were recorded during micro-dialysis blood sampling. The
heartbeat interval time series obtained from the highlighted section is shown in Figure 25 for
578 beats. Under the no-stress condition, the lobster exhibited a dynamically changing pattern
(Figure 25, red line) indicated by numerous spikes in the data. This is evidence that the heart
received an inhibitory command from CI. In contrast, the lobster under the MD stress condition
did not exhibit such a dynamic pattern (Figure 25, black line). Inhibitory neural control was
not evident, suggesting the stressed state is a state dominated by acceleratory neurons.
The scaling nature is expressed as a slope in the mDFA graph. The scaling nature of the no
stress and MD stress states are presented in Figure 26. mDFA computation revealed a signif‐
icant difference between the two states. Stress (caused by an approaching human) clearly
decreased the slope (Figure 26 and 27). SI values of approximately 0.55 and 1.0 were obtained
when a human did or did not approach the lobsters, respectively (Figure 27). These animal
model experiments suggested that it may be possible to quantify human stress using the mDFA
technique.
Figure 24. EKGs measured under no-stress (A) and MD-stress (B) conditions (these data were collected from the same
lobster used in Figures 3 and 7).
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Figure 25. Interval time series obtained from data presented in Figure 24.
Figure 26. Results of mDFA (program A). Slope and SI for no-stress and MD stress conditions.
Figure 27. Scaling exponent (SI) computed from EKGs under no stress and MD stress conditions. SI computations from
various time periods are shown by bars (a, b, c,---ac, ad).




Human EKGs were analyzed using mDFA. Table 1 indicates considerable differences in SI
values between stressed and non-stressed individuals. Stress significantly lowers SI. mDFA
revealed that the President and Dean of the University had low SIs, whereas teaching-only
professors had healthy SIs close to 1.0.
The Appendix in Table 1 shows that heart muscle injury (such as myocardial cell damage
caused by ischemia or heart operations) can be identified using mDFA. People with a poor
medical history have high SIs, considerably higher than 1.0. It is possible that the hearts of
patients who suffered from cardiac disease and recovered through successful medical
treatment may have scar-like non-muscle tissue; i.e., a fibrous matrix or debris following
necrosis. This tissue might cause abnormal fluctuation of heartbeats, which can be detected by
mDFA. Although there is no mathematical explanation as to why the SI values are so high, it
is notable that mDFA was able to distinguish ischemic hearts from healthy ones. It is remark‐
able that injured hearts have exceptionally high SIs. In fact, they echo previous findings of
heart damage in crabs and lobsters that died suddenly during experimentation (Presented at
international conferences: Yazawa et al. Neurodynamical Control of the Heart of Healthy and
Dying Crustacean Animals. CCCT2005 Proceedings Vol. 1, pp. 367-372; Best Papers of IIIS
Conference WMSCI 2006, DFA on Cardiac Rhythm: Fluctuation of the Heartbeat Interval
Contains Useful Information for the Risk of Mortality in Both Animal Models and Humans)
Table 1. Comparizon: Stress level and exponent value (Indonesia, 2012, working with Prof. A. Hutapea)
Categories Age Stress leel (Interview) SI
Business owner (a company) No. 1 50s, Male Fairly low 1.03
Business owner (a company) No. 2 50s, Male High 0.72
Top management, President of a Univ. 60s, Male High 0.84
Top management, Vice President of a Univ. 40s, Female High 0.84
Middle management, Dean 40s, Male High 0.72
Middle management, Secretary of president 40s, Female High 0.76
Ordinary employee, Teaching only professor, No. 1 50s, Male Fairly low 1
Ordinary employee, Teaching only professor, No. 2 50s, Female Fairly low 0.98
Table 1. Appendix: Cardiac disease Age Daily life SI
Patient with stent-placement 60, Male OK 1.26
Patient with bypass-surgery 45, Male OK 1.38
Patient with inplantable cardioverter 53, Male OK 1.22
Ventricular septal defect (20 y ago operation) 48, Female OK 1.41
Healthy representative, housewife 46, Female OK 1.03
Stress lev I i  
Table 1. Comparizon: Stress level and exponent value (Indonesia, 2012, working with Prof. A. Hutapea
The SI data presented in Table 1 (and explained in Figure 28) show that mDFA is able to detect
job-related stress. Some of the subjects presented in Figure 28 are the same as those shown in
Table 1. Interestingly, the people who had administrative and teaching-professor obligations
were somewhat serious during the EKG measurements and exhibited low scaling exponents.
However, teaching-only professors who appeared happy (they laughed and spoke during the
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The SI data presented in Table 1 (and explained in Figure 28) show that mDFA is able to detect
job-related stress. Some of the subjects presented in Figure 28 are the same as those shown in
Table 1. Interestingly, the people who had administrative and teaching-professor obligations
were somewhat serious during the EKG measurements and exhibited low scaling exponents.
However, teaching-only professors who appeared happy (they laughed and spoke during the
Advances in Bioengineering376
EKG measurements) had healthy exponents with values near 1.0. It is likely that mDFA can
quantify stress; however, additional empirical results on a greater number of samples are
needed before a definite conclusion can be reached.
Figure 28. Job-related stress determined using mDFA (some are identical data shown in Table 1)
12. The heart reflects neural activity: Individual stories
A subject who volunteered for a long-term follow-up study had her EKG measured yearly
under sitting and talking conditions, always on a September afternoon at approximately 3 PM.
In 2006, she had a good SI and after that appeared normal in terms of mDFA. However, as can
be seen in Figure 29, her SI changed dramatically over the years.
This subject did not disclose any personal issue until 2009 when she related that she experi‐
enced difficult conditions in her work place in 2007 and 2008 and wanted to relocate. In
addition, she lost a loved one to illness in 2008 and left her office job at the end of 2009. Her
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environment improved greatly by 2010; her EKG was not measured in 2011, and she had a
good SI in 2012 (data not shown).
Another subject was caring for her aging mother at home (Figure 30). The caregiver did not
sleep from 28–29 September because her mother did not sleep. Consequently, the subject’s SI
was very low (3 PM on 29 September). However, she slept well the following two nights
because her mother slept well. This subject visited my exhibition booth at Innovation Japan
2011.
Figure 29. EKG data from a woman aged 27 years collected in September 2006 at 3 PM and five-year follow-up results.
Figure 30. Sleep deprivation decreases SI. These data were collected from a woman in her 50s who was taking care of
her aging mother.
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I am currently collaborating with a company to construct a device equipped with a stable-
baseline (meaning, the EKG trace is NOT lost from the recorder chart or screen) EKG amplifier
and data logger. In the future, an mDFA program will be incorporated into the device. The
device will instantaneously compute SI, and EKG data, mDFA results, and SI values will be
stored on an SD memory card. All data will be transmitted to a PC through a web-based system
(Figure 31).
Figure 31. A device that records stable-baseline EKG (Symphodia Phil Confidential, Japan).
14. Discussion
Unique characteristics of mDFA are shown in Figure 18 and 20. In addition, the unique mDFA
computation is specified in equation (2); DFA does not use this procedure.
mDFA calculates SI using a method that includes preparation of time series data, removing
trends from the data, determining statistical variations, constructing a graph of F(n) vs. (n),
where F(n) is variance and (n) is box size, and determining the slope, i.e., SI. In order to
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construct a gadget that rapidly calculates SI, I determined an appropriate scaling zone where
a straight line and a regression line were drawn using the least-squares method; this zone is
[30: 270] in beat per min (BPM).
Until now, a DFA-user must determine the box range before drawing a regression line to obtain
the SI. I determined the best range to compute SI automatically is [30: 270]. Biological systems
do not operate optimally because ranges that are too small or too large are avoided. As a
biomedical tool, however, mDFA uses a special box-range [30: 270]. Currently, people can
construct their own device to analyze their own cyclic phenomena. The device would auto‐
matically return SI values when people include time series data, and SI could be computed for
any time series interval.
The time length of 270 heartbeats in the [30: 270] box range corresponds to 270 sec if the heart
beats at a steady ratio of 60 BPM, which is equivalent to 3–4 min. This time length has a
particular significance with respect to neuroscience, because internal biochemical reactions
can retain a steady state for this length of time. I can wait for three minutes before instant
noodles are cooked. A boxer fights with full power for three minutes. The neuron network
functions under the three-minute law. Short-term memory and acute stress, for example, can
last for three minutes but they can also decline after three min. The length [30: 270] (three min)
could be a biologically important number.
15. Conclusion
mDFA and SI provide useful information. mDFA can be incorporated in the future into a device
for checking health and stress levels. It is possible that anyone could construct their own mDFA
program for developing such a device.
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